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Abstract
Recent scientific advances in imaging technology mean the development of fluorescent
and radiopharmaceutical probes have great potential for the measurement of pathological
processes involved in various diseases, including neurodegenerative diseases and cancers.
This thesis describes the design, synthesis, and biological studies of fluorescent and
radiopharmaceutical (tau ligands) probes for imaging neurodegenerative diseases.

Eight novel fluorescent probes based on the 6-chloro-2-phenylimidazo[1,2-a]pyridine-3yl acetamide ligands featuring the 7-nitro-2-oxa-1,3-diazol-4-yl (NBD) were synthesized
and biologically evaluated. The TSPO affinity of the synthesised fluorescent probes was
measured on rat tissue homogenates using a [11C]PK11195 radioligand binding assay. All
the new probes showed moderate to high affinity binding to the TSPO with Ki values
ranging from 3.28 μM – 0.58 nM. It was found that the attachment of NBD to the
acetamide side chain of the parent ligands led to moderate binding affinity for the TSPO.
The conjugation of NBD to the phenyl ring led to a significant improvement in binding
affinity for the TSPO, as exemplified by probes 56a, 56b, and 89.

Spectroscopic studies using UV-Vis absorption and fluorescence measurements showed
that most of the probes exhibited favourable spectroscopic properties, especially in nonpolar environments. In vitro fluorescence staining using brain section from
lipopolysaccharide (LPS) injected mice with probes as well as anti-TSPO antibody
indicated that the green signals derived from the tested probes and red signals derived
from anti-TSPO antibody were partially colocalized in several probes, suggesting binding
activity of probes to TSPO at the mitochondrial level. Furthermore, in vivo real-time twophoton laser scanning studies revealed that some fluorescent probes were apparently
i

unable to cross the blood-brain barrier (BBB), however, this property may not be crucial
for in vitro applications. Several probes, including 56a and 56b can be considered to be
eligible imaging agents for investigating TSPO expression in peripheral cells,
postmortem, and biopsy tissues from patients affected by neurodegenerative diseases and
other diseases (e.g. cancers) in which the TSPO density is altered.
Additionally, 42 novel tau ligands based on the modification of trans-butadiene bridge
on PBB3 30 compound were synthesised for potential labelling with carbon-11 and
fluorine-18. Several ligands were selected for biological studies. The in vitro fluorescence
staining with synthesised tau ligands was investigated in sections of AD brains bearing
β-amyloids and tau. PBB3 30 was used as a positive control due its capability to visualise
not only tau lesions but also several types of senile plaques, particularly dense core
plaques.

Fluorescence staining indicated that several triazole ligands showed good visualisation of
Aβ plaques, but failed to recognise the NFTs in human brain sections. Moreover, this
study revealed that triazole ligands containing alkyl alcohols (59a-d) and alkoxy alcohol
(59e) failed to detect Aβ plaques and NFTs by fluorescence microscopy. Interestingly,
NFT in sections of AD brains can be observed using ligands 61b (amide derivative) and
62c (ester derivative). Results from the heterologous binding assay revealed that most of
the tau ligands exhibited very few to low % inhibition (1.5 – 36.8%) against [11C]PBB3
30. Furthermore, these ligands showed low to high affinities (Ki = >1.5 mM – 0.46 nM )
at the shared binding site(s) with [11C]PBB3 30.
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Chapter 1: Introduction

1.1 Neurodegenerative Diseases
Neurodegenerative disease is an umbrella term that describes the progressive
degeneration of nerve structure and function in the brain, leading to either functional loss
(ataxia) or sensory dysfunction (dementia). These diseases are incurable and generally
affect the neurons of the central nervous system (CNS) which gradually damage their
function.1 The exact cause of neurodegeneration is not completely known, however, it is
believed that environmental factors along with genetic mutations, brain aging, and
cellular and molecular events (e.g. oxidative stress, loss of mitochondrial functions, and
deposition of misfolded proteins) may contribute to neuronal injury and cell death.2-3

As neurons are sensitive cells, and normally do not divide and replace themselves directly,
the repair process can be slow. As a result, neurodegenerative diseases can be destructive
and permanent with few available treatments,4 and demonstrate the progressive loss of
neurological functions in the patient without any apparent cause, for example, no
infection, neoplasm, localized vascular disease, and toxicity.5

Neuronal degeneration and CNS inflammation, which may be indicated by the presence
of specific protein aggregates, are the main pathological features of various
neurodegenerative diseases and are generally observed in the elderly with age-related
disorders such as Alzheimer’s disease (AD), Parkinson’s diseases (PD), Huntington’s
disease (HD), multiple sclerosis (MS), progressive supranuclear palsy (PSP),
frontotemporal dementia (FTD), dementia with Lewy body (DLB), prion disease, and
1

amyotrophic lateral sclerosis (ALS). The pathological changes (macroscopic and
microscopic) within the nervous system at the affected brain regions determine the
clinical features of the diseases (Figure 1.1).6

Figure 1.1. Brain regions affected by various neurodegenerative diseases and anatomical images
of primary macro- and microscopic changes (misfolded proteins) associated with each of these
diseases.6 Image reproduced from ref. 6.

Emerging evidence indicates that the inflammatory processes are closely associated with
multiple neurodegenerative pathways. For instance, specific inducers of inflammation
have been linked with neurodegenerative diseases coverage in mechanisms responsible
in the transduction, sensing, and amplification of the inflammatory processes that result
in the accumulation of neurotoxic substances, including interleukins and cytokines.
Despite different triggering events, these substances are associated with several
neurodegenerative disorders, such as AD, PD, ALS, and MS.7 Furthermore, recent
advances in molecular imaging have led to the recognition that glia, particularly
microglia,

respond

to

tissue

insults

(e.g. allergy,

chronic

infections,

and

neurodegeneration).8-9

2

Until recently, it was considered impossible to find a common molecular mechanism for
neurodegenerative diseases. It is also difficult to diagnose these types of pathologies
quickly and accurately as multiple potential risk factors may play a causal role. Known
risk factors for neurodegenerative diseases are genetic polymorphisms, age, and gender.
Other possible risk factors may include endocrine conditions, oxidative stress, depression,
vitamin deficiencies, immune and metabolic conditions, chemical exposure, education,
and some chronic diseases like stroke, hypertension, infection, tumours, diabetes, and
inflammation.10-11

Several studies have indicated that the prevalence and incidence of neurodegenerative
diseases rise dramatically with increasing age, thus the number of cases is expected to
increase in the foreseeable future as lifespans in many countries continue to grow. A
recent study from the United Nations (2015) estimated that the number of people over 60
years worldwide is expected to more than double in the next 35 years, reaching a
population of almost 2.1 billion.12 Given that people, especially in developed countries
(e.g. Australia, Japan, the USA, Germany, Finland, France, and Austria) are living longer,
age-related neurodegenerative diseases have become more common, and have gained
increased attention over the past 20-30 years due to their irreversible characteristics, lack
of effective therapy, and accompanied social and economic burden on society.13-14

Although dementia has become the major health challenge in developed as well as
developing countries with a new case occurring every three seconds, policies and plans
for the financing or provision of long-term care are still limited.15 Therefore, a greater
understanding of the comprehensive pathologies of neurodegenerative diseases is
urgently needed. This can then enable scientists, policymakers, and healthcare
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professionals to provide better solutions. In the following, the two most common
neurodegenerative diseases, AD and PD will be described in more detail.
1.1.1 Alzheimer’s Disease
AD is recognized as the major cause of dementia among older people, accounting for 6080% of cases.16 AD has become the most common neurodegenerative disease in the last
25 years,17 affecting approximately 35 million people worldwide.18 This is a type of
dementia that causes cognitive decline, including memory loss, spatial disorientation,19
language impairment, mood swings, and behaviour issues.20 Although the underlying
cause of AD remains substantially unknown,21 accumulating evidence suggest that the
risk of developing AD is multifactorial instead of a single cause.

The main risk factor for late-onset AD is age, although other factors such as the family
history of AD patients and the presence of e4 allele gene (ApoE) may also contribute.22
Recent studies indicated that e-4 allele gene triples the risk of AD, and the risk of AD
increase 7-fold in individual homozygous for the e-4 allele gene. Other possible causes
of AD may include brain injury, hypertension, smoking, sedentary lifestyle, obesity, and
type 2 diabetes.23

Due to the increase in life expectancy, the number of people living with dementia will
double every 20 years to reach 131.5 million by 2050.24 The global prevalence of
dementia in 2010 was estimated to be 4.7% in people 60+ years old.15, 25 In Australia, it
was estimated that 400,833 people suffered from dementia in 2016, predicted to increase
to 1,100,890 in 2056. Additionally, dementia is the single greatest cause of disability in
people over the age of 65 years26 and has become the second leading cause of death in
Australia, contributing to approximately 5.4% of all mortality in males and 10.6% of all
mortality in females annually.27 It is estimated that $A 3.2 billion is spent annually by the
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Australian government in direct care of AD patients and this is predicted to increase by
2.8 billion every 5 years.28

In the USA, there are approximately 5.7 million people living with AD and it is predicted
that 14 million people will be diagnosed by 2050. Moreover, AD has taken over from
cancer to become America’s most feared disease15 and is an incredibly expensive
disorder, with an estimated cost of $ 277 billion for direct treatment of AD every year.29
In other developed countries, such as Japan, the burden of dementia is also large and
continues to grow. With the world’s fastest aging population, it is projected that one in
five of the elderly in Japan will be living with dementia by 2025, representing
approximately 7 million people.16

AD was first described by and later named after the German psychiatrist and
neuropathologist Aloysius (Alois) Alzheimer in 1906.17 The two main pathological
hallmarks found in the brain of individuals with AD are extracellular amyloid plaques
and phosphorylated tau fibrils (neurofibrillary tangles), along with cerebral amyloid
angiopathy and glia activation (Figure 1.2).20, 30
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Figure 1.2 Main pathological features of Alzheimer’s disease. Extracellular accumulation of Aβ
fibrils forms the Aβ plaques, while intracellular accumulation of tau filaments forms the
neurofibrillary tangle (NFT). Activated microglia and reactive astrocytes surround the Aβ within
the compact plaques in the brain of patients with AD.31 Image reproduced from ref. 31.

Amyloid plaques are primarily formed by amyloid beta protein (Aβ) and are commonly
found outside neurons in the brain.19 Aβ is an amino acid peptide formed by proteolytic
cleavage of amyloid protein precursor (APP) by β- and γ-secretase enzymes. This process
will result in Aβ1-40 and Aβ1-42 protein fragments.23 Though the production of Aβ1-42
is less than Aβ1-40, Aβ1-42 is more prone to aggregation and more neurotoxic as
compared with Aβ1-40.32

Overproduction and accumulation of amyloid in the brain can trigger the pathogenic
process leading to early-onset AD. On the other hand, the imbalance between Aβ
production and clearance may contribute to the late-onset sporadic AD.33 A study
suggests that dysfunction in Aβ clearance in the CNS due to aging promotes the
6

accumulation, aggregation, and deposition of Aβ1-40 and Aβ1-42, indicating that
amyloid clearance may be clinically important in the development of AD.34
According to the amyloid-cascade hypothesis, accumulation of Aβ is considered to be the
most crucial pathophysiological hallmark of AD. This hypothesis, which is widely
accepted,35 suggests that production and accumulation of Aβ aggregates in the brain play
a vital role in AD development and progression. Aβ aggregates are believed to have a
toxic effect and continued accumulation in the brain activates the inflammation cascade
leading to neuronal death in AD patient.36 Several studies have revealed the role of Aβ,
including cholesterol transport, antioxidative activity, antimicrobial activity, and a role in
synaptic plasticity. However, the exact role of Aβ accumulation in sporadic AD remains
unknown.37

The mutations in the APP have been linked to the early onset of AD, of which
approximately 25 mutations are pathogenic and cause autosomal dominant AD.38 Despite
the mechanism underlying the effect of APP mutation being unclear, it has been reported
that some APP and Aβ mutations increase Aβ production and/or extend the half-life of
Aβ in the brain.36

Another hallmark of AD pathology, hyperphosphorylated tau proteins, also called NFTs,
are the major microtube-associated proteins (MAPs) which present in the CNS. The basic
role of tau proteins is believed to be stabilization of microtube cell cytoskeleton. In
pathogenic conditions, accumulated amyloid plaques along with neuroinflammation
subsequently lead to hyperphosphorylation of tau proteins.39 This results in the damage
of the microtubules, affecting cell function and viability.37
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The involvement of various biochemical processes in the pathological features of AD
reflects the complexity of the disease. Thus, finding adequate treatment has proved to be
difficult. Since 1993, several drugs have been approved by the Food and Drug
Administration (FDA) to treat AD symptoms (Table 1.1). These drugs ameliorate the
symptoms and partially restore memory and cognitive function in a moderate way, but
unfortunately, they are not curative.40-41

Table 1.1 US FDA-approved drugs for the treatment of AD symptoms
Generic Name

Structure

Tacrine

Year of
Approval

Approved
For

1993

Mild to
moderate
stage

1996

All stages

2000

Mild to
moderate
stage

2001

Mild to
moderate
stage

2003

Mild to
severe stage

1

Donepezil
2

Rivastigmine
3

Galantamine

4

Memantine
5
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1.1.2 Parkinson’s Disease
PD is recognized as the second most common neurodegenerative disease after AD, caused
by the dysfunction of dopaminergic neurons in the pars compacta of the substantia nigra
(SNpc).42 The lack of dopamine promotes the malfunctioning of the brain, affecting the
communication among its neurons. Consequently, signals from cells are not sent
correctly, which lead to progressive movement disorders. PD patients may also
experience depression, sleep disturbances, dementia, psychotic conditions, and
autonomic disorder.43 The clinical symptoms of PD typically do not develop before 7080% of dopaminergic neurons have already been damaged. Thus, identifying as well as
developing effective neuroprotective treatment strategies for PD patients at an early stage
is a major challenge.44

Among the potential biomarkers of PD that have been evaluated (e.g. orexin, 8-hydroxy2'-deoxyguanosine, peripheral proteasomes, dopamine, and α-synuclein), various forms
of α-synuclein protein aggregates have attracted the most attention and were considered
as a primary pathological hallmark of the disease which can be found at the core of Lewy
bodies (LBs).45 α-Synuclein, which belongs to a small group of natively unfolded proteins
can adopt several conformational states, including unfolded monomer, β-sheet rich
oligomer, protofibril, and amyloid fibrils.46
Recent studies suggest that α-synuclein can be secreted into the extracellular environment
of the brain which can then spread via the bloodstream and cerebrospinal fluid (CSF)
leading to its deposition and subsequent damage of healthy neurons. Furthermore,
biomarker evaluation has shown that α-synuclein may also cross the BBB, as indicated
by the changes in the level of α-synuclein in the blood plasma of PD patients.44 In its
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misfolded fashion, α-synuclein becomes insoluble and aggregates to form intracellular
inclusions with the cell bodies (LBs).42

PD, the most common movement disorder (tremor, rigidity, bradykinesia), affecting
millions of people worldwide,47-48 was first described by James Parkinson in 1817.43 Its
incidence ranges from 10 to 18 per 100,000 population per year.49 The prevalence of PD
in aging people is much higher compared to a young population, ranging from 1% in
people above 60, and increasing to 4% in those above 85 years old.50 In Europe, the
prevalence of PD in 2007 was reported as 3.5% in ages 85-89.51 According to the National
Parkinson’s Foundation, the number of new cases diagnosed every year ranges from
50,000 to 60,000 individuals.43

PD is a multifactorial disorder, which is mainly determined by the interaction of genetic
and environmental factors.52 Potential risk factors include genetic defects, environmental
toxins, drugs, pesticides, focal cerebrovascular damage, brain microtrauma, and type 2
diabetes mellitus.44 Fifteen genes responsible for monogenic forms of PD pathology have
been identified, including SNCA, LRRK2, MAPT, and GBA.45 Although PD is primarily
a movement disorder, patients with PD are 2 to 6 times more likely to develop non-motor
symptoms such as dementia compared to healthy controls.53
In PD, microglia are activated by α-synuclein fibrils in neurons, dendrites, presynaptic
terminals and glia46, 54 resulting from the mutation of the GBA1 gene which encodes the
lysosomal hydrolase β-glucocerebrosidase. The mutation in the GBA1 gene results in the
decreasing activity of β-glucocerebrosidase leading to lysosomal dysfunction and
deposition of its substrate “glucosylceramide” and related lipid derivatives.
Consequently, decreasing glucosylceramide levels may influence the loss of neuron
activity since this substrate is important in stabilising the toxic oligomeric form of α10

synuclein.50 Until recently, α-synuclein has become a valuable marker for PD but the
combined evaluation of oligomeric and phosphorylated α-synuclein in the CSF seems to
be more accurate for PD diagnosis and prognosis.55 However, the loss of
glucosylceramide activity is not the only neuropathological factor in PD as microglial
upregulation and an increase in astroglia cells and lymphocyte infiltration also occur in
the brain.47

1.2 Introduction to Neurodegenerative Diseases Imaging
In an era of disease-modifying therapies (DMTs), molecular imaging has the potential to
revolutionize diagnostic medicine that allows the visualization, characterization, and
quantification of pathophysiological processes at a cellular and molecular level without
disturbing living subjects.56-57 This technique has been widely employed in many aspects
of biomedical applications, especially in early detection and for studying various
pathologies, including neurodegeneration, inflammation, and cancer.58 Therefore,
effective imaging using advanced modalities has been highly sought in modern medicine,
which can be achieved using high spatial and temporal resolution combined with
exceptional sensitivity imaging modalities. Consequently, it is necessary to combine
morphological information with in vivo molecular imaging to reveal the real
physiological time-varying processes.59

Initially, the availability of computed tomography (CT) and magnetic resonance imaging
(MRI) greatly contributed to the understanding of dementia. More recently, numerous
imaging modalities such as positron emission tomography (PET) and single-photon
emission computed tomography (SPECT) offer more accurate detection of pathologies,
and are now leading tools for imaging and staging of many diseases, including brain
inflammation as well as in the assessment of novel disease-modifying agents.60-61
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PET-CT (PET combined with CT) imaging using targeted and specific radiolabelled
molecular probes offer excellent potential for the in vivo, non-invasive imaging of
inflammatory processes prior to the onset of neurodegeneration and much earlier than the
corresponding anatomical imaging modalities. Furthermore, the biological information
can be obtained quantitatively in real-time with exquisite sensitivity.62-63 More recently,
fluorescent probes bearing related targeting molecules to those PET have become
valuable tools to complement the use of radiotracers.64 The different imaging modalities
are generally considered complementary rather than competitive, for instance, the use of
several NIRF imaging (optical imaging) probes for in vivo detection of Aβ-plaques.
Although PET/SPECT probes is an established clinical modalities, they are limited by
high cost, radiation exposure, and single signal readout. Therefore, optical imaging may
provide the ideal strategy for the early diagnosis of AD using real-time imaging with the
option of multitargets tracing in vivo and in vitro and high-resolution imaging depending
on the specific technique used.18, 64

The utilization of imaging agents to provide better diagnostic outcomes and most
importantly to develop effective disease-modifying therapies has attracted interest among
clinicians and scientists worldwide. Central to this outcome is the identification of
specific molecular biomarkers that are overexpressed in disease, and subsequently the
discovery and development of highly specific imaging probes that target these
biomarkers. The identification of reliable biomarkers in the biological system is crucial
for optimizing precise diagnostic processes and to study the biochemical processes
associated with inflammation and neurodegenerative disease. Considerable progress has
been made to understand biological mechanisms underlying the pathogenesis of
neurodegenerative diseases, resulting in a number of potent imaging agents targeting
biomarkers which are involved in the progression of the disease. Therefore, biomarkers
12

have played a crucial role in the early identification of disease progression using advanced
imaging modalities.65

Neurodegenerative conditions are increasingly being realized to have common cellular
and molecular mechanisms, and are found to be associated with the accumulation of
filamentous and/or soluble oligomeric aggregates of a specific protein in the affected
brain region.66 Thus, inflammatory conditions have been proposed as a very common and
viable cellular mechanism that is strongly associated with deteriorating cellular and
protein conditions leading to neurodegenerative disorders.9

Currently, biological fluids in the CSF are extensively studied to explore suitable markers
underlying pathological processes in the CNS of affected individuals.67 However, the
subtle and transient nature of inflammatory markers in the CNS has made them difficult
to detect, study, and measure. Even though PET and SPECT imaging have demonstrated
the capability to detect the presence of inflammatory conditions caused by microglial and
astrocyte activation by observing the upregulation of specific protein, predicting the
appropriate time for imaging has been difficult in routine clinical settings. Consequently,
a simpler, non-invasive, and inexpensive in vitro test, for example using fluorescent
probes that enable the detection of pro-inflammatory biomarkers would be highly
desirable and serve as the decision point for further, more expensive PET or SPECT
imaging.68 Therefore, a more comprehensive procedure in the detection of
neurodegenerative diseases has been proposed by our research group (Figure 1.3). In this
approach, patients with early clinical symptoms (e.g. memory loss, tremor, and mild
cognitive impairment) can undergo simple in vitro blood or CSF biomarker test (nonimaging procedure), for instance using a specific fluorescent probe. If the test indicates
an abnormal feature of the certain protein (biomarker), further PET imaging using TSPO
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radiotracers is needed. Subsequently, after the presence of neuroinflammation is
confirmed by both non-imaging and TSPO radiotracer imaging, the diagnosis procedure
will proceed to the next level exploiting tau PET ligands to further investigate the
progression and severity of the disease. Although this strategy looks ideal, simple insults
such as infection and anxiety can also increase TSPO level in a transient manner,69 and
therefore such effects need to be taken into account.

Cannot justify
PET or SPECT
imaging at this
stage

Early clinical
symptoms, e.g.
memory loss, tremor

Early stage
biomarkers, e.g.
TSPO

Note: it could be a
simple paper or
haematocrit tube test
for upregulation of
TSPO

Note: no good
fluorescent TSPO
available-clinical
need NOT met

If +ve
test

Proceed to PET-CT
imaging using
TSPO radiotracers

This fluorescent
probe can be used for
other applications
such as in vivo
imaging in animal

CSF biomarker test
e.g. fluorescent
TSPO probe

Note: many TSPO
ligands availableclinical need is met

Figure 1.3. Screening and early detection strategies in patients with neurological symptoms in
nuclear medicine.

Studies have also suggested that specific CSF constituents are associated with prognosis,
disease progression, and severity of cognitive decline. Although the biochemical feature
of CSF constituents is associated with inflammatory conditions that lead to abnormal
protein cleavage, folding and aggregation, how early this happens and at what stage is
this occurring are not fully understood. Thus, the lack of suitable biomarkers for specific
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diagnosis of neurodegenerative diseases such as DLB, FTD, and vascular dementia
remains a big challenge.67

A highly relevant molecular target that is overexpressed in inflammatory tissue following
inflammation and neuronal damage is the translocator protein 18 kDa (TSPO), formerly
known as the peripheral benzodiazepine receptor (PBR).70 The TSPO is highly
overexpressed in AD,71 PD,72 MS,73 HS,74 atherosclerosis,75 stroke,76 arthritis,177 type 1
diabetes,78 Crohn's disease,79 and epilepsy patients.80 Hence the ability to assess and
quantify the expression levels of TSPO in living subjects using PET-CT would greatly
facilitate research into the causes, diagnosis, and treatment of neurodegenerative diseases.
Other protein markers such as tubulin-associated unit (tau), p-tau, and Aβ peptides in the
CSF were found to correlate with β-amyloid plaque and NFTs in the brain which are
typical but not restricted to AD.67 Beside AD, accumulation of tau protein was observed
in other diseases (known as tauopathies), including FTD, frontotemporal dementia with
parkinsonism (FTLD-17), and Pick’s disease.30 In FTD, FTD-tau protein is commonly
accepted as a valuable marker for diagnostic purposes. Nevertheless, imaging FTD can
be challenging as tau inclusions are present in other neurodegenerative diseases.81
Additionally, misfolded proteins were also found in many neurodegenerative diseases,
for example in HT, which is characterized by an expanded CAG repeat in the Huntingtin
(HTT) gene on chromosome 4.74
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1.3 Microglia and TSPO in Neuroinflammation
1.3.1 Microglial Phenotypes
Microglia are the most abundant of the resident macrophage populations in the central
nervous system, and play a significant role in establishing and maintaining the function
of the nervous system.7, 82-83 As resident immune cells, it is the microglia that respond to
brain injury or disease, and as a consequence of CNS imbalance, microglia undergo
changes from a resting phenotype to an activated phenotype.84-85 They are widely
distributed throughout the brain and account for almost 10% of the total glial cell
population within the CNS.86

The presence of pathogens, trauma, infection, stroke, and degenerative disorders may
stimulate the activation of microglia, cause the release of proinflammatory, chemokines
and cytokines.71 Consequently, nearly all brain diseases show the presence of activated
microglia cells in the areas of progressive disease or abnormal tissue. As part of the
macrophages (histiocytes), microglia play a significant role in human neurogenerative
diseases such as AD and PD, epilepsy, multiple sclerosis, HIV-associated dementia,85
along with neuronal damage and inflammation.87

Active brain disease causes a change in the phenotype of the microglia. This change is
correlated with the de novo expression of the TSPO.88 More importantly, the expression
levels of the TSPO seem to parallel the activation state of the microglia and astrocytes.89
This suggests that the presence of a large amount of TSPO in the nervous system typically
correlates with a disease event, often correlating with neurological or cognitive deficits.88
Accordingly, the TSPO has been considered as an important and sensitive marker of
microglial-astrocyte activation and thus inflammation, with extensive studies focused on
measuring and monitoring changes to TSPO expression in CNS disorders, including
16

AD.90-91 As neuroinflammation is associated with increased levels of TSPO binding sites
for TSPO radiotracers, the TSPO is considered as a biomarker of inflammation and that
PET imaging of TSPO is being investigated as a means of monitoring neuroinflammation
and neurodegeneration in preclinical and clinical studies (Figure 1.4).92-93

Neuroinflammation

Healthy Brain

Abnormal Brain/Inflammation
Upregulation!

Normal state

TSPO

Mitochondrion

TSPO

Mitochondrion

Figure 1.4. Schematic illustration of TSPO expression in the healthy and abnormal brain affected
by neuroinflammation. TSPO is overexpressed in response to brain inflammation.

1.3.2 Structure of the TSPO
The TSPO is a five trans-membrane helical structure forming a hetero-oligomeric
complex with the 32 kDa voltage-dependent anion channel (VDAC) and the 30 kDa
adenine nucleotide translocase (ANT), that together constitute the mitochondrial
permeability transition pore.94-95 The TSPO is an evolutionary, well-conserved protein
mainly located on the outer mitochondrial membrane where it has been reported to be
involved in several cellular functions, including cholesterol transport, steroidogenesis,
inhibition of reactive oxygen species, induction of apoptosis, regulation of immune
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functions, mitophagy, transport of porphyrin, heme synthesis and stress sensing.96-98 This
receptor is also ubiquitously expressed in peripheral tissue (e.g. steroid producing tissues,
heart, kidney, lung, immune system), and in lower concentrations in the central nervous
system, where it is mainly located in the parenchymal glial cells, ependyma, choroid
plexus, and olfactory bulb.88, 99

Although the TSPOs are primarily located in the outer mitochondrial membrane of the
cells, they have also been reported in red blood cells, which are devoid of mitochondria,100
as well as in the plasma membrane of certain peripheral organs, such as the liver.101 Other
studies suggest that low concentration of TSPO may be localized to adrenal glands, male
and female gonads,96 and nucleus and perinuclear area in malignant human breast
cancer.102 Therefore, it is suggested that TSPO is predominantly mitochondrial although
some other tissue regions of expression are possible.

TSPO interacts with the mitochondrial permeability transition pore and binds with high
affinity to cholesterol and different types of ligands.96, 103 This receptor is relatively
sensitive to a wide variety of CNS imbalances and rapidly becomes activated in response
to a pathological incident.104 In the normal brain, there is low TSPO expression on
microglia. However, TSPO expression is increased after brain injury and inflammation.
It is also upregulated in neurodegenerative conditions.105 Moreover, studies suggest that
elevated TSPO levels are well documented in oncology and have been linked with disease
progression in brain, breast and prostate cancer.106

The TSPO gene is located on chromosome 22q13.3 and contains four exons and encodes
169 amino acids. The TSPO receptor is obtained from an alternative splicing variant
named PBR-S lack exon 2, which consists of an open reading frame that differs from
TSPO.107 A recent study has revealed that a single-nucleotide polymorphism in exon 4
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has a predominant effect on ligand-binding. There are two different forms of TSPO, coded
by the rs6971 single nucleotide polymorphism (SNP). The fact that TSPO has two
different forms was first shown through PET study using [11C]PBR28.108

1.3.3 Interaction of TSPO with Ligands
Many studies showed that brain-related disorders were associated with a change in the
functional state of microglia with the number of reports relating to this covering a wide
range of research fields. For instance, a comprehensive study of TSPO ligand binding on
activated microglia using PK11195 6 (see page 24) in the brain disorder was reported by
Banati and colleagues (2002). It was confirmed that neuroinflammation and hence
activation of the resident microglia resulted in a large increase in the expression of the
TSPO.

Microglial activation with the concomitant increase in the ligand binding site after nerve
injury can be observed as a retrograde or anterograde microglial reaction in the gracile
nucleus after sciatic nerve injury. Trans-synaptic microglial activation is not commonly
seen in acute brain disorder, however, it can be relevant in human brain diseases where
pathological states can persist for decades.109 A study by Bolmont and colleagues (2008)
revealed that in AD pathology, microglial aggregation around amyloid plaques was
increased, and the release of cytokines causing neuronal death was also observed.110
Accordingly, it has been hypothesised that dysfunctional microglia could play a crucial
role in amyloid plaque aggregation.71

The structure of the TSPO provides fundamental information regarding its function as
well as its interaction with some ligands. Several techniques have been used to investigate
the topology of TSPO, including crystallographic, hydrophobicity analysis of the amino
acid sequences, and molecular dynamics simulations. Hydrophobicity analysis of the 169
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amino sequences of TSPO revealed the presence of five hydrophobic regions in each of
the receptor. Moreover, the investigation of the pentahelical structure by crystallographic
analysis suggested that the intramitochondrial N-terminal was shorter than
extramitochondrial C-terminal. Furthermore, the molecular dynamic study suggested that
the α-helices were too short to cross the whole bilayer membrane. It was also suggested
that five transmembrane α-helices can form a groove of approximately 3-4 Å to
accommodate cholesterol transport.111

The model structure of TSPO was described by Jeremko and co-workers (2014). They
revealed that TSPO is formed by an integral membrane protein consisting of five
transmembrane alpha-helices, two extramitochondrial loops, two intramitochondrial
loops, one extramitochondrial C-terminus, and one intramitochondrial N-terminus.112
Previous studies reported TSPO as a monomer but recent studies revealed that it can form
oligomeric complexes with itself and other proteins. It has also been indicated that TSPO
can transform to homo-oligomers which provides a binding site for cholesterol.113 Further
study on the C-terminal peptide (sequences 144-169) showed that the helical
conformation for the L144 to S159 was important for cholesterol binding sites.88

In addition, a model of ligand binding sites was proposed by Liauzun and colleagues
(1997) (Figure 1.5), which showed that a specific ligand can bind to certain amino acid
sequences, for instance PK11195 6 (see page 23) can bind to arginine, glutamic acid,
leucine, proline, serine, and tryptophan, much like a key fits into a lock. It was also
revealed by amino acid sequence analysis that C-terminus, to which cholesterol can bind,
was highly charged.111
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Figure 1.5. The topology structure of TSPO and ligands binding sites in the membrane proposed
by Liauzun and colleagues (1997).111 Image reproduced from ref. 111.

1.4 Radiopharmaceuticals
Radiopharmaceuticals are pharmaceutical formulations composed of a radioactive
substance (molecules labelled with radioisotopes), for specific localisation in distinct
regions and tissues in the body, which are intended for use either in diagnosis or treatment
of disease. In nuclear medicine, radiopharmaceuticals can be injected into the body and
the energy emitted can be detected by the non-invasive imaging modalities using PET or
SPECT, thus providing functional information of the target tissue or organ (Figure 1.6).
This technique relies on the radiopharmaceutical agent binding to a specific tissue or
organ

system

in

a

selective

manner.114-115

Additionally,

several

metabolic

radiopharmaceuticals (e.g. fluorodeoxyglucose ([18F]FDG)) can be phosphorylated by
hexokinase in high glucose using cells such as brain, kidney, and cancer cells as a result
of uptake mechanism.116
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Figure 1.6. The basic principle of PET and SPECT in providing target organ/tissue image:
comprehensive detection via a fixed camera (PET) vs direction-selected detection via a rotating
camera (SPECT).117 Image reproduced from ref. 117.

The field of nuclear imaging using PET and SPECT has recently experienced significant
advances in the area of neurodegenerative diseases. PET and SPECT supply a variety of
applications for in vivo brain imaging. Developed in the 1950s, PET imaging has become
an important research and routine clinical tool. It provides excellent image visualization
for non-invasive applications, including detection of radiotracer biodistribution in the
human body through emitted energy determination in sub-nanomolar level. Thus, PET is
one of the most powerful modalities to detect and analyse the progression of the disease
(staging) in neurodegenerative pathologies.118 In the body, radiotracers based on
radionuclides carbon-11 and fluorine-18 undergo radioactive decay, subsequently
producing small particles called positrons which annihilate upon collision with electrons
to produce γ-rays that are detected and measured by PET cameras. The energy decay
visualizes the topology of specific biological targets and determining the physiological
processes involved in the disease.119
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To date, more PET tracers are labelled with fluorine-18 (t1/2 = 109.77 min) rather than
carbon-11 (t1/2 = 20.38 min) to enable regional distribution to imaging facilities without a
cyclotron.120 Until recently, PET imaging is still an extremely powerful tool for the
purpose of non-invasive detection of neurodegenerative diseases. However, the main
limitation of PET imaging is its low spatial resolution and lack of anatomical reference
frame. For this reason, multimodality imaging devices that combine PET with CT or MRI
have to a large degree ameliorated these limitations. SPECT imaging is considerably less
sensitive tool compared to PET but is less expensive, and more clinically available for
medical use. This modality provides 3D images using a different nuclear decay
mechanism from specific radioisotopes (e.g. indium-111, iodine-123, and technetium99m) which takes place with the emission of a γ ray (energy of which depends on the type
of the radioisotope).117, 121

1.4.1

Radiolabelled TSPO ligands

Most of the physiological processes are associated with the interaction of small biological
molecules or even relatively big molecules (e.g. polypeptides) with their cellular
receptors. One of the most interesting trends in the area of nuclear medicine is the
interaction of receptor active sites with numerous small ligands, for example the
interaction of activated microglia (TSPO) with some ligands in brain disorders. Evidence
suggested that TSPO can bind to putative endogenous ligands, including protoporphyrin
IX and cholesterol.122

Studies have also revealed that TSPO binds a range of synthetic ligands such as first
generation TSPO radiotracers: isoquinoline carboxamides (e.g. [11C]PK 11195 6)123 and
benzodiazepines (e.g. [11C]Ro5-4864 7)124 (Figure 1.7); second generation TSPO
radiotracers: imidazopyridines (e.g. [123I]CLINDE 8125 and [11C]CLINME 9124), 2-aryl23

8-oxodihydropurine acetamides (e.g. [18F]FEDAC 10),126 phenoxyarylacetamides (e.g.
[18F]DAA1106 11),127 aryloxyanilides (e.g. [11C]PBR28 12),128 (Figure 1.8); and new
generation TSPO radiotracers: trycyclic indoles (e.g. [18F]GE180 15)129 (Figure 1.10).
These radiotracers have been used for imaging cancers and neuroinflammation.

Benzodiazepines are important drugs that have been used routinely for muscle relaxants,
anticonvulsants, anxiolytics, and sedative-hypnotics. These effects arise by the mediation
of central benzodiazepine receptors (CBRs) located in the central nervous system.130 The
classic benzodiazepine, Ro5-4864 7 (4'-chlorodiazepam-class molecule) was the first
ligand able to differentiate the TSPO from CBR. A binding study of [11C]Ro5-4864 7 in
patients with brain tumours show high non-specific binding and low affinity in human
brain tissue.124 [11C]Ro5-4864 7 has also shown neuroprotective properties to reduce βamyloid deposit in neurodegenerative animal models.105

[11C]PK11195 6

[11C]Ro5-4864 7

Figure 1.7 First generation radiolabelled TSPO ligands.

PK 11195 6 is the first nonbenzodiazepine ligand identified to bind the TSPO with high
affinity, and broadly used ligand along with Ro5-4864 7 in animal models and humans
with numerous CNS diseases. The PK 11195 6 binds to the peripheral benzodiazepine
receptor, in particular, in peripheral organs and haematogenous cells associated with γaminobutyric acid (GABA)-regulated channels. Interestingly, this ligand only binds with
active microglia and not resting microglia. The binding properties of [11C]PK 11195 6
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ligand in patients with AD and MS was associated with the increased activation of
microglia. These findings indicate that the TSPO might be a clinically useful biomarker
for imaging such diseases using PET.109

The binding sites of PK11195 6 can also be found in non-mitochondrial fragments of the
brain and mitochondrial-free erythrocytes.131 A study by Gavish et al. (1992) revealed
that PK11195 6 showed superior binding affinity to TSPO in both mice and rats as
compared with Ro 5-4864 7.130 Moreover, a binding study using membranes from rat
kidney tissues and radiolabelled ligand [3H]-PK11195 demonstrated that the affinity of
PK11I95 6 was 9.3 nM (Ki). This study also revealed that PK11195 6 had high selectivity,
indicated

by

its

low

activity

in

central

benzodiazepine,

benzodiazepine,

catecholaminergic, GABAergic, and opiate receptors.122

PK11195 6 labelled with radioisotope carbon-11 for in vivo PET imaging studies in the
animal model and patients with neurodegenerative diseases (e.g. AD, PD, ALS, HD,
FTD, and MS) have demonstrated varying degrees of success. Despite some encouraging
in vitro data, the low signal to noise ratios has limited the use of [11C]-PK11195 6 in in
vivo imaging studies.132 Consequently, several second generation TSPO-selective ligands
have been developed from different structural classes to visualise activated microglia
using both PET and SPECT imaging.
The imidazopyridines derivative,

123

I-CLINDE 8 has raised significant interest as it

demonstrated a high binding affinity for the TSPO. In vitro binding assays in adrenal,
kidney, and cortex mitochondrial membranes demonstrated that the ligand binds to TSPO
with affinities of 12.6, 0.20, and 3.84 nM (Kd), respectively.133 Another member of the
imidazopyridines class, [11C]-CLINME 9, was reported with improved imaging
compared to [11C]PK11195 6 in PET imaging of rodents induced with local acute
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neuroinflammation.124 In a different example, the binding affinity of [11C]-CLINME 9 is
at least as efficient as [11C]-PK 11195 6 and [18F]-PBR111 14.134
[18F]DAA1106 11 has also received much attention due to its high affinity for the TSPO
and selectivity over CBR. In a binding study using crude mitochondrial of rat whole brain,
DAA1106 11 showed an affinity (IC50) of 0.28 nM.135

[123I]CLINDE 8

[18F]FEDAC 10

[11C]CLINME 9

[18F]DAA1106 11

[11C]PBR28 12

Figure 1.8 Second generation radiolabelled TSPO ligands.

PBR28 12 has been used in vivo to study several CNS diseases, including epilepsy, AD,
and MS.80 Although this tracer has shown previously to be able to displace PK11195 6 in
vitro, the quantification of the in vivo binding has been limited by the lack of a valid
reference region.136 More recently, PBR28 12 analogue, [11C]ER176 demonstrated a 4
times higher of binding potential relative to nondisplaceable uptake (BPND) for HABs
compared to [11C]PBR28 12.137-138

In 2008, Fookes and colleagues described a new series of chemically related derivatives
of imidazopyridines PBR102 13 and PBR111 14 (Figure 1.9) for visualization of the
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TSPO, all containing fluorine in their structures, which therefore led to the potential
labelling with fluorine-18. All ligands were evaluated for TSPO affinity, and found to be
potent and selective with Ki for the TSPO and CBR were 3.7 – 5.8 nM and 800 – > 5000
nM, respectively.139

PBR102 n = 1 13
PBR111 n = 2 14
Figure 1.9 Second generation of 18F-labelled TSPO ligands.

[18F]GE180 (futriciclamide) 15, a new generation of TSPO tracer exhibited high signal in
the area of inflammation, low non-specific binding properties, and low radiometabolites
signals in preclinical models of middle cerebral artery occlusion and AD. Thus,
[18F]GE180 15 provides better imaging properties than [11C]PK11195 6 and
[18F]DPA714. However, in in vivo studies on MS patients, [18F]GE180 15 showed a low
volume of distribution, suggesting low brain penetration, and it has been suggested that
this low uptake produces an image quality that is not sufficient to detect differences in
binding to low affinity binders (LABs) and high affinity binders (HABs).140

Figure 1.10 Structure of [18F]GE180 15.
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1.4.2 Radiolabelled Tau Ligands
Development of therapeutic strategies for neurodegenerative diseases has proven difficult
with clinical diagnostic accuracy at 60-80%. In response to this issue, significant efforts
have been made to develop radiopharmaceuticals that exhibit better diagnostic outcomes.
In the field of AD, several radiotracers have been developed for amyloid imaging, which
allowed visualization of Aβ-plaque in vivo, including [11C]-Pittsburgh compound B
([11C]PiB) 16, [11C]SB13 17, [18F]BAY94-9172 (Florbetaben or Florpyramine) 18,
[18F]AV-45

(Florbetapir)

19,

[18F]flutemetamol

20,

[18F]AZD4694

21,

and

[11C]AZD2184 22 (Figure 1.11).141

[11C]PiB 16

[11C]SB-13 17

[18F]BAY94-9172 18

[18F]AV-45 19

[18F]flutemetamol 20

[18F]AZD5694 21

[18F]AZD2184 22

Figure 1.11 Structure of several 11C-labelled and 18F-labelled radiotracers for imaging Aβ-plaque
in Alzheimer’s disease patients.
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Among those radiotracers, [11C]PiB 16 is one of the most investigated amyloid imaging
agents used for visualization and quantification of Aβ-plaque which binds with high
affinity to the β-pleated sheet aggregates in AD. However, it is believed that more than
one neurodegenerative disease may associate with amyloid pathology (e.g. AD and DLB),
thus amyloid imaging alone is inadequate to differentiate dementia subtypes.120

Human postmortem studies have demonstrated that the density of NFT highly correlates
with neurodegeneration and cognitive decline in AD-type dementia. Therefore, it was
suggested that tau protein is a more selective biomarker for AD.142 To develop effective
tau imaging ligand, several factors need to be considered, including 1) Intracellular
deposition: suitable tau ligands are non-toxic lipophilic molecules with high cell
membranes as well as blood-brain barrier (BBB) permeability. Therefore, low molecular
weight molecules have been developed as tau PET tracers. 2) Different conformations of
tau proteins: tau proteins have six isoforms with either 3-repeate (3R) or 4-repeate (4R),
and multiple post-translational modifications, and therefore good tau ligands should
exhibit a wide spectrum binding availability in multiple ultrastructure of tau aggregates.
3) Selectivity over β-amyloid: tau ligands are expected to bind tau protein fibril in high
affinity (nanomolar/sub nanomolar/picomolar) and should be highly selective over βamyloid.143-144

Despite the challenge inherent in imaging tau, encouraging results toward the
development of potent tau radiotracers were reported over the last few years. To date,
several first generation radiolabelled tau ligands have been designed and evaluated in in
vitro and clinical investigation, including [18F]FDDNP 23,145 [18F]THK5117 24,
[18F]THK5351 25,146 [18F]T807 (AV-1451) 26, [18F]T808 (AV-680) 27141 (Figure 1.12)
and PBB1-PPB5 28-32 (Figure 1.13).35
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[18F]FDDNP 23

[18F]THK5117 24

[18F]THK5351 25

[18F]T807 26

[18F]T808 27

Figure 1.12 Structure of first generation tau radiotracers.
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Figure 1.13 Structures and design of PBB compounds (PBB1 – PBB5) for labelling with carbon11.

[18F]FDDNP 23 was the first PET tracer developed to visualize tau pathology in living
human subjects, binding to both Aβ-plaques and tau protein. Unfortunately, due to lack
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of specificity and selectivity in vivo, it has been replaced by tau or Aβ-specific ligands.145
However, the discovery of [18F]FDDNP 23 was an important milestone for both amyloid
and tau PET imaging in AD.30

In 2013, a class of potent and specific ligands for tau, PBB1-PPB5 28-32 was discovered,
based on the structure of the pyridinylbutadienylbenzothiazole. The most promising of
this series, PBB3 30 has a 50-fold higher affinity to tau over Aβ-plaques. Although in
vitro data looks promising, this radiotracer suffers from stability issues.147 It is suggested
that [11C]PBB3 30 was photoisomerised by fluorescent light, which limited its application
in in vitro study and in vivo acquisitions.148 In addition, [11C]PBB3 30 utility was
hampered due to high white matter uptake, low target to white matter ratio, and its fast
metabolism in vivo.145

The THK series of tau ligands were developed at Tohuku University, Japan, with the most
widely used being the 2-arylquinoline derivatives [18F]THK5117 24 and [18F]THK5351
25. [18F]THK5117 24 demonstrated favourable imaging properties, indicated by higher
grey matter and lower white matter uptake but lower lipophilicity.145 In the preclinical
study, [18F]THK5351 25 demonstrated a greater binding affinity for hippocampal
homogenates from AD brain section and faster dissociation from the white-matter tissue
as compared with [18F]THK5117 24. Moreover, autoradiography data of [18F]THK5351
25 showed selective binding to neurofibrillary tangles with a better signal to background
ratio.146 However, recent developments have shown that [18F]THK5351 25 also exhibits
binding to monoamine oxidase B (MAO-B), thus compromising its selectivity and
specificity for tau protein aggregates.149
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More recently, promising results toward the development of selective imaging agents for
tau were reported, including the benzimidazole pyrimidine derivatives, [18F]T807 (AV1451) 26 and [18F]T808 (AV-680) 27, developed by Siemens Molecular Imaging
Biomarker Research Group. These radiotracers displayed excellent binding affinity for
tau aggregates with Kd values of 15 and 22 nM, respectively and > 25-fold selectivity for
PHF-tau over Aβ-plaque.141 Autoradiography data showed that [18F]T807 26 binding
colocalized with tau filaments, but not with Aβ-deposit, α-synuclein, and TDP-43 protein
deposits, suggesting that the radiotracer has good selectivity properties.144

In a search for new tau PET tracers with improved affinity, selectivity, and other
pharmacokinetic properties, second generation of tau ligands were designed and
synthesised, including [18F]RO-948 33,144 [18F]MK6240 34,150 and [18F]JNJ311 35,151
and [18F]PM-PBB3 36 35 (Figure 1.14).

[18F]RO948 33

[18F]MK6240 34

[18F]JNJ311 35

[18F]PM-PBB3 36

Figure 1.14 Structure of second generation tau radiotracers.

Developed by Roche, [18F]RO948 33 was identified as a promising tau radiotracer, with
desirable clinical profile and kinetic characteristic. The tracer demonstrated a high affinity
for tau and superior selectivity against Aβ-plaques in AD brain tissues. Additionally,
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[18F]RO948 33 displayed a low binding affinity for MAO-A and MAO-B, and suitable
pharmacokinetic and metabolic properties in preclinical studies.144
In 2016, a new tau PET tracer [18F]MK6240 34 was discovered by Merck laboratory.
[18F]MK6240 34 has high specificity and selectivity for tau as well as suitable
physicochemical properties and good in vivo pharmacokinetic characteristics.150 In
autoradiography studies, this radiotracer showed a good grey matter/white matter binding
ratio. Self-blocking studies in Rhesus monkey indicated no evidence of off-target binding
in all brain regions, constituting a potential advantage over the widely used [18F]T807
26.148
[18F]JNJ311 35 is another tau PET tracer developed by Rombousts and colleagues (2016)
and has gained much attention due to its appropriate pharmacokinetic profile. It has high
affinity for tau (Ki = 7.9 nM) and selectivity for Aβ-deposits (Ki = > 4300 nM). This
radiotracer also possesses moderate initial brain uptake and rapid brain wash-out.
Radiometabolite analyses in rodents revealed the existence of a polar radiometabolite in
plasma, but not in the brain. Additionally, semi-quantitative autoradiography studies on
postmortem tissue sections of human AD brain demonstrated superior displaceable
binding to tau-rich regions. Results from these biological evaluations suggest that
[18F]JNJ311 35 is a promising tau PET tracer candidate for visualization tau pathology.151152

To overcome several of the drawbacks associated with the [11C]PBB3 30,

18

F-labelled

PBB derivatives, [18F]AM-PBB3 and [18F]PM-PBB3 36 have been developed by the
National Institute of Radiological Sciences in Japan. Preliminary study of [18F]AM-PBB3
and [18F]PM-PBB3 36 in 4 AD patients and 4 healthy controls showed that [18F]AMPBB3 yielded a 1.5- and 2-fold greater dynamic range than its [11C] based predecessor in
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detecting of tau lesions. In addition, these tracers showed greater signal-to-background
ratio and less off-target signals in the basal ganglia.35

1.5 Fluorescent Probes
To complement the application of radiotracers in imaging studies, fluorescence imaging
using the appropriate ligand has been one of the most powerful and popular tools for
visualizing the pathological process.153 To date, advances in fluorescence instrumentation
and probe development provide new opportunities to investigate molecular events
involved in various physiological and pathophysiological processes in cells and in small
animals,154 and be in a position to complement PET, SPECT, and MRI.

The application of fluorescent probes in modern imaging has aided the role of PET. This
can be seen in PET fluorescence imaging probe, which allows the detection of specific
biomarkers expressed on the extracellular membrane, for instance in cancers cells.155
Furthermore, fluorescence imaging could also aid in other biological studies, including
fluorescence studies postmortem, histological tissue analysis,156 fluorescence imageguided surgery (FGS),157 and in vivo preclinical animal imaging.158 The advantages of
fluorescence imaging include simple and relatively low-cost procedures and the use of
non-ionizing radiation in laboratories that are not equipped with handling radioactive
materials.70

Over the last decades, fluorescent probes have been used for visualizing activated
microglia in some diseases by fluorescence microscopy. Moreover, a high-emitting
probe, for instance the near-infrared fluorescence (NIRF) with an emission from 650 to
900 nm has an advantage for in vivo visualization of molecular targets at both microscopic
and macroscopic levels using a light source (e.g. laser light). In this technique, the use of
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fluorescent agents with fluorescence emission in the near-infrared region allows adequate
in-depth penetration of tissue.70

Lately, several NIRF imaging probes for in vivo detection of Aβ-plaques have been
developed, including DANIR 2c 37 and its analogues (MAAD 3 38, DMDAD 3 39,
MCAAD 3 40, and DMMAD 3 41), THK-265 42, curcumin derivatives (CRANAD-2 43,
CRANAD-5 44, CRANAD-17 45), and BODIPY7 46 (Figure 1.15). Most of these
probes exhibit high affinity for Aβ in vitro.18 For example, Ono and colleagues (2009)
showed that BODIPY7 46 had high in vitro affinity for Aβ(1-42)-plaques with Ki value
of 108 nM and clearly stained Aβ-plaques in mouse brain. BODIPY7 46 exhibited peaks
of absorption/emission at 606/613 nm. This probe was also labelled with iodine-125,
serves as dual-functional imaging (SPECT/fluorescent probe).159
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DANIR 2c 37

MAAD-3 38

DMDAD 3 39

MCAAD 3 40

DMAAD 3 41

THK-265 42

CRANAD-2 43

CRANAD-5 44

CRANAD-17 45

BODIPY7 46

Figure 1.15 Chemical structures of several NIR fluorescence probes developed for imaging Aβplaques.

In addition, some TSPO ligands from a variety of structure classes, including 2phenylindolglyoxylamides,160

imidazopyridines,85

benzodiazepines,161

and

phenylquinazolines162 have been developed as potent fluorescent probes for imaging
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activated microglia by fluorescence microscopy, including fluorescent probes from the
conjugation of TSPO ligands with the green fluorophores (47-50) (Figure 1.16)85, 160, 162163

and NIR fluorophores (51 and 52) (Figure 1.17).164

Ki = 19.2 nM162

Ki = 12.0 nM160

47

48

Ki = 0.31 nM163
49

IC50 = 8.34 nM85
50
Figure 1.16 Example of structures of green fluorescent probes for the visualization of TSPO.
Colours represent different structure moieties: blue (ligand), magenta (linker), and green
(fluorophore).
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Ki = 42.0 nM164
51

Ki = 0.91 nM164
52
Figure 1.17 Structure example of NIR fluorescent probes for the visualization of TSPO. Colours
represent different structure moieties: blue (ligand), magenta (linker), and red (fluorophore).

Due to the requirement for facile entry from blood into brain, suitable fluorescent probes
are based on low molecular weight drug-like molecules. Several small polar molecules
may cross the BBB by an intracellular mechanism at the tight junction, but this pathway
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is usually negligible. In general, charged molecules are excluded from passage across the
BBB, except the specific transporter proteins, such as some amino acids and nucleosides.
Additionally, efflux transporter action plays an important role in preventing the delivery
of specific molecules to the brain. Emerging evidence suggests that human efflux
transporters are correlated with P-glycoprotein (P-gp). P-gp is an ATP-dependent active
efflux pump, which leads to lower intracellular aggregation of its substrates. Currently,
tariquidar seems most promising for inhibiting P-gp in human subjects.165-166 Many
developers of drugs for CNS have utilised the logBB (log[brain]/[blood]) values to predict
the ability of a molecule to enter the brain. Generally, a Kp value (concentration ratio of
unbound drug in brain to blood) of > 2, equivalent to logBB > 3, has been sought in CNS
drug discovery. Consequently, several parameters have been developed for predicting BB
values, including molecular size (MW), lipophilicity index (logP), charge (pKa),
molecular volume (Vx), polarity, shape, and hydrogen bonding capability.166

The conjugation of a variety of TSPO ligands with a fluorophore to produce TSPO
fluorescent probes offer significant advantages in biological studies to complement the
use of radiolabelled probes. However, as with the development of highly specific,
selective, and high affinity PET radiotracers, the development of fluorescent or dualmodality PET-fluorescent imaging agents on small drug-like molecules is not only
synthetically challenging,167 but the steric impact resulting from conjugating the
relatively large fluorescent dye on the binding and biodistribution of the imaging agent
towards the biological target has been difficult. The common approach to develop
fluorescent probes has been the attachment of the fluorophore to the parent ligand through
the use of linkers (spacers) to minimise interference between the binding domain of the
targeting ligand and the biological target.70 It is also well recognized that the type and

39

length of the linkers have an enormous effect on the ligand binding affinity, selectivity,
and the pharmacokinetic and pharmacodynamic properties in vivo.158, 160

It is important to note that the majority of TSPO ligands cannot be conjugated directly
with a fluorophore as their structures do not contain the potential binding substituents
such as amino, hydroxyl, methoxy, and carboxylic acid.70 Therefore, molecular
modification of the ligands is required to allow subsequent formation with fluorophores.
Experimental evidence also indicates that the introduction of various substituents on the
ligand appears to be related to the potential binding to the receptor. For instance the
introduction of polar substituents and ionizable functional groups at the 2- and 8- position
of the imidazopyridine skeleton of the ligands led to high affinity for TSPO.168 Similarly,
the effect of halogenation has significantly influenced the ligand binding affinity in the
isoquinoline carboxamides group as reported by Cappelli et al. (2006).169 In addition,
Laquintana and co-workers (2007) showed that the length of the linker as well as the
conjugation position to the ligand seems to influence the fluorescent properties of the
probes.158

In general, a fluorescent probe is a derivative from a known potent ligand that allows
visualization of the target receptor while maintaining a reasonable binding affinity and
selectivity of the parent compound.95 In some applications, the combination of the
fluorescent probe with a radioactive probe (dual-imaging modality) may provide better
outcomes due to their complementary nature and matching sensitivity.64 In principle, an
ideal fluorescent probe should demonstrate some fundamental characteristics such as high
selectivity and binding affinity for the receptor, high quantum yield and a significant
change in fluorescence upon binding to the receptor, high extinction coefficient to avoid
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high excitation power, perfect photostability, and possesses a good blood-brain
penetration.158, 170

1.6 Project Aims
The goal of this project is to design, synthesise, and develop novel high affinity and
selective fluorescent and radiopharmaceutical probes for imaging neurodegenerative
diseases. In order to achieve this goal, the work is divided into two components:

1). The design and synthesis of novel fluorescent probes targeting TSPO (discussed in
Chapter 2). The substituted 2-phenylimidazopyridine-3-acetamide ligands which exhibit
high binding affinity and selectivity have been chosen in this work as an inspiration to
design and synthesise new fluorescent probes for visualization of TSPO-expressing
neurodegenerative diseases. The well-known 7-nitrobenz-2-oxa-1,3-diazol-4-yl (NBD)
54 will be used as the fluorophore as its small size does not generally influence the affinity
of the ligand. Further conjugation of NBD compounds 54 to the acetamide side chain and
phenyl ring of the ligand 53 could generate fluorescent probes 55 and 56, respectively
(Figure 1.18).
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53
R1 = OMe, OH
R2 = OH, NH(CH2CH3)2

54

TSPO ligand scaffold

NBD compound (fluorophore)

Fluoresccent Probes A 55

Fluorescent Probes B 56

Figure 1.18 TSPO ligand scaffolds 53, fluorophore (NBD) 54, and the target molecules
(fluorescent probes 55 and 56).

2). The design and synthesis of novel tau PET ligands for imaging intracellular
neurofibrillary tangles (NFTs)/tau protein (discussed in Chapter 3). This work is inspired
by evidence that in clinical practice, suitable radiotracers for visualization of tau
pathology are still needed. The focus of this work is to overcome the stability issue of the
PBB3 ligand 30 by replacing the photoisomerizable butadiene bridge with a 1,2,3triazole, amide, and ester linker (Figure 1.19). The rational design, synthesis, and
structural optimisation of the target molecules are based on PBB3 30 structure. The
presence of 1,2,3- triazole, amide, and ester linkers will provide the ligand candidates
with better stability. Moreover, the linkers can potentially be functional moieties by
forming hydrogen bonds on the active sites of the tau protein. Subsequently, the number
of carbon atoms (n) will be varied to further explore the hypothesis that these molecules
bind to the same binding pocket (region) as the ligand PBB3 30. Therefore, several novel
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tau ligands (57-62) from the modification of PBB3 30 molecule were selected for
synthesis.

57

58

30
59

60
R1 = OH, OMe, Me
R2 = F, CF3, CN, Me, NO2, OH
X = N, C (H)
n = small alkyl
Figure 1.19 Design of PBB3 30 derivatives by replacing the photoisomerizable butadiene bridge
with 1,2,3-triazole, amide, and ester linkers to produce photostable compounds 57-62 for
visualization of tau pathology.

Therefore, the aims of this project are to:
1. Design and synthesise of novel fluorescent probes 55 and 56 from the conjugation
of substituted 2-phenylimidazopyridine-3-acetamide ligands 53 with 7-nitrobenz2-oxa-1,3-diazol-4-yl 54 (fluorophore).
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2. Determine the binding properties of the fluorescent probes 55 and 56 by obtaining
inhibitory constant (Ki) against [11C]PK11195 from in vitro receptor binding
assay (displacement studies).
3. Evaluate and visualize the specific binding of the fluorescent probes 55 and 56 at
the mitochondrial level by in vitro fluorescence staining and colocalization
studies.
4. Evaluate the transfer of fluorescent probes 55 and 56 from plasma to the brain
(brain uptake), brain wash-out, and fluorescence signals by in vivo real-time twophoton studies.
5. Design and synthesise of novel tau ligands 57-62 that have the potential to be
labelled with an appropriate PET isotope (carbon-11 or ideally fluorine-18) for
visualisation of tau protein.
6. Evaluate and visualise tau pathologies in the brain section of AD patients by in
vitro fluorescence staining studies using tau ligands 57-62.
7. Determine the binding properties of tau ligands 57-62 by obtaining inhibitory
constant (Ki) and % inhibition against [11C]PBB3 30 by heterologous blocking
assay at brain homogenates of AD patients.
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Chapter 2: Synthesis of Novel TSPO
Fluorescent Probes

2.1 2-Phenylimidazopyridine-3-acetamide for the TSPO
While many TSPO ligands labelled with either SPECT or PET isotopes have been
developed in the past decades, it is surprising that only a few TSPO fluorescent probes
have been reported. The first fluorescent probe 66 targeting the TSPO was introduced by
Kozikowski and colleagues in 1997, obtained from a simple two-step synthesis by
conjugating the fluorogenic 4-chloro-7-nitrobenzofurazan (NBD-Cl) 54 to the indole-3acetamide derivative 65 through a hexamethylenediamine linker (Scheme 2.1). The probe
showed a promising affinity for the TSPO at nanomolar levels similar to other
indoleacetamide ligands.171

Scheme 2.1 Synthesis of TSPO fluorescent probe 65 by Kozikowski and colleagues (1997).171
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Subsequently, several papers reported the synthesis and biological evaluation of
fluorescent probes as candidate compounds for in vitro and in vivo imaging of TSPO in
cancers and neurodegenerative diseases. Early in 2007, Laquintana and co-workers
developed several TSPO optical probes and investigated the impact of linkers and ligand
units on binding affinity and fluorescence properties.158 Taliani et al. (2007) described a
series of new probes, suggesting that the polarity of the medium can influence the
quantum yield of the probes.160 By conjugating the pyrazolopyrimidine TSPO ligands
with fluorescein isothiocyanate (FITC), Li and colleagues (2017) discovered seven
candidate optical probes for glioma cell imaging. The most promising candidate bearing
an 8-carbon linker exhibited subnanomolar affinity (Ki = 0.31 nM) for the TSPO.163 Such
outcomes clearly demonstrate that several essential molecular aspects may contribute to
the discovery of potent TSPO fluorescent probes, including the type of TSPO ligand,
fluorophore properties, and the length of the linker (spacer) between ligand and
fluorophore.

In this project, the search for potent TSPO fluorescent probes began with screening the
literature

for

TSPO

ligand

classes,

including

imidazopyridineacetamides,

phenoxyarylacetamides, isoquinoline carboxamides, and benzodiazepines, with the aim
of finding a high affinity TSPO compound for potential conjugation with a fluorophore.
From this screening, the candidate narrowed to the substituted 2-phenylimidazopyridine3-acetamide ligands 53 (Figure 2.1). These ligands, with functional modifications at R1and R2- positions, were found to be highly potent and selective for the TSPO. For
instance, the ligand with the ethoxy and 3-amino-2-fluoropyridine substituents at R1 and
R2, respectively displayed high affinity (Ki = 2.6 nM) and selectivity for the TSPO.172
Moreover,

some

of

the

imidazopyridine

derivatives

exhibited

favourable

pharmacological profiles, and have been labelled either with PET isotopes, carbon-11 (t1/2
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= 20.4 min)172 or with the longer half-life isotope, fluorine-18 (t1/2 = 109.8 min), or with
SPECT isotope (e.g. iodine-123 (t1/2 = 13.2 h)173 for brain imaging TSPO expression in
neurodegenerative diseases.139

Among these ligands were those with branched alkyl chains (dimethyl, diethyl, dipropyl)
and heterocyclic substituents at R1, and halogens (chlorine, fluorine, iodine), hydrogen,
and flexible alkyl chains at R2. The presence of these substituents provides an opportunity
to further modify both R1 and R2 into functional groups such as methoxy, hydroxy, amino,
and carboxylic acid for the attachment of the fluorophore. It was postulated that by
changing R1 or R2, the affinity and selectivity for the TSPO would not be significantly
affected, leading to potent ligand derivatives for TSPO fluorescent probes. Therefore, the
functional modification of 2-phenylimidazopyridine-3-acetamide 53 at R1- and R2position

gave

the

TSPO

ligand

scaffold

67:

2-(6-chloro-2-(4-

methoxyphenyl)imidazo[1,2-a]pyridin-3-yl)acetamide that will be used for the synthesis
of fluorescent probes (Figure 2.1).

Figure 2.1 General structure of 2-phenylimidazopyridine-3-acetamide ligands 53 and the target
TSPO ligand scaffold 67.

2.1.1 General Synthetic Strategy
The synthesis of scaffold 67 can be achieved using standard method A (Scheme 2.2)139
or method B (Scheme 2.3).168 In method A, the synthesis of imidazopyridine 70 is
planned by a standard condensation of commercially available 5-chloropyridin-2-amine
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68 and 2-bromo-4′-methoxyacetophenone 69 in ethanol at reflux. The imidazopyridine
70 subsequently undergoes a Mannich condensation with aqueous formaldehyde (H2CO)
and dimethylamine (NH(CH3)2) in acetic acid (AcOH) solution to give tertiary amine 71,
followed by quaternization with methyl iodide (CH3I) at room temperature (rt) to produce
the ammonium iodide 72. This is a key intermediate in the synthesis which can be
converted to scaffold 67 via nitrile substitution, followed by the hydrolysis of the
intermediate nitrile under strongly alkaline conditions (Scheme 2.2).

Scheme 2.2 General synthesis of scaffold 67 via method A.139
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In method B, the synthesis is planned by a Fischer esterification of acid 73 to give ester
74, followed by bromination to generate bromoketoacid 75. Condensation of
bromoketoacid 75 with 5-chloropyridine-2-amine 69 will give imidazopyridine 76, which
subsequently undergoes hydrolysis to form acid 77. Finally, amidation of acid 77 gives
the target scaffold 67 (Scheme 2.3).

Scheme 2.3 General synthesis of scaffold 67 via method B.168

Both strategies (method A and B) represent a facile and convenient approach to the
realisation of target scaffold 67. In this work, the scaffold 67 was prepared via method A
as described by Fookes and colleagues (2008) with minor modifications,139 as it requires
fewer synthetic steps than method B.
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2.1.2 Synthesis of TSPO Ligand Scaffold 67
2.1.2.1 Synthesis of Imidazopyridine
Synthesis of imidazopyridine 70 from commercially available 5-chloropyridin-2-amine
68 and 2-bromo-1-(4-methoxyphenyl)ethan-1-one 69 was achieved by a standard
condensation procedure139 in 73% yield, and was used in the next step without further
purification (Scheme 2.4).

Scheme 2.4 Synthesis of imidazopyridine 70.

The key step of this reaction was the intramolecular nucleophilic aromatic substitution of
bromide by the pyridine-nitrogen in 2-aminopyridine.174 Evidence of the imidazopyridine
70 formation was seen in 1H NMR spectrum through the appearance of a resonance at δ
8.26, assigned to H3, and a prominent singlet at δ 3.81 assigned to the aryl methoxy group.
The 13C NMR spectrum showed a resonance at δ 117.8, assigned to the C3 of the pyridine
unit. Analysis of the low resolution mass spectrometry (LRMS) spectrum revealed a 3:1
ratio of two peaks at m/z 259 and 261, assigned to the isotopic molecular ions 35Cl [M +
H]+ and 37Cl [M + H]+, confirming the formation of 70.
2.1.2.2 Installation of Dimethylamine Side Chain
The dimethylamine side chain was introduced at 3-position of the imidazopyridine 70 via
a Mannich condensation using aqueous H2CO and NH(CH3)2 at reflux for 18 h, followed
by recrystallisation from EtOH/H2O139 to afford the tertiary amine 71 as a pale yellow
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crystal in 69% yield (Scheme 2.5). The Mannich reaction started with the formation of
the iminium ion from the condensation of NH(CH3)2 and H2CO,175 followed by the
nucleophilic addition of imidazopyridine (enol form) to the iminium ion to generate a
carbon-carbon bond.176

Scheme 2.5 Synthesis of tertiary amine 71 via Mannich condensation.

The 1H NMR spectrum of 71 displayed a prominent singlet at δ 2.16, integrating to six
protons, assigned to the newly introduced tertiary amine. The introduction of the
dimethylamine group was further confirmed by the appearance of a new

13

C NMR

resonance at δ 44.4 assigned to the carbons of the N,N-dimethylamino group. Analysis of
the LRMS spectrum revealed two peaks at m/z 316 and 318 in a 3:1 ratio, assigned to the
isotopic pair of (35Cl [M + H]+ and (37Cl [M + H]+) molecular ions.

2.1.2.3 Quaternization of Tertiary Amine
The quaternization of tertiary amine 71 was realized in 84% yield by reaction with CH3I
in toluene at rt for 48 h to afford the key ammonium iodide 72 as a light yellow solid
(Scheme 2.6).139

Scheme 2.6 Synthesis of key intermediate ammonium iodide 72.
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TLC and NMR analysis indicated that ammonium iodide 72 has low stability at ambient
conditions, and therefore was used in the next reaction step immediately or stored in the
freezer for a limited time. Analysis of the 1H NMR spectrum of 72 revealed a resonance
at δ 2.89 corresponding to the nine protons of the quaternary amine. LRMS spectrum of
72 displayed two isotopic molecular ions at m/z 330 and 332 in a 3:1 ratio, assigned to the
35

Cl [M]+ and 37Cl [M]+, respectively.

2.1.2.4 Nitrile Substitution and Hydrolysis of Ammonium Salt
As described in Section 2.1, scaffold 67 was proposed as a starting point for the new
series of fluorescent probes. The synthesis of 67 was accomplished in 71% yield via a
nitrile substitution, followed by base-promoted hydrolysis under strongly alkaline
reaction conditions in EtOH/H2O (1:1) (Scheme 2.7).139

Scheme 2.7 Synthesis of scaffold 67.

Analysis of the 1H NMR spectrum of 67 revealed the appearance of two broad singlets at
δ 7.80 and 7.24, assigned to the NH2 protons, and the disappearance of key quaternary
amine resonance at δ 2.89 of the starting ammonium iodide 72. The new acetamide unit
was confirmed by the existence of a resonance at δ 170.3 in 13C NMR spectrum, assigned
to the carbonyl carbon. Analysis of the HMBC spectrum indicated that the carbonyl
resonance correlated with proton H1'' while the resonance at δ 160.7, which demonstrated
a three-bond HMBC correlation with a CH3, was assigned to the quaternary carbon C4'.
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A strong three-bond HMBC correlation was present between H1'' and the quaternary 13C
resonance at δ 143.7, assigned to C2 (Figure 2.2).

Figure 2.2 HMBC spectrum of scaffold 67 in DMSO (400 MHz).

The molecular formula of 67 was verified by the presence of two isotopic peaks at m/z
316 and 318 in LRMS that were assigned to the molecular ions 35Cl [M + H]+ and 37Cl
[M + H]+, respectively.

2.2 Toward the Synthesis of TSPO Fluorescent Probes
The molecular structure of scaffold 67 allows the conjugation of a fluorophore unit either
at the acetamide side chain or at the phenyl ring, leading to the synthesis of fluorescent
probes A (55) and B (56) (Scheme 2.8). The well-known NBD-Cl 54 (Figure 1.18,
Chapter 1) was selected as the fluorophore as NBD-containing ligands typically exhibit
a low quantum yield in aqueous solutions and protic environments, but are highly
fluorescent in non-polar media or when bound to membranes or hydrophobic residues in
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the protein pockets.162 Additionally, this fluorophore has demonstrated long emission
wavelength and good cell permeability.177 A further advantage is its small size which does
not generally influence the affinity of the parent ligand.95

The synthesis of fluorescent probes A (55) and B (56) can be achieved by converting the
acetamide group of scaffold 67 to the carboxylic acid, and the methoxy unit to the phenol
group. Scaffold 67 therefore represents a point of divergence for the synthesis of probes
with the attachment of the fluorophore unit possible at either the 3-acetamide side chain
(Path A – probes A) or at the phenyl ring of the imidazopyridine structure (Path B –
probes B) (Scheme 2.8). These positions were selected as they are likely to be most
tolerant of large group substitution whilst maintaining reasonable binding affinity for the
TSPO.158

Scheme 2.8 Two synthetic pathways (Path A and B) to prepare the fluorescent probes A (55) and
B (56) from scaffold 67.
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2.3 Synthesis of TSPO Fluorescent Probes A
2.3.1 General Synthetic Strategy
As part of our strategy to identify structurally novel fluorescent probes with high affinity
and selectivity for the TSPO, we investigated the incorporation of the carbon linker
between the ligand and fluorophore. Previous studies had revealed that this type of linker
could be used to retain reasonable binding affinity and selectivity of the ligand for the
TSPO.95, 158, 160, 162-163, 171

The proposed synthetic pathway of fluorescent probes A (Scheme 2.9) is a four-step
synthesis, beginning with the hydrolysis of scaffold 67 under alkaline conditions to give
the corresponding imidazopyridine carboxylic acid 78. The amide coupling reaction of
acid 78 with the appropriate mono-N-Boc-protected diamine 79a-d will generate the
protected amines 80a-d. Subsequently, Boc deprotection of protected amines 80a-d using
trifluoroacetic acid (TFA) should produce the target ligands 81a-d with different lengths
of carbon linkers, which can undergo condensation reactions with fluorogenic compound
NBD-Cl 54 to afford the fluorescent probes A (55a-d).
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Scheme 2.9 Proposed synthetic pathway of fluorescent probes A.

2.3.2 Synthesis of Fluorescent Probes A
2.3.2.1 Synthesis of Imidazopyridine Carboxylic Acid
Using a base-promoted hydrolysis reaction,178 potassium hydroxide (KOH) was added to
the scaffold 67 in EtOH/H2O (6:1), and the reaction was stirred at reflux for 18 h to afford
the acid 78 in 94% yield (Scheme 2.10).
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Scheme 2.10 Synthesis of imidazopyridine carboxylic acid 78.

Analysis of the 1H NMR spectrum of the acid 78 revealed the disappearance of two broad
singlets at δ 7.80 and 7.24 of the acetamide NH2 protons from scaffold 67 (Figure 2.3).
Confirmation of 78 was achieved through a pair of isotopic peaks at m/z 317 and 319 in
the LRMS spectrum, assigned to the molecular ions

35

Cl [M + H]+ and 37Cl [M + H]+,

respectively.

Figure 2.3 1H NMR spectra (400 MHz, DMSO) of scaffold 67 (top) and acid 78 (bottom). The
letters A and B indicate the two broad singlets corresponding to the NH2 protons.
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2.3.2.2 Amide Bond Formation
The Boc-protected amines 80a-d were synthesised in high yields (74-96%) via amide
coupling179 by condensing the acid 78 with the appropriate mono-N-Boc-protected
diamines 79a-d in the presence of N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide
(EDCl), N-hydroxybenzotriazole (HOBT), and N,N′-diisopropylethylamine (DIPEA)
(Scheme 2.11). Initial experiments were performed in the absence of DIPEA but led to
the slow consumption of starting acid 78, as indicated by TLC analysis, with complete
consumption only observed after 38 h. Moreover, the products were isolated in relatively
low yield (26 – 41%). Therefore, the presence of DIPEA was found to be highly important
for the efficient formation of the amide bond in these compounds.

Scheme 2.11 Amide coupling in the presence of EDCl, HOBT, and DIPEA.

Key 1H NMR and 13C NMR assignments for the target Boc-protected amines 80a-d are
summarised in Table 2.1. Typically, 1H NMR spectra of Boc-protected amines 80a-d
displayed a prominent singlet resonance ranging from δ 1.36 – 1.34, integrating to nine
protons, that was not observed in the 1H NMR spectrum of the starting acid 78. This
singlet was assigned to the newly introduced Boc group protons.
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Table 2.1 Key 1H NMR and 13C NMR assignments for Boc-protected amines 80a-d

1H

Compound
Alkyl chain (n)

80a (n=2)

80b (n=3)

13C

NMR

NMR

Secondary

Boc

Carbonyl group

amine (NH x 2)

group

((C=O) x 2)

3.37 (dt)

6.71 (br s)

1.36

168.7

3.20 (dt)

4.83 (br s)

3.27 (dt)

6.92 (br s)

3.03 (dt)

4.71 (t)

Solvent

CDCl3

157.2
1.34

168.4

CDCl3

156.9

1.58 – 1.51 (m)
80c (n=4)

3.10 (dt)

8.32 (t)

2.95 (dt)

6.78 (t)

1.36

168.0

DMSO

155.6

1.45 – 1.37 (m)
80d (n=6)

3.11 (dt)

8.32 (t)

2.90 (dt)

6.74 (t)

1.36

168.1

DMSO

155.7

1.46 – 1.21 (m)

Analysis of the IR spectra of the protected amines 80a-d revealed a broad absorption
within the range of 3256 – 3344 cm-1, assigned to the NH group. The molecular formulae
of compounds 80a-d were verified by HRMS, with the presence of peaks at m/z 459.1792
([C23H2835ClN4O4]+,

80a),

473.1947

([C24H3035ClN4O4]+,

80b),

487.2105

([C25H3235ClN4O4]+, 80c), and 515.2429 ([C27H3635ClN4O4]+, 80d).

The formation of amide bonds from the union of carboxylic acids and amines utilises the
carbodiimide reagents, such as EDCl continues to be one of the most common synthetic
procedures.180 The mechanism of amide coupling in the presence of EDCI and HOBT181
is shown in Scheme 2.12.
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Scheme 2.12 Mechanism of amide coupling in the presence of EDCI and HOBT. Both the product
pathway (magenta) and the unwanted side reaction (blue) are displayed.181

The first step involves the reaction of the carboxylic acid with EDCl to generate an Oacylisourea intermediate, which undergoes intramolecular acyl transfer, yielding an
inactive N-acylurea by-product, thus consuming the acid starting material without the
formation of the product amide.181-182

To optimise amide bond formation, additives such as HOBT are used for the generation
of active esters capable of efficient acylation of the amino group by reacting with the
active O-acylisourea intermediate. The HOBT ester intermediate can then directly react
with the amine to yield the desired amide and the urea by-product.180 This step can be
accelerated by the addition of a sterically hindered base such as diisopropylethylamine
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(DIPEA/Hünig’s base) or N-methylmorpholine (NMM).183 These bases have been
considered as practical catalysts in amide synthesis due to the low nucleophilic property
of the base itself.184
As one of the possible side reaction, epimerization of the stereogenic α-carbon on the Oacylisourea intermediate can occur through simple enolate formation or via the formation
of the planar 5(4H)-oxazolone intermediate after generation of the O-acylisourea.181
However, the use of HOBT in amide coupling may improve the reaction yield with low
epimerisation levels.179

2.3.2.3 Synthesis of TSPO ligand derivatives
With the goal of this project being the synthesis of fluorescent probes, Boc deprotection
of amines 80a-d was required before conjugations with NBC-Cl 54. Using standard
deprotection conditions,185 an excess of TFA was added to the solutions of 80a-d in
CH2Cl2, before being stirred at rt for 4 h. The reactions proceeded smoothly to generate
ligands 81a-d in high yields (85 – 89%) after purification by flash silica gel column
chromatography (Scheme 2.13).

Scheme 2.13 Boc deprotection of protected-amines 80a-d using TFA.

Analysis of the 1H NMR spectrum of ligands 81a-d revealed the presence of a broad
singlet within the range of δ 3.47 – 8.05, integrating to two protons corresponding to the
free amine group. Additionally, the presence of only one carbonyl resonance in the 13C
NMR spectra of 81a-d provided further evidence for the removal of the Boc-protecting
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groups. The molecular formulae of 81a-d were verified by HRMS, with the presence of
peaks at m/z 359.1263 ([C18H2035ClN4O2]+, 81a), 373.1424 ([C19H2235ClN4O2]+, 81b),
387.1583 ([C20H2435ClN4O2]+, 81c), and 415.1895 ([C22H2835ClN4O2]+, 81d).

The Boc-protecting group is one of the most used for the protection of amines and
alcohols as it is relatively easy to remove either using a large quantity of an acid such as
TFA or a small quantity of a stronger acid such as hydrochloric acid (HCl).186 TFA is
known to deprotect t-butyl carbamates,187 yielding the free amines and two volatile byproducts (CO2 and isobutene).181

The Boc deprotection mechanism is initiated by the protonation of the carbamate oxygen
generating a cationic charge on the oxygen, followed by the heterolytic cleavage of the
O-C(CH3)3 bond to liberate the carbamic acid intermediate and the stable t-butyl
carbocation. Subsequently, proton transfer promotes the spontaneous decomposition of
the deprotonated carbamic acid intermediate to generate CO2 along with the free amine
product, whereas the t-butyl carbocation undergoes deprotonation, yielding isobutene as
a by-product.181

2.3.2.4 Conjugation of TSPO ligands 81a-d with NBD-Cl 54
The ligands 81a-d were then conjugated with NBD-Cl 54 in anhydrous DMF in the
presence of DIPEA to give fluorescent probes 55a-d in moderate yields (42 – 57%) after
preparative TLC plate chromatography (CH2Cl2/MeOH – 93:7) (Scheme 2.14).
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Scheme 2.14 Synthesis of fluorescent probes A (55a-d) by condensation of ligands 81a-d with
NBD-Cl 54.

The probes 55a-d were found to be highly fluorescent in a wide range of solvents (e.g.
MeOH, CH2Cl2, DMSO, dioxane, and H2O) under ambient conditions and upon longwave (λ = 365 nm) UV irradiation (Figure 2.4). This will be explained in detail in Section
2.5.

Figure 2.4 Fluorescent probes 55a-d in MeOH (⁓1.0% (w/v)) upon UV irradiation (λ = 365 nm).

The yields of probes 55a-d were not optimised, and these moderate yields could be due
to the formation of side products, evidenced by the presence of some UV-active
compounds (impurities) along with the product, but no starting materials identified by
TLC analysis. This was not entirely unexpected as NBD-Cl 54 is considered as a highly
electrophilic compound (like other aryl-halide compounds containing electron63

withdrawing substituents)188 that could potentially lead to undesired side reactions. The
impurities from the reaction of ligand 81a with NBD-Cl 54 exhibited intense colours in
solution (CH2Cl2/MeOH (95:5)) (Figure 2.5), and NMR experiments were unable to
determine structures due to insufficient material.

Figure 2.5 Impurities from the crude residue of fluorescent probe 55a were isolated by flash
chromatography over SiO2 gel (CH2Cl2/MeOH – 95:5).

Initially, the crude residue of probe 55a was purified using flash chromatography over
SiO2 gel (CH2Cl2/MeOH – 95:5). However, this method was found to have poor
separation, with a significant intersection between the product and impurities. Hence,
preparative TLC plate chromatography (CH2Cl2/MeOH – 95:5) using PLC silica gel 60
F254 1 mm plates (20 x 20 cm2) was employed to purify probe 55a and other probes (55bd).
Analysis of the 1H NMR spectrum of probe 55a showed eleven resonances in the aromatic
region (including two NH resonances), and provided evidence for the conjugation of the
NBD-Cl 54 unit to ligand 81a. Further analysis of the 1H NMR spectrum revealed a set
of coupled resonances in the aromatic region at δ 8.31 (d, J = 8.5 Hz, 1H) and 6.31 (d, J
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= 8.5 Hz, 1H), corresponding to the two protons of NBD moiety. This was supported by
the correlation of these two resonances in COSY experiment (Figure 2.6). The resonance
at δ 6.31 was assigned to the H5''', an aromatic proton adjacent to a secondary amine
group (NH), while the more downfield resonance at δ 8.31 was assigned to the H6''' due
to the strong electron withdrawing effect of the nitro substituent.

Figure 2.6 COSY spectrum of fluorescent probe 55a in DMSO (500 MHz).

Two resonances at δ 99.3 and 138.2 in the 13C NMR spectrum were assigned to C5''' and
C6''', respectively. Additionally, the 13C resonances at δ 129.5, 125.3, 123.1, 117.6, 114.3
were assigned to carbons (C2', C6'), C7, C5, C8, and (C3', C5'), respectively. These
assignments were supported by analysis of the HSQC spectrum (Figure 2.7).
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Figure 2.7 HSQC spectrum of fluorescent probe 55a in DMSO (500 MHz).

The distinctive imidazopyridine resonances at δ 7.20 (J = 9.5 Hz, 1H) and δ 7.57 (J = 9.5
Hz, 1H) were assigned to the pair of coupled protons H7 and H8, respectively, as
evidenced by COSY correlations, and the presence of a strong three-bond HMBC
correlation between H8 and the quaternary

13

C NMR resonance at δ 119.1, assigned to

C6 (Figure 2.6, Figure 2.8). A more upfield

C NMR resonance at δ 159.4 which

13

showed a strong three-bond HMBC correlation with resonance (H2', H6') was assigned
to C4', a quaternary carbon adjacent to methoxy group (Figure 2.8).
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Figure 2.8 HMBC spectrum of fluorescent probe 55a in DMSO (500 MHz).

In general, the NMR spectroscopic pattern of probes 55b, 55c, and 55d revealed similar
characteristics to those of 55a, with variations due to the different carbon linkers between
the ligand and the fluorophore.
Analysis of the IR spectrum of probe 55a revealed a sharp absorbance at 1523 cm-1,
assigned to the nitro N-O stretch of the NBD moiety. In probes 55b, 55c, and 55d, N-O
nitro fingerprints were observed at 1523, 1506, and 1527 cm-1, respectively. HRMS
analysis revealed a peak at m/z 520.1136, assigned to the molecular ion
[C24H1935ClN7O5]–, which verified the molecular formula of 55a. Confirmation of 55b-d
were provided via peaks at m/z 534.1305 ([C25H2135ClN7O5]–, 55b), 550.1601
([C26H2535ClN7O5]+, 55c), and 578.1911 ([C28H2935ClN7O5]+, 55d).

The proposed mechanism for the formation of probes 55a-d is illustrated in Scheme 2.15.
In the presence of DIPEA, the ligands 81a-d underwent a nucleophilic aromatic
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substitution reactions with NBD-Cl 54 to form a Meisenheimer complex before the
elimination of chlorine atom and generation of the target probes 55a-d. The generation
of Meisenheimer intermediate is a reversible reaction, however, in the presence of DIPEA
the adduct transforms into the NBD-containing product.189 In a nucleophilic aromatic
substitution reaction, the Meisenheimer complex is a crucial intermediate, resulting from
the reaction of electron rich species with aromatic compounds that contain strong electron
withdrawing group, including aromatic nitro compounds.190

Scheme 2.15 Proposed mechanism for the formation of fluorescent probes 55a-d.

The simple aryl halides are not normally susceptible to nucleophilic attack in either SN1
or SN2 reactions. However, this can be changed and nucleophilic substitution becomes
rapid in aryl halides with electron withdrawing groups, such as NO2, and when very
strongly basic nucleophilic reagents are used.191
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2.3.2.5 Synthesis of Fluorescent Probe 83 by Direct Conjugation
To further investigate the role of carbon linkers, and expand structure-activity relationship
(SAR) studies, fluorescent probe 83 was synthesised from the direct conjugation of acid
78 with NBD-NH2 82 (Scheme 2.16). Synthesis of probe 83 started with a nucleophilic
aromatic substitution reaction of NBD-Cl 54 with NH4OH, providing NBD-NH2 82 in
51% yield. Subsequently, NBD-NH2 82 was subjected to acid 78 in DMF in the presence
of EDCI, HOBT, and DIPEA to afford probe 83 in 62% yield after flash chromatography
over SiO2 gel (CH2Cl2/MeOH – 95:5).

Scheme 2.16 Synthesis of NBD-NH2 82, followed by direct conjugation to the acid 78 via amide
coupling, yielding fluorescent probe 83.

Like probes 55a-d, probe 83 was also found to be highly fluorescent in a wide range of
solvents (e.g. MeOH, CH2Cl2, DMSO, dioxane, and H2O) under ambient conditions and
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upon long-wave (λ = 365 nm) UV irradiation. This will be explained in detail in Section
2.5.

Analysis of the

13

C NMR spectrum of 83 revealed four resonances at δ 149.7, 132.8,

131.1, and 124.5, corresponding to the quaternary NBD carbons, and two resonances at δ
138.8 and 112.6, assigned to the tertiary NBD carbons, which were not seen in the

13

C

NMR spectrum of the starting acid 75. A significantly downfield resonance at δ 170.2
was assigned to the carbonyl carbon.
Analysis of the IR spectrum of probe 83 revealed a sharp band at 1539 cm-1, assigned to
the nitro N-O stretch. The molecular formula of 83 was verified by HRMS, with the
appearance of a peak at m/z 477.0714, assigned to the molecular ion [C22H1435ClN6O5]+.

2.4 Synthesis of TSPO Fluorescent Probes B
2.4.1 General Synthetic Strategy
The synthetic approach to the desired fluorescent probes B is shown in Scheme 2.17,
which involves the conversion of scaffold 67 to acid 84 by reaction with AcOH and HBr,
followed by amide coupling with NH(CH2CH3)2. The resulting diethylacetamide 85 is
reacted with the appropriate Boc-protected bromoamine 86a-b to give the O-alkylated
phenol 87a-b. Subsequently, Boc deprotection of O-alkylated phenol 87a-b using TFA
gives the ligands 88a-b with different lengths of carbon linker, which can undergo
condensation reactions with fluorogenic compound NBD-Cl 54 to give probes 56a-b.
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Scheme 2.17 Proposed synthetic pathway of fluorescent probes B (56a-b).

The key point of this strategy was the introduction of diethylamine substituent at the
acetamide side chain of the scaffold 67. It was observed that the binding affinity for the
TSPO was high for the ligands with diethylamine substituent at acetamide side chain.
Moreover, this type of substituent resulted in favourable pharmacokinetic characteristics
in vivo.139, 192
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2.4.2 Synthesis of Fluorescent Probes B
2.4.2.1 Conversion of Scaffold 67
The conversion of scaffold 67 to the acid 84 was achieved by hydrolysis and
demethylation reactions139 in 63% yield (Scheme 2.18).

Scheme 2.18 Hydrolysis and demethylation of scaffold 67.

Analysis of the 1H NMR spectrum of acid 84 revealed the disappearance of two broad
singlets at δ 7.80 and 7.24 and one singlet at δ 3.85 that were seen in the 1H NMR of 67.
Furthermore, a significant downfield broad singlet at δ 10.16 was assigned to the highly
deshielded phenolic proton. The molecular formula of acid 84 was verified through a pair
of peaks at m/z 303 and 305 in LRMS spectrum, assigned to the molecular ions 35Cl [M
+ H]+ and 37Cl [M + H]+, respectively.

2.4.2.2 Introduction of Diethylamine Substituent
Traditional amide coupling179 allowed the incorporating of a diethylamine group to the
acid 84 structure. The substrate acid 84 was reacted with diethylamine in the presence of
EDCl, HOBT, and DIPEA in anhydrous DMF139 to give the diethylacetamide 85 in 74%
yield (Scheme 2.19). During the formation of 85, there was precedent that the phenol
could react with carboxyl group to generate unwanted dimeric and trimeric species, and
therefore to prevent this side reaction, an excess diethylamine (1.8 eq) was added.139
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Scheme 2.19 Synthesis of diethylacetamide 85.

Analysis of the 1H NMR spectrum of diethylacetamide 85 showed two pair of resonances
at δ 3.44 (q, J = 7.2 Hz, 2H) and 3.32 (q, J = 7.2 Hz, 2H), and 1.16 (t, J = 7.2 Hz, 3H) and
1.06 (t, J = 7.2 Hz, 3H), assigned to the diethylamine group. The presence of the new
diethylamine group was confirmed by the

13

C NMR resonance at δ 41.7 and 39.9

(assigned to the (CH2) x 2) and δ 14.1 and 13.1 (assigned to the (CH3) x 2). LRMS
analysis revealed two isotopic molecular ions 35Cl [M + H]+ and 37Cl [M + H]+ at m/z 358
and 360, respectively assigned to 85.

2.4.2.3 Phenol Alkylation
In order to install the carbon linkers, phenol alkylation of diethylacetamide 85 with Boc–
protected bromoamines 86a-b was employed. The reactions were performed in anhydrous
DMF with the presence of 4.0 eq K2CO3 to give the O-alkylated phenol 87a-b in good
yields (71 – 72%) (Scheme 2.20).

Scheme 2.20 Phenol alkylation of diethylacetamide 85 with Boc–protected bromoamine 86a-b.
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Analysis of the 1H NMR spectrum of O-alkylated phenol 87a and 87b revealed a
prominent singlet resonance at δ 1.38 and 1.39, respectively corresponding to nine
protons of the Boc group. Additionally, resonances seen between δ 29.2 – 66.5 in the 13C
NMR spectra were assigned to the methylene carbons of the linkers.

Analysis of the IR spectra of 87a and 87b revealed broad absorption bands at 3458 and
3394 cm-1, respectively, assigned to the aliphatic NH groups. The molecular formulae of
87a and 87b were verified by HRMS via peaks at m/z 501.2269 ([C26H3435ClN4O4]+) and
515.2426 ([C27H3635ClN4O4]+), respectively.

2.4.2.4 Boc Deprotection
The ligands 88a-b were synthesised in 88 – 92% yields by treating O-alkylated phenol
87a-b with excess TFA185 in CHCl2 (Scheme 2.21).

Scheme 2.21 Boc deprotection of O-alkylated phenol 87a-b using TFA.
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Analysis of the 1H NMR spectra of ligands 88a and 88b revealed the disappearance of
the (CH3)3 singlet resonances, which were seen in the 1H NMR spectra of 87a-b.
Additionally, analysis of the 13C NMR spectra revealed the presence of only one carbonyl
resonance, confirming the removal of Boc moiety from 87a-b.

Analysis of the IR spectra of ligand 88a and 88b showed the broad bands at 3303 and
3367 cm-1, respectively, assigned to the aliphatic primary amine group (N-H stretch). The
molecular formulae of 88a and 88b were verified by HRMS, with the presence of peaks
at m/z 401.1744 ([C21H2635ClN4O2]+) and 415.1901 ([C22H2835ClN4O2]+), respectively.

2.4.2.5 Conjugation of TSPO ligands 88a-b with NBD-Cl 54
The final synthetic step towards the synthesis of fluorescent probes B was the conjugation
of ligands 88a-b with NBD-Cl 54. Using identical reaction conditions as described for
the synthesis of probes 55a-d in Section 2.3, the synthesis of probes 56a-b were
accomplished in moderate yields (42 – 44%) after preparative TLC plate chromatography
(CH2Cl2/MeOH – 93:7) (Scheme 2.22). The yields of probes 56a-b were not optimised,
and these moderate yields could be due to the same factors as discussed previously
(Section 2.3).
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Scheme 2.22 Synthesis of fluorescent probes B (56a-b) by condensation of ligands 88a-b with
NBD-Cl 54.

As expected, the probes 56a-b were found to be highly fluorescent in a wide range of
solvents (e.g. MeOH, CH2Cl2, DMSO, dioxane, and H2O) under ambient conditions and
upon long-wave (λ = 365 nm) UV irradiation (Figure 2.9). This will be explained in detail
in Section 2.5.

Figure 2.9 Fluorescent probes 56a-b in MeOH (⁓1.0% (w/v)) upon UV irradiation (λ = 365 nm).
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Analysis of the 1H NMR spectrum of probe 56a displayed a set of coupled protons in the
aromatic region at δ 8.56 (d, J = 9.0 Hz, 1H) and 6.58 (d, J = 9.0 Hz, 1H) corresponding
to the protons H6''' and H5''', respectively (NBD moiety), which was supported by the
correlation of these two resonances in COSY spectrum (Figure 2.10).
Two resonances at δ 99.7 and 137.9 in the 13C NMR spectrum were assigned to C5''' and
C6''', respectively. Moreover, carbon resonances at δ 129.0, 124.8, 123.0, 117.2, 114.7
were assigned to (C2', C6'), C7, C5, C8, and (C3', C5'), respectively. These assignments
were supported by analysis of the HSQC spectrum (Figure 2.11).

Figure 2.10 COSY spectrum of fluorescent probe 56a in DMSO (500 MHz).
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Figure 2.11 HSQC spectrum of fluorescent probe 56a in DMSO (500 MHz).

The resonance at δ 127.0 was assigned to the quaternary carbon C1', which demonstrated
three-bond correlation with symmetric protons (H3', H5') in the phenyl ring. Moreover
the resonance at δ 157.9 which showed a three-bond correlation with the symmetric
protons (H2', H6') was assigned to the quaternary carbon C4' (Figure 2.12).
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Figure 2.12 HMBC spectrum of fluorescent probe 56a in DMSO (500 MHz).

The NMR spectroscopic pattern of probe 56b revealed similar characteristics to those of
56a, except for the resonances generated by the carbon linkers between the ligand and the
NBD moiety.
Analysis of the IR spectrum of probe 56a revealed a sharp absorbance at 1583 cm-1,
assigned to the nitro N-O stretch of the NBD moiety. The analogous N-O absorbance in
probe 56b was observed at 1582 cm-1. HRMS analysis revealed a peak at m/z 564.1762,
assigned to the molecular ion [C27H2735ClN7O5]+, which verified the molecular formula
of probe 56a. Formation of 56b was evidenced via a peak at m/z 578.1919, assigned to
the molecular ion [C28H2935ClN7O5]+.

2.4.2.6 Synthesis of Fluorescent Probe 89 by Direct Conjugation
The reaction of diethylacetamide 85 with NBD-Cl 54 in DMF for 18 h gave fluorescent
probe 89 in 43% yield after flash chromatography over SiO2 gel (CH2Cl2/MeOH – 95:5)
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(Scheme 2.23). The conjugation reaction requires the presence of a base (DIPEA) which
can facilitate deprotonation of phenolic proton of the diethylacetamide 85, followed by
the formation of Meisenheimer complex, and finally the elimination of chlorine atom to
give the conjugated product. This probe was found to have weak fluorescence
characteristics in a wide range of solvents (e.g. MeOH, CH2Cl2, DMSO, dioxane, and
H2O) under ambient conditions and upon long-wave (λ = 365 nm) & short-wave (λ = 254
nm) UV irradiations. This will be explained in detail in Section 2.5.

Scheme 2.23 Synthesis of fluorescent probe 89 by condensation of diethylacetamide 85 with
NBD-Cl 54.

The 1H NMR spectrum of probe 89 displayed ortho coupled resonances at δ 8.67 (d, J =
8.4 Hz, 1H) and 6.84 (d, J = 8.4 Hz, 1H), assigned to the protons H6''' and H5''',
respectively (NBD moiety).

13

C NMR analysis revealed the presence of a highly

deshielded carbon at δ 166.9, which was assigned to the carbonyl carbon.
Analysis of the IR spectrum of probe 89 revealed a sharp band at 1521 cm-1, assigned to
the nitro N-O stretch of the NBD moiety. HRMS analysis verified the molecular formula
of 89 with a peak observed at m/z 521.1340 assigned to the molecular ion
[C25H2135ClN6O5]+.
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2.4.2.7 Attempted Synthesis of Fluorescent Probes 93a-b
The synthesis of fluorescent probes 93a-b was attempted, and the outcomes are
summarised in Scheme 2.24.

Scheme 2.24 Attempted synthesis of fluorescent probes 93a-b.
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The reaction of diethylacetamide 85 with bromoacetates 90a-b gave the acetoxy
derivatives 91a-b in 45 – 47% yields. Subsequent treatment with CsCO3 in MeOH cleanly
converted the acetoxy 91a-b to the alcohol 92a-b in 67 – 69% yields. Although the TSPO
ligand 92a has been reported,7 the corresponding derivative 92b has not previously been
published. In an attempt to synthesise probe 93a, DIPEA (1.4 eq) and NBD-Cl 54 were
added to a solution of ligand 92a in DMF at 0 ºC, and the reaction was stirred at rt for 24
h under N2 atmosphere in the dark (conditions A). TLC analysis indicated that no reaction
had taken place, and after work-up and column chromatography, only ligand 92a could
be isolated (93% recovery). Moreover, the disappearance of NBD-Cl 54 suggested that
undesired side reaction(s) involved this compound had occurred. This was also supported
by the presence of several spots observed in TLC analysis.

The incapability of DIPEA to deprotonate free alcoholic proton was identified as the main
issue in this reaction. Therefore, the number of attempts to conjugate the ligand 92a with
NBD-Cl 54 were performed using stronger bases in the reactions (Table 2.2).
Unfortunately, none of these reaction conditions could give the desired product. In
conditions B, only ligand 92a and several unidentified compounds were observed with
no sign of fluorescent probe 93a after 24 h of reaction time. From conditions C, a large
amount of unreacted ligand 92a (90% recovery after column chromatography) and
several unidentified compounds were observed after a 28 h reaction time. When using a
stronger base (lithium diisopropylamide (LDA)), both ligand 92a and NBD-Cl 54 were
decomposed after 30 min reaction time (conditions D).
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Table 2.2 Attempted conjugation reactions of the ligand 92a with NBD-Cl 54 using
different bases.
Condition
A

B

C

D

E
a

Ligand

NBD-Cl

Base

pKa

Time

Outcomea

25 mg

12 mg

DIPEA

11.00

24 h

No reaction

(1.0 eq)

(1.0 eq)

(1.4 eq)

25 mg

12 mg

TEA

10.75

24 h

No reaction

(1.0 eq)

(1.0 eq)

(3.0 eq)

25 mg

12 mg

(CH3)3COK

17.00

28 h

No reaction

(1.0 eq)

(1.0 eq)

(1.5 eq)

25 mg

12 mg

LDA

36.00

30 min

No reaction

(1.0 eq)

(1.0 eq)

(1.5 eq)

25 mg

24 mg

DIPEA

11.00

24 h

No reaction

(1.0 eq)

(2.0 eq)

(1.4 eq)

Reactions success were monitored by TLC and LRMS analysis. All reactions were

performed at 0º C – rt in anhydrous DMF under N2 atmosphere in the dark.

Due to the limited success of the conjugation procedure described in Table 2.2
(conditions A-D), a final attempt for the synthesis of probe 93a was performed with 2.0
eq NBD-Cl 54 and 1.0 eq ligand 92a (conditions E). Again, TLC and LRMS analysis of
this reaction revealed the presence of unreacted ligand 92a and several impurities
(unidentified) with no sign of the desired fluorescent probe 93a, therefore no work-up
and purification were performed.

With the conjugation reaction unsuccessful, the synthesis of probes 93a-b using the
strategy described in Scheme 2.24 was abandoned. However, it was anticipated that the
presence of large amount of base (or stronger base) in the reactions resulted in
unfavourable conditions for NBD-Cl 54 as evidenced by the disappearance of this reagent
in the reactions (conditions A-E). Therefore, it was hypothesised that the unsuccessful
conjugation of the ligand 92a with NBD-Cl 54 could be caused by several factors,
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including the incapability of the bases to deprotonated alcoholic proton in the ligand 92a,
decomposition of NBD-Cl 54 under strongly basic conditions, and the presence of side
reactions which lead to full consumption of NBD-Cl 54 before the conjugation reaction
occurred. There is evidence that NBD-Cl 54 could react with tertiary amine groups, which
proceed through the Meisenheimer complex and quaternary salt.189 In response to these
issues, a new synthetic strategy for probes 93a-b was proposed (Scheme 2.25).

The synthesis starts with the conversion of diethylacetamide 85 to the corresponding
imidazopyridine bromide 95a-b. NBD-Cl 54 undergoes condensation reaction, producing
NBD-OCH3 96, followed by demethylation reaction to give NBD-OH 97. The final step
involves the conjugation of both fragments (imidazopyridine bromide 95a-b and NBDOH 97) to generate probes 93a-b. Unfortunately, due to time constraint, the synthesis
were not attempted.
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Scheme 2.25 New strategy for the synthesis of fluorescent probes 93a-b.

85

2.5 UV-Vis and Fluorescence (Spectroscopic) Studies
The ultraviolet absorption (UV-Vis) and fluorescence properties of the selected
fluorescent compounds 56a, 56b and 89 were investigated in different solvents. These
probes were selected for spectroscopic studies as they showed excellent binding affinity
for the TSPO (see Chapter 4).

2.5.1 UV-Vis studies
In the UV-Vis studies, probes 56a, 56b and 89 were dissolved in dimethyl sulfoxide
(DMSO), diluted at a final concentration of 10 µM in different assay solutions from 0%
dioxane to 75% v/v dioxane/phosphate-buffered saline (PBS). The percentage of DMSO
used in the assay did not exceed 1% of the final volume solution.162

In aqueous solution (0% v/v dioxane/PBS), the spectrum of probe 56a (Figure 2.13) is
characterized by two absorptions maxima at λ 340 and 490 nm, showing extinction
coefficients of ε = 11000 M-1cm-1 and 10400 M-1cm-1, respectively. When probe 56a was
dissolved in 25% v/v dioxane/PBS, the spectrum was characterized by two absorption
maxima at λ 330 and 470 nm, and an increase of the extinction coefficients (ε = 15800
M-1cm-1 and 18700 M-1cm-1, respectively). A further increase in hydrophobicity of the
medium (50% v/v dioxane/PBS) caused an increase of the extinction coefficients to
24700 M-1cm-1 and 24500 M-1cm-1, respectively. In the PBS solution containing 75%
dioxane (v/v), the extinction coefficients remained almost constant.

The absorption spectra of probe 56b (Figure 2.14) show a similar profile with that of
probe 56a, suggesting that higher hydrophobicity of the medium can promote the increase
of the extinction coefficient. From this probe, the highest extinction coefficient (ε = 19200
M-1.cm-1) was observed in 75% v/v dioxane/PBS solution at λ 470 nm.
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Figure 2.13 Ultraviolet absorption spectra of fluorescent probe 56a at 10 µM in solutions varying
from 0% to 75% v/v dioxane in PBS.
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Figure 2.14 Ultraviolet absorption spectra of fluorescent probe 56b at 10 µM in solutions varying
from 0% to 75% v/v dioxane in PBS.
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The absorption maxima of probe 89 (Figure 2.15) was generally lower compared to both
probes 56a and 56b with the spectra characterized by two absorption maxima at λ 330
and 470 nm, and the highest extinction coefficient (ε = 19200 M-1.cm-1) was observed at
λ 470 nm in the PBS solution containing 75% dioxane (v/v).

Fluorescent Probe 86

Absorbance

0.30
0.25
0.20
0.15
0.10
0.05
0.00
300

350

400

450

500

550

600

Wavelength (nm)
Dioxane 0%

Dioxane 25%

Dioxane 50%

Dioxane 75%

Figure 2.15 Ultraviolet absorption spectra of fluorescent probe 89 at 10 µM in solutions varying
from 0% to 75% v/v dioxane in PBS.

2.5.2 Fluorescence studies
From the fluorescence studies, probes 56a and 56b displayed emission maxima at λ ⁓535
nm, which corresponded to the NBD moiety emission.193 Interestingly, probe 56b (Figure
2.17) with the longer carbon linker (n = 3) showed a significant increase of fluorescence
intensity compared to probe 56a (n = 2) (Figure 2.16). Additionally, decreasing the
polarity of the medium from 0% to 75% v/v dioxane in PBS promoted an approximate
10-fold and 32-fold increase in the fluorescence intensity of probes 56a and 56b,
respectively. This suggests that the NBD-containing compound exhibits a high degree of
environmental sensitivity.194
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Figure 2.16 Effect of the polarity of the medium on the fluorescence of probe 56a at 10 µM in
solutions varying from 0% to 75% v/v dioxane in PBS.
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Figure 2.17 Effect of the polarity of the medium on the fluorescence of probe 56b at 10 µM in
solutions varying from 0% to 75% v/v dioxane in PBS.

89

In contrast, probe 89 without a carbon linker between the ligand and NBD moiety
demonstrated very low fluorescence intensity at λ 500 to 600 nm, probably caused by
intramolecular fluorescence quenching.195 However, an increased fluorescence intensity
was observed at a wavelength of λ ⁓410 nm (Figure 2.18).
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Figure 2.18 Effect of the polarity of the medium on the fluorescence of probe 89 at 10 µM in
solutions varying from 0% to 75% v/v dioxane in PBS.

The NBD moiety is an intramolecular charge transfer (ICT) fluorophore, 196 and when
conjugated with several strong electron withdrawing groups (EWGs), the fluorescence of
the NBD derivative is weak (e.g. NBD-Cl).197 However, the presence of electron donating
groups (EDG) will promote the ICT process, and thus enhancing the fluorescence
intensity (e.g. NBD-NH2) (Figure 2.19).198
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Figure 2.19 Change of fluorescence properties of NBD induced by EWG-EWD systems.

The presence of an amino group (NH) in the NBD moiety at 4-position of probes 56a and
56b caused significant fluorescence enhancement (Figure 2.16, Figure 2.17).
Nevertheless, replacing the NH group with an oxygen atom resulted in a weak
fluorescence intensity due to the lack of push-pull effect on the NBD moiety, as can be
seen from the fluorescence spectra of probe 89 (Figure 2.18).

2.6 Conclusions
Fluorescent probes A and B were synthesised from scaffold 67, with subsequent
biological studies for the TSPO performed, including radioligand binding assay,
fluorescence microscopy, and in vivo brain uptake (Chapter 4). The functional
modifications of scaffold 67 provided an opportunity to further incorporate the NBD-Cl
54 to the ligands. This strategy also allows flexibility as many derivatives can be
synthesised by changing the length of the carbon linkers.

From a synthetic point of view, lower than expected yields were obtained for the
conjugation reactions of ligands with NBD-Cl 54. However, conjugation reactions on
NBD-Cl 54 are known to proceed in relatively low yields, with Laquintana and colleagues
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(2007) reporting isolated yields of 30 – 65% when conjugating a NBD-Cl 54 with a series
of TSPO ligands. The number of attempts to conjugate NBD-Cl 54 to ligands 92a-b were
performed under standard condensation procedure employed different bases, but TLC and
LRMS analysis indicated that no reaction had occurred. Therefore, a new synthetic
pathway was proposed. Unfortunately, due to time constraint, the synthesis were not
attempted.

Most of the synthetised probes were found to be highly fluorescent in a wide range of
solvents under ambient conditions and when exposed to long-wave (λ = 365 nm) UV
irradiation. The UV-vis and fluorescence studies have been performed on probes 56a,
56b and 89. As expected, the presence of a push-pull system on probes 56a and 56b
significantly contributed to their attractive spectroscopic properties, especially in less
polar solvents.
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Chapter 3: Synthesis of Novel
Tau Ligands

3.1 Basis of The Project
Imaging tau pathologies using existing radiotracers is still inadequate,144 and requires the
development of the next generation of ligands targeting the tau protein. This is evidenced
by the growing number of publications on tau PET tracers in recent years.148 A number
of tau ligands have emerged based on different scaffolds, which show promise, however,
limitations including off-target binding, poor specificity, and low stability147,

199

still

hinder their potential use in clinical settings.
Developed by Higuchi and colleagues, [11C]PBB3 30 is a clinically used PET tracer for
in vivo detection of tau deposits in AD and non-AD tauopathies in the human brain.200
Recent clinical studies revealed that it clearly differentiated tau in AD brains from healthy
control brains, and specific binding was observed in the CA1 and subiculum areas in the
hippocampus where a high accumulation of fibrillar tau protein exists.144

Despite the favourable in vivo properties, PBB3 30 suffers from stability issue and has
limited structure-activity relationship data, and was therefore selected as an excellent
structural platform for further development. In this project, efforts focused on generating
a new series of tau ligands by replacing the photoisomerisable trans-butadiene bridge of
PBB3 30 with 1,2,3-triazole, amide, and ester moieties (Figure 3.1), with the aim of
finding molecules with better stability and in vivo properties.
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Figure 3.1 Strategy for the development of novel tau ligands through modification of the transbutadiene bridge on PBB3 30.

The 1,2,3‐triazole moieties were chosen as the connecting units because they are stable
to metabolic degradation and capable of hydrogen bonding, which can be favourable in
the binding of biomolecular targets. Moreover, it has been proposed that higher paired
helical filament tau selectivity can be achieved by incorporating bulky hydrophilic
groups, which prevent binding to Aβ aggregates.201 It was also anticipated that the triazole
moieties may induce constrain in conformation. To avoid this potential issue, one or two
additional carbons can be introduced between the triazole and pyridine/phenyl unit.

3.2 Synthesis of 1,4-Disubstituted 1,2,3-Triazole Derivatives
The key component in the synthesis of the target 1,4-disubstituted 1,2,3-triazole
derivatives was the preparation of the alkynes and azides intermediates. Furthermore,
click reaction between alkynes and azides functionalities allow for the synthesis of Series
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A (57), B (58), C (59) and D (60) (Figure 1.19, Chapter 1) for possible radiolabelling
with either carbon-11 or fluorine-18.

3.2.1 Synthesis of Series A
3.2.1.1 Synthesis of Alkyne
The synthesis of key intermediate alkyne 101 was accomplished as previously reported,202
with minor modifications (Scheme 3.1).

Scheme 3.1 Synthesis of free alkyne 101 from the amino benzothiazole precursor 98.

Therefore, the diazotization of the commercially available 6-methoxybenzo[d]thiazol-2amine 98, followed by Sandmeyer iodination gave iodobenzothiazole 99 in 70% yield.
Analysis of the 1H NMR spectrum of 99 revealed three resonances at δ 7.89, 7.28, and
7.03, all with a relative integration of one, corresponding to the benzothiazole moiety,
and a prominent resonance at δ 3.86, assigned to CH3. The molecular formula of 99 was
verified by LRMS, with the appearance of a peak at m/z 292, assigned to the molecular
ion [M + H]+.

95

Compound 99 was subjected to a Sonogashira cross-coupling reaction in the presence of
2.0 equivalents of ethynyltrimethylsilane to generate the protected alkyne 100 in 66%
yield. The 1H NMR spectrum of 100 displayed a prominent resonance at δ 0.30,
integrating to nine protons, assigned to the silyl group. LRMS of 100 indicated peak at
m/z 262, assigned to the molecular ion [M + H]+.

Discovered by Sonogashira and colleagues (1975), this palladium-catalysed crosscoupling of vinyl or aryl halides and terminal alkynes has become a popular procedure
for the formation of C(sp2)-C(sp) bonds. The mechanism of the Sonogashira coupling is
not completely understood due to the complexities arising from the use of two metals
(Pd/Cu) during the catalysis.203-204 The generally accepted mechanism for the copper cocatalysed Sonogashira cross-coupling reaction is outlined in Scheme 3.2.
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Scheme 3.2 Pd/Cu-catalysed Sonogashira cross-coupling reaction mechanism.204-206

This mechanism comprises oxidative addition, transmetalation, trans/cis isomerisation,
and reductive elimination. The oxidative addition step allows the insertion of Pd(0)
species between the halide and the R1, which is considered to be the rate-limiting step of
the reaction, and is facilitated by electron withdrawing groups in the substrate (cycle A).
Formation of a π-alkyne-Cu complex (cycle B) results in the increase in the acidity of the
terminal proton in the alkyne, which allows triethylamine to deprotonate the alkyne to
form the copper acetylide which promotes the transmetalation step. Due to the reductive
elimination, two metal-ligand bonds are disintegrated, and one new ligand-ligand bond is
generated, completing the cycle.204-206
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The final step in the synthesis of alkyne intermediate was the deprotection of 100 with
KF in MeOH at rt for 4 h to give free alkyne 101 in 98% yield after flash chromatography.
The 1H NMR spectrum of 101 showed the presence of three resonances at δ 7.93, 7.27,
and 7.12, assigned to the protons H4, H7, and H5, respectively. This was supported by
the correlation of these resonances to each other by analysis of the COSY spectrum
(Figure 3.2).

Figure 3.2 COSY spectrum of free alkyne 101 in CDCl3 (400 MHz), showing the correlations
between H4, H5 and H7.

Further analysis of the 1H NMR spectrum revealed the presence of resonances at δ 3.88
and 3.55, which corresponded to methoxy protons and terminal alkyne proton,
respectively. Additionally, resonances at δ 124.6, 116.8, and 103.5 in the

13

C NMR

spectrum were assigned to C4, C5, and C7, supported by analysis of the HSQC spectrum
(Figure 3.3).
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Figure 3.3 HSQC spectrum of free alkyne 101 in CDCl3 (400 MHz).

The resonance at δ 144.8 in the 13C NMR spectrum was assigned to C2, evidenced by a
strong three-bond HMBC correlation with terminal alkyne proton (H2'). The resonance
at δ 159.1, which demonstrated a strong three-bond HMBC correlation to H4, was
assigned to C6 (Figure 3.4).
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Figure 3.4 HMBC spectrum of free alkyne 101 in CDCl3 (400 MHz).

Analysis of the LRMS of 101 revealed a peak at m/z 190, assigned to the molecular ion
[M + H]+.

3.2.1.2 Synthesis of Azides
The synthesis of aryl azide 103 via a proline-promoted CuI-catalyzed coupling reactions
started with the reaction of aryl halides with NaN3 under CuI/L-proline catalysis (Scheme
3.3). This usually works at relatively low temperature to generate aryl azides in good
yields,207 however, the reaction of aryl bromide 102 with NaN3 at rt gave azide 103 in
considerably low yields (6%) with a large amount of unreacted starting bromide 102.
With further increases of reaction temperature (70 ºC), the yield of azide 103 improved
to 14% (conditions A); while a further increase of reaction temperature may lead to an
enhanced yield, with the potential explosive nature of NaN3, especially at high
temperature,208 the synthesis of azide 103 at temperature higher than 70 ºC could not be
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realised. A series of trial azidations were then performed using a different stabilising
ligand, namely N,N'-dimethylethylenediamine (DMEDA)209 (conditions B) (Scheme
3.3).

Scheme 3.3 Synthesis of aryl azide 103 under CuI/L-proline catalysis (conditions A) and
CuI/DMEDA (conditions B).

The optimisation of reaction conditions through careful choice of solvent mixture and
temperature (Table 3.1) improved the yield of azide 103 to 45% (Entry 4), although
incompleted consumption of starting bromide 102 was observed. Generally, lower
reaction temperatures gave an incomplete conversion of aryl bromide 102 to azide 103
(Entry 1 – 4), whereas at 70 ºC the azide 103 eventually decomposed with no sign of the
starting bromide 102 (Entry 5). Therefore, a compromise temperature of 65 ºC straddled
the reactivity of the bromide 102 in the nucleophilic substitution to azide 103 and the
stability of the in situ formed azide 103.
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Table 3.1 Optimisation of the azidation reaction of aryl bromide 102 using DMEDA as
a stabilising ligand for the generation of aryl azide 103.
Entry

Solvent

Temp

Time

Yield

Unreacted aryl

(ºC)

(h)

(%)

bromide (%)a

1

DMSO/H2O (1:1)

65

8

25

51

2

DMSO/H2O (7:3)

65

8

22

50

3

EtOH/H2O (1:1)

65

8

40

46

4

EtOH/H2O (7:3)

65

8

45

40

5

EtOH/H2O (7:3)

70

8

11

-

aUnreacted

aryl bromides were obtained as the percent recovery (%) after flash

chromatography over SiO2 gel (CH2Cl2/MeOH – 90:10)

The 1H NMR spectrum of azide 103 displayed three resonances in the aromatic region (δ
7.84, 7.16, and 6.53) corresponding to the pyridine moiety protons, and a broad singlet at
δ 4.44, assigned to the primary amine group. Analysis of the 13C NMR spectrum revealed
five resonances in the aromatic region (δ 156.0, 139.1, 128.9, 127.7, and 109.5)
corresponding to pyridine carbons. The formation of 103 was confirmed by HRMS
analysis, with a peak observed at m/z 136.0623, assigned to the molecular ion [M + H]+
(calcd for C5H6N5+ 136.0618).

The aryl azide 105 was prepared over a two-step procedure, starting with N-methylation
of aryl bromide 102, followed by azidation reaction (Scheme 3.4). The N-monomethyl
104 was realised in 70% yield by condensation of aryl bromide 102 with
paraformaldehyde in the presence of NaOMe in MeOH, followed by reduction with
sodium borohydride (NaBH4). The formation of 104 using this method instead of direct
methylation procedure with methyl iodide210 ensured that only mono methylation
occurred.
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Scheme 3.4 Synthesis of aryl azide 105 using DMEDA.

Aryl azide 105 was synthesised in 23% yield using the same procedure as for azide 103
(Scheme 3.4). A lower than expected yield was caused by the low conversion of starting
aryl bromide 104 to the corresponding azide 105. After workup, the product azide 105
was obtained as a mixture along with the starting bromide 104 in approximately a 1:1
ratio as indicated by 1H NMR spectral analysis (Figure 3.5). TLC analysis using different
eluents indicated that the mixture was inseparable, with all attempts to separate the
mixture using column chromatography and preparative TLC plate unsuccessful.
Therefore, the azide 105 was used in the next reaction step as a mixture including 104.
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Figure 3.5 1H NMR spectrum showed the inseparable mixture of starting bromide 104 and azide
105 in a 1:1 ratio.

3.2.1.3 Synthesis of 1,4-Disubstituted-1,2,3-Triazole Derivatives
3.2.1.3.1 Synthesis of 1,4-Disubstituted-1,2,3-Triazole 57a-b
The discovery of the Cu-catalysed azide-alkyne cycloaddition (CuAAC) by the groups of
Meldal and Sharpless211 allows the development of 1,4-disubstituted-1,2,3-triazole
molecules for a broad number of applications, including organic synthesis, biological
science, medicinal chemistry, and material science.212 Until recently, the CuAACcatalysed process was the widely used click reaction, which exclusively transforms
organic azides and free alkynes into the corresponding 1,4-disubstituted 1,2,3-triazoles.213

CuAAC is compatible with most functional groups, and the product is metabolically
inert,211 both major advantages of this reaction. Therefore, the synthesis of triazole 57ab was achieved via CuAAC reactions. For example, 57a was realised in 69% yield by
reaction of azide 103 (2.0 eq) and alkyne 101 (1.0 eq) in the presence of Cu(II)/ascorbate
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in t-BuOH/H2O at rt for 24 h (Scheme 3.5). Due to its poor solubility in many solvents,
57a was purified by trituration214 with CH2Cl2, MeCN, and hot MeOH. Although
trituration using these solvents slightly dissolved the product (as evidenced by HPLC
analysis of the supernatant), and consequently decreased the yield, a highly pure
recovered product was obtained.

Scheme 3.5 Cu-catalysed cycloaddition between alkyne 98 and azide 100 or 102.

Analysis of the 1H NMR spectrum of 57a revealed the disappearance of singlet resonance
at δ 3.55 (terminal alkyne proton) that was observed in the 1H NMR spectrum of 101, and
the appearance of a significantly downfield resonance at δ 9.35, assigned to the triazole
proton. Analysis of the 13C NMR spectrum showed a resonance at δ 121.4, assigned to
the tertiary triazole carbon as supported by analysis of the HSQC spectrum. Additionally,
resonances at δ 140.8, 130.7, 123.1, 116.0, 107.8, and 105.0 were assigned to carbons
C6'', C4, C4'', C5, C3'', and C7, respectively. These assignments were supported by the
analysis of the HSQC spectrum (Figure 3.6).
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Figure 3.6 HSQC spectrum of 57a in DMSO (400 MHz).

The resonance at δ 156.1, which demonstrated a strong three-bond HMBC correlation to
resonance H5' was assigned to C2. A more downfield resonance at δ 157.6 was assigned
to C6, supported by its strong three-bond HMBC correlation with resonance H4 and
methoxy protons.
Analysis of the IR spectrum of 57a revealed a broad band at 3462 cm-1, assigned to the
aryl amine (N-H stretch). HRMS analysis confirmed the molecular formula of 57a, as a
peak was observed at m/z 325.0872, assigned to the molecular ion [M + H]+ (calcd for
C15H13N6OS+ 325.0866).

Cu(I) has been the best catalyst of choice in the exclusive formation of 1,4-disubstituted
1,2,3-triazoles from azides and terminal alkynes under ambient or mild conditions.215 This
catalyst can be added directly or prepared in situ by reduction of a Cu(II) salt with an
excess of a reducing agent (e.g. sodium ascorbate) under an inert atmosphere.181
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Although the direct use of Cu(I) catalyst was effective, in situ generation of catalytic
Cu(I) species was more reliable and afforded similar conversions with higher purity.216
Thus, the initial Fokin-Sharpless catalyst CuSO4 + sodium ascorbate in aqueous medium
is widely used and remains the most practical catalytic system.217

The generally accepted mechanism of CuAAC reaction is based on kinetic analysis and
density functional theory (DFT) calculations. The reaction path starts with the π
coordination of alkyne to the first Cu centre. The deprotonation results in second
coordination of alkyne to another Cu centre. This binuclear complex and azide molecule
generate a six-membered ring, which subsequently transforms into a five-membered
triazolide ring.215 The coordination of the primary azide nitrogen to the terminal Cuacetylide complex allows [3 + 2]-cycloaddition and therefore only the 1,4-regioisomer is
formed.181

3.2.1.3.2 Attempted Synthesis of 1,4-Disubstituted-1,2,3-Triazole 57c via ODemethylation
The literature is rich with O-demethylation methods for the synthesis of phenols from
their parent aryl methoxy compounds. BBr3 and HBr are perhaps the most popular
reagents for O-demethylation,218 with the use of reagents such as sodium sulfide (NaSH),
sodium thioethoxide (NaSEt), and less odorous thiols (e.g. 1-dodecanethiol) also recently
reported.219

The reported demethylation of the benzothiazole moiety to the corresponding phenol
proceeded smoothly using BBR3 in CH2Cl2, produced an isolated yield of 69% when
synthesising PBB3 30 from its methoxy precursor.220 However, 57a and 57b were found
to have poor solubility in CH2Cl2. Therefore, the focus was shifted to the use of HBr as a
demethylation reagent.
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In an attempt to synthesise 57c, an excess of 48% HBr in H2O was added to 57b, and the
reaction stirred at 110 ºC for 24 h (Scheme 3.6). However, the starting material was
poorly soluble during the reaction, and TLC analysis revealed only unreacted 57b with
no sign of triazole 57c. The reaction was repeated using 48% HBr in AcOH, and heated
at reflux (110 ºC). Although 57b has better solubility in AcOH, no conversion to 57c was
observed after 48 h reaction time, with starting material recovered in almost quantitative
yield. The third attempt used 48% HBr in AcOH with longer reaction time (96 h),
however, TLC and LRMS analysis revealed the presence of 57c and starting material 57b.

Scheme 3.6 Synthesis of 1,4-disubstituted 1,2,3-triazole 57c using an excess of 48% HBr in
AcOH. A mixture of product 57c and starting material 57b were identified by TLC, LRMS, and
1
H NMR analysis.

Analysis of the 1H NMR spectrum of the crude product revealed the ratio of 57c to 57b
was 1:9. Separation of this mixture using column chromatography, preparative TLC plate,
and high-performance liquid chromatography (HPLC) was not successful.

O-Demethylation reactions using HBr are known to often give incomplete conversion of
aryl methyl ethers to their corresponding phenols, even under harsh conditions, probably
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due to the poor solubility of the organic substrates,219 and is likely the reason for the low
conversion of 57b.

The limited success of O-demethylation reactions prompted the search for a better
demethylation reagent, and therefore the number of attempts were performed using
NaSEt221 (Table 3.2).

Table 3.2 Attempted O-demethylation of 1,4-disubstituted 1,2,3-triazole 57b using
NaSEt
Entry Reagent

Solvent

Temp

Time

Outcomea

1

NaSEt (5.0 eq)

DMF

65 ºC

24 h

No reaction

2

NaSEt (7.5 eq)

DMF

85 ºC

24 h

No reaction

3

NaSEt (10.0 eq)

DMF

110 ºC

24 h

No reaction

4

NaSEt (10.0 eq)

DMF

110 ºC

72 h

No reaction

5

NaSEt (5.0 eq)

DMSO

65 ºC

24 h

No reaction

6

NaSEt (7.5 eq)

DMSO

85 ºC

24 h

No reaction

7

NaSEt (10.0 eq)

DMSO

110 ºC

24 h

No reaction

8

NaSEt (10.0 eq)

DMSO

110 ºC

72 h

No reaction

aReaction

progress was monitored by TLC and LRMS analysis.

The reaction was performed with a 5.0 eq excess of NaSEt (Entry 1), however, TLC and
LRMS analysis revealed no reaction had taken place. Increasing the reaction temperature
to 85 ºC (Entry 2) and 110 ºC (Entry 3) produced the same result. Extended reaction time
(Entry 4) and repeating the reactions in DMSO (Entries 5-8) had no effect.

3.2.1.3.3 New Synthetic Strategy for 1,4-Disubstituted-1,2,3-Triazole 57c
After the unsuccessful attempts at synthesising triazole 57c, a new synthetic pathway via
alkyne 112 was proposed (Scheme 3.7). Although the benzothiazole 108 and protected
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phenol 109 have been reported, the subsequent intermediates (110 and 111) and the target
alkyne 112 have not been previously published.

Scheme 3.7 Synthesis of free alkyne 112.

The synthesis of benzothiazole core 108 was achieved in 72% yield by an acid-catalysed
condensation reaction of benzoquinone 106 with thiourea 107 in EtOH at rt for 48 h.
Subsequently, benzothiazole 108 underwent diazotization – Sandmeyer iodination
reaction to generate the corresponding iodobenzothiazole. However, this reaction proved
to be ineffective with several impurities obtained along with the product, as well as low
yield (6%). The presence of a free hydroxy substituent (nucleophile) in 108 was identified
as a plausible cause of limited success in the formation of iodobenzothiazole, which can
enter into other unwanted reactions, such as nucleophilic aromatic substitution. To
overcome these problems, the benzothiazole 108 was protected with t-butyldimethylsilyl
(TBDMS) group in the presence of imidazole in DMF to give the protected phenol 109
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in 41% yield as a reddish oil after flash chromatography. The TBDMS group was chosen
to protect the phenol as it is easily introduced and removed under a variety of
conditions.222 It was though that this functionality is well tolerated for different reaction
conditions in the subsequent steps before a fluoride desilylation.
The diazotization – Sandmeyer iodination of phenol 109 in the presence of p-TsOH.H2O,
NaNO2, and KI gave iodobenzothiazole 110 as a grey solid in 63% yield. Analysis of the
1

H NMR spectrum of 110 revealed the disappearance of a broad singlet at δ 5.85 that was

present in the 1H NMR spectrum of 109. 13C NMR spectrum of 110 displayed a resonance
at δ 102.2, assigned to the quaternary carbon adjacent to iodine atom. The presence of
iodine atom caused a significant upfield shift of this carbon relative to the same carbon
atom of starting phenol 109 (δ 165.2). Analysis of the HRMS spectrum of 110 revealed a
peak at m/z 391.997, assigned to the molecular ion [C13H19INOSSi+]+.

Iodobenzothiazole 110 was then subjected to Sonogashira cross-reaction conditions using
ethynyltrimethylsilane in CH2Cl2/triethylamine at reflux for 4 h in the presence of
Pd(PPh3)2Cl2 (0.02 eq) and CuI (0.02 eq). Work-up and flash chromatography afforded
the protected alkyne 111 in 55% yield. Optimal conditions were found using DMF as the
solvent, with Pd(PPh3)2Cl2 (0.02 eq) and CuI (0.04 eq) at reflux for 6 h, which gave 111
in 74% yield after flash chromatography over SiO2 gel (EtOAc/hexanes – 20:80). TLC
and 1H NMR analysis indicated that 111 had low stability at ambient conditions, and
therefore was used in the next reaction step immediately. The 1H NMR spectrum of 111
displayed a resonance at δ 0.30, integrating to nine protons, assigned to the newly
introduced silyl group. The molecular formula of 111 was verified by HRMS, with the
presence of a peak at m/z 362.1426, assigned to the molecular ion [C18H28NOSSi2]+.
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The synthesis of free alkyne 112 was achieved in 86% yield via fluoride desilylation of
111 using an excess of potassium fluoride (KF) in MeOH. Analysis of the 1H NMR
spectrum of 112 revealed a resonance at δ 5.03, which did not show COSY correlation to
other proton resonances, assigned to the terminal alkyne proton, and a significantly
downfield broad singlet at δ 10.11, assigned to the highly deshielded phenolic proton.
Analysis of the IR spectrum of 112 revealed an absorbance at 1370 cm-1, assigned to the
O-H bending. The molecular formula of 112 was verified by HRMS via a peak at m/z
174.0019, assigned to the molecular ion [C9H4NOS]–.

The key click reaction between free alkyne 112 and aryl azide 105 in the presence of
Cu(II)/ascorbate in t-BuOH/H2O gave 57c as a brown solid in 53% yield (Scheme 3.8).
This compound was found to have low solubility in most of the solvents, with only
slightly soluble in DMSO and DMF. Therefore, successful purification was achieved by
trituration with CH2Cl2, MeCN, and hot MeOH.

Scheme 3.8 Synthesis of 1,4-disubstituted 1,2,3-triazole 57c.
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Analysis of the 1H NMR spectrum of 57c revealed nine resonances in the aromatic region.
Two broad singlets at δ 8.58 and 6.65 were assigned to H6'' and H3''. These resonances
are broadened probably due to non-homogenous NMR sample223 (may be caused by poor
solubility in DMSO-d6), although other factors such as the presence of paramagnetic
oxygen and chemical exchange223-224 are possible. When a higher temperature 1H NMR
experiment (75 ºC) was performed on the sample, the expected splitting pattern for H6''
(doublet) and H3'' (doublet) were observed.
A significant downfield broad singlet at δ 9.99 was assigned to the highly deshielded
phenolic proton, and a broad singlet at δ 7.12 was assigned to the secondary amine proton.
Further analysis of the 1H NMR spectrum revealed a resonance at δ 9.36 which did not
show COSY correlations to other proton resonances, and was assigned to the triazole
proton. Analysis of the 13C NMR spectrum revealed thirteen resonances in the aromatic
region, which indicated the lack of one carbon resonance. After intensive 2D NMR
analyses (COSY, HSQC and HMBC), the missing carbon resonance was likely the C5'',
a quarternary pyridine carbon attached to the triazole moiety. The lack of C5'' resonance
most likely due to the poor solubility of 57c which allowed only a small amount of sample
can be dissolved in DMSO-d6 for NMR studies. This analysis was supported by the fact
that the carbon C5'' resonance was present in other analogues that demonstrated better
solubility in DMSO-d6 (e.g. 57a).
Analysis of the IR spectrum of 57c revealed two broad bands at 3243 and 3096 cm-1,
corresponding to aryl amine (N-H stretch) and phenol unit (O-H stretch). The molecular
formula of 57c was verified by HRMS, with the appearance of a peak at m/z 325.0866,
assigned to the molecular ion [M + H]+ (calcd for C15H13N6OS+ 325.0866).
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3.2.2 Synthesis of Series B
In search of new derivatives with improved solubility, Series B were designed and
synthesised investigating the substitution of different groups on the benzothiazole moiety
(R) and phenyl ring (R1 and R2), and the importance of the carbon linker (n) between the
triazole unit and phenyl functionality (Figure 3.7).

Figure 3.7 Rational design of Series B.

3.2.2.1 Synthesis of Alkyne
The synthesis of free alkyne 116 was accomplished using the same procedure as for
alkyne 101, and the outcomes are summarised in Scheme 3.9.

Scheme 3.9 Synthesis of free alkyne 116 from the amino benzothiazole precursor 113.
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The iodobenzothiazole 114 was realised in 71% yield by reaction of commercially
available 6-methylbenzo[d]thiazol-2-amine 113 with p-TsOH.5H2O, NaNO2, and KI in
MeCN at rt for 18 h. The protected alkyne 115 was formed by Sonogashira cross-coupling
reaction of 114 with ethynyltrimethylsilane in DMF/TEA in 76% yield, followed by
deprotection with KF to give the free alkyne 116 in 96% yield.
Analysis of the 1H NMR spectrum of 116 revealed three resonances at δ 7.94, 7.65, and
7.32, all with a relative integration of one, assigned to the aromatic protons of the
benzothiazole moiety, and two resonances at δ 3.56 and 2.49, assigned to the terminal
alkyne proton and methyl group, respectively. Analysis of the IR spectrum of 116
revealed an absorbance at 2103 cm-1, assigned to the carbon-carbon triple bond (alkyne
unit). The molecular formula of 116 was verified by HRMS, with the presence of a peak
at m/z 174.0377 (calcd for C10H8NS+ 174.0372).
3.2.2.2 Synthesis of Azide
The synthesis of benzyl azides 119a-f and phenylethyl azides 120a-d was achieved in
high to excellent yields (74 – 90%) by reacting the appropriate benzyl/phenylethyl
bromides with NaN3 in DMF at 55 ºC for 24 h,225 and the outcomes are summarised in
Table 3.3.

Table 3.3. Summary of the synthesis of azides 117a-f and 118a-d.

Azide

R1

R2

n

Yield (%)a

119a

F

H

1

83

119b

H

F

1

75
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a

119c

CF3

H

1

87

119d

H

H

1

90

119e

NO2

H

1

77

119f

CN

H

1

77

120a

F

H

2

74

120b

CF3

H

2

83

120c

OH

H

2

78

120d

NO2

H

2

78

Isolated yield after purification with flash chromatography.

All the azide products were obtained as oils.

Analysis of the 1H NMR spectrum of azide 117a displayed two multiplets at δ 7.32 – 7.28
and δ 7.10 – 7.06 corresponding to phenyl protons, and a resonance at δ 4.32, assigned
to CH2 in the linker. Due to the 13C-19F coupling to the fluorine atom, aromatic carbon
resonances were observed as doublets. For example, the C4 carbon (a carbon adjacent to
F atom) resonance showing a short-range
1

13

C-19F coupling with a coupling constant of

JCF = 245.0 Hz. The molecular formula of 117a was verified by LRMS, with the presence

of a peak at m/z 152, assigned to the molecular ion [M + H]+.

3.2.2.3 Synthesis of 1,4-Disubstituted-1,2,3-Triazole Derivatives
The synthesis of 1,4-disubstituted-1,2,3-triazole derivatives (Series B) was realised in
moderate to high yields via CuAAC reactions between the free alkyne 101 or 116 and the
appropriate benzyl azides 119a-f or phenylethyl azides 120a-d in the presence of
Cu(II)/ascorbate in t-BuOH/H2O at rt for 24 h (Table 3.4).
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Table 3.4. Summary of the synthesis of 1,4-disubstituted-1,2,3-triazole derivatives
(Series B) via CuAAC reactions

Compound

R

R1

R2

n

Yield (%)

58a

OCH3

F

H

1

77

58b

OCH3

F

H

2

69

58c

OCH3

H

F

1

84

58d

OCH3

CF3

H

1

74

58e

OCH3

CF3

H

2

71

58f

OCH3

H

H

1

86

58g

OCH3

OH

H

2

70

58h

OCH3

NO2

H

1

79

58i

OCH3

NO2

H

2

75

58j

OCH3

CN

H

1

73

58k

CH3

F

H

1

78

58l

CH3

F

H

2

69

58m

CH3

CF3

H

1

73

58n

CH3

OH

H

2

81

58o

CH3

NO2

H

1

75

The successful formation of derivatives 58a-o was confirmed by NMR, IR, and HRMS
analysis. For example, the 1H NMR spectrum of the triazole 58a displayed a resonance at
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δ 8.95, which did not show COSY correlation to other proton resonances, assigned to the
triazole proton, and a resonance at δ 3.85, assigned to CH3. The resonance at δ 123.4 in
the 13C NMR spectrum was assigned to the tertiary triazole carbon and was confirmed by
a HSQC correlation with the 1H NMR resonance at δ 8.95 (triazole proton). Additionally,
analysis of the

13

C NMR revealed that each the four aromatic carbon atoms of the

fluorinated ring showing

13

C-19F coupling to the fluorine atom, and were therefore

observed as doublets of varying coupling constants (Figure 3.8).

Figure 3.8 Aromatic region of the 13C NMR spectrum of 58a in DMSO (125 MHz). Short and
long-range 13C-19F coupling can be observed as doublets in the spectrum.

Analysis of the IR spectrum of 58a revealed a sharp absorbance at 1128 cm-1, assigned to
the C-F stretch. The molecular formula of 58a was verified by HRMS, with the
appearance of a peak at m/z 341.0872, assigned to the molecular ion [M + H]+ (calcd for
C17H14FN4OS+ 341.0867).
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3.2.3 Synthesis of Series C
To investigate the role of alkyl alcohol substituents for tau binding, 1,4-disubstituted1,2,3-triazole derivatives (Series C) were synthesised. This started with the azidation of
bromo alkyl alcohols 121a-d using NaN3 in DMF at 55 ºC for 24 h (Scheme 3.10),
followed by CuAAC reactions with free alkyne 112.

Scheme 3.10 Synthesis of alkyl azide 122a-e from the bromo alkyl alcohol precursors 121a-e.

Using standard CuAAC reaction conditions, sodium ascorbate (0.2 eq), CuSO4.5H2O (0.1
eq), and alkyne 101 (1.0 eq) were added to the solution of azides 122a-e in t-BuOH/H2O
(1:1), before being stirred at rt for 24 h. The reaction proceeded smoothly to give triazoles
59a-e in high yields (73 – 84%) after purification by preparative TLC plate
chromatography (Scheme 3.11).
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Scheme 3.11 Synthesis of 1,2,3-triazole derivatives (Series C) via CuAAC reactions.

Formation of products could easily be confirmed by a downfield resonance around δ 8.70,
corresponding to triazole proton. For example, analysis of the 1H NMR spectrum of 59a
revealed a resonance at δ 8.78 which did not show COSY correlation to other proton
resonances, assigned to the triazole proton (Figure 3.9), and the resonances at δ 7.91,
7.73, and 7.14, all with a relative integration of one, corresponding to the aromatic protons
of the benzothiazole moiety, which was supported by the correlation of these resonances
in COSY spectrum (Figure 3.9). Additionally, the resonances at δ 4.52 and 3.86, assigned
to the alkyl chain protons, and a resonance at δ 5.09, assigned to OH. Analysis of the 13C
NMR spectrum revealed a resonance at δ 123.7, assigned to the tertiary triazole carbon,
which was confirmed by a HSQC correlation with the triazole proton.
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Figure 3.9 COSY spectrum of triazole 59a in DMSO (400 MHz).

Analysis of the IR spectrum of 59a revealed a broad band at 3216 cm-1, assigned to the
O-H stretch. The molecular formula of 59a was verified by HRMS, with the appearance
of a peak at m/z 277.0754, assigned to the molecular ion [M + H]+ (calcd for
C12H13N4O2S+ 277.0754).

3.2.4 Synthesis of Series D
To further investigate the role of triazole linkers, and expand structure-activity
relationship (SAR) studies, the synthesis of Series D (configurational isomer of 57c) was
undertaken. In this series, only 1,4-disubstituted-1,2,3-triazole 60b and its carbon-11
radiolabelled precursor 60a were synthesised (Scheme 3.12).

121

Scheme 3.12 Strategy for the synthesis of 1,2,3-triazole derivatives (Series D) via CuAAC
reactions.

The strategy towards the triazoles 60a-b involved the formation of the protected alkynes
123a-b through Sonogashira cross-couplings. The alkynes 123a-b subsequently undergo
deprotections using KF to give free alkynes 124a-b. Reaction of amino benzothiazole 108
with NaN3 gives the benzothiazole azide 125, which through CuAAC reactions with
alkyne 124a-b could generate target triazoles 60a-b.

3.2.4.1 Synthesis of Alkyne Intermediates 124a-b
The synthesis of protected alkynes 123a-b was achieved through Sonogashira crosscoupling reactions of 99-100 with ethynyltrimethylsilane in THF/TEA at 65 ºC for 8 h.
Purification by flash chromatography gave the alkynes products in 73-82% yields. The
protected alkynes 123a-b (1.0 eq) and KF (3.0 eq) were then dissolved in MeOH, and the
mixture was stirred at rt for 2 h. After purification by flash chromatography, the free
alkynes 124a-b were obtained (Scheme 3.13).
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Scheme 3.13 Synthesis of alkyne intermediates 124a-b.

3.2.4.2 Synthesis of Benzothiazole Azide Intermediate 125
Following a literature procedure,226 the reaction between amino benzothiazole 108, 2.0
M sulfuric acid (H2SO4), 3.0 M sodium nitrite (NaNO2), and 3.0 M NaN3 in 1,4-dioxane
at -15 ºC for 4 h gave the benzothiazole azide 125 in 4% yield (Scheme 3.14), indicating
the need for reaction optimisation, summarised in Table 3.5.

Scheme 3.14 Synthesis of benzothiazole azide 125.

Analysis of the 1H NMR spectrum of 125 revealed a significantly downfield resonance at
δ 9.04, assigned to the highly deshielded phenolic proton. Additionally, the resonances at
δ 7.91, 7.73, and 7.14, all with a relative integration of one, were assigned to the aromatic
protons of the benzothiazole moiety. Analysis of the

13

C NMR spectrum revealed a
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resonance at δ 156.0, assigned to the quaternary carbon adjacent to azide fragment. This
carbon had now become more shielded (relative to the carbon in starting amino
benzothiazole 108 (δ 164.4)) due to the disappearance of amino group. The molecular
formula of 125 was verified by HRMS, with the presence of a peak at m/z 191.0028,
assigned to the molecular ion [M – H]– (calcd for C7H3N4OS– 191.0033).

Table 3.5. Optimisation experiments for the azidation of amino benzothiazole 108
Entry

1

2

3

4

5

6

7

8

9

10
a

Acid

Nitrating

Azidating

reagent

reagent

H2SO4

NaNO2

NaN3

(5.0 eq)

(2.0 eq)

H2SO4

Temp

Time

Yield

(ºC)

(h)

(%)

1,4-

-15 (30

12

5

(3.0 eq)

dioxane/H2O

min), rt

NaNO2

NaN3

1,4-

0 - rt

12

11

(5.0 eq)

(2.0 eq)

(3.0 eq)

dioxane/H2O

H2SO4

NaNO2

NaN3

1,4-

0 - rt

24

14

(5.0 eq)

(2.0 eq)

(3.0 eq)

dioxane/H2O

H2SO4

NaNO2

NaN3

DMF/H2O

0 - rt

24

11

(5.0 eq)

(2.0 eq)

(3.0 eq)

HCl

NaNO2

NaN3

1,4-

-15 (30

4

4

(5.0 eq)

(2.0 eq)

(2.0 eq)

dioxane/H2O

min), rt

HCl

NaNO2

NaN3

1,4-

-15 (30

24

4

(5.0 eq)

(2.0 eq)

(3.0 eq)

dioxane/H2O

min), rt

N/Aa

t-BuONO

NaN3

1,4-

-15 (30

24

NRb

(2.0 eq)

(2.0 eq)

dioxane/H2O

min), rt

t-BuONO

NaN3

1,4-

-15 (30

24

NRb

(2.0 eq)

(3.0 eq)

dioxane/H2O

min), rt

t-BuONO

NaN3

DMF

0 - rt

36

NR

(2.0 eq)

(3.0 eq)

t-BuONO

NaN3

DMF

0 – 65 ºC

36

NR

(2.0 eq)

(3.0 eq)

N/Aa

N/A

N/A

Solvent

N/A = Not applicable; bNR = No reaction
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The amino benzothiazole 108 showed low conversions to the corresponding azide 125
under acidic conditions (Entries 1 – 6), along with several side products, as evidenced by
TLC analysis. When the reaction was performed in 1,4-dioxane/H2O (-15 ºC to rt) for 12
h, only a low yield of 5% was obtained (Entry 1). Performing the reaction at 0 ºC – rt in
1,4-dioxane/H2O improved the yield to 11% (Entry 2), and when the reaction time
prolonged to 24 h, a yield of 14% was obtained (Entry 3). The reaction was also carried
out in DMF/H2O, and an isolated yield of 11% was obtained (Entry 4), suggesting that
the solvents may not play a significant role in the formation of 125.

A different acid (HCl) was utilised in order to improve the reaction efficiency (Entries 56), however lower yields were obtained as compared to Entries 1-4 when H2SO4 were
used. The reactions were also performed using t-BuONO as a nitrating agent under neutral
conditions227 (Entries 7-9), but no azide products were formed. Performing the reaction
at 65 ºC (Entry 10) also gave no conversion to the product, and only unreacted starting
material was recovered after 36 h, which highlighted the importance of the acid in this
reaction.

The final attempt to improve reaction yield was performed using the diazotransfer reagent
(imidazole-1-sulfonyl azide). This reagent was prepared in situ in an EtOAC solution as
previously described.228 To the diazotransfer solution in MeOH was then added the
starting amino benzothiazole 108, CuSO4.5H2O and K2CO3, and the mixture was stirred
at rt for 24 h (Scheme 3.15). TLC and LRMS analysis indicated that no reaction had
occurred, and after flash chromatography over SiO2 gel (EtOAc/hexanes – 80:20) only
unreacted starting material was isolated (86% recovery) with no sign of side products.
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Scheme 3.15 Attempted synthesis of 125 using diazotransfer reagent (imidazole-1-sulfonyl
azide).

It was anticipated that 108 too reactive in the harsh conditions (Entries 1-6), resulted in
multiple side reactions, and therefore decreased yields. Entries 7-9 were the attempts at
decreasing the harsh conditions, but led to no formation of the desired product. The
unsuccessful synthesis of 125 using the diazotransfer reagent more likely due to the poor
solubility of the starting material in MeOH/EtOAc.

3.2.4.3 CuAAC reactions
The benzothiazole azide 125 was allowed to undergo CuAAC reactions with free alkynes
124a-b in the presence of CuSO4.5H2O and sodium ascorbate in t-BuOH/H2O (1:1) to
afford regioselectivity 1,4-disubstituted-1,2,3-triazoles 60a-b (Scheme 3.16).
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Scheme 3.16 Synthesis of 1,2,3-triazole derivatives (Series D) via CuAAC reactions.

Analysis of the 1H NMR spectrum of 60a revealed six resonances in the aromatic region:
three resonances at δ 7.89, 7.86, 6.99, assigned to the aromatic protons of the
benzothiazole moiety, and three resonances at δ 9.06, 7.43, 7.22, assigned to the aromatic
protons of the pyridine unit. A significant downfield resonance at δ 9.36 which did not
show COSY correlation to other proton resonances, assigned to the triazole proton.
Analysis of the
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C NMR spectrum revealed fourteen resonances, all in the aromatic

region, thus supported the formation of 60a, for example, a resonance at δ 122.2 was
assigned to the tertiary triazole carbon as supported by analysis of the HSQC spectrum.
Analysis of the IR spectrum of 60a revealed a broad band at 3401 cm-1, assigned to the
O-H stretch. The molecular formula of 60a was verified by HRMS, with the appearance
of a peak at m/z 309.0559, assigned to the molecular ion [M – H]– (calcd for C14H9N6OS–
309.0564).
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3.3 Synthesis of Amide Derivatives
The traditional amide coupling allowed for the synthesis of amide derivatives from
benzothiazole carboxylic acid and commercially available amines. The synthesis of acid
127 was achieved through the addition of 1.0 N NaOH (1.1 eq) to a solution of the
benzothiazole nitrile 126 in EtOH and heating at reflux for 18 h. Acidification of reaction
mixture to pH 3 with a solution of HCl (18%) gave the acid 127 in 92% yield. The
synthesis of amide derivatives 61a-m was realised in high yields (68 – 85%) via amide
coupling under EDCl and HOBT conditions in DMF at rt for 24 h (Scheme 3.17), and
the outcomes are summarised in Table 3.6.

Scheme 3.17 Synthesis of amide derivatives.
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Table 3.6 Summary of the synthesis of amide derivatives 61a-m via amide coupling
Compound

R

Yield (%)

Compound

R

Yield (%)

61a

70

61h

82

61b

77

61i

85

61c

75

61j

83

61d

76

61k

76

61e

73

61l

68

61f

77

61m

73

61g

71

Formation of amide products could easily be confirmed by 1H NMR spectra analysis
through the presence of a broad singlet, with an integration of one proton, assigned to
NH, corresponding to the newly formed amide bond. Moreover, all products exhibited a
significantly downfield resonance at δ ⁓160 in the

13

C NMR spectrum, assigned to the

carbonyl carbon. For example, analysis of the 1H NMR and 13C NMR of 61a revealed the
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presence of resonances at δ 11.17 (assigned to NH) and 161.2 (assigned to C=O),
respectively.

3.4 Synthesis of Ester Derivatives
The general synthetic route pursued towards ester derivatives 62a-d and the outcomes are
outlined in Scheme 3.18. The strategy involved the conversion of benzothiazole
carboxylic acid 127 to the corresponding sodium salt 129 in 98% yield. Reaction of
benzothiazole salt 129 with the commercially available alkyl bromides 130a-d in DMF
at rt for 24 h gave the ester products in high to excellent yield (75 – 88%).

Compound
62a

R

Yield (%)
85

62b

88

62c

78

62d

75

Scheme 3.18 Synthesis of ester derivatives.

130

Analysis of the 1H NMR of 62a revealed a singlet at δ 5.53, assigned to the methylene
protons. Additionally, the

C NMR spectrum showed a resonance at δ 160.6, which

13

demonstrated a three-bond HMBC correlation with the alkyl protons was assigned to
carbonyl carbon. Analysis of the IR spectrum of 62a revealed the absorbances at 1682
and 2224 cm-1, assigned to C=O and C

N stretch, respectively. The molecular formula

of 62a was verified by HRMS, with the appearance of a peak at m/z 325.0631, assigned
to the molecular ion [M + H]+ (calcd for C17H13N2O3S+ 325.0631).

3.5 Conclusions
Over the past ten years, several tau imaging probes were developed for in vivo detection
of tau deposits, including [11C]PBB3 30. In this project PBB3 30 was selected as an
excellent structural platform for the development of potential tau ligands, resulting in
forty-two novel compounds (57-62). As expected, these compounds exhibit good stability
in a variety of conditions.

A number of methods and optimisations were involved during the synthesis of tau ligands,
for example, the synthesis of aryl azide 103 was proved to be more efficient when
DMEDA was used as a stabilising ligand under CuI-catalyzed coupling conditions. The
synthesis of final ligands via click reactions (CuAAC), amide couplings, and simple
nucleophilic substitutions were achieved in satisfying yields (50 – 86%). Although some
synthetic ligands exhibit poor solubility, most of them could easily be purified by
trituration with CH2Cl2, MeCN, and hot MeOH.

The synthetic tau ligands (57-62) were validated via a series of in vitro studies, including
heterologous blocking assay and fluorescence staining (Chapter 4). The successful
candidates will be further radiolabelled either with carbon-11 or fluorine-18 to generate
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PET tracers for visualisation of tau pathology in neurodegenerative diseases. Several
radiolabelling strategies with quite a variety of different PET isotopes, including carbon11 have been reported.229 For example, the radiolabelled analogue of 60b can be prepared
from precursor 60a, starting with the protection of the free phenol group with TBDMS,
followed by N-methylation reaction with 11CH3OTf in the presence of KOH in DMSO at
100 ºC for 5 min, and deprotection under a high-temperature conditions in aqueous
medium (Scheme 3.19).220

Scheme 3.19 Radiosynthesis strategy for 1,4-disubstituted 1,2,3-triazole derivative 60b.

In other examples, the radiolabelled analogue of 61a ([11C]61a) can be synthesised via
direct O-alkylation of compound 133 (precursor) with 11CH3I in the presence of K2CO3
in DMF at 80 ºC for 5 min (Scheme 3.20).230 For fluorine-containing compounds, such
as ligand 62b, the radiolabelled analogue [18F]62b can be prepared by reaction of the nitro
precursor 134 with K[18F] in the presence of kryptofix in DMF at 140 ºC for 4 min150
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(Scheme 3.21). However, due to time constraint, the radiolabelling studies could not be
realised during the time frame of the project.

Scheme 3.20 Radiosynthesis strategy for amide derivative 61a.

Scheme 3.21 Radiosynthesis strategy for ester derivative 62b.
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Chapter 4: Biological Studies of Fluorescent
Probes and Tau Ligands

4.1 General Information
This chapter reports the results of the biological studies performed on synthesised
fluorescent probes and tau ligands (Figure 4.1).

Figure 4.1 Overview of the biological studies on fluorescent probes and tau ligands.

All biological studies were performed at National Institute of Radiological Sciences
(NIRS) and National Institutes For Quantum And Radiological Science and Technology
(QST) by project collaborators. The purity of all evaluated compounds was determined
by HPLC, and it was found to be higher than 95%.
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4.2 Biological Studies of Fluorescent Probes
4.2.1 TSPO Binding Affinity
The in vitro binding affinity (Ki) of the fluorescent probes for the TSPO was determined
by measuring the displacement of [11C]PK11195 bound to rat kidney mitochondrial
membranes.231 The effect of chemical modification on the acetamides side chain, the
length of the linker between ligand and fluorophore, and the different positions of the
fluorophore attachment were studied. The probes are moderate to highly potent at the
TSPO, with Ki values ranging from micromolar to nanomolar unit (Table 4.1). Ligand
binding studies for other receptors including the central benzodiazepine receptor (CBR)
have not been carried out at this time.

Table 4.1 TSPO binding affinity of the fluorescent probes

Probe
n
IC50 (µM)
Ki (nM)
55a
2
7.09 ± 0.05
242.43 ± 37.92
55b
3
34.87 ± 7.16
1205.57 ± 439.37
55c
4
84.13 ± 10.07
2896.57 ± 813.60
55d
6
100.50 ± 97.45 3276.30 ± 2775.55
83
NA
2.28 ± 0.58
76.91 ± 7.24
56a
2
0.01 ± 0.01
1.35 ± 0.92
56b
3
0.005 ± 0.00
0.58 ± 0.16
89
NA
0.04 ± 0.00
1.44 ± 0.17
PK11195
0.008 ± 0.00
0.59 ± 0.20
50
IC and Ki values were determined from six concentrations
of the displacers, each performed in duplicate.
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Overall, fluorescent probes with the attachment of the NBD at the 3-acetamide side chain
(probes A) showed lower affinities for the TSPO compared to probes with the attachment
of the NBD at the phenyl ring of the imidazopyridine structure (probes B). Fluorescent
probes 55a-d with carbon linker (n) varying from 2 to 6, generally exhibited low to
moderate affinity for the TSPO, ranging from 76.91 – 3276.30 nM. In this subset,
significant improvement in affinity was observed by reducing the length of the linkers.
Additionally, probe 83, which represents the fluorescent compound without a carbon
linker demonstrated higher affinity than compounds 55a-d which showed progressive
reduction in affinity with increasing carbon linker length.
On the other hand, the attachment of the NBD on the para-position of the phenyl ring of
the ligand resulted in an excellent binding affinity as exemplified by compounds 56a, 56b
and 89. The fluorescent compound bearing a 2-carbon linker (56a) exhibited the highest
binding affinity (Ki = 0.58 nM), which was 2-fold higher than compound 56b and 86,
respectively. To the best of our knowledge, compound 56b is currently the highest affinity
fluorescent probe among the NBD-based TSPO fluorescent probes that have been
reported. More interestingly, the affinity of this compound is higher compared to some
TSPO ligand analogues, for example, PBR102 13 (Ki = 5.8 nM) and PBR111 14 (Ki = 3.7
nM) (Figure 1.9, Chapter 1), suggesting that the introduction of the fluorophore may not
always decrease the affinity of the parent ligand. This may be as a result of successful
accommodation of NBD moiety into the pocket of the receptor binding site.
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4.2.2 Fluorescence Staining
To confirm the probe binding to TSPO expressed with inflammation, in vitro fluorescence
staining using brain section from lipopolysaccharide (LPS) injected mice232 was carried
out. In this study, 4 μg of LPS was injected into striatum of right hemisphere, and the
induction of TSPO expression with LPS injection was confirmed by immunostaining with
anti-TSPO antibody (Table 4.2).

Table 4.2 Fluorescent images of brain sections from LPS injected mice stained with antiTSPO antibody and fluorescent probes
Mouse 1

Region
STR left

Anti-PBR
antibody

STR left

STR right

STR right

50 µm

50 µm

55a

55b

55c

137

55d

Mouse 2
Anti-PBR
antibody

83

56a

56b

89

Double staining of brain sections from LPS injected mice with probes as well as antiTSPO antibody illustrated that the green signals derived from the tested probes and red
signals derived from anti-TSPO antibody were partially colocalized in several probes,
including 55a-d and 56a-b (Table 4.3). Theses data suggested the binding activity of
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probes to TSPO in the tissue slices of mouse brain evoked inflammation under the
environment where high concentrations of probe (17.3-19.2 μM) can interact with TSPO.

Table 4.3 Binding of probes to TSPO in the brain section from LPS injected mouse
Mouse 1

Probe

Anti-TSPO
antibody

Merge

55a

20 µm

55b

55c

55d

Mouse 2

Probe

Anti-TSPO
antibody

Merge

83

139

56a

56b

89

4.2.3 Real-Time Two-Photon Laser Scanning
To investigate the transfer of fluorescent probes from the plasma compartment into the
brain, in vivo real-time two-photon laser scanning233 was performed on mice
intraperitoneally administrated probes 55a, 56a-b, and 89. The fluorescence signals from
each mouse before the treatment was also obtained. Overall, the fluorescence signals of
all probes in the mice brain were almost constant over time (pre-treatment – 90 min),
suggesting that unlike the parent imidazopyridine TSPO ligands, the NBD injected probes
may not be able to cross the BBB (Table 4.4).

The inability of the tested probes to cross the BBB is probably due to their relatively high
lipophilicity and possibly large high plasma binding which makes passive diffusion
across the BBB unlikely to occur.234 The calculated LogP values of these probes were
found to be in the range of 4.80 and 6.07, which are relatively high for effective CNS
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drugs (Table 4.4). According to theoretical studies, optimal BBB penetration occurs
when the cLogP values are in the range of 1.5 – 2.7.235 Therefore, the poor brain entry of
the tested probes may be a result of their high lipophilicity (clogP > 4). Another important
factor may be their high plasma binding. It is generally known that molecules with
binding to plasma proteins have low availability (low concentration of free ligand in
plasma), thus low extraction across the BBB.236 Although these probes possess poor
permeability to cross the BBB in in vivo applications, this property may not be crucial for
in vitro applications.

Table 4.4 Real-time two-photon laser scanning images of mice injected with probes 55a,
56a-b, and 89
Probe
(cLogP)

Pre-treatment

10 min

Time
30 min

60 min

90 min

55a
(4.49)

20 µm

56a
(5.49)

56b
(5.76)

89
(5.70)

Sulforhodamine 101 (Red): Blood vessel
LogP values were calculated using the Molinspiration Cheminformatics software
(web-base)
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4.3 Biological Studies of Tau Ligands
4.3.1 Fluorescence Staining
The in vitro fluorescence staining with the synthesised tau ligands was examined in
sections of AD brains bearing β-amyloids and tau. PBB3 30 was used as a positive control
due to its capability to label not only tau lesions but also several types of senile plaques,
particularly dense core plaques233 (Figure 4.2).

PBB3 30 (ex 370 nm/ em 540 nm), FITC.
Section: AD, 12-73, Mid-frontal, Paraffin.
White arrow: Dense-core plaque
Aβ plaques
White arrowhead: Primitive plaque
Yellow arrow: Neurofibrillary tangle
Tau
Yellow arrowhead: Neuropil thread

57a

57b

57c

58a

58d

58f

58h

58i

58j
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58n

58l

Figure 4.2 In vitro histochemical staining of postmortem AD brain tissues with selected
triazole derivatives (Series A and B). Tissues: AD, mid-frontal; paraffin. Filter cube for
DAPI: [excitation] band-pass at 340-380 nm; [suppression] low-pass with 425 nm cutoff.

The in vitro staining assay of selected triazole derivatives revealed that ligands with
pyridine units (57a-c) poorly stained Aβ plaques and NFTs. The fact that Aβ plaques and
NFTs are undetectable by 57a-c may be due to the poor solubility properties of these
probes in water, which limits tissues penetration, leading to insufficient imaging.
However, this assumption needs to be confirmed by further experiments. The substitution
of a pyridine unit with phenyl moieties containing different substituents, and the
introduction of the carbon linker between triazole and phenyl moieties improved
histology results. For example, ligands 58d and 58l which contain fluorine atoms
displayed good staining of both dense-core plaque and primitive plaque (Aβ plaques) in
human brain sections. This also suggests that the substitution of a methoxy group with a
methyl group in the benzothiazole moiety improved the imaging of Aβ plaques as can be
observed on probe 58l. Furthermore, the introduction of either a nitro (58i), nitrile (58j),
or hydroxy (58n) substituent on the phenyl ring led to ligands that showed good
visualisation of Aβ plaques in human brain sections. It was also found that probe
unsubstituted phenyl (58f) intensely stained Aβ plaques. Unfortunately, all triazole
derivatives failed to detect NFTs in AD brain sections.
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Unexpectedly, triazole ligands containing alkyl alcohols (59a-d) and an alkoxy alcohol
(59e) (Figure 4.3) failed to detect Aβ plaques and NFTs by fluorescence microscopy.
Therefore, it is hypothesised that the phenyl core may play an important role in the
recognition of Aβ plaques.

59a

59b

59d

59e

59c

Figure 4.3 In vitro histochemical staining of postmortem AD brain tissues with triazole
derivatives containing alkyl alcohols and alkoxy alcohol (Series C). Tissues: AD, midfrontal; paraffin.
In addition, most of the amide derivatives have also failed to visualise Aβ plaques and
NFTs. However, ligand 61b with a nitrogen atom at 1-position of the phenyl ring
selectively detected NFT (Figure 4.4). The limited success to visualise Aβ plaques and
NFTs can be attributed to low contrast to the background in AD brain sections.

61a

61b

61c
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61d

61e

61f

61g

61h

61i

61j

61k

61l

61m
Figure 4.4 In vitro histochemical staining of postmortem AD brain tissues with amide
derivatives. Tissues: AD, sup temporal; paraffin. Filter cube for DAPI: [excitation] bandpass at 340-380 nm; [suppression] low-pass with 425 nm cut-off. White arrowhead:
Primitive plaque; Yellow arrow: NFT.
In addition, the ester derivative 62c bearing a trifluoro substituent on the para-position of
the phenyl ring and one carbon linker between the ester group and the phenyl moiety
exhibited specific staining to NFT. However, ligands with a nitrile (62a) and fluorine
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(62b) substituent at the phenyl ring were unsuccessful in detecting Aβ and tau aggregates
in postmortem AD brain tissues (Figure 4.5).

62a

62b

62c

Figure 4.5 In vitro histochemical staining of postmortem AD brain tissues with ester
derivatives. Tissues: AD, sup temporal; paraffin. Filter cube for DAPI: [excitation] bandpass at 340-380 nm; [suppression] low-pass with 425 nm cut-off. Yellow arrow: NFT.

4.3.2 Heterologous Blocking Assay
A heterologous blocking assay237 was performed to quantitatively evaluate the binding
properties of tau ligands by obtaining the % inhibition and inhibitory constant (Ki) against
[11C]PBB3 30 in brain homogenates of Alzheimer’s disease (AD) patients (postmortem).
The binding efficiency is categorised according to the shared binding site with [11C]PBB3
30 (% inhibition) and affinity at the shared binding site (s) with [11C]PBB3 30 (Ki) as
outlined in Table 4.5.

Table 4.5 Binding efficiency of tau ligands in heterologous binding assay
Shared binding site with PBB3 30

Affinity at the shared binding site(s) with

(% inhibition)

PBB3 30 (Ki)

Full

95 – 100%

Middle

50 – 94%

High affinity (> PPB3)

Low

25 – 49%

Similar to PBB3 (=PBB3) 4 nM < Ki < 10 nM

Very few 1 – 25%
None

Low affinity (<PBB3)

Ki < 4 nM

Ki > 10 nM

0%, Ki not determinable
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The selected triazole ligands were tested in an in vitro heterologous blocking assay and
the results are shown in Table 4.6. Overall, the ligands showed none to low % inhibition
(0.0 – 36.8%) at the shared binding site with [11C]PBB3 30. The ligands with a pyridine
moiety (57a-c) demonstrated very few to low % inhibition to [11C]PBB3 30. Among the
examples of this subset, the ligand with the mono N-methyl group (57b) exhibited better
inhibition (32.3%) than the ligand with a free amine group (57a) (19.9%), suggesting that
methyl substituent at pyridine unit may play an important role for the binding. However,
the substitution of methoxy on 57b with hydroxy unit (57c) led to a decrease in inhibition
value (14.3%).

The substitution of the pyridine unit with a phenyl moiety resulted in lower inhibition of
[11C]PBB3 30 (0.2 – 13.5%). However, the hydroxy group attached to the phenyl ring in
para-position may be essential for achieving good inhibition, as exemplified by ligand
58g with an inhibition value of 27.2%.

Furthermore, the substitution of the pyridine unit with small alkyl alcohol (59a-e) led to
very few inhibitions of [11C]PBB3 30 (3.3 – 13.6%). The ligand 59c with seven alkyl
carbons was more effective among these derivatives, and lower inhibitions were observed
by either increasing or decreasing the alkyl carbon length. Interestingly, the presence of
an oxygen atom in the middle of the carbon chain led to a significant decrease in inhibition
of [11C]PBB3 30, as observed in ligand 59e (% inhibition = 3.3%).
In addition, three amide derivatives (61b, 61c, and 61g) displaced 16.3 – 36.8% of
[11C]PBB3 30 binding in the AD tissue. Among these derivatives, generally the 1pyridine (61b) and 4-hydoxymethyl (61g) units were associated with better activity than
3-cyano unit (61c). Testing of ester derivatives (62a-c) indicated that these ligands
minimally blocked the specific [11C]PBB3 30 binding with inhibitions ≤ 7.9%.
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Table 4.6 Binding affinity and cLogP of selected tau ligands
Ligand

Structure

Inhibition

Ki

cLogP

57a

19.9%

6.3 nM

2.78b

57b

32.3%

39.4 nM

3.08b

57c

14.3%

8.1 nM

2.82b

58a

10.1%

3.8 nM

4.43b

58d

1.5%

84.8 nM

5.48b

58f

5.7%

341.4 nM

4.27b

58g

27.2%

171.3 nM

4.17b

58h

13.5%

1.5 mM

3.67c

58i

0.2%

28.1 nM

3.88c

58j

7.7%

0.46 nM

4.31b
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58l

NDa

NDa

5.33b

59a

8.9%

59.4 nM

2.03b

59b

8.0%

28.5 nM

2.13b

59c

13.6%

45.5 nM

3.84b

59d

7.9%

241.7 nM

4.25b

59e

3.3%

13.6 nM

1.87b

61b

36.8%

761 nM

2.24b

61c

16.3%

> 1.5 mM

3.61b

61g

34.7%

215 nM

3.00b

62a

NDa

NDa

4.36b

62b

7.9%

13.2 nM

4.48b

149

62c

0.0%

2.4 nM

5.25b

Tissues: middle frontal cortex; patients: male, age of death 58; Braak stage: 3
a
ND = not determinable
b
LogP values were calculated using ChemDraw Professional v18.1
c
LogP values were calculated using Molinspiration Cheminformatics software (webbase)
The Kd of control (PBB3 30) = 7.7 nM

Recent molecular modeling studies by Murugan and colleagues (2018) revealed four
binding sites (1-4) in tau fibril which available for many of the studied tau tracers (Figure
4.6). From this study, it was found that PBB3 30 binds most strongly to site 4, and
interestingly, this region is not a preferable site for any other tracers.238 Therefore, the
low inhibition values showed by the tested ligands indicated that these ligands may have
different binding site(s) to PBB3 30. However, further binding studies using different
tracers (e.g. THK5351 25 – binds to sites 3 and 1, MK6240 34 and T807 26 – bind to site
1) will be required to confirm this assumption.

Figure 4.6 Various high-affinity binding sites of tau protofibril. Three core sites (sites 1,
3, and 4) and one surface site (site 2) are displayed.238 Image reproduced from ref. 238.
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Analysis of the binding affinity (Ki) revealed that ligands 57a and 57b exhibited
nanomolar affinity at the shared binding site(s) with [11C]PBB3 30 with Ki values of 6.3
and 39.4 nM, respectively. Substituting the methoxy unit on 57b with a hydroxy group
(57c) improved the affinity by approximately 5-fold.

The replacement of the pyridine unit with fluorobenzene along with the introduction of a
one carbon linker between the triazole and phenyl moiety improved the affinity, as can
be observed on ligand 58a (Ki = 3.77 nM). Furthermore, the substitution of the fluorine
atom in 58a with a hydrogen atom (58f) and a nitro group (58h) decreased the binding
affinity, suggesting that high electronegative property of fluorine may be important for
the binding. However, the replacement of fluorine atom with polar nitrile group (58j) led
to improvement in affinity (Ki = 0.46 nM). Ligands 58d, 58g, 58j, and 58l, which
represent derivatives containing ethyl linkers between triazole and phenyl units exhibited
various affinities in nanomolar range (Ki = 28.1 – 171.3 nM).

Ligands 59a-e also showed nanomolar affinities at the shared binding site(s) with
[11C]PBB3 30 (Ki = 13.6 – 241.7 nM), and interestingly, ligand 59e showed the highest
affinity (Ki = 13.6 nM) compared to other ligands in this series. The superior affinity of
ligand 59e suggests that the additional oxygen on the molecule should favourably interact
with the site of the receptor.

Furthermore, amide derivatives 61b, 61c, and 61g exhibited low affinity at the shared
binding site(s) with [11C]PBB3 30 (Ki > 10 nM). By contrast, ester derivatives generally
demonstrated better affinity than amide derivatives with the best ligand, 62c, having Ki
value of 2.4 nM.
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Tau ligands with appropriate lipophilicity, low molecular weights, and low plasma
binding are important requisites for good BBB permeability and rapid clearance from the
body. The calculated logP values of tau ligands in Table 4.6 were found to be in the range
of 1.87 and 5.25. A logP vale of 2.00 – 3.50 is considered optimal for brain PET tracer as
the compound is sufficiently lipophilic to rapidly cross the bilipid membrane, but not so
lipophilic as to bind to plasma proteins, P-glycoprotein, or other non-specific targets.239
Additionally, all tested compounds have a molecular weight below 500 Da. Therefore,
the ligands that exhibit appropriate lipophilicity may potentially be used as in vivo
imaging agents for neurodegenerative diseases.

4.4 Conclusions
A series of novel fluorescent probes based on the 6-chloro-2-phenylimidazo[1,2a]pyridine-3-yl acetamide structure were developed, bearing the 7-nitro-2-oxa-1,3diazol-4-yl (NBD) moiety on the 2-(4'-phenyl) position as well as on the 3-acetamide side
chain. All of the new fluorescent probes demonstrated moderate to high binding affinity
(Ki) values for the TSPO, with nanomolar binding of ligands bearing the NBD in the 2(4'-phenyl) position compared to micromole affinity those on the 3-acetamide side chain.

Results from fluorescence studies indicated that fluorescence signals derived from the
tested probes and red signals derived from anti-TSPO antibody were partially colocalized
in several probes, including 55a-d and 56a-b. Additionally, in vivo two-photon laser
scanning studies on mice revealed that fluorescent probes 55a, 56a, 56b and 86 were
apparently unable to cross the BBB.

Tau ligands with triazole, amide, and ester linkers between benzothiazole and
pyridine/phenyl moieties were biologically characterised using fluorescence microscopy
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and ligand binding assay. Several triazole derivatives showed good visualisation of Aβ
plaques but failed to detect the NFTs in human brain sections. However, NFT can be
observed using amide (61b) and ester (62c) derivatives. From heterologous binding assay,
selected tau ligands exhibited none to low % inhibition (0.0 – 36.8%) against [11C]PBB3
30. Moreover, the ligands showed low to high affinities (Ki = > 1.5 mM – 0.46 nM) at the
shared binding site(s) with [11C]PBB3 30.
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Chapter 5: Conclusions and Future Directions

5.1 General Remarks
The study of molecular imaging probes is an important tool in the discovery of new
potents imaging agents for the measurement of biological processes at the cellular,
subcellular, or even molecular level in living subjects. As part of our ongoing effort to
develop new molecular probes, we present a series of fluorescent probes and tau ligands
for imaging neurodegenerative diseases. In summation, a total of 50 novel compounds (8
fluorescent probes & 42 tau ligands) were synthesised and fully characterised in this
project. The synthesis of these compounds involved the synthesis of 110 compounds (74
novel compounds and 36 known compounds).

5.2 Fluorescent Probes
The synthesis of eight novel fluorescent probes was achieved. The synthetic strategy for
these probes included preparation of TSPO ligand scaffold 67, from which probes A and
B were prepared. Most of the probes were found to be highly fluorescent in a wide range
of solvents under ambient conditions and when exposed to long-wave (λ = 365 nm) UV
irradiation. As expected, the presence of a push-pull system in the probes significantly
contributed to their attractive spectroscopic properties, especially in less polar solvents.

The TSPO binding affinity of the probes was determined by measuring the displacement
of [11C]PK11195 from rat kidney mitochondrial membranes. The effect of chemical
modification on the acetamides side chain, the length of the linker between ligand and
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fluorophore, and the different positions of the NBD attachment were examined. All
probes are moderate to highly potent at the TSPO, with Ki values ranging from
micromolar to nanomolar unit. The attachment of NBD to the phenyl ring of TSPO
ligands (probes B) led to the excellent binding affinity for the TSPO. In this series,
significant improvement in affinity was observed by increasing the length of the linkers.
This led to the discovery of a novel probe 56b with a Ki value of 0.58 nM. To the best of
our knowledge, probe 56b is the highest affinity fluorescent probe among the NBD-based
TSPO fluorescent probes that have been reported. However, the attachment of NBD to
acetamide side chain decreased the TSPO binding affinity.

The in vitro fluorescence staining and colocalization studies using brain section from
lipopolysaccharide (LPS) injected mice revealed that fluorescence signals of several
probes and red signals derived from anti-TSPO antibody were partially colocalized in
several probes, including 55a-d and 56a-b, suggesting binding activity of the probes to
TSPO at the mitochondrial level. Furthermore, in vivo real-time two-photon laser
scanning data suggest that several probes (55a, 56a-b, and 89) may not be able to cross
the BBB, probably due to their large molecular sizes and/or inappropriate cLogP values.
Although these probes possess poor membrane-permeability to cross the BBB, this
property may not be crucial for in vitro applications.

Due to their excellent binding affinity for the TSPO and attractive spectroscopic
properties, probes B, especially 56a and 56b can be considered to be the new diagnostic
markers eligible for investigating TSPO expression in peripheral cells, postmortem, and
biopsy tissues from patients affected by neurodegenerative diseases and other diseases
(e.g. cancers) in which the TSPO density is altered.
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Progress to date has given us an insight on the structural modifications required to give
high affinity TSPO fluorescent probes using the NBD moiety. With this information we
intend to expand the variety of optical probes covering a greater range of wavelengths to
expand the utility of these probes in biological applications.

5.3 Tau Ligands
As part of our molecular imaging probes project, PBB3 30 was selected as an excellent
structural platform for the development of potential tau ligands. The core structure of
PBB3 30 consists of two building blocks; a benzothiazole and a pyridine, connected by a
trans-butadiene bridge. Replacing the photoisomerisable trans-butadiene bridge on PBB3
30 allowed significant structural modifications covering the benzothiazole region, carbon
linker, and pyridine unit; potentially offering photostability, increased radioactive halflife, and a variety of possible substitution patterns. This led to the discovery of 42 novel
potential tau ligands (57-62) for possible radiolabelling with either carbon-11 or fluorine18.

Several ligands were selected for biological evaluations. The in vitro fluorescence
staining revealed that some triazole derivatives showed good visualisation of Aβ plaques,
but failed to detect the NFTs in human brain sections. However, NFT can be observed
using ligands 61b (amide derivative) and 62c (ester derivative). Results from
heterologous binding assay showed that selected tau ligands exhibited none to low %
inhibition (0.0 – 36.8%) against [11C]PBB3 30. It was anticipated that one of the
contributing factors to the apparent lack of inhibition of PBB3 30 was the different
binding site(s) between the tested ligands and PBB3 30. Furthermore, the ligands showed
low to high affinities (Ki = > 1.5 mM – 0.46 nM) at the shared binding site(s) with PBB3
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30. Ligands 57a and 58a were found to have a similar affinity with PBB3 30 with Ki of
6.3 and 3.8 nM, respectively.

Further biological studies with synthesized tau ligands could include the binding assay
against different tau tracers (e.g. THK5351 25 and MK6240 34), radiosynthesis with
either carbon-11 or fluorine-18, followed by biodistribution and in vivo preclinical
imaging, and affinity assays in regards to other proteins involved in neurodegenerative
diseases, including α-synuclein (Parkinson’s disease) and TDP-43 (amyotrophic lateral
sclerosis).

It should be pointed out that all except one of the novel tau ligands synthesised and tested
to date bore either a methoxy or methyl substituent on the 6-position of the benzothiazole
ring. PiB 16, PBB3 30 and many related amyloid and tau ligands are prepared with a free
hydroxy group. It is not clear whether biological efficacy can be improved following
demethylation, although one analogue 57c bearing the hydroxy group did not show
improve binding.
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Chapter 6: Experimental

6.1 General Experimental Information
6.1.1 Synthesis
Unless stated otherwise, all chemicals were laboratory or reagent grade and were
purchased from Merck (Australia) or AK Scientific, Inc (USA), and were used as
received. All solvents were analytical grade, except HPLC grade for HPLC and mass
spectromentry, and when necessary, were purified and dried by standard methods.
Solvent mixtures are stated as volume to volume (v/v) proportion. Water was purified via
Millipore filtration prior to use. HOBT was purchased with added stabilizer (10% w/w
H2O), and therefore, the quantity required for reactions was adjusted accordingly and is
reflected in the reagent mass reported in the experimental.

All reactions requiring anhydrous conditions were conducted under a positive atmosphere
of nitrogen in oven-dried glassware. Cold reaction temperatures were obtained by an ice
bath (0 ºC). The heating of reactions was performed with a paraffin oil bath. Standard
syringe and autopipette techniques were used for the anhydrous addition of liquids.
Reactions were routinely monitored by TLC analysis performed on aluminium-backed
SiO2 gel plates (F254 grade – 0.20 mm thickness) or by low resolution mass spectrometry
(LRMS) on Shimadzu LC-2010 mass spectrometer. Visualization on TLC plates was
achieved with UV light (λ = 254, 365 nm), ninhydrin stain, or cerium ammonium
molybdate stain.
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All filtrations were conducted as a gravity filtration through a filter paper Whatman Grade
4 (20-25 µm) or as a vacuum filtration through a sintered glass funnel (medium porosity).
Vacuum filtration was achieved with the aid of a vacuum pump. Organic solutions were
dried over anhydrous Na2SO4. Solvent removal via concentration was performed on a
rotary evaporator under reduced pressure. Normal phase flash column chromatography
was performed on SiO2 gel 60 (0.063 – 0.200 mm) with a positive air pressure.
Preparative TLC was run using PLC silica gel 60 F254 1 mm plates (20 x 20 cm2). All
synthesized compounds were dried under high vacuum (< 1 mbar) before the
determination of chemical yields and spectroscopic characterization.

6.1.2 Characterization and Analysis
Melting points were determined on a Gallenkamp melting point apparatus in open
capillary tubes and were uncorrected. 1H and 13C NMR spectra were recorded on a Bruker
Avance 400 (400 MHz) or Varian Inova 500 (500 MHz) NMR spectrometer. Chemical
shifts (δ) were reported in parts per million (ppm) relative to the internal standard.
Multiplicities are reported as singlets (s), doublets (d), triplets (t), doublet of doublets
(dd), quartets (q), quintets (quint), or multiplets (m). Samples were dissolved in CDCl3
(with TMS as the internal standard – 0.00 ppm), CD3OD (solvent resonance as internal
standard – 3.31 ppm) or DMSO-d6 (solvent resonance as internal standard – 2.50 ppm).
13

C NMR signal assignments were confirmed by analysis of NMR experiments: APT,

gCOSY, gHSQC, gHMBC, zTOCSY, NOESY and/or gHSQC-TOCSY.

Low resolution mass spectrometry (LRMS) spectra were recorded on a Shimadzu LC2010 mass spectrometer in electrospray positive and negative ionization modes (ESIMS). High resolution mass spectrometry (HRMS) spectra were recorded on a Waters
Quadrupole-Time of Flight (QTOF) Xevo spectrometer or Thermo LTQ Orbitrap XL
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spectrometer in electrospray positive and negative ionization modes (ESI-MS). All mass
spectrometry samples were dissolved in HPLC grade MeOH. Peaks assigned to the
molecular ion are denoted as [M+H]+ or [M+Na]+ or [M-H]–. Solid-state infrared
spectroscopy was performed on a Bruker Vertex 70 FTIR spectrometer in combination
with a MIRacle 10 Single Reflection Attenuated Total Reflectance accessory outfitted
with a 1.5 mm round diamond crystal. IR peaks are reported as the wavenumber (𝜈 max in
cm-1) of the maximum absorption. Ultraviolet absorption spectra were recorded on a
Schimadzu 1800 spectrometer. Fluorescence spectra were recorded on a Cary Eclipse
fluorescence spectrophotometer. Both ultraviolet absorption and fluorescence spectra
were recorded at ambient temperature (23 ± 2 ºC). Compounds were prepared as stock
solutions in DMSO and diluted such that the DMSO concentration did not exceed 1%
v/v.
Analytical HPLC was performed on a Shimadzu LC-2030C 3D UV/vis detector (λ = 254
nm) using: a biphenyl column Kinetex 100 Å (150 × 4.60 mm; 5 μm) at 25 °C using
mobile phases A (water and 0.1% trifluoracetic acid (TFA)) and B (MeCN and 0.1%
TFA) at a flow rate of 1 mL.min−1. The following gradient was applied: gradient elution
for 35 min at 0 – 50% of solvent B, linear increase from 0 – 50% of solvent B over 25
min, hold at 50% of solvent B for 10 min (fluorescence compounds); and a C-18 column
(5 μm, 4.9 x 150 mm) at 25 °C using mobile phases A (water and 0.1% trifluoracetic acid
(TFA)) and B (MeCN and 0.1% TFA) at a flow rate of 1 mL.min −1. The following
gradient was applied: gradient elution for 35 min at 0 – 100% of solvent B, linear increase
from 0 – 100% of solvent B over 25 min, hold at 100% of solvent B for 10 min (tau
ligands). All analytical HPLC samples were filtered through Whatman syringe filter 0.45
µm.
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6.1.3 Notes and Other Consideration
All known compounds are marked with a reference after the compound title, and all
compounds without a reference are new. The experimental data is divided into:
1. Experimental procedures for the synthesis of fluorescent probes
2. Experimental procedures for the synthesis of tau ligands
3. Experimental procedures for the biological studies

6.2 Experimental Procedures for the Synthesis of Fluorescent Probes
6.2.1 Synthesis of TSPO Ligand Scaffold
6-Chloro-2-(4-methoxyphenyl)imidazo[1,2-a]pyridine 70139
To a solution of 2-bromo-4'-methoxyacetophenone 69
(15.00 g, 65.48 mmol) in EtOH (150 mL) was added 2amino-5-chloropyridine 68 (8.42 g, 65.48 mmol), and the reaction was stirred at reflux
for 2 h. NaHCO3 (3.25 g, 38.69 mmol) was added, and heating continued for another 8 h.
Additional NaHCO3 (2.25 g, 26.81 mmol) was added, and stirring continued for a further
30 min. After cooling at 4 ºC for 18 h, the resulting solid was collected by filtration, and
washed with cold EtOH (50 mL), H2O (100 mL), and EtOH (50 mL). The solid was then
boiled with EtOH (100 mL) for 15 min, cooled, filtered, and washed with EtOH (50 mL)
again, and dried in vacuo to afford the imidazopyridine 70 (12.32 g, 73%) as an off-white
solid. The spectroscopic data was in agreement with that previously reported. TLC
(CH2Cl2/MeOH – 95:5): Rf = 0.85. 1H NMR (400 MHz, DMSO) δ 8.78 (dd, J = 2.0, 0.8
Hz, 1H, H5), 8.26 (s, 1H, H3), 7.89 (d, J = 8.8 Hz, 2H, H2', H6'), 7.59 (d, J = 9.6 Hz, 1H,
H8), 7.26 (dd, J = 9.6, 2.0 Hz, H7), 7.01 (d, J = 8.8 Hz, 2H, H3', H5'), 3.81 (s, 3H,
ArOCH3). 13C NMR (400 MHz, DMSO) δ 159.2 (C4'), 145.5 (C2), 143.2 (C8a), 127.0
(C2', C6'), 126.0 (C1'), 125.4 (C7), 124.6 (C5), 118.7 (C6), 117.1 (C8), 114.2 (C3', C5'),
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108.7 (C3), 55.1 (ArOCH3). MS (ESI +ve) m/z 259 (35Cl [M + H]+, 100%), 261 (37Cl [M
+ H]+, 33%).

1-(6-Chloro-2-(4-methoxyphenyl)imidazo[1,2-a]pyridin-3-yl)-N,Ndimethylmethanamine 71139
To a solution of imidazopyridine 70 (12.00 g, 46.35 mmol)
in acetic acid (145 mL) was slowly added an aqueous
solution of NH(CH3)2 (40% w/w – 74 mL, 0.58 mol),
followed by aqueous H2CO (37% w/w – 30 mL, 0.40 mol). The resulting mixture was
stirred at 55 ºC for 18 h. After cooling to rt, the solution was concentrated, and the syrupy
residue was dissolved in a mixture of H2O (60 mL) and CHCl3 (120 mL). Aqueous NaOH
(10% w/v) was added dropwise until the pH was 12. The organic layer was separated, and
the aqueous layer was further extracted with CHCl3 (2 x 30 mL). The combined organic
layers were extracted with 2 N HCl (3 x 60 mL), and the extract partially neutralized with
NaOH (8.70 g) to pH 3. After standing at rt for 18 h, the precipitated hydroxymethyl byproduct (1.03 g) was filtered. The cold filtrate (ice bath) was basified to pH 12 with
NaOH, and the resulting solid was filtered, dried in vacuo, and recrystallized from
EtOH/H2O to afford the imidazopyridine dimethylmethanamine (tertiary amine) 71
(10.05 g, 69%) as a pale yellow crystals. The spectroscopic data was in agreement with
that previously reported. TLC (CH2Cl2/MeOH – 95:5): Rf = 0.75. 1H NMR (400 MHz,
DMSO) δ 8.64 (dd, J = 2.0, 0.8 Hz, 1H, H5), 7.78 (d, J = 8.8 Hz, 2H, H2', H6'), 7.62 (dd,
J = 9.6, 0.8 Hz, 1H, H8), 7.31 (dd, J = 9.6, 2.0 Hz, 1H, H7), 7.04 (d, J = 8.8 Hz, 2H, H3',
H5'), 3.89 (s, 2H, H1''), 3.80 (s, 3H, ArOCH3), 2.16 (s, 6H, H3''). 13C NMR (400 MHz,
DMSO) δ 159.0 (C4'), 144.5 (C2), 142.3 (C8a), 129.6 (C2', C6'), 126.5 (C1'), 125.2 (C7),
123.5 (C5), 118.5 (C6), 117.8 (C3), 117.2 (C8), 113.9 (C3', C5'), 55.1 (ArOCH3), 51.4
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(C1''), 44.4 (C3''). MS (ESI +ve) m/z 316 (35Cl [M + H]+, 100%), 318 (37Cl [M + H]+,
33%).

1-(6-Chloro-2-(4-methoxyphenyl)imidazo[1,2-a]pyridin-3-yl)-N,N,Ntrimethylmethanaminium iodide 72139
To a solution of tertiary amine 71 (8.76 g, 27.83 mmol) in
toluene (110 mL) was added CH3I (6.0 mL, 96.38 mmol),
and the mixture was stirred at rt for 48 h in darkness. The
precipitate was filtered, washed with toluene (10 mL), and dried in vacuo to afford the
ammonium iodide 72 (10.66 g, 84%) as a light yellow solid. The product was used in the
next reaction step immediately or stored in the freezer for a limited time due to stability
issues. The spectroscopic data was in agreement with that previously reported. TLC
(CH2Cl2/MeOH – 90:10): Rf = 0.66. 1H NMR (400 MHz, DMSO) δ 9.26 (br s, 1H, H5),
7.79 (d, J = 8.8 Hz, 2H, H2', H6'), 7.75 (d, J = 9.6 Hz, 1H, H8), 7.50 (dd, J = 9.6. 2.0 Hz,
1H, H7), 7.06 (d, J = 8.8 Hz, 2H, H3', H5'), 5.22 (s, 2H, H1''), 3.83 (s, 3H, ArOCH3), 2.89
(s, 9H, H3''). 13C NMR (400 MHz, DMSO) δ 159.5 (C4'), 149.0 (C2), 144.2 (C8a), 130.0
(C2', C6'), 127.3 (C7), 125.8 (C1'), 123.3 (C5), 120.4 (C6), 118.0 (C8), 114.3 (C3', C5'),
109.8 (C3), 56.4 (C1''), 55.2 (ArOCH3), 51.4 (C3''). MS (ESI) m/z 330 (35Cl [M], 100%),
332 (37Cl [M], 33%).
2-(6-Chloro-2-(4-methoxyphenyl)imidazo[1,2-a]pyridin-3-yl)acetamide 67139
A solution of ammonium iodide 72 (4.00 g, 8.74 mmol)
and KCN (3.90 g, 59.89 mmol) in EtOH/H2O (1:1, 150
mL) was stirred at reflux for 48 h. The solution was cooled
to rt and evaporated to dryness under a stream of N2. H2O (10 mL) was added, and the
solid was filtered, washed with H2O (5 mL), and dried in vacuo to afford the acetamide
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67 (1.96 mg, 71%) as a brown solid. The spectroscopic data was in agreement with that
previously reported. TLC (CH2Cl2/MeOH – 95:5): Rf = 0.71. 1H NMR (400 MHz,
DMSO) δ 8.61 (d, J = 2.0 Hz, 1H, H5), 7.80 (br s, 1H, C=ONH), 7.73 (d, J = 8.8 Hz, 2H,
H2', H6'), 7.61 (d, J = 9.6 Hz, 1H, H8), 7.29 (dd, J = 9.6, 2.0 Hz, 1H, H7), 7.24 (br s, 1H,
C=ONH), 7.05 (d, J = 8.8 Hz, 2H, H3', H5'), 3.98 (s, 2H, H1''), 3.81 (s, 3H, ArOCH3).
C NMR (400 MHz, DMSO) δ 170.6 (C2''), 159.0 (C4'), 143.7 (C2), 142.2 (C8a), 129.1

13

(C2', C6'), 126.5 (C1'), 124.8 (C7), 122.9 (C5), 118.6 (C6), 117.2 (C8), 116.1 (C3), 114.1
(C3', C5'), 55.2 (ArOCH3), 30.5 (C1''). MS (ESI +ve) m/z 316 (35Cl [M + H]+, 100%),
318 (37Cl [M + H]+, 33%).

6.2.2 Synthesis of Fluorescent Probes A
2-(6-Chloro-2-(4-methoxyphenyl)imidazo[1,2-a]pyridin-3-yl)acetic acid 78178
To a solution of acetamide 67 (1.60 g, 5.07 mmol) in EtOH
(35 mL) was added a solution of KOH (2.42 g, 43.10
mmol) in H2O (6.0 mL). The reaction was stirred at reflux
for 18 h. The EtOH was removed, and the minimum volume of H2O was added to the
residue to dissolve completely any solid material. Acidification to pH = 4 with an aqueous
HCl solution (12% v/v, 9 mL) precipitated the product which was filtered, washed with
H2O (20 mL), and dried in vacuo to afford the imidazopyridine carboxylic acid 78 (1.51
g, 94%) as a grey solid. The spectroscopic data was in agreement with that previously
reported. TLC (CH2Cl2/MeOH – 95:5): Rf = 0.62. 1H NMR (400 MHz, DMSO) δ 9.24 (br
s, 1H, H5), 7.99 – 7.93 (m, 2H, H7, H8), 7.67 (d, J = 8.8 Hz, 2H, H2', H6'), 7.20 (d, J =
8.8 Hz, 2H, H3', H5'), 4.26 (s, 2H, H1''), 3.85 (s, 3H, ArOCH3).
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C NMR (400 MHz,

DMSO) δ 169.8 (C2''), 160.7 (C4'), 138.3 (C2), 135.2 (C8a), 132.5 (C1'), 129.8 (C2', C6'),
125.2 (C7), 123.2 (C5), 119.2 (C6), 116.8 (C8), 114.9 (C3', C5'), 113.4 (C3), 55.5
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(ArOCH3), 29.4 (C1''). MS (ESI +ve) m/z 317 (35Cl [M + H]+, 100%), 319 (37Cl [M +
H]+, 33%).
General Procedure A: Amide Coupling
The imidazopyridine carboxylic acid (1.0 eq), the appropriate mono-N-Boc-protected
diamine (1.2 eq), HOBT (1.0 eq), EDCI (1.3 eq), and DIPEA (4.0 eq) were combined in
anhydrous DMF (6.0 mL/mmol acid), and stirred at rt for 24 h under N2 atmosphere. The
resulting reaction mixture was poured into H2O (25 mL) and extracted with EtOAc (3 x
25 mL). The organic layer was washed with H2O (2 x 25 mL), brine (2 x 25 mL), dried
(Na2SO4), filtered, and concentrated. The residue was subjected to flash chromatography
over SiO2 gel (CH2Cl2/MeOH – 95:5) to afford the desired amide (Boc-protected amine).
Tert-butyl (2-(2-(6-chloro-2-(4-methoxyphenyl)imidazo[1,2-a]pyridin-3yl)acetamido)ethyl)carbamate 80a
Following

General

Procedure

A,

imidazopyridine carboxylic acid 78 (220 mg,
0.69 mmol), tert-butyl (2-aminoethyl)carbamate
79a (133 mg, 0.83 mmol), HOBT (103 mg, 0.69 mmol), EDCI (173 mg, 0.90 mmol), and
DIPEA (357 mg, 2.76 mmol) were stirred in anhydrous DMF (4.1 mL) for 24 h to afford
the amide 80a (233 mg, 74%) as a pale yellow oil after flash chromatography. TLC
(CH2Cl2/MeOH – 95:5): Rf = 0.78. 1H NMR (400 MHz, CDCl3) δ 8.12 (br s, 1H, H5),
7.64 (d, J = 8.8 Hz, 2H, H2', H6'), 7.53 (d, J = 9.6 Hz, 1H, H8), 7.16 (dd, J = 9.6, 2.0 Hz,
1H, H7), 6.99 (d, J = 8.8 Hz, 2H, H3', H5'), 6.71 (br s, 1H, H3''), 4.83 (br s, 1H, H6''),
3.93 (s, 2H, H1''), 3.85 (s, 3H, ArOCH3), 3.37 (dt, J = 5.6, 5.2 Hz, 2H, H4''), 3.20 (dt, J =
5.6, 5.2 Hz, 2H, H5''), 1.36 (s, 9H, H9'').
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C NMR (400 MHz, CDCl3) δ 168.7 (C2''),

159.9 (C4'), 157.2 (C7''), 145.8 (C2), 143.7 (C8a), 129.7 (C2', C6'), 126.2 (C1'), 126.1
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(C7), 121.6 (C5), 120.9 (C6), 117.8 (C8), 114.5 (C3', C5'), 113.7 (C3), 80.1 (C8''), 55.5
(ArOCH3), 41.5 (C5''), 40.5 (C4''), 32.7 (C1'), 28.4 (C9''). IR (neat) 𝜈 max 3310 (br), 3256
(m), 2935 (w), 2361 (w), 2339 (w), 1810 (w), 1770 (w), 1683 (s), 1638 (s), 1539 (s), 1465
(s), 1390 (m), 1285 (m), 1249 (s), 1174 (s), 1010 (s), 992 (s), 623 (s), 522 (s) cm-1. MS
(ESI +ve) m/z 459 (35Cl [M + H]+, 100%), 461 (37Cl [M + H]+, 33%). HRMS (ESI +ve
TOF) calcd for C23H2835ClN4O4 459.1794, found 459.1792 ([M + H]+).

Tert-butyl (3-(2-(6-chloro-2-(4-methoxyphenyl)imidazo[1,2-a]pyridin-3yl)acetamido)propyl)carbamate 80b
Following

General

Procedure

A,

imidazopyridine carboxylic acid 78 (300 mg,
0.95

mmol),

tert-butyl

(3-

aminopropyl)carbamate 79b (196 mg, 1.14 mmol), HOBT (141 mg, 0.95 mmol), EDCI
(238 mg, 1.24 mmol), and DIPEA (491 mg, 3.80 mmol) were stirred in anhydrous DMF
(5.6 mL) for 24 h to afford the amide 80b (364 mg, 81%) as a pale yellow oil after flash
chromatography. TLC (CH2Cl2/MeOH – 95:5): Rf = 0.76. 1H NMR (400 MHz, CDCl3) δ
8.16 (br s, 1H, H5), 7.68 (d, J = 8.8 Hz, 2H, H2', H6'), 7.55 (d, J = 9.6 Hz, 1H, H8), 7.16
(dd, J = 9.6, 2.0 Hz, 1H, H7), 6.99 (d, J = 8.8 Hz, 2H, H3', H5'), 6.92 (br s, 1H, H3''), 4.71
(t, J = 5.2 Hz, 1H, H7''), 3.95 (s, 2H, H1''), 3.85 (s, 3H, ArOCH3), 3.27 (dt, J = 6.4, 5.6
Hz, 2H, H4''), 3.03 (dt, J = 6.4, 5.6 Hz, 2H, H6''), 1.58 – 1.51 (m, 2H, H5''), 1.34 (s, 9H,
H10''). 13C NMR (400 MHz, CDCl3) δ 168.4 (C2''), 159.8 (C4'), 156.9 (C8''), 145.7 (C2),
143.7 (C8a), 129.7 (C2', C6'), 126.4 (C1'), 125.9 (C7), 121.6 (C5), 120.8 (C6), 117.9 (C8),
114.4 (C3', C5'), 114.0 (C3), 79.7 (C9''), 55.5 (ArOCH3), 36.8 (C6''), 35.9 (C4''), 32.8
(C1''), 30.3 (C5''), 28.4 (C10''). IR (neat) 𝜈 max 3344 (br), 3308 (w), 2980 (w), 2361 (w),
2340 (w), 1800 (w), 1776 (w), 1682 (s), 1644 (s), 1528 (s), 1457 (s), 1389 (m), 1364 (m),
1285 (m), 1246 (s), 1171 (s), 1027 (m), 787 (s), 626 (m), 531 (m) cm-1. MS (ESI +ve) m/z
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473 (35Cl [M + H]+, 100%), 475 (37Cl [M + H]+, 33%). HRMS (ESI +ve TOF) calcd for
C24H3035ClN4O4 473.1950, found 473.1947 ([M + H]+).

Tert-butyl (4-(2-(6-chloro-2-(4-methoxyphenyl)imidazo[1,2-a]pyridin-3yl)acetamido)butyl)carbamate 80c
Following

General

Procedure

A,

imidazopyridine carboxylic acid 78 (300
mg,

0.95

mmol),

tert-butyl

(4-

aminobutyl)carbamate 79c (215 mg, 1.14 mmol), HOBT (141 mg, 0.95 mmol), EDCI
(238 mg, 1.24 mmol), and DIPEA (491 mg, 3.80 mmol) were stirred in anhydrous DMF
(5.6 mL) for 24 h to afford the amide 80c (420 mg, 91%) as a pale yellow oil after flash
chromatography. TLC (CH2Cl2/MeOH – 95:5): Rf = 0.71. 1H NMR (400 MHz, DMSO)
δ 8.61 (br s, 1H, H5), 8.32 (t, J = 5.6 Hz, 1H, H3''), 7.72 (d, J = 8.8 Hz, 2H, H2', H6'),
7.61 (d, J = 9.6 Hz, 1H, H8), 7.29 (dd, J = 9.6, 2.0 Hz, 1H, H7), 7.03 (d, J = 8.8 Hz, 2H,
H3', H5'), 6.78 (t, J = 5.6 Hz, 1H, H8''), 3.98 (s, 2H, H1''), 3.81 (s, 3H, ArOCH3), 3.10
(dt, J = 5.6, 5.2 Hz, 2H, H4''), 2.95 (dt, J = 5.6, 5.2 Hz, 2H, H7''), 1.45 – 1.37 (m, 4H,
(H5'', H6''), 1.36 (s, 9H, H11''). 13C NMR (400 MHz, DMSO) δ 168.0 (C2''), 159.0 (C4'),
155.6 (C9''), 143.6 (C2), 142.2 (C8a), 129.1 (C2', C6'), 126.5 (C1'), 124.8 (C7), 122.9
(C5), 118.6 (C6), 117.2 (C8), 115.9 (C3), 114.0 (C3', C5'), 77.3 (C10''), 55.1 (ArOCH3),
40.2 (C7''), 38.6 (C4''), 30.7 (C1''), 28.2 (C11''), 27.0 (C5'' or C6''), 26.4 (C5'' or C6''). IR
(neat) 𝜈 max 3310 (br), 3256 (br), 2935 (w), 1790 (w), 1780 (w), 1682 (m), 1639 (m), 1560
(m), 1535 (m), 1500 (m), 1365 (m), 1285 (m), 1249 (s), 1174 (m), 1025 (s), 990 (s), 623
(s), 522 (s) cm-1. MS (ESI +ve) m/z 487 (35Cl [M + H]+, 100%), 489 (37Cl [M + H]+, 33%).
HRMS (ESI +ve TOF) calcd for C25H3235ClN4O4 487.2107, found 487.2105 ([M + H]+).
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Tert-butyl (6-(2-(6-chloro-2-(4-methoxyphenyl)imidazo[1,2-a]pyridin-3yl)acetamido)hexyl)carbamate 80d
Following General Procedure A,
imidazopyridine carboxylic acid 78
(300 mg, 0.95 mmol), tert-butyl (6aminohexyl)carbamate 79d (247 mg, 1.14 mmol), HOBT (141 mg, 0.95 mmol), EDCI
(238 mg, 1.24 mmol), and DIPEA (491 mg, 3.80 mmol) were stirred in anhydrous DMF
(5.6 mL) for 24 h to afford the amide 80d (470 mg, 96%) a pale yellow oil after flash
chromatography. TLC (CH2Cl2/MeOH – 95:5): Rf = 0.70. 1H NMR (400 MHz, DMSO)
δ 8.60 (br s, 1H, H5), 8.32 (t, J = 5.6 Hz, 1H, H3''), 7.74 (d, J = 8.8 Hz, 2H, H2', H6'),
7.62 (d, J = 9.6 Hz, 1H, H8), 7.31 (dd, J = 9.6, 2.0 Hz, 1H, H7), 7.04 (d, J = 8.8 Hz, 2H,
H3', H5'), 6.74 (t, J = 5.6 Hz, 1H, H10''), 3.98 (s, 2H, H1''), 3.81 (s, 3H, ArOCH3), 3.11
(dt, J = 5.6, 5.2 Hz, 2H, H4''), 2.90 (dt, J = 5.6, 5.2 Hz, 2H, H9''), 1.46 – 1.21 (m, 8H,
H5'', H6'', H7'', H8''), 1.36 (s, 9H, H13'').
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C NMR (400 MHz, DMSO) δ 168.1 (C2''),

159.1 (C4'), 155.7 (C11''), 143.6 (C2), 142.3 (C8a), 129.3 (C2', C6'), 126.5 (C1'), 125.0
(C7), 122.9 (C5), 118.8 (C6), 117.3 (C8), 116.0 (C3), 114.1 (C3', C5'), 77.5 (C12''), 55.2
(ArOCH3), 40.0 (C9''), 39.0 (C4''), 30.8 (C1''), 29.6 (C5'' or C6'' or C7'' or C8''), 29.1 (C5''
or C6'' or C7'' or C8''), 28.4 (C13''), 26.2 (C5'' or C6'' or C7'' or C8''), 26.1 (C5'' or C6'' or
C7'' or C8''). IR (neat) 𝜈 max 3292 (br), 2931 (w), 1800 (w), 1776 (w), 1688 (s), 1651 (s),
1500 (s), 1456 (m), 1390 (s), 1364 (s), 1329 (m), 1248 (s), 1172 (s), 1026 (s), 837 (s), 799
(s), 626 (s) cm-1. MS (ESI +ve) m/z 515 (35Cl [M + H]+, 100%), 517 (37Cl [M + H]+, 33%).
HRMS (ESI +ve TOF) calcd for C27H3635ClN4O4 515.2420, found 515.2429 ([M + H]+).
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General Procedure B: Amine Deprotection
The Boc-protected amine (1.0 eq) in CH2Cl2 (10 mL/mmol amine) was treated with
CF3CO2H (3.0 mL/mmol amine). The reaction mixture was stirred at rt for 4 h followed
by removal of the solvent. The residue was dissolved in EtOAc (25 mL), neutralized with
saturated aqueous NaHCO3, and then washed with H2O (2 x 25 mL). The organic layer
was dried (Na2SO4) and concentrated. The residue was subjected to flash chromatography
over SiO2 gel (CH2Cl2/MeOH – 95:5) to afford the desired free amine (final ligand).

N-(2-Aminoethyl)-2-(6-chloro-2-(4-methoxyphenyl)imidazo[1,2-a]pyridin-3yl)acetamide 81a
Following General Procedure B, Boc-protected amine
80a (110 mg, 0.24 mmol) was dissolved in CHCl2 (2.4
mL) and treated with CF3CO2H (0.7 mL) to afford the
final ligand 81a (75 mg, 87%) as a pale yellow foam that collapsed into a translucent gum
after flash chromatography. TLC (CH2Cl2/MeOH – 95:5): Rf = 0.50. 1H NMR (400 MHz,
DMSO) δ 8.59 (br s, 1H, H5), 8.49 (t, J = 5.6 Hz, 1H, H3''), 7.68 (d, J = 8.8 Hz, 2H, H2',
H6'), 7.61 (d, J = 9.2 Hz, 1H, H8), 7.31 (dd, J = 9.2, 2.0 Hz, 1H, H7), 7.04 (d, J = 8.8 Hz,
2H, H3', H5'), 4.03 (s, 2H, H1''), 3.80 (s, 3H, ArOCH3), 3.47 (br s, 2H, H6''), 3.38 (dt, J
= 6.0, 5.6 Hz, 2H, H4''), 2.92 (t, J = 6.0 Hz, 2H, H5''). 13C NMR (400 MHz, DMSO) δ
169.3 (C2''), 159.1 (C4'), 143.8 (C2), 142.4 (C8a), 129.3 (C2', C6'), 126.5 (C1'), 125.2
(C7), 123.1 (C5), 118.8 (C6), 117.3 (C8), 115.6 (C3), 114.2 (C3', C5'), 55.3 (ArOCH3),
38.9 (C5''), 36.9 (C4''), 30.8 (C1''). IR (neat) 𝜈 max 3336 (br), 3085 (w), 2944 (w), 1779
(m), 1661 (m), 1563 (m), 1509 (m) 1260 (m), 1224 (s), 1140 (s), 1026 (m), 834 (s), 809
(s), 704 (s), 517 (s) cm-1. MS (ESI +ve) m/z 359 (35Cl [M + H]+, 100%), 361 (37Cl [M +
H]+, 33%). HRMS (ESI +ve TOF) calcd for C18H2035ClN4O2 359.1269, found 359.1263
([M + H]+).
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N-(3-Aminopropyl)-2-(6-chloro-2-(4-methoxyphenyl)imidazo[1,2-a]pyridin-3yl)acetamide 81b
Following General Procedure B, Boc-protected
amine 80b (200 mg, 0.42 mmol) was dissolved in
CHCl2 (4.2 mL) and treated with CF3CO2H (1.3 mL) to
afford the final ligand 81b (140 mg, 89%) as a pale yellow foam that collapsed into a
translucent gum after flash chromatography. TLC (CH2Cl2/MeOH – 95:5): Rf = 0.49. 1H
NMR (400 MHz, DMSO) δ 8.89 (br s, 1H, H5), 8.54 (t, J = 5.6 Hz, 1H, H3''), 7.89 – 7.79
(m, 3H, H7, H7''), 7.70 (d, J = 8.8 Hz, 2H, H2', H6'), 7.64 (d, J = 9.2 Hz, 1H, H8), 7.12
(d, J = 8.8 Hz, 2H, H3', H5'), 4.07 (s, 2H, H1''), 3.83 (s, 3H, ArOCH3), 3.22 (dt, J = 6.0,
5.6 Hz, 2H, H4''), 2.86 – 2.76 (m, 2H, H6''), 1.76 (quint, J = 6.0 Hz, 2H, H5''). 13C NMR
(400 MHz, DMSO) δ 167.7 (C2''), 161.2 (C4'), 138.6 (C8a), 135.1 (C2), 133.1 (C8),
130.4 (C2', C6'), 125.8 (C5), 123.8 (C1'), 119.5 (C6), 118.2 (C3), 115.4 (C3', C5'), 113.6
(C7), 56.0 (ArOCH3), 37.1 (C6''), 36.6 (C4''), 30.4 (C1''), 27.5 (C5''). IR (neat) 𝜈 max 3370
(br), 2962 (w), 2728 (w), 1656 (s), 1508 (m), 1420 (m), 1354 (m), 1301 (m), 1255 (m),
1174 (s), 1125 (s), 1019 (m), 833 (s), 795 (s), 720 (s), 518 (s) cm-1. MS (ESI +ve) m/z
373 (35Cl [M + H]+, 100%), 375 (37Cl [M + H]+, 33%). HRMS (ESI +ve TOF) calcd for
C19H2235ClN4O2 373.1426, found 373.1424 ([M + H]+).

N-(4-Aminobutyl)-2-(6-chloro-2-(4-methoxyphenyl)imidazo[1,2-a]pyridin-3yl)acetamide 81c
Following General Procedure B, Boc-protected
amine 80c (200 mg, 0.41 mmol) was dissolved in
CHCl2 (4.1 mL) and treated with CF3CO2H (1.2 mL)
to afford the final ligand 81c (135 mg, 85%) as a pale yellow foam that collapsed into a
translucent gum after flash chromatography. TLC (CH2Cl2/MeOH – 95:5): Rf = 0.46. 1H
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NMR (400 MHz, DMSO) δ 8.87 (br s, 1H, H5), 8.47 (t, J = 5.6 Hz, 1H, H3''), 7.90 – 7.80
(m, 3H, H7, H8''), 7.70 (d, J = 8.8 Hz, 2H, H2', H6'), 7.63 (d, J = 9.2 Hz, 1H, H8), 7.12
(d, J = 8.8 Hz, 2H, H3', H5'), 4.05 (s, 2H, H1''), 3.84 (s, 3H, ArOCH3), 3.13 (dt, J = 6.0,
5.6 Hz, 2H, H4''), 2.85 – 2.76 (m, 2H, H7''), 1.60 – 1.46 (m, 4H, H5'', H6''). 13C NMR
(400 MHz, DMSO) δ 167.5 (C2''), 161.1 (C4'), 138.5 (C8a), 134.9 (C2), 133.1 (C8), 130.4
(C2', C6'), 125.8 (C5), 123.7 (C1'), 119.5 (C6), 118.3 (C3), 115.3 (C3', C5'), 113.6 (C7),
60.0 (ArOCH3), 38.7 (C7''), 38.7 (C4''), 30.4 (C1''), 26.4 (C5''or C6''), 24.8 (C5''or C6'').
IR (neat) 𝜈 max 3300 (br), 3161 (w), 2960 (w), 1777 (w), 1640 (m), 1611 (m), 1555 (m),
1510 (m), 1260 (m), 1180 (s), 1130 (s), 1023 (m), 906 (m), 820 (s), 796 (s), 704 (s), 518
(s) cm-1. MS (ESI +ve) m/z 387 (35Cl [M + H]+, 100%), 389 (37Cl [M + H]+, 33%). HRMS
(ESI +ve TOF) calcd for C20H2435ClN4O2 387.1582, found 387.1583 ([M + H]+).

N-(6-Aminohexyl)-2-(6-chloro-2-(4-methoxyphenyl)imidazo[1,2-a]pyridin-3yl)acetamide 81d
Following General Procedure B, Bocprotected amine 80d (225 mg, 0.44 mmol) was
dissolved in CHCl2 (4.4 mL) and treated with
CF3CO2H (1.3 mL) to afford the final ligand 81d (160 mg, 87%) as a pale yellow foam
that collapsed into a translucent gum after flash chromatography. TLC (CH2Cl2/MeOH –
95:5): Rf = 0.45. 1H NMR (400 MHz, DMSO) δ 9.22 (br s, 1H, H5), 8.68 (t, J = 5.6 Hz,
1H, H3''), 8.05 (br s, 2H, H10''), 7.99 – 7.93 (m, 2H, H7, H8), 7.77 (d, J = 8.8 Hz, 2H,
H2', H6'), 7.16 (d, J = 8.8 Hz, 2H, H3', H5'), 4.14 (s, 2H, H1''), 3.85 (s, 3H, ArOCH3),
3.11 (dt, J = 6.0, 5.6 Hz, 2H, H4''), 2.77 – 2.69 (m, 2H, H9''), 1.58 – 1.24 (m, 8H, H5'',
H6'', H7'', H8''). 13C NMR (400 MHz, DMSO) δ 167.3 (C2''), 161.1 (C4'), 138.8 (C8a),
135.6 (C2), 132.6 (C7), 130.4 (C2', C6'), 125.6 (C5), 123.5 (C6), 120.0 (C1'), 118.3 (C3),
115.2 (C3', C5'), 113.9 (C8), 56.0 (ArOCH3), 30.4 (C1''), 29.2 (C9''), 27.3 (C4''), 27.2
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(C5'' or C6'' or C7'' or C8''), 26.4 (C5'' or C6'' or C7'' or C8''), 26.0 (C5'' or C6'' or C7'' or
C8''), 25.8 (C5'' or C6'' or C7'' or C8''). IR (neat) 𝜈 max 3337 (br), 3086 (w), 2943 (w), 1779
(m), 1661 (m), 1609 (m), 1563 (m), 1510 (m), 1240 (m), 1139 (s), 1026 (s), 908 (m), 834
(s), 784 (s), 704 (s), 516 (s) cm-1. MS (ESI +ve) m/z 415 (35Cl [M + H]+, 100%), 417 (37Cl
[M + H]+, 33%). HRMS (ESI +ve TOF) calcd for C22H2835ClN4O2 415.1895, found
415.1895 ([M + H]+).

General Procedure C: Synthesis of Fluorescent Probes
The ligand (1.0 eq) was dissolved in anhydrous DMF (20 mL/mmol amine) with magnetic
stirring. The solution was brought to 0 ºC (ice bath) followed by sequential dropwise
addition of DIPEA (1.4 eq) and a solution of NBD-Cl (1.0 eq) in DMF (1.0 mL) under a
flow of N2 gas. The reaction vessel was then sealed and allowed to warm to rt and stirring
was continued for 18 h under N2 atmosphere in darkness. The solution was partitioned
between CHCl3 (100 mL) and H2O (100 mL). The aqueous phase was separated, and
extracted with CHCl3 (5 x 50 mL). The combined organic extracts were washed with H2O
(2 x 100 mL), brine (2 x 100 mL), dried (Na2SO4), filtered, and concentrated. The residue
was purified by preparative TLC plate chromatography to afford the desired fluorescent
probe.

2-(6-Chloro-2-(4-methoxyphenyl)imidazo[1,2-a]pyridin-3-yl)-N-(2-((7nitrobenzo[c][1,2,5]oxadiazol-4-yl)amino)ethyl)acetamide 55a
Following General Procedure C, ligand 81a
(40 mg, 0.11 mmol) was dissolved in DMF
(1.1 mL) followed by sequential addition of
DIPEA (19 mg, 0.15 mmol) and NBD-Cl 54
(22 mg, 0.11 mmol) to afford the desired fluorescent probe 55a (31 mg, 54%) as a light
172

brown solid after preparative TLC plate chromatography (CH2Cl2/MeOH – 95:5). TLC
(CH2Cl2/MeOH – 95:5): Rf = 0.33. Mp 207 ºC. 1H NMR (500 MHz, DMSO) δ 9.31 (br
s, 1H, H6''), 8.54 – 8.48 (m, 2H, H5, H3''), 8.31 (d, J = 8.5 Hz, 1H, H6'''), 7.71 (d, J = 8.5
Hz, 2H, H2', H6'), 7.57 (d, J = 9.5 Hz, 1H, H8), 7.20 (d, J = 9.5 Hz, 1H, H7), 6.92 (d, J =
8.5 Hz, 2H, H3', H5'), 6.31 (d, J = 8.5 Hz, 1H, H5'''), 3.97 (s, 2H, H1''), 3.77 (s, 3H,
ArOCH3), 3.60 (br s, 2H, H5''), 3.50 – 3.45 (m, 2H, H4''). 13C NMR (500 MHz, DMSO)
δ 169.4 (C2''), 159.4 (C4'), 145.9 (C7'''), 144.8 (C4'''), 144.5 (C3'''a), 144.1 (C2), 142.7
(C8a), 138.2 (C6'''), 129.5 (C2', C6'), 126.8 (C1'), 125.3 (C7), 123.1 (C5), 121.4 (C7'''a),
119.1 (C6), 117.6 (C8), 115.7 (C3), 114.3 (C3', C5'), 99.3 (C5'''), 55.5 (ArOCH3), 43.2
(C5''), 38.4 (C4''), 31.3 (C1''). IR (neat) 𝜈 max 3363 (br), 3276 (w), 3100 (w), 1760 (w),
1654 (m), 1632 (m), 1589 (s), 1539 (s), 1517 (s), 1303 (s), 1137 (s), 1022 (m), 999 (s),
828 (s), 778 (s), 738 (s), 623 (s) cm-1. MS (ESI -ve) m/z 520 (35Cl [M – H]–, 100%), 522
(37Cl [M – H]–, 33%). HRMS (ESI -ve TOF) calcd for C24H1935ClN7O5 520.1142, found
520.1136 ([M – H]–).

2-(6-Chloro-2-(4-methoxyphenyl)imidazo[1,2-a]pyridin-3-yl)-N-(3-((7nitrobenzo[c][1,2,5]oxadiazol-4-yl)amino)propyl)acetamide 55b
Following General Procedure C, ligand
81b (150 mg, 0.40 mmol) was dissolved in
DMF (3.0 mL) followed by sequential
addition of DIPEA (72 mg, 0.56 mmol) and
NBD-Cl 54 (80 mg, 0.40 mmol) to afford the desired fluorescent probe 55b (90 mg, 42%)
as a light brown solid after preparative TLC plate chromatography (CH2Cl2/MeOH –
90:10). TLC (CH2Cl2/MeOH – 90:10): Rf = 0.48. Mp 208 ºC. 1H NMR (400 MHz,
DMSO) δ 9.47 (t, J = 4.4 Hz, 1H, H7''), 8.64 (br s, 1H, H5), 8.47 (d, J = 9.2 Hz, 1H, H6'''),
8.38 (t, J = 4.4 Hz, 1H, H3''), 7.73 (d, J = 8.8 Hz, 2H, H2', H6'), 7.62 (d, J = 9.6 Hz, 1H,
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H8), 7.29 (dd, J = 9.6, 2.0 Hz, 1H, H7), 7.01 (d, J = 8.8 Hz, 2H, H3', H5'), 6.34 (d, J =
9.2 Hz, 1H, H5'''), 4.02 (s, 2H, H1''), 3.78 (s, 3H, ArOCH3), 3.49 (br s, 2H, H6''), 3.28 –
3.23 (m, 2H, H4''), 1.92 – 1.85 (m, 2H, H5''). 13C NMR (400 MHz, DMSO) δ 168.8 (C2''),
159.5 (C4'), 145.6 (C7'''), 144.9 (C4'''), 144.6 (C3'''a), 143.9 (C2), 142.6 (C8a), 138.3
(C6'''), 129.6 (C2', C6'), 126.8 (C1'), 125.5 (C7), 123.4 (C5), 121.3 (C7'''a), 119.2 (C6),
117.6 (C8), 116.2 (C3), 114.5 (C3', C5'), 99.5 (C5'''), 55.6 (ArOCH3), 41.6 (C6''), 37.0
(C4''), 31.2 (C1''), 28.1 (C5''). IR (neat) 𝜈 max 3231 (br), 3072 (w), 2966 (w), 1717 (w),
1633 (m), 1582 (m), 1523 (m), 1495 (m), 1446 (m), 1293 (s), 1249 (s), 1175 (s), 1137
(s), 1010 (m), 802 (s), 597 (s), 526 (s) cm-1. MS (ESI -ve) m/z 534 (35Cl [M – H]–, 100%),
536 (37Cl [M – H]–, 33%). HRMS (ESI -ve TOF) calcd for C25H2135ClN7O5 534.1298,
found 534.1305 ([M – H]–).

2-(6-Chloro-2-(4-methoxyphenyl)imidazo[1,2-a]pyridin-3-yl)-N-(4-((7nitrobenzo[c][1,2,5]oxadiazol-4-yl)amino)butyl)acetamide 55c
Following General Procedure C,
ligand 81c (100 mg, 0.26 mmol) was
dissolved in DMF (1.6 mL) followed by
sequential addition of DIPEA (47 mg,
0.36 mmol) and NBD-Cl 54 (52 mg, 0.26 mmol) to afford the desired fluorescent probe
55c (82 mg, 57%) as a light brown solid after preparative TLC plate chromatography
(CH2Cl2/MeOH – 93:7). TLC (CH2Cl2/MeOH – 93:7): Rf = 0.31. Mp 208 ºC. 1H NMR
(500 MHz, DMSO) δ 9.55 (t, J = 4.4 Hz, 1H, H8''), 8.61 (s, 1H, H5), 8.40 (d, J = 9.2 Hz,
1H, H6'''), 8.36 (t, J = 4.4 Hz, 1H, H3''), 7.72 (d, J = 8.8 Hz, 2H, H2', H6'), 7.61 (d, J =
9.6 Hz, 1H, H8), 7.27 (d, J = 9.6 Hz, 1H, H7), 6.99 (d, J = 8.8 Hz, 2H, H3', H5'), 6.38 (d,
J = 9.2 Hz, 1H, H5'''), 3.97 (s, 2H, H1''), 3.77 (s, 3H, ArOCH3), 3.46 (br s, 2H, H7''), 3.19
(dt, J = 6.0, 5.6 Hz, 2H, H4''), 1.74 – 1.66 (m, 2H, H5'' or H6''), 1.61 – 1.53 (m, 2H, H5''
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or H6'').
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C NMR (500 MHz, DMSO) δ 168.6 (C2''), 159.4 (C4'), 145.6 (C7'''), 144.9

(C2), 142.6 (C8a), 138.4 (C6'''), 133.0 (C4'''), 131.0 (C3'''a), 129.6 (C2', C6'), 126.8 (C1'),
125.4 (C7), 123.4 (C5), 121.1 (C7'''a), 119.1 (C6), 117.6 (C8), 116.4 (C3), 114.4 (C3',
C5'), 99.5 (C5'''), 55.6 (ArOCH3), 44.4 (C7''), 38.8 (C4''), 31.2 (C1''), 27.0 (C5'' or C6''),
25.5 (C5'' or C6''). IR (neat) 𝜈 max 3368 (br), 3218 (w), 3081 (w), 2914 (w), 1735 (w), 1661
(m), 1620 (m), 1564 (m), 1506 (m), 1461 (m), 1316 (s), 1231 (s), 1172 (s), 1017 (s), 908
(m), 829 (s), 807 (s), 741 (s), 599 (s), 523 (s) cm-1. MS (ESI +ve) m/z 550 (35Cl [M + H]+,
100%), 552 (37Cl [M + H]+, 33%). HRMS (ESI +ve TOF) calcd for C26H2535ClN7O5
550.1600, found 550.1601 ([M + H]+).

2-(6-Chloro-2-(4-methoxyphenyl)imidazo[1,2-a]pyridin-3-yl)-N-(6-((7nitrobenzo[c][1,2,5]oxadiazol-4-yl)amino)hexyl)acetamide 55d
Following General Procedure C,
ligand 81d (100 mg, 0.24 mmol)
was dissolved in DMF (1.4 mL)
followed by sequential addition of
DIPEA (44 mg, 0.34 mmol) and NBD-Cl 54 (48 mg, 0.24 mmol) to afford the desired
fluorescent probe 55d (78 mg, 56%) as a light brown solid after preparative TLC plate
chromatography (CH2Cl2/MeOH – 90:10). TLC (CH2Cl2/MeOH – 90:10): Rf = 0.30. Mp
210 ºC. 1H NMR (400 MHz, DMSO) δ 9.53 (t, J = 4.4 Hz, 1H, H10''), 8.60 (s, 1H, H5),
8.48 (d, J = 9.2 Hz, 1H, H6'''), 8.32 (t, J = 4.4 Hz, 1H, H3''), 7.73 (d, J = 8.8 Hz, 2H, H2',
H6'), 7.60 (d, J = 9.6 Hz, 1H, H8), 7.27 (dd, J = 9.6, 2.0 Hz, 1H, H7), 7.00 (d, J = 8.8 Hz,
2H, H3', H5'), 6.36 (d, J = 9.2 Hz, 1H, H5'''), 3.98 (s, 2H, H1''), 3.78 (s, 3H, ArOCH3),
3.33 (br s, 2H, H9''), 3.12 (dt, J = 6.4, 5.6 Hz, 2H, H4''), 1.69 (quint, J = 6.4 Hz, 2H, H5''
or H8''), 1.48 (quint, J = 6.4 Hz, 2H, H5'' or H8''), 1.46 – 1.35 (m, 4H, H6'', H7'').
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NMR (400 MHz, DMSO) δ 168.0 (C2''), 158.9 (C4'), 145.1 (C7'''), 144.4 (C4'''), 144.1
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(C3'''a), 143.5 (C2), 142.1 (C8a), 137.9 (C6'''), 129.1 (C2', C6'), 126.4 (C1'), 124.9 (C7),
122.8 (C5), 120.5 (C7'''a), 118.6 (C6), 117.2 (C8), 115.9 (C3), 113.9 (C3', C5'), 99.0
(C5'''), 55.1 (ArOCH3), 43.3 (C9''), 38.7 (C4''), 30.7 (C1''), 28.9 (C5'' or C8''), 27.6 (C5''
or C8''), 26.1 (C6'' or C7''), 26.0 (C6'' or C7''). IR (neat) 𝜈 max 3255 (br), 3225 (w), 2922
(w), 2852 (w), 1640 (w), 1650 (w), 1615 (m), 1527 (m), 1496 (m), 1442 (m), 1292 (s),
1245 (s), 1173 (s), 1025 (m), 998 (m), 903 (m), 836 (m), 801 (m), 739 (m), 595 (s), 520
(s) cm-1. MS (ESI +ve) m/z 578 (35Cl [M + H]+, 100%), 580 (37Cl [M + H]+, 33%). HRMS
(ESI +ve TOF) calcd for C28H2935ClN7O5 578.1913, found 578.1911 ([M + H]+).
7-Nitrobenzo[c][1,2,5]oxadiazol-4-amine 82153
To a stirred solution of 4-chloro-7-nitrobenzofurazan 54 (500 mg, 2.51
mmol) in MeOH (25 mL) at 0 ºC (ice bath) was added dropwise NH4OH
(30% v/v – 10 mL, 1.48 mol). The reaction was allowed to warm to rt and
stirring was continued for 24 h under N2 atmosphere in darkness. The solvent was
evaporated in vacuo, and the residue was purified by flash chromatography over SiO2 gel
(EtOAc/hexanes – 70:30) to afford the NBD amine 82 (229 mg, 51%) as a dark brown
solid. The spectroscopic data was in agreement with that previously reported. TLC
(EtOAc/hexanes – 70:30): Rf = 0.50. 1H NMR (400 MHz, DMSO) δ 8.83 (br s, 2H, NH2),
8.45 (d, J = 8.8 Hz, 1H, H6), 6.37 (d, J = 8.8 Hz, 1H, H5). 13C NMR (400 MHz, DMSO)
δ 147.7 (C7), 144.6 (C4), 144.4 (C3a), 138.3 (C6), 120.8 (C7a), 103.1 (C5). MS (ESI ve) m/z 179 ([M – H]–, 100%).
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2-(6-Chloro-2-(4-methoxyphenyl)imidazo[1,2-a]pyridin-3-yl)-N-(7nitrobenzo[c][1,2,5]oxadiazol-4-yl)acetamide 83
To a stirred solution of the imidazopyridine
carboxylic acid 78 (33 mg, 0.10 mmol) in anhydrous
DMF (2.0 mL) was added HOBT (15 mg, 0.10
mmol), EDCI (25 mg, 0.13 mmol), DIPEA (52 mg,
0.40 mmol), and NBD-NH2 82 (20 mg, 0.10 mmol). Stirring was prolonged at rt for 48 h,
and the resulting reaction mixture was poured into H2O (25 mL) and extracted with
EtOAc (3 x 25 mL). The organic solution was separated, washed with H2O (2 x 25 mL),
brine (2 x 25 mL), dried (Na2SO4), filtered, and concentrated. The residue was subjected
to flash chromatography over SiO2 gel (CH2Cl2/MeOH – 95:5) to afford the desired
fluorescent probe 83 (30 mg, 62%) as a light brown solid. TLC (CH2Cl2/MeOH – 95:5):
Rf = 0.63. Mp 168 ºC. 1H NMR (500 MHz, CD3OD) δ 8.97 (br s, 1H, H5), 8.47 (d, J =
8.0 Hz, 1H, H6'''), 7.92 – 7.87 (m, 1H, H8), 7.85 (d, J = 8.0 Hz, 1H, H5'''), 7.64 (d, J =
9.0 Hz, 2H, H2', H6'), 7.16 (d, J = 9.0 Hz, 2H, H3', H5'), 6.40 (d, J = 8.0 Hz, 1H, H7),
4.22 (s, 2H, H1''), 3.89 (s, 3H, ArOCH3). 13C NMR (500 MHz, CD3OD) δ 171.6 (C2''),
163.0 (C4'), 148.5 (C7'''), 148.2 (C2), 145.6 (C6'''), 145.6 (C8a), 140.3 (C4'''), 138.4
(C3'''a), 138.1 (C7), 134.0 (C1'), 131.2 (C2', C6'), 126.2 (C5), 125.8 (C7'''a), 120.6 (C6),
118.3 (C8), 116.1 (C3', C5'), 114.3 (C3), 103.2 (C5'''), 56.1 (ArOCH3), 30.1 (C1''). IR
(neat) 𝜈 max 3335 (br), 2930 (w), 1700 (w), 1647 (w), 1558 (m), 1539 (s), 1507 (m), 1251
(s), 1174 (s), 1024 (s), 992 (s), 796 (s), 732 (s), 612 (s) cm-1. MS (ESI -ve) m/z 477 (35Cl
[M – H]–, 100%), 479 (37Cl [M – H]–, 33%). HRMS (ESI -ve TOF) calcd for
C22H1435ClN6O5 477.0720, found 477.0714 ([M – H]–).
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6.2.3 Synthesis of Fluorescent Probes B
2-(6-Chloro-2-(4-hydroxyphenyl)imidazo[1,2-a]pyridin-3-yl)acetic acid
hydrobromide hydrate 84139
Acetamide 67 (1.60 g, 5.07 mmol) was dissolved in
acetic acid (12.5 mL, 0.21 mol) with magnetic stirring,
and the solution was brought to 0 ºC (ice bath). HBr
(48% w/w – 25 mL, 0.22 mol) was added dropwise, the ice bath removed, and the reaction
solution heated to 110 ºC for 48 h. The solution was cooled to rt, then placed at 4 ºC for
18 h to give a brown precipitate. The precipitate was filtered, washed with acetic acid (10
mL), and dried in vacuo to afford the imidazopyridine carboxylic acid 84 (1.22 g, 63%)
as a light brown solid. The spectroscopic data was in agreement with that previously
reported. TLC (CH2Cl2/MeOH – 90:5): Rf = 0.58. 1H NMR (400 MHz, DMSO) δ 10.16
(br s, 1H, ArOH), 9.28 (s, 1H, H5), 8.03 – 7.96 (m, 2H, H7, H8), 7.52 (d, J = 8.8 Hz, 2H,
H2', H6'), 7.02 (d, J = 8.8 Hz, 2H, H3', H5'), 4.24 (s, 2H, H1'').

13

C NMR (400 MHz,

DMSO) δ 169.8 (C2''), 159.4 (C4'), 137.9 (C8a), 135.1 (C2), 132.8 (C7), 129.9 (C2', C6'),
125.4 (C5), 123.5 (C6), 117.1 (C1'), 116.7 (C3', C5'), 116.3 (C3), 113.2 (C8), 29.3 (C1'').
MS (ESI +ve) m/z 303 (35Cl [M + H]+, 100%), 305 (37Cl [M + H]+, 33%).

2-(6-Chloro-2-(4-hydroxyphenyl)imidazo[1,2-a]pyridin-3-yl)-N,N-diethylacetamide
85139
A mixture of imidazopyridine carboxylic acid 84 (830
mg, 2.16 mmol), HOBT (295 mg, 2.16 mmol), EDCI
(539 mg, 2.81 mmol), diethylamine (268 µL, 2.59
mmol), and DIPEA (1.58 mL, 8.64 mmol) was stirred in anhydrous DMF (8.0 mL) at rt
for 24 h under N2 atmosphere. H2O (43 mL) and acetic acid (0.4 mL) were added, stirred
for 5 min, and placed at 4 ºC for 18 h to give a brown precipitate which was filtered,
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washed with H2O (20 mL), and dried in vacuo. Anhydrous DMF (4.0 mL) and
diethylamine (0.4 mL) were added to the crude product and heated to 110 ºC for 6 h until
the diethylamine was evaporated from the solution. After cooling to 80 ºC, EtOAc (8.0
mL) was added rapidly. The solution was cooled to 4 ºC for 18 h to form a white
crystalline solid, which was filtered, washed with cold ethyl acetate (4.0 mL), and dried
in vacuo to afford diethylacetamide 85 (570 mg, 74%) as white needles. The
spectroscopic data was in agreement with that previously reported. TLC (CH2Cl2/MeOH
– 95:5): Rf = 0.67. 1H NMR (400 MHz, DMSO) δ 9.62 (br s, 1H, ArOH), 8.50 (dd, J =
0.8, 2.0 Hz, 1H, H5), 7.59 (dd, J = 9.6, 0.8 Hz, 1H, H8), 7.42 (d, J = 8.8 Hz, 2H, H2',
H3'), 7.27 (dd, J = 9.6, 2.0 Hz, 1H, H7), 6.84 (d, J = 8.8 Hz, 2H, H3', H5'), 4.18 (s, 2H,
H1''), 3.44 (q, J = 7.2 Hz, 2H, H4'' or H5''), 3.32 (q, J = 7.2 Hz, 2H, H4'' or H5''), 1.16 (t,
J = 7.2 Hz, 3H, H6'' or H7''), 1.06 (t, J = 7.2 Hz, 3H, H6'' or H7''). 13C NMR (400 MHz,
DMSO) δ 167.1 (C2''), 157.2 (C4'), 143.9 (C2), 142.1 (C8a), 129.1 (C2', C6'), 125.0 (C1'),
124.5 (C7), 123.0 (C5), 118.3 (C6), 117.0 (C8), 116.1 (C3), 115.4, (C3', C5'), 41.7 (C4''
or C5''), 39.9 (C4'' or C5''), 28.7 (C1''), 14.1 (C6'' or C7''), 13.1 (C6'' or C7''). MS (ESI
+ve) m/z 358 (35Cl [M + H]+, 100%), 100%), 360 (37Cl [M + H]+, 33%).

General Procedure D: Phenol Alkylation
To a stirred solution of the phenol (diethylacetamide) (1.0 eq) in anhydrous DMF (15
mL/mmol phenol) was added K2CO3 (4.0 eq) and the appropriate Boc–protected
bromoamine (1.2 eq). Stirring was prolonged at rt for 48 h under N2 atmosphere, and the
resulting reaction mixture was poured into H2O (25 mL) and extracted with EtOAc (3 x
25 mL). The organic solution was separated, washed with H2O (2 x 25 mL), brine (2 x 25
mL), dried (Na2SO4), filtered, and concentrated. The residue was purified by preparative
TLC plate chromatography (CH2Cl2/MeOH – 95:5) to afford the desired O-alkylated
phenol.
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Tert-butyl (2-(4-(6-chloro-3-(2-(diethylamino)-2-oxoethyl)imidazo[1,2-a]pyridin-2yl)phenoxy)ethyl)carbamate 87a
Following General Procedure D,
phenol 85 (250 mg, 0.70 mmol) was
dissolved in anhydrous DMF (10.5
mL) followed by sequential addition of
K2CO3 (387 mg, 28 mmol) and tert-butyl (2-bromoethyl)carbamate 86a (188 mg, 0.84
mmol) to afford the O-alkylated phenol 87a (250 mg, 71%) as a pale yellow foam after
preparative TLC plate chromatography. TLC (CH2Cl2/MeOH – 95:5): Rf = 0.74. 1H NMR
(400 MHz, DMSO) δ 8.52 (br s, 1H, H5), 7.60 (d, J = 9.6 Hz, 1H, H8), 7.52 (d, J = 8.8
Hz, 2H, H2', H6'), 7.28 (dd, J = 9.6, 2.0 Hz, 1H, H7), 7.05 – 7.01 (m, 3H, H3', H5', H9'),
4.20 (s, 2H, H1''), 4.01 (t, J = 6.4 Hz, 2H, H7'), 3.45 (q, J = 7.2 Hz, 2H, H4'' or H5''), 3.36
– 3.29 (m, 4H, H8', H4'' or H5''), 1.39 (s, 9H, H12''), 1.16 (t, J = 7.2 Hz, 3H, H6'' or H7''),
1.07 (t, J = 7.2 Hz, 3H, H6'' or H7''). 13C NMR (400 MHz, DMSO) δ 167.0 (C2''), 158.2
(C4'), 155.7 (C10'), 143.4 (C2), 142.2 (C8a), 129.0 (C2', C6'), 126.7 (C1'), 124.7 (C7),
123.0 (C5), 118.4 (C6), 117.1 (C8), 116.4 (C3), 114.6 (C3', C5'), 77.8 (C11'), 66.5 (C7'),
63.6 (C8'), 41.7 (C4'' or C5''), 38.3 (C4'' or C5''), 28.7 (C1''), 28.2 (C12'), 14.1 (C6'' or
C7''), 13.0 (C6'' or C7''). IR (neat) 𝜈 max 3458 (br), 3273 (br), 2975 (w), 1703 (m), 1638
(m), 1500 (m), 1390 (w), 1245 (m), 1171 (m), 1035 (s), 1025 (s), 1010 (s), 820 (m), 758
(m), 525 (m) cm-1. MS (ESI +ve) m/z 501 (35Cl [M + H]+, 100%), 503 (37Cl [M + H]+,
33%). HRMS (ESI +ve TOF) calcd for C26H3435ClN4O4 501.2263, found 501.2269 ([M
+ H]+).
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Tert-butyl (3-(4-(6-chloro-3-(2-(diethylamino)-2-oxoethyl)imidazo[1,2-a]pyridin-2yl)phenoxy)propyl)carbamate 87b
Following General Procedure D,
phenol 85 (250 mg, 0.70 mmol) was
dissolved in anhydrous DMF (10.5
mL) followed by sequential addition
of K2CO3 (387 mg, 28 mmol) and tert-butyl (3-bromopropyl)carbamate 86b (200 mg,
0.84 mmol) to afford the O-alkylated phenol 87b (261 mg, 72%) as a pale yellow foam
after preparative TLC plate chromatography. TLC (CH2Cl2/MeOH – 95:5): Rf = 0.76. 1H
NMR (400 MHz, DMSO) δ 8.51 (br s, 1H, H5), 7.60 (d, J = 9.6 Hz, 1H, H8), 7.52 (d, J
= 8.8 Hz, 2H, H2', H6'), 7.27 (dd, J = 9.6, 2.0 Hz, 1H, H7), 7.01 (d, J = 8.8 Hz, 2H, H3',
H5'), 6.90 (t, J = 5.2 Hz, 1H, H10'), 4.20 (s, 2H, H1''), 4.02 (t, J = 6.4 Hz, 2H, H7'), 3.44
(q, J = 7.2 Hz, 2H, H4'' or H5''), 3.33 (q, J = 7.2 Hz, 2H, H4'' or H5''), 3.10 (dt, J = 6.4,
5.6 Hz, 2H, H9'), 1.85 (quint, J = 6.4 Hz, 2H, H8'), 1.38 (s, 9H, H13'), 1.17 (t, J = 7.2 Hz,
3H, H6'' or H7''), 1.07 (t, J = 7.2 Hz, 3H, H6'' or H7''). 13C NMR (400 MHz, DMSO) δ
167.0 (C2''), 158.3 (C4'), 155.6 (C11'), 143.4 (C2), 142.2 (C8a), 129.0 (C2', C6'), 126.5
(C1'), 124.7 (C7), 123.0 (C5), 118.4 (C6), 117.1 (C8), 116.4 (C3), 114.5 (C3', C5'), 77.5
(C12'), 65.3 (C7'), 63.6 (C8'), 41.7 (C4'' or C5''), 36.9 (C4'' or C5''), 29.2 (C9'), 28.7 (C1''),
28.2 (C13''), 14.1 (C6'' or C7''), 13.0 (C6'' or C7''). IR (neat) 𝜈 max 3394 (br), 3250 (br),
2974 (w), 1633 (m), 1501 (m), 1391 (w), 1332 (w), 1248 (m), 1048 (m), 1037 (s), 998
(s), 823 (m), 761 (m), 525 (m) cm-1. MS (ESI +ve) m/z 515 (35Cl [M + H]+, 100%), 517
(37Cl [M + H]+, 33%). HRMS (ESI +ve TOF) calcd for C27H3635ClN4O4 515.2420, found
515.2426 ([M + H]+).
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General Procedure E: Amine Deprotection
The O-alkylated phenol (1.0 eq) in CH2Cl2 (3.0 mL/mmol phenol) was treated with
CF3CO2H (3 mL/mmol amine). The reaction mixture was stirred at rt for 4 h followed by
removal of the solvent. The residue was dissolved in EtOAc (25 mL), neutralized with
saturated aqueous NaHCO3, and then washed with H2O (2 x 25 mL). The organic layer
was dried (Na2SO4) and concentrated. The residue was purified by preparative TLC plate
chromatography (CH2Cl2/MeOH – 95:5) to afford the desired free amine (final ligand).

2-(2-(4-(2-Aminoethoxy)phenyl)-6-chloroimidazo[1,2-a]pyridin-3-yl)-N,Ndiethylacetamide 88a
Following General Procedure E, O-alkylated
phenol 87a (200 mg, 0.40 mmol) was dissolved
in CHCl2 (4.0 mL) and treated with CF3CO2H
(1.2 mL) to afford the final ligand 88a (141 mg,
88%) a pale-yellow foam that collapsed into a translucent gum after preparative TLC
plate chromatography. TLC (CH2Cl2/MeOH – 95:5): Rf = 0.50. 1H NMR (400 MHz,
DMSO) δ 8.53 (br s, 1H, H5), 7.61 (d, J = 9.6 Hz, 1H, H8), 7.54 (d, J = 8.8 Hz, 2H, H2',
H6'), 7.29 (dd, J = 9.6, 2.0 Hz, 1H, H7), 7.05 (d, J = 8.8 Hz, 2H, H3', H5'), 4.22 (s, 2H,
H1''), 4.00 (t, J = 5.6 Hz, 2H, H7'), 3.46 (q, J = 7.2 Hz, 2H, H4'' or H5''), 3.38 – 3.24 (m,
4H, H9', H4'' or H5''), 2.94 (t, J = 5.6 Hz, 2H, H8'), 1.18 (t, J = 7.2 Hz, 3H, H6'' or H7''),
1.08 (t, J = 7.2 Hz, 3H, H6'' or H7''). 13C NMR (400 MHz, DMSO) δ 167.0 (C2''), 158.3
(C4'), 143.4 (C2), 142.2 (C8a), 129.0 (C2', C6'), 126.6 (C1'), 124.7 (C7), 123.0 (C5),
118.4 (C6), 117.1 (C8), 116.4 (C3), 114.6 (C3', C5'), 69.6 (C7'), 41.7 (C4'' or C5''), 40.6
(C8'), 40.2 (C4'' or C5''), 28.7 (C1''), 14.2 (C6'' or C7''), 13.1 (C6'' or C7''). IR (neat) 𝜈 max
3303 (br), 2973 (w), 2932 (w), 1699 (m), 1634 (m), 1521 (m), 1364 (m), 1330 (m), 1244
(s), 1170 (s), 1141 (m), 1097 (w), 1025 (m), 794 (w), 759 (w), 525 (w) cm -1. MS (ESI
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+ve) m/z 401 (35Cl [M + H]+, 100%), 403 (37Cl [M + H]+, 33%). HRMS (ESI +ve TOF)
calcd for C21H2635ClN4O2 401.1736, found 401.1744 ([M + H]+).

2-(2-(4-(3-Aminopropoxy)phenyl)-6-chloroimidazo[1,2-a]pyridin-3-yl)-N,Ndiethylacetamide 88b
Following General Procedure E, O-alkylated
phenol 87b (206 mg, 0.40 mmol) was
dissolved in CHCl2 (4.0 mL) and treated with
CF3CO2H (1.2 mL) to afford the final ligand
88b (152 mg, 92%) a pale-yellow foam that collapsed into a translucent gum after
preparative TLC plate chromatography. TLC (CH2Cl2/MeOH – 95:5): Rf = 0.55. 1H NMR
(400 MHz, DMSO) δ 8.51 (br s, 1H, H5), 7.60 (d, J = 9.6 Hz, 1H, H8), 7.53 (d, J = 8.8
Hz, 2H, H2', H6'), 7.27 (dd, J = 9.6, 2.0 Hz, 1H, H7), 7.02 (d, J = 8.8 Hz, 2H, H3', H5'),
4.21 (s, 2H, H1''), 4.06 (t, J = 5.6 Hz, 2H, H7'), 3.46 (q, J = 7.2 Hz, 2H, H4'' or H5''), 3.45
– 3.34 (m, 4H, H10', H4'' or H5''), 2.75 (t, J = 5.6 Hz, 2H, H9'), 1.83 (quint, J = 5.6 Hz,
2H, H8'), 1.17 (t, J = 7.2 Hz, 3H, H6'' or H7''), 1.05 (t, J = 7.2 Hz, 3H, H6'' or H7''). 13C
NMR (400 MHz, DMSO) δ 167.0 (C2''), 158.4 (C4'), 143.5 (C2), 142.2 (C8a), 129.0 (C2',
C6'), 126.5 (C1'), 124.7 (C7), 123.0 (C5), 118.4 (C6), 117.1 (C8), 116.4 (C3), 114.6 (C3',
C5'), 65.5 (C7'), 63.5 (C9'), 41.7 (C4'' or C5''), 38.0 (C4'' or C5''), 31.6 (C8'), 28.7 (C1''),
14.2 (C6'' or C7''), 13.0 (C6'' or C7''). IR (neat) 𝜈 max 3367 (br), 2968 (w), 2932 (w), 1715
(w), 1632 (s), 1500 (m), 1389 (m), 1331 (m), 1246 (s), 1175 (m), 1141 (m), 1097 (w),
1025 (s), 795 (w), 761 (w), 526 (w) cm-1. MS (ESI +ve) m/z 415 (35Cl [M + H]+, 100%),
417 (37Cl [M + H]+, 33%). HRMS (ESI +ve TOF) calcd for C22H2835ClN4O2 415.1895,
found 415.1901 ([M + H]+).
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2-(6-Chloro-2-(4-(2-((7-nitrobenzo[c][1,2,5]oxadiazol-4yl)amino)ethoxy)phenyl)imidazo[1,2-a]pyridin-3-yl)-N,N-diethylacetamide 56a
Following General Procedure C,
final ligand 88a (66 mg, 0.16 mmol)
was dissolved in DMF (3.2 mL)
followed by sequential addition of
DIPEA (30 mg, 0.22 mmol) and NBD-Cl 54 (33 mg, 0.16 mmol) to afford the desired
fluorescent probe 56a (40 mg, 44%) as a light brown solid after preparative TLC plate
chromatography (CH2Cl2/MeOH – 98:2). TLC (CH2Cl2/MeOH – 98:2): Rf = 0.30. Mp
103 ºC (decomp). 1H NMR (500 MHz, DMSO) δ 9.63 (br s, 1H, H9'), 8.56 (d, J = 9.0 Hz,
1H, H6'''), 8.52 (s, 1H, H5), 7.61 (d, J = 9.5 Hz, 1H, H8), 7.54 (d, J = 9.0 Hz, 2H, H2',
H6'), 7.29 (dd, J = 9.5, 2.0 Hz, 1H, H7), 7.06 (d, J = 9.0 Hz, 2H, H3', H5'), 6.58 (d, J =
9.0 Hz, 1H, H5'''), 4.36 (t, J = 6.0 Hz, 2H, H7'), 4.20 (s, 2H, H1''), 3.92 (s, 2H, H8'), 3.45
(q, J = 7.0 Hz, 2H, H4'' or H5''), 3.31 (q, J = 7.0 Hz, 2H, H4'' or H5''), 1.17 (t, J = 7.0 Hz,
3H, H6'' or H7''), 1.07 (t, J = 7.0 Hz, 3H, H6'' or H7''). 13C NMR (500 MHz, DMSO) δ
167.0 (C2''), 157.9 (C4'), 145.3 (C7'''), 144.5 (C4'''), 144.1 (C3'''a), 143.3 (C2), 142.2
(C8a), 137.9 (C6'''), 129.0 (C2', C6'), 127.0 (C1'), 124.8 (C7), 123.0 (C5), 121.2 (C7'''a),
118.5 (C6), 117.2 (C8), 116.5 (C3), 114.7 (C3', C5'), 99.7 (C5'''), 65.6 (C5'), 43.0 (C6'),
41.7 (C4'' or C5''), 40.1 (C4'' or C5''), 28.7 (C1''), 14.2 (C6'' or C7''), 13.1 (C6'' or C7'').
IR (neat) 𝜈 max 3243 (br), 2976 (w), 1636 (m), 1583 (s), 1499 (s), 1444 (s), 1326 (m), 1292
(s), 1250 (s), 1128 (m), 1026 (m), 994 (m), 799 (m), 739 (m), 595 (m), 523 (m) cm-1. MS
(ESI +ve) m/z 564 (35Cl [M + H]+, 100%), 566 (37Cl [M + H]+, 33%); (ESI –ve) m/z 562
(35Cl [M – H]–, 100%), 564 (37Cl [M – H]–, 33%). HRMS (ESI +ve TOF) calcd for
C27H2735ClN7O5 564.1757, found 564.1762 ([M + H]+).
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2-(6-Chloro-2-(4-(3-((7-nitrobenzo[c][1,2,5]oxadiazol-4yl)amino)propoxy)phenyl)imidazo[1,2-a]pyridin-3-yl)-N,N-diethylacetamide 56b
Following General Procedure C,
final ligand 88b (80 mg, 0.19
mmol) was dissolved in DMF (3.8
mL)

followed

by

sequential

addition of DIPEA (34 mg, 0.27 mmol) and NBD-Cl 54 (38 mg, 0.19 mmol) to afford the
desired fluorescent probe 56b (46 mg, 42%) as a light brown solid after preparative TLC
plate chromatography (CH2Cl2/MeOH – 98:2). TLC (CH2Cl2/MeOH – 98:2). Rf = 0.41.
Mp 106 ºC (decomp). 1H NMR (500 MHz, DMSO) δ 9.58 (br s, 1H, H10'), 8.52 (s, 1H,
H5), 8.49 (d, J = 9.0 Hz, 1H, H6'''), 7.60 (d, J = 9.5 Hz, 1H, H8), 7.53 (d, J = 9.0 Hz, 2H,
H2', H6'), 7.28 (dd, J = 9.5, 2.0 Hz, 1H, H7), 7.04 (d, J = 9.0 Hz, 2H, H3', H5'), 6.45 (d,
J = 9.0 Hz, 1H, H5'''), 4.20 (s, 2H, H1''), 4.15 (t, J = 6.0 Hz, 2H, H7'), 3.67 (br s, 2H,
H9'), 3.44 (q, J = 7.0 Hz, 2H, H4'' or H5''), 3.32 (q, J = 7.0 Hz, 2H, H4'' or H5''), 2.17
(quint, J = 6.0 Hz, 2H, H8'), 1.16 (t, J = 7.0 Hz, 3H, H6'' or H7''), 1.06 (t, J = 7.0 Hz, 3H,
H6'' or H7''). 13C NMR (500 MHz, DMSO) δ 167.0 (C2''), 158.2 (C4'), 145.2 (C7'''), 144.5
(C4'''), 144.2 (C3'''a), 143.4 (C2), 142.2 (C8a), 137.9 (C6'''), 129.0 (C2', C6'), 126.7 (C1'),
124.7 (C7), 123.0 (C5), 120.7 (C7'''a), 118.4 (C6), 117.1 (C8), 116.4 (C3), 114.6 (C3',
C5'), 99.2 (C5'''), 65.1 (C7'), 41.7 (C4'' or C5''), 40.4 (C9'), 40.1 (C4'' or C5''), 28.7 (C1''),
27.5 (C8'), 14.2 (C6'' or C7''), 13.1 (C6'' or C7''). IR (neat) 𝜈 max 3231 (br), 2967 (w), 1632
(m), 1582 (s), 1493 (s), 1464 (m), 1344 (s), 1284 (s), 1240 (m), 1136 (s), 1027 (m), 1009
(m), 802 (m), 740 (w), 596 (m), 525 (m) cm-1. MS (ESI +ve) m/z 578 (35Cl [M + H]+,
100%), 580 (37Cl [M + H]+, 33%); (ESI –ve) m/z 576 (35Cl [M – H]–, 100%), 578 (37Cl
[M – H]–, 33%). HRMS (ESI +ve TOF) calcd for C28H2935ClN7O5 578.1913, found
578.1919 ([M + H]+).
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2-(6-Chloro-2-(4-((7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)oxy)phenyl)imidazo[1,2a]pyridin-3-yl)-N,N-diethylacetamide 89
Diethylacetamide 85 (175 mg, 0.49 mmol)
was dissolved in DMF (4 mL) with
magnetic stirring. The solution was brought
to 0 ºC (ice bath) followed by sequential
dropwise addition of DIPEA (256 µL, 1.47 mmol) and a solution of NBD-Cl 54 (98 mg,
0.49 mmol) in DMF (1.0 mL) under a flow of N2 gas. The reaction vessel was then sealed
and allowed to warm to rt and stirring was continued for 18 h under N2 atmosphere in
darkness. The solution was partitioned between CHCl3 (100 mL) and H2O (100 mL). The
aqueous phase was separated and extracted with CHCl3 (3 x 50 mL). The combined
organic extracts were washed with H2O (2 x 100 mL), brine (2 x 100 mL), dried (Na2SO4),
filtered, and concentrated. The residue was subjected to flash chromatography over SiO2
gel (CH2Cl2/MeOH – 95:5) to afford the fluorescent probe 89 (110 mg, 43%) as a brown
solid. TLC (CH2Cl2/MeOH – 90:10): Rf = 0.65. Mp = 99 ºC (decomp). 1H NMR (400
MHz, DMSO) δ 8.67 (d, J = 8.4 Hz, 1H, H6'''), 8.58 (dd, J = 2.0, 0.8 Hz, 1H, H5), 7.82
(d, J = 8.8 Hz, 2H, H2', H6'), 7.67 (dd, J = 9.6, 0.8 Hz, 1H, H8), 7.54 (d, J = 8.8 Hz, 2H,
H3', H5'), 7.35 (dd, J = 9.6, 2.0 Hz, 1H, H7), 6.84 (d, J = 8.4 Hz, 1H, H5'''), 4.31 (s, 2H,
H1''), 3.48 (q, J = 7.2 Hz, 2H, H4'' or H5''), 3.33 (q, J = 7.2 Hz, 2H, H4'' or H5''), 1.20 (t,
J = 7.2 Hz, 3H, H6'' or H7''), 1.07 (t, J = 7.2 Hz, 3H, H6'' or H7''). 13C NMR (400 MHz,
DMSO) δ 166.9 (C2''), 153.1 (C4'), 152.5 (C7'''), 145.4 (C4'''), 144.4 (C3'''a), 142.4 (C2),
142.3 (C8a), 135.5 (C6'''), 132.9 (C1'), 130.4 (C7), 129.9 (C2', C6'), 125.3 (C7'''a), 123.2
(C5), 121.0 (C3', C5'), 118.8 (C6), 117.6 (C8), 117.5 (C3), 110.0 (C5'''), 41.7 (C4'' or
C5''), 40.2 (C4'' or C5''), 28.7 (C1''), 14.2 (C6'' or C7''), 13.1 (C6'' or C7''). IR (neat) 𝜈 max
3404 (br), 2990 (w), 1632 (s), 1537 (s), 1521 (s), 1500 (s), 1450 (s), 1267 (s), 1257 (s),
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1203 (s), 1088 (s), 1025 (s), 996 (s), 803 (s) cm-1. MS (ESI +ve) m/z 521 (35Cl [M + H]+,
100%), 523 (37Cl [M + H]+, 100%); HRMS (ESI +ve TOF) calcd for C25H2135ClN6O5
521.1335, found 521.1340 ([M + H]+).

2-(4-(6-Chloro-3-(2-(diethylamino)-2-oxoethyl)imidazo[1,2-a]pyridin-2yl)phenoxy)ethyl acetate 91a139
A mixture of diethylacetamide 85 (300 mg,
0.80 mmol), K2CO3 (442 mg, 3.20 mmol),
KI (20 mg, 0.12 mmol), Bu4NI (6 mg, 0.02
mmol), and anhydrous DMF (2.0 mL) was stirred for 10 min before 2-bromoethyl acetate
90a (160 mg, 0.96 mmol) was added. The reaction was stirred at RT for 24 h and diluted
with EtOAc (10 mL). The organic extract was washed with H2O (3 × 10 mL), brine (10
mL), dried (Na2SO4), filtered, and concentrated to afford acetoxy 91a as an orange solid
(213 mg, 60%), which was hydrolysed without further purification. TLC (CH2Cl2/MeOH
– 95:5): Rf = 0.40. 1H NMR (400 MHz, DMSO) δ 8.51 (d, J = 2.2 Hz, 1H, H5), 7.60 (d,
J = 9.6 Hz, 1H, H8), 7.52 (d, J = 8.8 Hz, 2H, H2', H6'), 7.27 (dd, J= 9.6, 2.2 Hz, 1H, H7),
7.02 (d, J = 8.8 Hz, 2H, H3', H5'), 4.22 (m, 2H, H7'), 4.33 (m, 2H, H8'), 4.20 (s, 2H,
H1''), 3.44 (q, J = 7.2 Hz, 2H, H4'' or H5''), 3.33 (q, J = 7.2 Hz, 2H, H, H4'' or H5''), 2.04
(s, 3H, H10'), 1.17 (t, J = 7.2 Hz, 3H, H6'' or H7''), 1.07 (t, J = 7.2 Hz, 3H, H6'' or H7'').
MS (ESI +ve) m/z 444 (35Cl [M + H]+, 100%), 446 (37Cl [M + H]+, 33%).
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4-(4-(6-Chloro-3-(2-(diethylamino)-2-oxoethyl)imidazo[1,2-a]pyridin-2yl)phenoxy)butyl acetate 91b
A mixture of diethylacetamide 85 (300
mg, 0.80 mmol), K2CO3 (442 mg, 3.20
mmol), KI (20 mg, 0.12 mmol), Bu4NI
(6 mg, 0.02 mmol), and anhydrous
DMF (2.0 mL) was stirred for 10 min before 4-bromobutyl acetate 90b (187 mg, 0.96
mmol) was added. The reaction was stirred at RT for 24 h and diluted with EtOAc (10
mL). The organic extract was washed with H2O (3 × 10 mL), brine (10 mL), dried
(Na2SO4), filtered, and concentrated to afford acetoxy 91b as an orange solid (201 mg,
53%), which was hydrolysed without further purification. TLC (CH2Cl2/MeOH – 95:5):
Rf = 0.44. 1H NMR (400 MHz, DMSO) δ 8.51 (d, J = 2.2 Hz, 1H, H5), 7.60 (d, J = 9.6
Hz, 1H, H8), 7.52 (d, J = 8.8 Hz, 2H, H2', H6'), 7.27 (dd, J= 9.6, 2.2 Hz, 1H, H7), 7.02
(d, J = 8.8 Hz, 2H, H3', H5'), 4.22 (m, 2H, H7'), 4.33 (m, 2H, H10'), 4.20 (s, 2H, H1''),
3.44 (q, J = 7.2 Hz, 2H, H4'' or H5''), 3.33 (q, J = 7.2 Hz, 2H, H, H4'' or H5''), 2.04 (s,
3H, H12'), 1.93 (m, 2H, H8'), 1.86 (m, 2H, H9'), 1.17 (t, J = 7.2 Hz, 3H, H6'' or H7''),
1.07 (t, J = 7.2 Hz, 3H, H6'' or H7''). MS (ESI +ve) m/z 472 (35Cl [M + H]+, 100%), 479
(37Cl [M + H]+, 33%).

2-(6-Chloro-2-(4-(2-hydroxyethoxy)phenyl)imidazo[1,2-a]pyridin-3-yl)-N,Ndiethylacetamide 92a139
To a solution of acetoxy 91a (200 mg, 0.45
mmol) was in MeOH (2 mL) was added Cs2CO3
(587 mg, 1.80 mmol) in H2O (1 mL). After 24 h
of stirring at rt, a precipitate had formed, which
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was collected by filtration and washed with H2O (20 mL). The solid was recrystallized
from EtOAc/hexanes (1:1) to afford the free alcohol 92a as fine colorless needles (135
mg, 75%). TLC (CH2Cl2/MeOH – 90:10): Rf = 0.39. 1H NMR (400 MHz, DMSO) δ 8.51
(d, J = 2.2 Hz, 1H, H5), 7.60 (d, J = 9.6 Hz, 1H, H8), 7.52 (d, J = 8.8 Hz, 2H, H2', H6'),
7.27 (dd, J= 9.6, 2.2 Hz, 1H, H7), 7.02 (d, J = 8.8 Hz, 2H, H3', H5'), 4.87 (t, J = 5.4 Hz,
1H, OH), 4.22 (m, 2H, H7'), 4.33 (m, 2H, H8'), 4.20 (s, 2H, H1''), 3.44 (q, J = 7.2 Hz, 2H,
H4'' or H5''), 3.33 (q, J = 7.2 Hz, 2H, H, H4'' or H5''), 2.04 (s, 3H, H10'), 1.17 (t, J = 7.2
Hz, 3H, H6'' or H7''), 1.07 (t, J = 7.2 Hz, 3H, H6'' or H7''). 13C NMR (400 MHz, DMSO)
δ 167.0 (C2''), 158.2 (C4'), 143.4 (C2), 142.2 (C8a), 129.0 (C2', C6'), 126.7 (C1'), 124.7
(C7), 123.0 (C5), 118.4 (C6), 117.1 (C8), 116.4 (C3), 114.6 (C3', C5'), 69.6 (C7'), 59.6
(C8'), 41.7 (C4'' or C5''), 39.9 (C4'' or C5''), 28.7 (C1''), 14.1 (C6'' or C7''), 13.1 (C6'' or
C7''). MS (ESI +ve) m/z 402 (35Cl [M + H]+, 100%), 404 (37Cl [M + H]+, 33%).

2-(6-Chloro-2-(4-(4-hydroxybutoxy)phenyl)imidazo[1,2-a]pyridin-3-yl)-N,Ndiethylacetamide 92b
To a solution of acetoxy 91b (180 mg, 0.38)
in MeOH (2.0 mL) was added Cs2CO3 (497
mg, 1.53 mmol) in H2O (1 mL). After 24 h
of stirring at rt, a precipitate had formed,
which was collected by filtration and washed with H2O (20 mL). The solid was
recrystallized from EtOAc/hexanes (1:1) to afford the free alcohol 92b as fine colorless
needles (110 mg, 67%). TLC (CH2Cl2/MeOH – 90:10): Rf = 0.41. 1H NMR (400 MHz,
DMSO) δ 8.51 (d, J = 2.2 Hz, 1H, H5), 7.60 (d, J = 9.6 Hz, 1H, H8), 7.52 (d, J = 8.8 Hz,
2H, H2', H6'), 7.27 (dd, J= 9.6, 2.2 Hz, 1H, H7), 7.02 (d, J = 8.8 Hz, 2H, H3', H5'), 4.89
(t, J = 5.4 Hz, 1H, OH), 4.22 (m, 2H, H7'), 4.33 (m, 2H, H8'), 4.20 (s, 2H, H1''), 3.44 (q,
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J = 7.2 Hz, 2H, H4'' or H5''), 3.33 (q, J = 7.2 Hz, 2H, H, H4'' or H5''), 2.04 (s, 3H, H10'),
1.92 (m, 2H, H8'), 1.85 (m, 2H, H9'), 1.17 (t, J = 7.2 Hz, 3H, H6'' or H7''), 1.07 (t, J = 7.2
Hz, 3H, H6'' or H7'').

C NMR (400 MHz, DMSO) δ 167.0 (C2''), 158.2 (C4'), 143.4
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(C2), 142.2 (C8a), 129.0 (C2', C6'), 126.7 (C1'), 124.7 (C7), 123.0 (C5), 118.4 (C6),
117.1 (C8), 116.4 (C3), 114.6 (C3', C5'), 69.6 (C7'), 59.6 (C8'), 41.7 (C4'' or C5''), 39.9
(C4'' or C5''), 28.7 (C1''), 26.1 (C8'), 25.6 (C9'), 14.1 (C6'' or C7''), 13.1 (C6'' or C7''). MS
(ESI +ve) m/z 430 (35Cl [M + H]+, 100%), 432 (37Cl [M + H]+, 33%).

6.3 Experimental Procedures for the Synthesis of Tau Ligands
6.3.1 Synthesis of 1,4-Disubtituted-1,2,3-Triazole Derivatives
2-iodo-6-methoxybenzo[d]thiazole 99202
To a solution of 6-methoxybenzo[d]thiazol-2-amine 98 (4.50 g,
25.00 mmol) and p-toluenesulfonic acid monohydrate (15.07 g,
87.50 mmol) in MeCN (150 mL) was added a solution of NaNO2 (4.45 g, 50.00 mmol)
and KI (10.79 g, 65.00 mmol) in H2O (16 mL) at 0 ºC. The reaction was allowed to reach
rt, and was stirred for 18 h. The reaction mixture was quenched with H2O (350 mL) and
basified with 2 M NaHCO3 to pH 8-9, followed by addition of Na2S2O3 (20 mL), yielding
a brown precipitate. The precipitate was collected by filtration, washed with H2O (20
mL), and dried in vacuo to afford the iodobenzothiazole 99 (5.11 g, 70%) as a light brown
solid. The product was used directly for the next step without further purification. The
spectroscopic data was in agreement with that previously reported. TLC (EtOAc/hexanes
– 60:40): Rf = 0.85. 1H NMR (400 MHz, CDCl3) δ 7.89 (d, J = 9.2 Hz, 1H, H4), 7.28 (d,
J = 2.8 Hz, 1H, H7), 7.03 (dd, J = 9.2, 2.8 Hz, 1H, H5), 3.86 (s, 3H, ArOCH3). 13C NMR
(400 MHz, CDCl3) δ 158.1 (C6), 149.0 (C3a), 140.4 (C7a), 123.0 (C4), 115.6 (C5), 103.1
(C7), 101.5 (C2), 55.8 (ArOCH3). MS (ESI +ve) m/z 292 ([M + H]+, 100%).
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6-methoxy-2-((trimethylsilyl)ethynyl)benzo[d]thiazole 100202
To a solution of iodobenzothiazole 99 (1.86 g, 6.39 mmol),
PdCl2(PPh3)2 (90 mg, 0.13 mmol), CuI (26 mg, 0.14 mmol),
and triethylamine (4.0 mL, 28.70 mmol) in anhydrous DMF (8.0 mL) was added a
solution of ethynyltrimethylsilane (1.26 g, 12.83 mmol). The resulting mixture was stirred
at 65 ºC for 8 h. After cooling to rt, the solution was filtered through a layer of Celite,
and concentrated. The residue was subjected to flash chromatography over SiO2 gel
(EtOAc/hexanes – 60:40) to afford the protected alkyne 100 (1.10 g, 66%) as a light
yellow oil. The product was used in the next reaction step immediately or stored in the
freezer for a limited time due to stability issues. The spectroscopic data was in agreement
with that previously reported. TLC (EtOAc/hexanes – 60:40): Rf = 0.86. 1H NMR (400
MHz, CDCl3) δ 7.90 (d, J = 9.2 Hz, 1H, H4), 7.25 (d, J = 2.8 Hz, 1H, H7), 7.09 (dd, J =
9.2, 2.8 Hz, 1H, H5), 3.85 (s, 3H, ArOCH3), 0.30 (s, 9H, (CH3)3). 13C NMR (400 MHz,
CDCl3) δ 158.9 (C6), 147.3 (C3a), 145.6 (C2), 136.8 (C7a), 124.3 (C4), 116.6 (C5), 103.4
(C7), 102.3 (C2'), 97.0 (C1'), 55.8 (ArOCH3), 0.5 ((CH3)3). MS (ESI +ve) m/z 262 ([M +
H]+, 100%).
2-ethynyl-6-methoxybenzo[d]thiazole 101202
To a solution of the protected alkyne 100 (1.00 g, 3.83 mmol) in
MeOH (30 mL) was added KF (1.00 g, 17.21 mmol), and the
mixture was stirred at rt for 4 h. The solvent was removed, and the residue was subjected
to flash chromatography over SiO2 gel (EtOAc/hexanes – 60:40) to afford the free alkyne
101 (0.71 g, 98%) as a pale yellow solid. The spectroscopic data was in agreement with
that previously reported. TLC (EtOAc/hexanes – 60:40): Rf = 0.84. 1H NMR (400 MHz,
CDCl3) δ 7.93 (d, J = 9.2 Hz, 1H, H4), 7.27 (d, J = 2.8 Hz, 1H, H7), 7.12 (dd, J = 9.2, 2.8
Hz, 1H, H5), 3.88 (s, 3H, ArOCH3), 3.55 (s, 1H, H2'). 13C NMR (400 MHz, CDCl3) δ
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159.1 (C6), 147.3 (C3a), 144.8 (C2), 136.9 (C7a), 124.6 (C4), 116.8 (C5), 103.5 (C7),
83.4 (C1'), 77.0 (C2'), 55.9 (ArOCH3). MS (ESI +ve) m/z 190 ([M + H]+, 100%).

5-azidopyridin-2-amine 103
A solution of the 2-amino-5-bromopyridine 102 (1.00 g, 5.78
mmol), sodium ascorbate (60 mg, 0.30 mmol), CuI (116 mg, 0.61
mmol), and N,N′-dimethylethylenediamine (79 mg, 0.88 mmol) in
EtOH : H2O (2:1, 45 mL) was strirred at rt for 30 min. NaN3 (0.76 g, 11.69 mmol) was
added, and the reaction mixture was stirred at 65 ºC for 8 h. The solution was cooled to
rt, filtered through a layer of Celite, concentrated, and extracted with EtOAc (3 x 50 mL).
The combined organic extracts were washed with H2O (150 mL), brine (150 mL), dried
(Na2SO4), filtered, and concentrated. The residue was subjected to flash chromatography
over SiO2 gel (CH2Cl2/MeOH – 90:10) to afford the azide 103 as a grey solid (0.35 g,
45%) which was used directly in the subsequent step. The spectroscopic data was in
agreement with that previously reported. TLC (CH2Cl2/MeOH – 90:10): Rf = 0.41. 1H
NMR (400 MHz, CDCl3) δ 7.84 (d, J = 2.8 Hz, 1H, H6), 7.16 (dd, J = 8.8, 2.8 Hz, 1H,
H4) 6.53 (d, J = 8.8 Hz, 1H, H3), 4.44 (br s, 2H, NH2). 13C NMR (400 MHz, CDCl3) δ
156.0 (C2), 139.1 (C6), 128.9 (C4), 127.7 (C5), 109.5 (C3). MS (ESI +ve) m/z 136 ([M
+ H]+, 100%). HRMS (ESI +ve TOF) calcd for C5H6N5+ 136.0618, found 136.0623 ([M
+ H]+).
5-bromo-N-methylpyridin-2-amine 104240
To a stirred solution of 5-bromo-pyridin-2-amine 102 (2.50 g, 14.45
mmol) in anhydrous methanol (100 mL) was added NaOMe (3.90 g,
72.25 mmol), and followed by paraformaldehyde (2.17 g, 72.25 mmol).
After the reaction mixture was stirred at 60 ºC for 6 h, it was cooled to 0 ºC with continued
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stirring. NaBH4 (2.73 g, 72.25 mmol) was added partionwise. The mixture was heated at
reflux for another 2 h, cooled in an ice bath (0 ºC), H2O (50 mL) was added, and the
mixture was extracted with CH2Cl2 (3 x 150 mL). The combined organic layers were
washed with H2O (150 mL), brine (150 mL), dried (Na2SO4), filtered, and concentrated.
The residue was subjected to flash chromatography over SiO2 gel (CH2Cl2/MeOH –
90:10) to afford the mono-N-methyl 104 (1.90 g, 70%) as a pale yellow solid. TLC
(CH2Cl2/MeOH – 90:10): Rf = 0.49. 1H NMR (400 MHz, CDCl3) δ 8.11 (d, J = 2.0 Hz,
1H, H6), 7.49 (dd, J = 8.8, 2.0 Hz, 1H, H4) 6.30 (d, J = 8.8 Hz, 1H, H3), 4.59 (br s, 1H,
NH), 2.89 (d, J = 4.8 Hz, 3H, ArNHCH3). 13C NMR (400 MHz, CDCl3) δ 158.2 (C2),
148.8 (C6), 139.9 (C4), 107.8 (C3), 107.0 (C5), 29.3 (ArNHCH3). MS (ESI +ve) m/z 187
(79Br [M + H]+, 100%), 189 (81Br [M + H]+, 100%).

5-azido-N-methylpyridin-2-amine 105
A solution of the 5-bromo-N-methylpyridin-2-amine 104 (540 mg,
2.89 mmol), sodium ascorbate (30 mg, 0.15 mmol), CuI (58 mg,
0.31 mmol), and N,N′-dimethylethylenediamine (40 mg, 0.44
mmol) in EtOH/H2O (2:1, 22.5 mL) was stirred at rt for 30 min. NaN3 (0.38 g, 5.85 mmol)
was added, and the reaction mixture was stirred at 65 ºC for 8 h. The solution was cooled
to rt, filtered through a layer of Celite, concentrated, and extracted with EtOAc (3 x 50
mL). The combined organic extracts were washed with H2O (150 mL), brine (150 mL),
dried (Na2SO4), filtered, and concentrated. The residue was subjected to flash
chromatography over SiO2 gel (CH2Cl2/MeOH – 90:10) to afford the mixture of the azide
105 (100 mg, 23%) and starting material 5-bromo-N-methylpyridin-2-amine 104 (102
mg) as a grey solid which were unseparable. This mixture was used directly in the
subsequent step. TLC (CH2Cl2/MeOH – 90:10): Rf = 0.44. 1H NMR (400 MHz, CDCl3)
δ 7.86 (d, J = 2.8 Hz, 1H, H6), 7.15 (dd, J = 8.8, 2.8 Hz, 1H, H4) 6.29 (d, J = 8.8 Hz, 1H,
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H3), 4.63 (br s, 1H, NH), 2.89 (d, J = 4.8 Hz, 3H, ArNHCH3). MS (ESI +ve) m/z 150 ([M
+ H]+, 100%). HRMS (ESI +ve TOF) calcd for C6H8N5+ 150.0774, found 150.0773 ([M
+ H]+).

General Procedure A: Synthesis of 1,2,3-triazole product (copper catalyzed azidealkyne cycloaddition)
General Procedure A1: To a stirred solution of alkyne (1.0 eq) in t-BuOH/H2O (1:1, 20
mL/mmol alkyne) was added CuSO4.5H2O (0.1 eq), sodium ascorbate (0.2 eq), and the
appropriate azide (2.0 eq). Stirring was prolonged at rt for 24 h under N2 atmosphere, and
the resulting reaction mixture was poured into H2O (25 mL), and extracted with EtOAc
(3 x 25 mL). The organic solution was separated, washed with H2O (2 x 25 mL), brine (2
x 25 mL), dried (Na2SO4), filtered, and concentrated. The residue was purified by
preparative TLC plate chromatography to afford the 1,4-disubtituted-1,2,3-triazole
product.

General Procedure A2: To a stirred solution of alkyne (1.0 eq) in t-BuOH/H2O (1:1, 20
mL/mmol alkyne) was added CuSO4.5H2O (0.1 eq), sodium ascorbate (0.2 eq), and the
appropriate azide (2.0 eq). Stirring was prolonged at rt for 24 h under N2 atmosphere, and
the resulting precipitate was filtered. The residue was triturated with sequential addition
of CH2Cl2, MeCN, and hot MeOH to afford the 1,4-disubtituted-1,2,3-triazole product.

5-(4-(6-methoxybenzo[d]thiazol-2-yl)-1H-1,2,3-triazol-1-yl)pyridin-2-amine 57a
Following General Procedure A2, alkyne 101 (40
mg, 0.21 mmol), CuSO4.5H2O (5 mg, 0.02 mmol),
sodium ascorbate (8 mg, 0.04 mmol), and azide
103 (57 mg, 0.42 mmol) were stirred in t-BuOH/H2O (1:1, 4.2 mL) to afford the 1,4disubtituted-1,2,3-triazole 57a (40 mg, 59%) as a pale yellow solid after sequential
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trituration with CH2Cl2, MeCN, and hot MeOH. TLC (CH2Cl2/MeOH – 90:10): Rf = 0.03.
Mp 182 ºC (decomp). 1H NMR (400 MHz, DMSO) δ 9.35 (s, 1H, H5'), 8.47 (d, J = 2.4
Hz, 1H, H6''), 7.93 (dd, J = 8.8, 2.4 Hz, 1H, H4''), 7.92 (d, J = 9.2 Hz, 1H, H4), 7.76 (d,
J = 2.4 Hz, 1H, H7), 7.16 (dd, J = 9.0, 2.4 Hz, 1H, H5), 6.61 (d, J = 8.8 Hz, 1H, H3''),
6.50 (br s, 2H, NH2), 3.87 (s, 3H, ArOCH3). 13C NMR (400 MHz, DMSO) δ 160.3 (C2''),
157.6 (C6), 156.1 (C2), 147.6 (C3a), 142.6 (C4'), 140.8 (C6''), 135.5 (C7a), 130.7 (C4),
123.4 (C5''), 123.1 (C4''), 121.4 (C5'), 116.0 (C5), 107.8 (C3''), 105.0 (C7), 55.8
(ArOCH3). IR (neat) 𝜈 max 3462 (m), 3331 (m), 3222 (m), 3051 (w), 1645 (s), 1608 (m),
1563 (s), 1516 (s), 1466 (m), 1430 (m), 1413 (m), 1324 (s), 1249 (m), 1225 (s), 1079 (m),
1018 (s), 942 (s), 887 (s) cm-1. MS (ESI +ve) m/z 325 ([M + H]+, 100%). HRMS (ESI
+ve TOF) calcd for C15H13N6OS+ 325.0866, found 325.0872 ([M + H]+).

5-(4-(6-methoxybenzo[d]thiazol-2-yl)-1H-1,2,3-triazol-1-yl)-N-methylpyridin-2amine 57b
The mixture of the azide 105 (100 mg, 0.67 mmol)
and 5-bromo-N-methylpyridin-2-amine 104 (102
mg) was dissolved in t-BuOH/H2O (1:1, 10 mL),
and alkyne 101 (127 mg, 0.67 mmol), CuSO4.5H2O
(18 mg, 0.07 mmol), and sodium ascorbate (67 mg, 0.34 mmol) were added, and the
reaction was stirred at rt for 24 hours. The resulting precipitate was filtered, and triturated
with hot MeCN (5 mL) to afford the 1,4-disubtituted-1,2,3-triazole 57b (156 mg, 69%)
as a pale yellow solid. TLC (CH2Cl2/MeOH – 90:10): Rf = 0.05. Mp 189 ºC (decomp).
1

H NMR (400 MHz, DMSO) δ 9.35 (s, 1H, H5'), 8.55 (d, J = 2.4 Hz, 1H, H6''), 7.93 (dd,

J = 8.8, 2.4 Hz, 1H, H4''), 7.92 (d, J = 9.2 Hz, 1H, H4), 7.76 (d, J = 2.4 Hz, 1H, H7), 7.15
(dd, J = 9.0, 2.4 Hz, 1H, H5), 7.07 (q, J = 4.8 Hz, 1H, NH), 6.63 (d, J = 8.8 Hz, 1H, H3''),
3.86 (s, 3H, ArOCH3), 2.84 (d, J = 4.8 Hz, 3H, ArNHCH3). 13C NMR (400 MHz, DMSO)
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δ 159.6 (C2''), 157.6 (C6), 156.2 (C2), 147.7 (C3a), 142.6 (C4'), 140.6 (C6''), 135.5 (C7a),
130.2 (C4), 124.2 (C5'', observed by HMBC), 123.1 (C4''), 121.3 (C5'), 116.0 (C5), 107.8
(C3''), 105.0 (C7), 55.8 (ArOCH3), 28.0 (ArNHCH3). IR (neat) 𝜈 max 3317 (m), 3100 (m),
3051 (w), 1608 (s), 1537 (s), 1493 (m), 1453 (m), 1401 (m), 1313 (s), 1290 (m), 1255
(m), 1218 (s), 1182 (m), 1079 (m), 1058 (m), 945 (s), 871 (s) cm-1. MS (ESI +ve) m/z 339
([M + H]+, 100%). HRMS (ESI +ve TOF) calcd for C16H15N6OS+ 339.1023, found
339.1028 ([M + H]+).
2-aminobenzo[d]thiazol-6-ol 108241
To a stirred solution of thiourea 107 (7.60 g, 0.10 mol) in EtOH
(200 mL) and concentrated HCl (9.0 mL) was added a hot solution
of 1,4-benzoquinone 106 (21.60 g, 0.20 mol) in EtOH (400 mL). The mixture was stirred
at rt for 48 h. The solvent was evaporated, and the residue triturated with hot MeCN (100
mL). This process was repeated until TLC analysis of the solid showed only one
component. The solid was collected and washed with cold EtOH (10 mL) to afford the
product as the hydrochloride salt. The free base was obtained by dissolving the salt in a
minimal volume of H2O, followed by neutralisation using NaOAc. The resulting
precipitated was collected by filtration, yielding the hydroxy benzothiazole 108 (12.05 g,
72%) as a dark grey solid. The spectroscopic data was in agreement with that previously
reported. TLC (CH2Cl2/MeOH – 90:10): Rf = 0.41. 1H NMR (400 MHz, CD3OD) δ 7.20
(d, J = 8.8 Hz, 1H, H4), 7.01 (d, J = 2.4 Hz, 1H, H7), 6.73 (dd, J = 8.8, 2.4 Hz, 1H, H5).
C NMR (400 MHz, CD3OD) δ 164.4 (C2), 152.6 (C6), 146.1 (C3a), 132.3 (C7a), 118.6
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(C4), 114.0 (C5), 107.4 (C7). MS (ESI +ve) m/z 167 ([M + H]+, 100%).
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6-((tert-butyldimethylsilyl)oxy)benzo[d]thiazol-2-amine 109
To a stirred solution of hydroxy benzothiazole 108 (5.00
g, 30.1 mmol) in anhydrous DMF was added TBDMS-Cl
(5.40 g, 36.1 mmol) and imidazole (2.46 g, 36.1 mmol).
The reaction was stirred at rt for 24 h, and partitioned between H2O (150 mL) and EtOAc
(150 mL). The aqueous phase was extracted with EtOAc (2 x 100 mL), and the combined
organic layers dried (Na2SO4), filtered, and concentrated. The residue was subjected to
flash chromatography over SiO2 gel (EtOAc/hexanes – 30:70) to afford the protected
phenol 109 (0.35 g, 41%) as a reddish oil. The spectroscopic data was in agreement with
that previously reported. TLC (EtOAc/hexanes – 30:70): Rf = 0.57. 1H NMR (400 MHz,
CDCl3) δ 7.35 (d, J = 8.4 Hz, 1H, H4), 7.05 (d, J = 2.4 Hz, 1H, H7), 6.80 (dd, J = 8.4, 2.4
Hz, 1H, H5), 5.85 (br s, 2H, ArNH2), 0.98 (s, 9H, H2'), 0.19 (s, 6H, H1'). 13C NMR (400
MHz, CDCl3) δ 165.2 (C2), 151.2 (C6), 146.5 (C3a), 132.2 (C7a), 119.2 (C4), 118.9 (C5),
112.0 (C7), 25.8 (C2'), 18.3 (C(CH3)3), -4.67 (C1'). MS (ESI +ve) m/z 281 ([M + H]+,
100%). HRMS (ESI +ve TOF) calcd for C13H21N2OSSi+ 281.1138, found 281.1138 ([M
+ H]+).

6-((tert-butyldimethylsilyl)oxy)-2-iodobenzo[d]thiazole 110
To a solution of protected phenol 109 (0.52 g, 1.86 mmol)
and p-toluenesulfonic acid monohydrate (1.12 mg, 6.51
mmol) in MeCN (55 mL) was added a solution of NaNO2
(0.26 g, 3.72 mmol) and KI (0.80 g, 4.83 mmol) in H2O (2.0 mL) at 0 ºC. The reaction
was allowed to reach rt, and was stirred for 18 h. The reaction mixture was quenched with
H2O (100 mL) and basified with 2 M NaHCO3 to pH 8-9, followed by addition of Na2S2O3
(10 mL), yielding a brown precipitate. The precipitate was collected by filtration, washed
with H2O (20 mL), and dried in vacuo. The residue was subjected to flash
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chromatography over SiO2 gel (EtOAc/hexanes – 30:70) to afford the iodobenzothiazole
110 (0.46 g, 63%) as a grey solid. TLC (EtOAc/hexanes – 30:70): Rf = 0.69. Mp 68 ºC.
1

H NMR (400 MHz, CDCl3) δ 7.86 (d, J = 8.4 Hz, 1H, H4), 7.26 (d, J = 2.4 Hz, 1H, H7),

6.94 (dd, J = 8.4, 2.4 Hz, 1H, H5), 1.00 (s, 9H, H2'), 0.22 (s, 6H, H1'). 13C NMR (400
MHz, CDCl3) δ 154.3 (C6), 149.6 (C3a), 140.3 (C7a), 123.0 (C4), 120.2 (C5), 110.7 (C7),
102.2 (C2), 25.8 (C2'), 18.4 (C(CH3)3), -4.28 (C1'). IR (neat) 𝜈 max 2954 (m), 2924 (m),
2852 (m), 1595 (m), 1555 (m), 1468 (s), 1438 (s), 1401 (m), 1360 (w), 1269 (s), 1252 (s),
1210 (s), 1004 (m), 928 (s), 834 (s), 780 (s) cm-1. MS (ESI +ve) m/z 392 ([M + H]+,
100%). HRMS (ESI +ve TOF) calcd for C13H19INOSSi+ 391.9996, found 391.9997 ([M
+ H]+).

6-((tert-butyldimethylsilyl)oxy)-2-((trimethylsilyl)ethynyl)benzo[d]thiazole 111
To a solution of iodobenzothiazole 110 (200 mg,
0.51 mmol), PdCl2(PPh3)2 (10 mg, 0.01 mmol),
CuI (3 mg, 0.02 mmol), and triethylamine (0.46
mL, 3.30 mmol) in anhydrous DMF (2.0 mL) was added a solution of
ethynyltrimethylsilane (100 mg, 1.02 mmol). The resulting mixture was stirred at 65 ºC
for 6 h. After cooling to rt, the solution was filtered through a layer of Celite, and
concentrated. The residue was subjected to flash chromatography over SiO2 gel
(EtOAc/hexanes – 20:80) to afford the protected alkyne 111 (136 mg, 74%) as a brown
oil. The product was used in the next reaction step immediately or stored in the freezer
for a limited time due to stability issues. TLC (EtOAc/hexanes – 20:80): Rf = 0.86. 1H
NMR (400 MHz, CDCl3) δ 7.88 (d, J = 8.5 Hz, 1H, H4), 7.25 (d, J = 2.5 Hz, 1H, H7),
7.01 (dd, J = 8.5, 2.5 Hz, 1H, H5), 1.00 (s, 9H, H2''), 0.30 (s, 9H, H3'), 0.22 (s, 6H, H1'').
C NMR (400 MHz, CDCl3) δ 155.0 (C6), 147.8 (C3a), 146.2 (C2), 137.0 (C7a), 124.3
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(C4), 120.9 (C5), 112 (C7), 102.5 (C2'), 97.1 (C1'), 25.8 (C2''), 18.4 (C(CH3)3), -0.38
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(C3'), -4.25 (C1''). IR (neat) 𝜈 max 2912 (m), 1610 (m), 1552 (m), 1461 (s), 1438 (s), 1404
(m), 1366 (w), 1289 (s), 1111 (m), 930 (s), 844 (s), 788 (s) cm-1. MS (ESI +ve) m/z 362
([M + H]+, 100%). HRMS (ESI +ve TOF) calcd for C18H28NOSSi2+ 362.1425, found
362.1426 ([M + H]+).

2-ethynylbenzo[d]thiazol-6-ol 112
To a solution of the protected alkyne 111 (110 mg, 0.30 mmol)
in MeOH (5.0 mL) was added KF (220 mg, 3.78 mmol), and the
mixture was stirred at rt for 4 h. The solvent was removed, and the residue was purified
by preparative TLC plate chromatography (CH2Cl2/MeOH – 90:10) to afford the free
alkyne 112 (45 mg, 86%) as a pale yellow solid. TLC (CH2Cl2/MeOH – 90:10): Rf = 0.10.
Mp 101 ºC (decomp). 1H NMR (500 MHz, DMSO) δ 10.14 (s, 1H, ArOH), 7.85 (d, J =
8.5 Hz, 1H, H4), 7.74 (d, J = 2.5 Hz, 1H, H7), 7.22 (dd, J = 8.5, 2.5 Hz, 1H, H5), 4.33 (s,
1H, H2').

C NMR (500 MHz, DMSO) δ 157.0 (C6), 145.7 (C3a), 143.2 (C2), 136.3
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(C7a), 124.2 (C4), 117.0 (C5), 106.4 (C7), 87.1 (C1'), 77.0 (C2'). IR (neat) 𝜈 max 3310 (w),
2977 (w), 2188 (w), 2134 (w), 1732 (s), 1615 (w), 1589 (w), 1530 (m), 1480 (m), 1450
(m), 1394 (m), 1370 (m), 1254 (s), 1153 (s), 1097 (s), 1030 (m), 798 (m), 761 (m) cm-1.
MS (ESI +ve) m/z 174 ([M – H]–, 100%). HRMS (ESI –ve TOF) calcd for C9H4NOS–
174.0019, found 174.0019 ([M – H]–).

2-(1-(6-(methylamino)pyridin-3-yl)-1H-1,2,3-triazol-4-yl)benzo[d]thiazol-6-ol 57c
Following General Procedure A2, alkyne 112 (37
mg, 0.21 mmol), CuSO4.5H2O (5 mg, 0.02 mmol),
sodium ascorbate (8 mg, 0.04 mmol), and azide 105
(63 mg, 0.42 mmol) were stirred in t-BuOH/H2O
(1:1, 4.2 mL) to afford the 1,4-disubtituted-1,2,3-triazole 57c (36 mg, 53%) as a brown
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solid after sequential trituration with CH2Cl2, MeCN, and hot MeOH. TLC
(CH2Cl2/MeOH – 90:10): Rf = 0.05. Mp 170 ºC (decomp). 1H NMR (500 MHz, DMSO,
75 ºC) δ 9.97 (s, 1H, ArOH), 9.36 (s, 1H, H5'), 8.58 (d, J = 2.4 Hz, 1H, H6''), 7.94 (dd, J
= 8.8, 2.4 Hz, 1H, H4''), 7.84 (d, J = 9.2 Hz, 1H, H4), 7.46 (d, J = 2.4 Hz, 1H, H7), 7.12
(br s, 1H, NH), 7.01 (dd, J = 9.0, 2.4 Hz, 1H, H5), 6.65 (d, J = 8.8 Hz, 1H, H3''), 2.83 (s,
3H, ArNHCH3).
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C NMR (500 MHz, DMSO) δ 159.6 (C2''), 156.0 (C6), 155.1 (C2),

146.8 (C3a), 142.8 (C4'), 140.6 (C6''), 135.5 (C7a), 130.2 (C4''), 123.3 (C4), 121.2 (C5'),
116.2 (C5), 108.2 (C3''), 107.0 (C7), 28.1 (ArNHCH3). IR (neat) 𝜈 max 3243 (m), 3096
(m), 1613 (s), 1555 (s), 1455 (m), 1403 (m), 1380 (m), 1260 (m), 1235 (m), 1168 (m),
1035 (m), 902 (s), 831 (m), 799 (m) cm-1. MS (ESI +ve) m/z 325 ([M + H]+, 100%).
HRMS (ESI +ve TOF) calcd for C15H13N6OS+ 325.0866, found 325.0866 ([M + H]+).

2-iodo-6-methylbenzo[d]thiazole 114
To a solution of 6-methylbenzo[d]thiazol-2-amine 113 (4.11 g,
25.00 mmol) and p-toluenesulfonic acid monohydrate (15.07 g,
87.50 mmol) in MeCN (150 mL) was added a solution of NaNO2 (4.45 g, 50.00 mmol)
and KI (10.79 g, 65.00 mmol) in H2O (16 mL) at 0 ºC. The reaction was allowed to reach
rt, and was stirred for 18 h. The reaction mixture was quenched with H2O (350 mL) and
basified with 2 M NaHCO3 to pH 8-9, followed by addition of Na2S2O3 (20 mL), yielding
a light brown precipitate. The precipitate was collected by filtration, washed with H2O
(20 mL), and dried in vacuo to afford the iodobenzothiazole 114 (4.90 g, 71%) as a light
orange solid. The product was used directly for the next step without further purification.
TLC (EtOAc/hexanes – 60:40): Rf = 0.88. Mp 96 ºC. 1H NMR (400 MHz, CDCl3) δ 7.89
(d, J = 8.4 Hz, 1H, H4), 7.60 (br s, 1H, H7), 7.23 (dd, J = 8.4, 1.6 Hz, 1H, H5), 2.46 (s,
3H, ArCH3). 13C NMR (400 MHz, CDCl3) δ 152.6 (C3a), 139.4 (C7a), 136.0 (C6), 128.0
(C5), 122.1 (C4), 120.3 (C7), 104.3 (C2), 21.6 (ArCH3). IR (neat) 𝜈 max 2910 (w), 1886
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(w), 1609 (m), 1505 (m), 1428 (m), 1394 (m), 1307 (m), 1232 (m), 1056 (m), 1042 (w),
954 (s), 875 (m), 854 (m), 807 (s), 584 (s). MS (ESI +ve) m/z 276 ([M + H]+, 100%).
HRMS (ESI +ve TOF) calcd for C8H7INS+ 275.9338, found 275.9344 ([M + H]+).

6-methyl-2-((trimethylsilyl)ethynyl)benzo[d]thiazole 115
To a solution of iodobenzothiazole 114 (1.76 g, 6.40
mmol), PdCl2(PPh3)2 (90 mg, 0.13 mmol), CuI (26 mg,
0.14 mmol), and triethylamine (4.0 mL, 28.70 mmol) in anhydrous DMF (8.0 mL) was
added a solution of ethynyltrimethylsilane (1.26 g, 12.83 mmol). The resulting mixture
was stirred at 65 ºC for 6 h. After cooling to rt, the solution was filtered through a layer
of Celite, and concentrated. The residue was subjected to flash chromatography over SiO2
gel (EtOAc/hexanes – 60:40) to afford the protected alkyne 115 (1.21 g, 76%) as a light
yellow oil. The product was used in the next reaction step immediately or stored in the
freezer for a limited time due to stability issues. TLC (EtOAc/hexanes – 60:40): Rf = 0.89.
1

H NMR (400 MHz, CDCl3) δ 7.91 (d, J = 8.4 Hz, 1H, H4), 7.62 (br s, 1H, H7), 7.30

(dd, J = 8.4, 1.6 Hz, 1H, H5), 2.48 (s, 3H, ArCH3), 0.30 (s, 9H, (CH3)3). 13C NMR (400
MHz, CDCl3) δ 151.0 (C3a), 147.3 (C2), 136.9 (C7a), 135.6 (C6), 128.5 (C5), 123.3 (C4),
121.1 (C7), 102.7 (C2'), 97.1 (C1'), 21.7 (ArCH3), 0.40 (C11). IR (neat) 𝜈 max 3215 (br),
2990 (w), 1608 (m), 1558 (m), 1493 (m), 1439 (m), 1384 (m), 1302 (m), 1211 (s), 1109
(m), 1053 (m), 922 (s), 877 (s), 708 (m). MS (ESI +ve) m/z 246 ([M + H]+, 100%). HRMS
(ESI +ve TOF) calcd for C13H16NSSi+ 246.0767, found 246.0767 ([M + H]+).

2-ethynyl-6-methylbenzo[d]thiazole 116
To a solution of the protected alkyne 115 (0.94 g, 3.83 mmol) in
MeOH (30 mL) was added KF (1.00 g, 17.21 mmol), and the
mixture was stirred at rt for 2 h. The solvent was removed, and the residue was subjected
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to flash chromatography over SiO2 gel (EtOAc/hexanes – 60:40) to afford the free alkyne
116 (0.64 g, 96%) as a pale yellow solid. TLC (EtOAc/hexanes – 60:40): Rf = 0.77. Mp
60 ºC. 1H NMR (400 MHz, CDCl3) δ 7.94 (d, J = 8.4 Hz, 1H, H4), 7.65 (br s, 1H, H7),
7.32 (dd, J = 8.4, 1.6 Hz, 1H, H5), 3.56 (s, 1H, H2'), 2.49 (s, 3H, ArCH3). 13C NMR (400
MHz, CDCl3) δ 150.9 (C3a), 146.4 (C2), 137.2 (C7a), 135.5 (C6), 128.8 (C5), 123.6 (C4),
121.1 (C7), 83.6 (C2'), 77.0 (C1'), 21.8 (ArCH3). IR (neat) 𝜈 max 3185 (br), 2945 (w), 2103
(m), 1604 (m), 1552 (m), 1476 (m), 1401 (m), 1310 (m), 1247 (w), 1116 (s), 1052 (m),
1034 (m), 874 (m), 809 (s), 742 (m), 686 (m), 559 (s). MS (ESI +ve) m/z 174 ([M + H]+,
100%). HRMS (ESI +ve TOF) calcd for C10H8NS+ 174.0372, found 174.0377 ([M + H]+).

General Procedure B: Azidation of benzyl bromide, phenylethyl bromide, and alkyl
bromide building blocks
The appropriate alkyl bromide or benzyl bromide or phenylethyl bromide (1.0 eq) and
NaN3 (1.5 eq) were combined in anhydrous DMF (20 mL), and stirred at 55 ºC for 24 h.
The resulting reaction mixture was poured into H2O (25 mL) and extracted with CH2Cl2
(3 x 25 mL). The organic layer was washed with H2O (2 x 25 mL), brine (2 x 25 mL),
dried (Na2SO4), filtered, and concentrated. The azide product was used for the next
reaction without further purification (alkyl azide) or purified by flash chromatography
(benzyl azide and phenylethyl azide) over SiO2 gel (CH2Cl2/MeOH).
1-(azidomethyl)-4-fluorobenzene 119a242
Following General Procedure B, benzyl bromide 117a (756 mg,
4.00 mmol) and NaN3 (390 mg, 6.00 mmol) were stirred in
anhydrous DMF (20 mL) to afford the azide 119a (500 mg, 83%) as a pale yellow oil
after flash chromatography (CH2Cl2/MeOH – 90:10). The spectroscopic data was in
agreement with that previously reported. TLC (CH2Cl2/MeOH – 90:10): Rf = 0.71. 1H
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NMR (400 MHz, CDCl3) δ 7.32 – 7.28 (m, 2H, H2, H6), 7.10 – 7.06 (m, 2H, H3, H5),
4.32 (s, 2H, H1'). 13C NMR (100 MHz, CDCl3) δ 162.8 (d, 1JCF = 245.0 Hz, C4), 131.3
(d, 4JCF = 4.0 Hz, C1), 130.13 (d, 3JCF = 8.0 Hz, C2, C6), 115.9 (d, 2JCF = 22.0 Hz, C3,
C5), 54.2 (C1'). MS (ESI +ve) m/z 152 ([M + H]+, 100%).
1-(azidomethyl)-3-fluorobenzene 119b242
Following General Procedure B, benzyl bromide 117b (756 mg,
4.00 mmol) and NaN3 (390 mg, 6.00

mmol) were stirred in

anhydrous DMF (20 mL) to afford the azide 119b (455 mg, 75%) as
a pale yellow oil after flash chromatography (CH2Cl2/MeOH – 90:10). The spectroscopic
data was in agreement with that previously reported. TLC (CH2Cl2/MeOH – 90:10): Rf =
0.86. 1H NMR (400 MHz, CDCl3) δ 7.40 – 7.33 (m, 1H, H5), 7.12 – 7.02 (m, 3H, H2,
H4, H6), 4.35 (s, 2H, H1'). 13C NMR (400 MHz, CDCl3) δ 163.1 (d, 1JCF = 245.0 Hz, C3),
138.0 (d, 3JCF = 7.0 Hz, C1), 130.6 (C5), 123.8 (C6), 115.2 (d, 2JCF = 41.0 Hz, C2), 115.2
(C4), 54.2 (C1'). MS (ESI +ve) m/z 152 ([M + H]+, 100%).
1-(azidomethyl)-4-(trifluoromethyl)benzene 119c243
Following General Procedure B, benzyl bromide 117c (956
mg, 4.00 mmol) and NaN3 (390 mg, 6.00 mmol) were stirred in
anhydrous DMF (20 mL) to afford the azide 119c (698 mg, 87%)
as a pale yellow oil after flash chromatography (CH2Cl2/MeOH – 99:1). The
spectroscopic data was in agreement with that previously reported. TLC (CH2Cl2/MeOH
– 99:1): Rf = 0.67. 1H NMR (400 MHz, CDCl3) δ 7.64 (d, J = 8.0 Hz, 2H, H3, H5), 7.46
(d, J = 8.0 Hz, 2H, H2, H6), 4.43 (s, 2H, H1'). 13C NMR (100 MHz, CDCl3) δ 139.6 (C1),
130.7 (q, 2JCF = 32.3 Hz, C4), 128.4 (C2, C6), 126.0 (q, 3JCF = 3.8 Hz, C3, C5), 125.7 (q,
1

JCF = 270.4 Hz, C8), 54.3 (C1'). MS (ESI +ve) m/z 202 ([M + H]+, 100%).
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Azidomethylbenzene 119d242
Following General Procedure B, benzyl bromide 117d (684 mg,
4.00 mmol) and NaN3 (390 mg, 6.00

mmol) were stirred in

anhydrous DMF (20 mL) to afford the azide 119d (480 mg, 90%) as a pale yellow oil
after flash chromatography (CH2Cl2/MeOH – 90:10). The spectroscopic data was in
agreement with that previously reported. TLC (CH2Cl2/MeOH – 90:10): Rf = 0.86. 1H
NMR (400 MHz, CDCl3) δ 7.43 – 7.33 (m, 5H, H2, H3, H4, H5, H6), 4.35 (s, 2H, H1').
C NMR (400 MHz, CDCl3) δ 135.5 (C1), 129.0 (C3, C5), 128.4 (C2, C6), 128.3 (C4),
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54.9 (C1'). MS (ESI +ve) m/z 134 ([M + H]+, 100%).
1-(azidomethyl)-4-nitrobenzene 119e243
Following General Procedure B, benzyl bromide 117e (864
mg, 4.00 mmol) and NaN3 (390 mg, 6.00 mmol) were stirred in
anhydrous DMF (20 mL) to afford the azide 119e (550 mg, 77%) as a yellow oil after
flash chromatography (CH2Cl2/MeOH – 90:10). The spectroscopic data was in agreement
with that previously reported. TLC (CH2Cl2/MeOH – 90:10): Rf = 0.65. 1H NMR (400
MHz, CDCl3) δ 8.20 (d, J = 8.8 Hz, 2H, H3, H5), 7.49 (d, J = 8.8 Hz, 2H, H2, H6), 4.49
(s, 2H, H1').
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C NMR (400 MHz, CDCl3) δ 174.7 (C4), 142.8 (C1), 128.6 (C2, C6),

124.0 (C3, C5), 53.7 (C1'). MS (ESI +ve) m/z 179 ([M + H]+, 100%).
4-(azidomethyl)benzonitrile 119f242
Following General Procedure B, benzyl bromide 117f (784 mg,
4.00 mmol) and NaN3 (390 mg, 6.00 mmol) were stirred in
anhydrous DMF (20 mL) to afford the azide 119f (490 mg, 77%)
as a yellow oil after flash chromatography (CH2Cl2/MeOH – 90:10). The spectroscopic
data was in agreement with that previously reported. TLC (CH2Cl2/MeOH – 90:10): Rf =
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0.88. 1H NMR (400 MHz, CDCl3) δ 7.67 (d, J = 8.8 Hz, 2H, H3, H5), 7.43 (d, J = 8.8 Hz,
2H, H2, H6), 4.44 (s, 2H, H1'). 13C NMR (400 MHz, CDCl3) δ 140.9 (C1), 132.7 (C3,
C5), 128.6 (C2, C6), 118.5 (C8), 112.3 (C4), 54.1 (C1'). MS (ESI +ve) m/z 159 ([M +
H]+, 100%).
1-(2-azidoethyl)-4-fluorobenzene 120a242
Following General Procedure B, phenylethyl bromide 118a
(812 mg, 4.00 mmol) and NaN3 (390 mg, 6.00 mmol) were
stirred in anhydrous DMF (20 mL) to afford the azide 120a (488
mg, 74%) as a pale yellow oil after flash chromatography (CH2Cl2/MeOH – 90:10). The
spectroscopic data was in agreement with that previously reported. TLC (CH2Cl2/MeOH
– 90:10): Rf = 0.69. 1H NMR (400 MHz, CDCl3) δ 7.20 – 7.16 (m, 2H, H2, H6), 7.03 –
6.99 (m, 2H, H3, H5), 3.49 (t, J = 6.8 Hz, 2H, H2'), 2.87 (t, J = 6.8 Hz, 2H, H1').
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NMR (100 MHz, CDCl3) δ 162.0 (d, 1JCF = 245.0 Hz, C4), 133.9 (d, 4JCF = 4.0 Hz, C1),
130.36 (d, 3JCF = 8.0 Hz, C2, C6), 115.6 (d, 2JCF = 22.0 Hz, C3, C5), 52.6 (C2'), 34.7
(C1'). MS (ESI +ve) m/z 166 ([M + H]+, 100%).
1-(2-azidoethyl)-4-(trifluoromethyl)benzene 120b244
Following General Procedure B, phenylethyl bromide 118b
(1.01 g, 4.00 mmol) and NaN3 (390 mg, 6.00 mmol) were
stirred in anhydrous DMF (20 mL) to afford the azide 120b
(711 mg, 83%) as a pale yellow oil after flash chromatography (CH2Cl2/MeOH – 90:10).
The spectroscopic data was in agreement with that previously reported. TLC
(CH2Cl2/MeOH – 90:10): Rf = 0.77. 1H NMR (500 MHz, CDCl3) δ 7.59 (d, J = 6.4 Hz,
2H, C3, C5), 7.34 (d, J = 6.4 Hz, 2H, C2, C6), 3.55 (t, J = 5.6 Hz, 2H, H2'), 2.95 (t, J =
5.6 Hz, 2H, H1'). 13C NMR (125 MHz, CDCl3) δ 142.3 (C1), 129.4 (q, 2JCF = 32.3 Hz,
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C4), 129.3 (C2, C6), 125.7 (q, 3JCF = 3.8 Hz, C3, C5), 125.6 (q, 1JCF = 270.4 Hz, C9),
52.1 (C2'), 35.3 (C1'). MS (ESI +ve) m/z 216 ([M + H]+, 100%).
4-(2-azidoethyl)phenol 120c242
Following General Procedure B, phenylethyl bromide 118c
(805 mg, 4.00 mmol) and NaN3 (390 mg, 6.00 mmol) were
stirred in anhydrous DMF (20 mL) to afford the azide 120c
(511 mg, 78%) as a colourless oil after flash chromatography (CH2Cl2/MeOH – 90:10).
The spectroscopic data was in agreement with that previously reported. TLC
(CH2Cl2/MeOH – 90:10): Rf = 0.60. 1H NMR (400 MHz, CDCl3) δ 7.09 (d, J = 8.8 Hz,
2H, H2, H6), 6.79 (d, J = 8.8 Hz, 2H, H3, H5), 5.15 (s, 1H, OH), 3.46 (t, J = 7.2 Hz, 2H,
H2'), 2.83 (t, J = 7.2 Hz, 2H, H1'). 13C NMR (400 MHz, CDCl3) δ 154.5 (C4), 130.3 (C1),
130.1 (C2, C6), 115.6 (C3, C5), 52.8 (C2'), 34.6 (C1'). MS (ESI +ve) m/z 164 ([M + H]+,
100%).
1-(2-azidoethyl)-4-nitrobenzene 120d245
Following General Procedure B, phenylethyl bromide 118d
(920 mg, 4.00 mmol) and NaN3 (390 mg, 6.00 mmol) were
stirred in anhydrous DMF (20 mL) to afford the azide 120d
(601 mg, 78%) as a yellow oil after flash chromatography (CH2Cl2/MeOH – 95:5). The
spectroscopic data was in agreement with that previously reported. TLC (CH2Cl2/MeOH
– 95:5): Rf = 0.63. 1H NMR (400 MHz, CDCl3) δ 8.17 (d, J = 7.2 Hz, 2H, H3, H5), 7.40
(d, J = 7.2 Hz, 2H, H2, H6), 3.58 (t, J = 5.2 Hz, 2H, H2'), 2.99 (t, J = 5.2 Hz, 2H, H1').
C NMR (400 MHz, CDCl3) δ 147.1 (C4), 145.9 (C1), 129.8 (C2, C6), 123.9 (C3, C5),
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51.8 (C2'), 35.3 (C1'). MS (ESI +ve) m/z 193 ([M + H]+, 100%).
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2-(1-(4-fluorobenzyl)-1H-1,2,3-triazol-4-yl)-6-methoxybenzo[d]thiazole 58a
Following General Procedure A1, alkyne 101
(40 mg, 0.21 mmol), CuSO4.5H2O (5 mg, 0.02
mmol), sodium ascorbate (8 mg, 0.04 mmol), and
azide 119a (64 mg, 0.42 mmol) were stirred in t-BuOH/H2O (1:1, 4.2 mL) to afford the
1,4-disubtituted-1,2,3-triazole 58a (55 mg, 77%) as a pale yellow solid after preparative
TLC plate chromatography (CH2Cl2/MeOH – 98:2). TLC (CH2Cl2/MeOH – 98:2): Rf =
0.55. Mp 175 ºC. 1H NMR (500 MHz, DMSO) δ 8.95 (s, 1H, H5'), 7.90 (d, J = 9.0 Hz,
1H, H4), 7.73 (d, J = 2.4 Hz, 1H, H7), 7.51 – 7.47 (m, 2H, H2'', H6''), 7.26 – 7.22 (m, 2H,
H3'', H5''), 7.15 (dd, J = 9.0, 2.4 Hz, 1H, H5), 5.84 (s, 2H, H1'''), 3.85 (s, 3H, ArOCH3).
C NMR (125 MHz, DMSO) δ 162.0 (d, 1JCF = 243.3 Hz, C4''), 157.6 (C6), 156.3 (C2),
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147.6 (C3a), 142.3 (C4'), 135.4 (C7a), 131.8 (d, 4JCF = 2.8 Hz, C1''), 130.5 (d, 3JCF = 8.6
Hz, C2'', C6''), 123.4 (C5'), 123.1 (C4), 115.8 (d, 2JCF = 44.4 Hz, C3'', C5''), 115.8 (C5),
104.9 (C7), 55.7 (ArOCH3), 52.5 (C1'''). IR (neat) 𝜈 max 3200 (w), 2831 (w), 2230 (w),
1605 (m), 1580 (w), 1557 (m), 1508 (m), 1489 (m), 1465 (m), 1435 (s), 1259 (s), 1219
(m), 1184 (m), 1157 (m), 1128 (s), 948 (m), 887 (s) cm-1. MS (ESI +ve) m/z 341 ([M +
H]+, 100%); (ESI –ve) m/z 339 ([M – H]–, 100%). HRMS (ESI +ve TOF) calcd for
C17H14FN4OS+ 341.0867, found 341.0872 ([M + H]+).

2-(1-(4-fluorophenethyl)-1H-1,2,3-triazol-4-yl)-6-methoxybenzo[d]thiazole 58b
Following General Procedure A1, alkyne 101
(40 mg, 0.21 mmol), CuSO4.5H2O (5 mg, 0.02
mmol), sodium ascorbate (8 mg, 0.04 mmol),
and azide 120a (69 mg, 0.42 mmol) were stirred in t-BuOH/H2O (1:1, 4.2 mL) to afford
the 1,4-disubtituted-1,2,3-triazole 58b (51 mg, 69%) as a pale yellow solid after
preparative TLC plate chromatography (CH2Cl2/MeOH – 98:2). TLC (CH2Cl2/MeOH –
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98:2): Rf = 0.57. Mp 149 ºC. 1H NMR (400 MHz, DMSO) δ 8.80 (s, 1H, H5'), 7.89 (d, J
= 9.0 Hz, 1H, H4), 7.72 (d, J = 2.4 Hz, 1H, H7), 7.28 – 7.24 (m, 2H, H2'', H6''), 7.14 –
7.10 (m, 2H, H3'', H5''), 7.09 (dd, J = 9.0, 2.4 Hz, 1H, H5), 4.73 (t, J = 7.2 Hz, 2H, H1'''),
3.85 (s, 3H, ArOCH3), 3.25 (t, J = 7.2 Hz, 2H, H2'''). 13C NMR (100 MHz, DMSO) δ
161.1 (d, 1JCF = 240.7 Hz, C4''), 157.5 (C6), 156.5 (C2), 147.6 (C3a), 141.9 (C4'), 135.3
(C7a), 133.6 (d, 4JCF = 3.1 Hz, C1''), 130.6 (d, 3JCF = 8.0 Hz, C2'', C6''), 123.3 (C5'), 123.1
(C4), 115.9 (C5), 115.2 (d, 2JCF = 21.0 Hz, C3'', C5''), 104.9 (C7), 55.7 (ArOCH3), 50.9
(C1'''), 34.5 (C2'''). IR (neat) 𝜈 max 3107 (w), 2841 (w), 2229 (w), 1610 (m), 1582 (m),
1554 (m), 1489 (m), 1466 (m), 1437 (s), 1325 (m), 1278 (s), 1215 (s), 1161 (m), 1116
(m), 943 (m), 877 (s) cm-1. MS (ESI +ve) m/z 355 ([M + H]+, 100%). HRMS (ESI +ve
TOF) calcd for C18H16FN4OS+ 355.1023, found 355.1029 ([M + H]+).

2-(1-(3-fluorobenzyl)-1H-1,2,3-triazol-4-yl)-6-methoxybenzo[d]thiazole 58c
Following General Procedure A1, alkyne 101
(40 mg, 0.21 mmol), CuSO4.5H2O (5 mg, 0.02
mmol), sodium ascorbate (8 mg, 0.04 mmol), and
azide 119b (63 mg, 0.42 mmol) were stirred in t-BuOH/H2O (1:1, 4.2 mL) to afford the
1,4-disubtituted-1,2,3-triazole 58c (60 mg, 84%) as a pale yellow solid after preparative
TLC plate chromatography (CH2Cl2/MeOH – 98:2). TLC (CH2Cl2/MeOH – 98:2): Rf =
0.50. Mp 170 ºC. 1H NMR (400 MHz, DMSO) δ 8.98 (s, 1H, H5'), 7.90 (d, J = 9.0 Hz,
1H, H4), 7.73 (d, J = 2.4 Hz, 1H, H7), 7.46 – 7.42 (m, 1H, H5''), 7.30 – 7.18 (m, 3H, H2'',
H4'', H6''), 7.14 (dd, J = 9.0, 2.4 Hz, 1H, H5), 4.74 (s, 2H, H1'''), 3.85 (s, 3H, ArOCH3).
C NMR (100 MHz, DMSO) δ 162.2 (d, 1JCF = 243.0 Hz, C3''), 157.6 (C6), 156.6 (C2),
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147.6 (C3a), 142.3 (C4'), 138.2 (d, 3JCF = 7.8 Hz, C1''), 135.4 (C7a), 131.0 (C5''), 130.9
(C6''), 124.2 (C4), 123.7 (C5'), 116.0 (C5), 115.1 (d, 2JCF = 40.4 Hz, C2''), 115.1 (C4''),
104.9 (C7), 55.7 (ArOCH3), 52.6 (C1'''). IR (neat) 𝜈 max 3121 (w), 2840 (w), 2220 (w),
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1608 (m), 1582 (m), 1553 (m), 1490 (m), 1460 (m), 1431 (s), 1319 (m), 1268 (s), 1211
(s), 1159 (m), 1130 (m), 943 (m), 878 (s) cm-1. MS (ESI +ve) m/z 341 ([M + H]+, 100%);
(ESI –ve) m/z 339 ([M – H]–, 100%). HRMS (ESI +ve TOF) calcd for C17H14FN4OS+
341.0867, found 341.0872 ([M + H]+).

6-methoxy-2-(1-(4-(trifluoromethyl)benzyl)-1H-1,2,3-triazol-4-yl)benzo[d]thiazole
58d
Following General Procedure A1, alkyne 101
(40 mg, 0.21 mmol), CuSO4.5H2O (5 mg, 0.02
mmol), sodium ascorbate (8 mg, 0.04 mmol),
and azide 119c (84 mg, 0.42 mmol) were stirred in t-BuOH/H2O (1:1, 4.2 mL) to afford
the 1,4-disubtituted-1,2,3-triazole 58d (61 mg, 74%) as a pale yellow solid after
preparative TLC plate chromatography (CH2Cl2/MeOH – 98:2). TLC (CH2Cl2/MeOH –
98:2): Rf = 0.66. Mp 174 ºC. 1H NMR (400 MHz, DMSO) δ 9.01 (s, 1H, H5'), 7.90 (d, J
= 8.8 Hz, 1H, H4), 7.78 (d, J = 8.0 Hz, 2H, H3'', H5''), 7.74 (d, J = 2.4 Hz, 1H, H7), 7.60
(d, J = 8.0 Hz, 2H, H2'', H6''), 7.14 (dd, J = 8.8, 2.4 Hz, 1H, H5), 5.85 (s, 2H, H1'''), 3.85
(s, 3H, ArOCH3). 13C NMR (100 MHz, DMSO) δ 158.1 (C6), 156.7 (C2), 148.1 (C3a),
142.9 (C4'), 140.7 (C1''), 135.9 (C7a), 129.3 (C2'', C6''), 129.3 (q, 2JCF = 31.8 Hz, C4''),
126.3 (q, 3JCF = 3.8 Hz, C3'', C5''), 125.0 (q, 1JCF = 270.4 Hz, ArCF3), 124.3 (C5'), 123.6
(C4), 116.5 (C5), 105.4 (C7), 56.2 (ArOCH3), 53.1 (C1'''). IR (neat) 𝜈 max 3142 (w), 2841
(w), 2215 (w), 1608 (m), 1579 (m), 1553 (m), 1491 (m), 1459 (m), 1436 (s), 1324 (m),
1272 (s), 1215 (s), 1160 (m), 1120 (m), 948 (m), 874 (s) cm-1. MS (ESI +ve) m/z 391 ([M
+ H]+, 100%); (ESI –ve) m/z 389 ([M – H]–, 100%). HRMS (ESI +ve TOF) calcd for
C18H14F3N4OS+ 391.0835, found 391.0840 ([M + H]+).
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6-methoxy-2-(1-(4-(trifluoromethyl)phenethyl)-1H-1,2,3-triazol-4yl)benzo[d]thiazole 58e
Following General Procedure A1, alkyne
101 (40 mg, 0.21 mmol), CuSO4.5H2O (5 mg,
0.02 mmol), sodium ascorbate (8 mg, 0.04
mmol), and azide 120b (90 mg, 0.42 mmol) were stirred in t-BuOH/H2O (1:1, 4.2 mL) to
afford the 1,4-disubtituted-1,2,3-triazole 58e (60 mg, 71%) as a pale yellow solid after
preparative TLC plate chromatography (CH2Cl2/MeOH – 98:2). TLC (CH2Cl2/MeOH –
98:2): Rf = 0.71. Mp 167 ºC. 1H NMR (500 MHz, DMSO) δ 8.86 (s, 1H, H5'), 7.89 (d, J
= 8.8 Hz, 1H, H4), 7.72 (d, J = 2.4 Hz, 1H, H7), 7.65 (d, J = 8.0 Hz, 2H, H3'', H5''), 7.47
(d, J = 8.0 Hz, 2H, H2'', H6''), 7.13 (dd, J = 8.8, 2.4 Hz, 1H, H5), 4.80 (t, J = 5.6 Hz, 2H,
H1'''), 3.85 (s, 3H, ArOCH3), 3.37 (t, J = 5.6 Hz, 2H, H2'''). 13C NMR (125 MHz, DMSO)
δ 157.6 (C6), 156.4 (C2), 147.6 (C3a), 142.4 (C4'), 142.0 (C1''), 135.3 (C7a), 129.6 (C2'',
C6''), 127.4 (q, 2JCF = 31.8 Hz, C4''), 125.3 (q, 3JCF = 3.8 Hz, C3'', C5''), 124.6 (q, 1JCF =
270.4 Hz, ArCF3), 123.3 (C5'), 123.1 (C4), 115.9 (C5), 104.9 (C7), 55.7 (ArOCH3), 50.4
(C1'''), 35.0 (C2'''). IR (neat) 𝜈 max 3107 (w), 2922 (w), 2229 (w), 1606 (m), 1570 (m),
1516 (s), 1484 (m), 1452 (m), 1344 (s), 1312 (m), 1228 (m), 1178 (m), 1130 (m), 1106
(m), 948 (s), 882 (s) cm-1. MS (ESI +ve) m/z 405 ([M + H]+, 100%); (ESI –ve) m/z 403
([M – H]–, 100%). HRMS (ESI +ve TOF) calcd for C19H16F3N4OS+ 405.0991, found 405.
0997 ([M + H]+).

2-(1-benzyl-1H-1,2,3-triazol-4-yl)-6-methoxybenzo[d]thiazole 58f
Following General Procedure A1, alkyne 101 (40
mg, 0.21 mmol), CuSO4.5H2O (5 mg, 0.02 mmol),
sodium ascorbate (8 mg, 0.04 mmol), and azide
119d (56 mg, 0.42 mmol) were stirred in t-BuOH/H2O (1:1, 4.2 mL) to afford the 1,4210

disubtituted-1,2,3-triazole 58f (58 mg, 86%) as a pale yellow solid after preparative TLC
plate chromatography (CH2Cl2/MeOH – 98:2). TLC (CH2Cl2/MeOH – 98:2): Rf = 0.67.
Mp 162 ºC. 1H NMR (500 MHz, DMSO) δ 8.95 (s, 1H, H5'), 7.90 (d, J = 9.0 Hz, 1H,
H4), 7.73 (d, J = 3.0 Hz, 1H, H7), 7.34 – 7.12 (m, 5H, H2'', H3'', H4'', H5'', H6''), 7.13
(dd, J = 9.0, 3.0 Hz, 1H, H5), 5.71 (s, 2H, H1'''), 3.85 (s, 3H, ArOCH3). 13C NMR (500
MHz, DMSO) δ 157.6 (C6), 156.3 (C2), 147.6 (C3a), 142.3 (C4'), 135.6 (C1''), 135.4
(C7a), 128.9 (C3'', C5''), 128.3 (C4''), 128.1 (C2'', C6''), 123.5 (C5'), 123.1 (C4), 116.0
(C5), 104.9 (C7), 55.7 (ArOCH3), 53.3 (C1'''). IR (neat) 𝜈 max 3140 (w), 2980 (w), 2241
(w), 1607 (s), 1576 (m), 1556 (m), 1489 (m), 1465 (m), 1430 (m), 1322 (s), 1255 (s),
1222 (m), 1180 (s), 1040 (m), 1026 (m), 945 (m), 887 (s) cm-1. MS (ESI +ve) m/z 323
([M + H]+, 100%). HRMS (ESI +ve TOF) calcd for C17H15N4OS+ 323.0961, found
323.0967 ([M + H]+).

4-(2-(4-(6-methoxybenzo[d]thiazol-2-yl)-1H-1,2,3-triazol-1-yl)ethyl)phenol 58g
Following General Procedure A2, alkyne
101 (40 mg, 0.21 mmol), CuSO4.5H2O (5 mg,
0.02 mmol), sodium ascorbate (8 mg, 0.04
mmol), and azide 120c (69 mg, 0.42 mmol) were stirred in t-BuOH/H2O (1:1, 4.2 mL) to
afford the 1,4-disubtituted-1,2,3-triazole 58g (52 mg, 70%) as a white solid after
sequential trituration with CH2Cl2, MeCN, and hot MeOH. TLC (CH2Cl2/MeOH –
90:10): Rf = 0.05. Mp 160 ºC (decomp). 1H NMR (400 MHz, DMSO) δ 9.25 (s, 1H, OH),
8.74 (s, 1H, H5'), 7.89 (d, J = 8.8 Hz, 1H, H4), 7.72 (d, J = 2.4 Hz, 1H, H7), 7.13 (dd, J
= 8.8, 2.4 Hz, 1H, H5), 7.00 (d, J = 8.4 Hz, 2H, H2'', H6''), 6.66 (d, J = 8.4 Hz, 2H, H3'',
H5''), 4.66 (t, J = 7.2 Hz, 2H, H1'''), 3.85 (s, 3H, ArOCH3), 3.12 (t, J = 7.2 Hz, 2H, H2''').
C NMR (400 MHz, DMSO) δ 157.5 (C6), 156.5 (C2), 156.0 (C4''), 147.6 (C3a), 141.8
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(C4'), 135.3 (C7a), 129.6 (C2'', C6''), 127.3 (C1''), 123.2 (C5'), 123.1 (C4), 115.9 (C5),
211

115.2 (C3'', C5''), 104.9 (C7), 55.7 (ArOCH3), 51.3 (C1'''), 34.7 (C2'''). IR (neat) 𝜈 max 3133
(br), 2981 (w), 2092 (br), 1610 (m), 1555 (m), 1516 (m), 1489 (m), 1463 (m), 1378 (w),
1356 (w), 1320 (s), 1238 (s), 1216 (m), 1131 (m), 1102 (m), 950 (m), 864 (s) cm-1. MS
(ESI +ve) m/z 353 ([M + H]+, 100%); (ESI –ve) m/z 351 ([M – H]–, 100%). HRMS (ESI
+ve TOF) calcd for C18H17N4O2S+ 353.1067, found 353.1072 ([M + H]+).

6-methoxy-2-(1-(4-nitrobenzyl)-1H-1,2,3-triazol-4-yl)benzo[d]thiazole 58h
Following General Procedure A2, alkyne 101
(40 mg, 0.21 mmol), CuSO4.5H2O (5 mg, 0.02
mmol), sodium ascorbate (8 mg, 0.04 mmol),
and azide 119e (75 mg, 0.42 mmol) were stirred in t-BuOH/H2O (1:1, 4.2 mL) to afford
the 1,4-disubtituted-1,2,3-triazole 58h (61 mg, 79%) as a pale yellow solid after
sequential trituration with CH2Cl2, MeCN, and hot MeOH. TLC (CH2Cl2/MeOH –
90:10): Rf = 0.24. Mp 162 ºC (decomp). 1H NMR (400 MHz, DMSO) δ 8.85 (s, 1H, H5'),
8.23 (d, J = 8.4 Hz, 2H, H3'', H5''), 7.89 (d, J = 8.8 Hz, 1H, H4), 7.66 (d, J = 2.4 Hz, 1H,
H7), 7.65 (d, J = 8.4 Hz, 2H, H2'', H6''), 7.14 (dd, J = 8.8, 2.4 Hz, 1H, H5), 5.88 (s, 2H,
H1'''), 3.89 (s, 3H, ArOCH3).
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C NMR (500 MHz, DMSO) δ 157.6 (C6), 156.2 (C2),

147.6 (C3a), 147.3 (C4''), 142.9 (C1''), 142.4 (C4'), 135.4 (C7a), 129.2 (C2'', C6''), 124.0
(C3'', C5''), 123.2 (C4), 122.3 (C5'), 116.0 (C5), 104.9 (C7), 55.7 (ArOCH3), 52.4 (C1''').
IR (neat) 𝜈 max 3121 (w), 2900 (w), 2089 (w), 1610 (m), 1555 (s), 1516 (s), 1489 (m), 1432
(m), 1378 (s), 1356 (m), 1320 (m), 1272 (s), 1215 (s), 1174 (s), 1044 (m), 1027 (m), 949
(m), 818 (m) cm-1. MS (ESI +ve) m/z 368 ([M + H]+, 100%). HRMS (ESI +ve TOF) calcd
for C17H14N5O3S+ 368.0812, found 368.0817 ([M + H]+).
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6-methoxy-2-(1-(4-nitrophenethyl)-1H-1,2,3-triazol-4-yl)benzo[d]thiazole 58i
Following General Procedure A2, alkyne
101 (40 mg, 0.21 mmol), CuSO4.5H2O (5 mg,
0.02 mmol), sodium ascorbate (8 mg, 0.04
mmol), and azide 120d (81 mg, 0.42 mmol) were stirred in t-BuOH/H2O (1:1, 4.2 mL) to
afford the 1,4-disubtituted-1,2,3-triazole 58i (60 mg, 75%) as a pale yellow solid after
sequential trituration with CH2Cl2, MeCN, and hot MeOH. TLC (CH2Cl2/MeOH –
90:10): Rf = 0.22. Mp 172 ºC (decomp). 1H NMR (400 MHz, DMSO) δ 8.85 (s, 1H, H5'),
8.15 (d, J = 8.4 Hz, 2H, H3'', H5''), 7.89 (d, J = 8.8 Hz, 1H, H4), 7.72 (d, J = 2.8 Hz, 1H,
H7), 7.53 (d, J = 8.4 Hz, 2H, H2'', H6''), 7.13 (dd, J = 8.8, 2.8 Hz, 1H, H5), 4.83 (t, J =
7.2 Hz, 2H, H1'''), 3.85 (s, 3H, ArOCH3), 3.43 (t, J = 7.2 Hz, 2H, H2'''). 13C NMR (400
MHz, DMSO) δ 157.6 (C6), 156.4 (C2), 147.6 (C3a), 146.4 (C4''), 145.7 (C1''), 142.0
(C4'), 135.3 (C7a), 130.1 (C2'', C6''), 123.5 (C3'', C5''), 123.3 (C5'), 123.1 (C4), 115.9
(C5), 104.9 (C7), 55.7 (ArOCH3), 50.2 (C1'''), 34.9 (C2'''). IR (neat) 𝜈 max 3131 (w), 2924
(w), 1604 (m), 1558 (s), 1512 (s), 1490 (m), 1438 (m), 1374 (s), 1342 (m), 1315 (m),
1259 (s), 1226 (s), 1178 (s), 1040 (m), 1021 (m), 945 (m), 827 (m) cm-1. MS (ESI +ve)
m/z 382 ([M + H]+, 100%). HRMS (ESI +ve TOF) calcd for C18H16N5O3S+ 382.0968,
found 382.0974 ([M + H]+).

4-((4-(6-methoxybenzo[d]thiazol-2-yl)-1H-1,2,3-triazol-1-yl)methyl)benzonitrile 58j
Following General Procedure A1, alkyne 101
(40 mg, 0.21 mmol), CuSO4.5H2O (5 mg, 0.02
mmol), sodium ascorbate (8 mg, 0.04 mmol),
and azide 119f (66 mg, 0.42 mmol) were stirred in t-BuOH/H2O (1:1, 4.2 mL) to afford
the 1,4-disubtituted-1,2,3-triazole 58j (53 mg, 73%) as a pale yellow solid after
preparative TLC plate chromatography (CH2Cl2/MeOH – 90:10). TLC (CH2Cl2/MeOH –
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90:10): Rf = 0.25. Mp 178 ºC (decomp). 1H NMR (400 MHz, DMSO) δ 9.00 (s, 1H, H5'),
7.92 (d, J = 8.8 Hz, 1H, H4), 7.87 (d, J = 8.4 Hz, 2H, H3'', H5''), 7.73 (d, J = 2.4 Hz, 1H,
H7), 7.56 (d, J = 8.4 Hz, 2H, H2'', H6''), 7.15 (dd, J = 8.8, 2.4 Hz, 1H, H5), 5.84 (s, 2H,
H1'''), 3.85 (s, 3H, ArOCH3).
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C NMR (400 MHz, DMSO) δ 157.6 (C6), 156.2 (C2),

147.6 (C3a), 142.4 (C4'), 140.9 (C1''), 135.4 (C7a), 132.8 (C3'', C5''), 128.8 (C2'', C6''),
123.9 (C5'), 123.2 (C4), 118.5 (C4''), 116.0 (C5), 111.1 (ArCN), 104.9 (C7), 55.8
(ArOCH3), 52.6 (C1'''). IR (neat) 𝜈 max 3143 (w), 2231 (w), 1607 (s), 1580 (m), 1509 (m),
1490 (m), 1459 (m), 1375 (w), 1253 (s), 1228 (s), 1038 (m), 1023 (m), 950 (m), 874 (s),
824 (m) cm-1. MS (ESI +ve) m/z 348 ([M + H]+, 100%), 370 ([M + Na]+, 20%); (ESI –
ve) m/z 346 ([M – H]–, 100%). HRMS (ESI +ve TOF) calcd for C18H14N5OS+ 348.0914,
found 348.0919 ([M + H]+).

2-(1-(4-fluorobenzyl)-1H-1,2,3-triazol-4-yl)-6-methylbenzo[d]thiazole 58k
Following General Procedure A1, alkyne 116 (36
mg, 0.21 mmol), CuSO4.5H2O (5 mg, 0.02 mmol),
sodium ascorbate (8 mg, 0.04 mmol), and azide
119a (63 mg, 0.42 mmol) were stirred in t-BuOH/H2O (1:1, 4.2 mL) to afford the 1,4disubtituted-1,2,3-triazole 58k (53 mg, 78%) as a pale yellow solid after preparative TLC
plate chromatography (CH2Cl2/MeOH – 98:2). TLC (CH2Cl2/MeOH – 98:2): Rf = 0.84.
Mp 184 ºC. 1H NMR (400 MHz, DMSO) δ 8.99 (s, 1H, H5'), 7.93 (br s, 1H, H7), 7.89 (d,
J = 9.0 Hz, 1H, H4), 7.51 – 7.47 (m, 2H, H2'', H6''), 7.35 (dd, J = 9.0, 2.4 Hz, 1H, H5),
7.27 – 7.22 (m, 2H, H3'', H5''), 5.71 (s, 2H, H1'''), 2.45 (s, 3H, ArCH3). 13C NMR (100
MHz, DMSO) δ 162.0 (d, 1JCF = 243.3 Hz, C4''), 157.8 (C2), 151.3 (C3a), 142.3 (C4'),
135.4 (C7a), 134.0 (C6), 131.8 (d, 4JCF = 2.8 Hz, C1''), 130.5 (d, 3JCF = 8.6 Hz, C2'', C6''),
128.1 (C5), 123.77 (C5'), 122.2 (C4), 121.9 (C7), 115.7 (d, 2JCF = 44.4 Hz, C3'', C5''),
52.5 (C1'''), 21.0 (ArCH3). IR (neat) 𝜈 max 3123 (w), 2912 (w), 1605 (m), 1551 (m), 1508
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(m), 1486 (m), 1461 (m), 1435 (s), 1353 (m), 1333 (m), 1221 (s), 1158 (m), 1128 (m),
1117 (s), 1090 (m), 950 (m), 818 (s) cm-1. MS (ESI +ve) m/z 325 ([M + H]+, 100%).
HRMS (ESI +ve TOF) calcd for C17H14FN4S+ 325.0918, found 325.0923 ([M + H]+).

2-(1-(4-fluorophenethyl)-1H-1,2,3-triazol-4-yl)-6-methylbenzo[d]thiazole 58l
Following General Procedure A1, alkyne 116 (36
mg, 0.21 mmol), CuSO4.5H2O (5 mg, 0.02 mmol),
sodium ascorbate (8 mg, 0.04 mmol), and azide
120a (69 mg, 0.42 mmol) were stirred in t-BuOH/H2O (1:1, 4.2 mL) to afford the 1,4disubtituted-1,2,3-triazole 58l (49 mg, 69%) as a pale yellow solid after preparative TLC
plate chromatography (CH2Cl2/MeOH – 95:5). TLC (CH2Cl2/MeOH – 95:5): Rf = 0.79.
Mp 178 ºC. 1H NMR (400 MHz, DMSO) δ 8.83 (s, 1H, H5'), 7.92 (br s, 1H, H7), 7.89 (d,
J = 9.0 Hz, 1H, H4), 7.35 (dd, J = 9.0, 2.4 Hz, 1H, H5), 7.28 – 7.24 (m, 2H, H2'', H6''),
7.13 – 7.08 (m, 2H, H3'', H5''), 4.73 (t, J = 7.2 Hz, 2H, H1'''), 3.25 (t, J = 7.2 Hz, 2H,
H2'''), 2.45 (s, 3H, ArCH3). 13C NMR (100 MHz, DMSO) δ 161.1 (d, 1JCF = 240.7 Hz,
C4''), 158.0 (C2), 151.3 (C3a), 142.0 (C4'), 135.3 (C7a), 133.9 (C6), 133.5 (d, 4JCF = 3.1
Hz, C1''), 130.6 (d, 3JCF = 8.0 Hz, C2'', C6''), 128.0 (C5), 123.6 (C5'), 122.1 (C4), 121.9
(C7), 115.2 (d, 2JCF = 21.0 Hz, C3'', C5''), 50.9 (C1'''), 34.5 (C2''), 21.0 (ArCH3). IR (neat)
𝜈 max 3129 (w), 2950 (w), 1609 (m), 1578 (m), 1516 (m), 1487 (m), 1450 (m), 1431 (s),
1382 (m), 1357 (m), 1269 (m), 1236 (m), 1131 (m), 1055 (m), 1024 (m), 973 (m), 809 (s)
cm-1. MS (ESI +ve) m/z 339 ([M + H]+, 100%). HRMS (ESI +ve TOF) calcd for
C18H16FN4S+ 339.1074, found 339.1078 ([M + H]+).

215

6-methyl-2-(1-(4-(trifluoromethyl)benzyl)-1H-1,2,3-triazol-4-yl)benzo[d]thiazole
58m
Following General Procedure A1, alkyne 116
(36 mg, 0.21 mmol), CuSO4.5H2O (5 mg, 0.02
mmol), sodium ascorbate (8 mg, 0.04 mmol), and
azide 119c (84 mg, 0.42 mmol) were stirred in t-BuOH/H2O (1:1, 4.2 mL) to afford the
1,4-disubtituted-1,2,3-triazole 58m (57 mg, 73%) as a pale yellow solid after preparative
TLC plate chromatography (CH2Cl2/MeOH – 95:5). TLC (CH2Cl2/MeOH – 95:5): Rf =
0.87. Mp 175 ºC. 1H NMR (400 MHz, DMSO) δ 9.05 (s, 1H, H5'), 7.94 (br s, 1H, H7),
7.91 (d, J = 9.0 Hz, 1H, H4), 7.77 (d, J = 8.4 Hz, 2H, H3'', H5''), 7.60 (d, J = 8.4 Hz, 2H,
H2'', H6''), 7.36 (dd, J = 8.4, 1.2 Hz, 1H, H5), 5.85 (s, 2H, H1''), 2.45 (s, 3H, ArCH3). 13C
NMR (100 MHz, DMSO) δ 157.8 (C2), 151.33 (C3a), 142.34 (C4'), 140.2 (C1''), 135.4
(C7a), 134.0 (C6), 128.9 (q, 2JCF = 31.8 Hz, C4''), 128.8 (C2'', C6''), 128.1 (C5), 125.7 (q,
3

JCF = 3.8 Hz, C3'', C5''), 124.4 (q, 1JCF = 270.4 Hz, ArCF3), 124.2 (C5'), 122.2 (C4),

122.0 (C7), 52.7 (C1'''), 21.0 (ArCH3). IR (neat) 𝜈 max 3138 (w), 2930 (w), 1609 (m), 1556
(m), 1507 (m), 1488 (m), 1454 (m), 1436 (s), 1323 (m), 1228 (s), 1174 (m), 1161 (m),
1119 (s), 1106 (m), 1066 (m), 949 (m), 808 (s) cm-1. MS (ESI +ve) m/z 375 ([M + H]+,
100%); (ESI –ve) m/z 373 ([M – H]–, 100%). HRMS (ESI +ve TOF) calcd for
C18H14F3N4S+ 375.0886, found 375.0891 ([M + H]+).

4-(2-(4-(6-methylbenzo[d]thiazol-2-yl)-1H-1,2,3-triazol-1-yl)ethyl)phenol 58n
Following General Procedure A2, alkyne 116
(36 mg, 0.21 mmol), CuSO4.5H2O (5 mg, 0.02
mmol), sodium ascorbate (8 mg, 0.04 mmol), and
azide 120c (69 mg, 0.42 mmol) were stirred in t-BuOH/H2O (1:1, 4.2 mL) to afford the
1,4-disubtituted-1,2,3-triazole 58n (57 mg, 81%) as a pale yellow solid after sequential
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trituration with CH2Cl2, MeCN, and hot MeOH. TLC (CH2Cl2/MeOH – 90:10): Rf = 0.41.
Mp 150 ºC (decomp). 1H NMR (400 MHz, DMSO) δ 9.24 (s, 1H, OH), 8.78 (s, 1H, H5'),
7.93 (br s, 1H, H7), 7.89 (d, J = 8.4 Hz, 1H, H4), 7.36 (dd, J = 8.4, 2.0 Hz, 1H, H5), 7.00
(d, J = 8.0 Hz, 2H, H2'', H6''), 6.65 (d, J = 8.0 Hz, 2H, H3'', H5''), 4.66 (t, J = 7.2 Hz, 2H,
H1'''), 3.13 (t, J = 7.2 Hz, 2H, H2'''), 2.49 (s, 3H, ArCH3). 13C NMR (400 MHz, DMSO)
δ 158.0 (C2), 156.0 (C4''), 151.3 (C3a), 141.8 (C4'), 135.3 (C7a), 133.9 (C6), 129.6 (C2'',
C6''), 128.0 (C5), 127.3 (C1''), 123.6 (C5'), 122.1 (C4), 121.9 (C7), 115.2 (C3'', C5''), 51.3
(C1'''), 34.7 (C2'''), 21.0 (ArCH3). IR (neat) 𝜈 max 3128 (br), 2950 (w), 1609 (m), 1589 (m),
1516 (m), 1486 (m), 1449 (m), 1381 (w), 1357 (w), 1314 (s), 1296 (m), 1268 (m), 1237
(s), 1197 (m), 1175 (m), 1131 (m), 973 (m), 872 (s). MS (ESI +ve) m/z 337 ([M + H]+,
100%); (ESI –ve) m/z 335 ([M – H]–, 100%). HRMS (ESI +ve TOF) calcd for
C18H17N4OS+ 337.1118, found 337.1123 ([M + H]+).

6-methyl-2-(1-(4-nitrobenzyl)-1H-1,2,3-triazol-4-yl)benzo[d]thiazole 58o
Following General Procedure A2, alkyne 116
(36 mg, 0.21 mmol), CuSO4.5H2O (5 mg, 0.02
mmol), sodium ascorbate (8 mg, 0.04 mmol), and
azide 119e (75 mg, 0.42 mmol) were stirred in t-BuOH/H2O (1:1, 4.2 mL) to afford the
1,4-disubtituted-1,2,3-triazole 58o (55 mg, 75%) as a pale yellow solid after sequential
trituration with CH2Cl2, MeCN, and hot MeOH. TLC (CH2Cl2/MeOH – 90:10): Rf = 0.44.
Mp 152 ºC (decomp). 1H NMR (500 MHz, DMSO) δ 9.06 (s, 1H, H5'), 8.25 (d, J = 9.0
Hz, 2H, H3'', H5''), 7.93 (br s, 1H, H7), 7.90 (d, J = 8.5 Hz, 1H, H4), 7.63 (d, J = 9.0 Hz,
2H, H2'', H6''), 7.36 (dd, J = 8.5, 2.0 Hz, 1H, H5), 5.91 (s, 2H, H1'''), 2.45 (s, 3H, ArCH3).
C NMR (500 MHz, DMSO) δ 157.7 (C2), 151.3 (C3a), 147.4 (C4''), 142.9 (C1''), 142.4
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(C4'), 135.4 (C7a), 134.0 (C6), 129.3 (C2'', C6''), 128.1 (C5), 124.3 (C5'), 124.0 (C3'',
C5''), 122.2 (C4), 122.0 (C7), 52.4 (C1'''), 21.1 (ArCH3). IR (neat) 𝜈 max 3108 (w), 2900
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(w), 2106 (w), 1607 (m), 1515 (s), 1484 (m), 1451 (m), 1345 (s), 1312 (m), 1269 (s),
1228 (s), 1174 (m), 1131 (m), 1039 (m), 1016 (m), 947 (m), 815 (s), 775 (s). MS (ESI
+ve) m/z 352 ([M + H]+, 100%). HRMS (ESI +ve TOF) calcd for C17H14N5O2S+
352.0863, found 352.0868 ([M + H]+).
2-azidoethan-1-ol 122a246
Following General Procedure B, alkyl bromide 121a (500 mg, 4.00
mmol) and NaN3 (390 mg, 6.00 mmol) were stirred in anhydrous
DMF (20 mL) to afford the azide 122a (315 mg, 90%) as a pale yellow oil which was
used for the next reaction without further purification. The spectroscopic data was in
agreement with that previously reported. TLC (CH2Cl2/MeOH – 99:1): Rf = 0.41. 1H
NMR (400 MHz, CDCl3) δ 3.77 (t, J = 5.2 Hz, 2H, H1), 3.44 (t, J = 5.2 Hz, 2H, H2) 2.14
(br s, 1H, OH). 13C NMR (400 MHz, CDCl3) δ 61.6 (C1), 53.7 (C2). MS (ESI +ve) m/z
88 ([M + H]+, 100%).
3-azidopropan-1-ol 122b247
Following General Procedure B, alkyl bromide 121b (556 mg,
4.00 mmol) and NaN3 (390 mg, 6.00

mmol) were stirred in

anhydrous DMF (20 mL) to afford the azide 122b (390 mg, 96%) as a pale yellow oil
which was used for the next reaction without further purification. The spectroscopic data
was in agreement with that previously reported. TLC (CH2Cl2/MeOH – 99:1): Rf = 0.44.
1

H NMR (400 MHz, CDCl3) δ 3.70 (t, J = 6.0 Hz, 2H, H1), 3.41 (t, J = 6.0 Hz, 2H, H3)

2.42 (br s, 1H, OH), 1.79 (quint, J = 6.0 Hz, 2H, H2). 13C NMR (400 MHz, CDCl3) δ 59.7
(C1), 48.5 (C3), 31.5 (C2). MS (ESI +ve) m/z 102 ([M + H]+, 100%).
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7-azidoheptan-1-ol 122c248
Following General Procedure B, alkyl bromide 121c
(780 mg, 4.00 mmol) and NaN3 (390 mg, 6.00 mmol)
were stirred in anhydrous DMF (20 mL) to afford the azide 122c (588 mg, 94%) as a pale
yellow oil which was used for the next reaction without further purification. The
spectroscopic data was in agreement with that previously reported. TLC (CH2Cl2/MeOH
– 95:5): Rf = 0.40. 1H NMR (400 MHz, CDCl3) δ 3.59 (t, J = 6.8 Hz, 2H, H1), 3.35 (t, J
= 6.8 Hz, 1H, OH) 3.22 (t, J = 6.8 Hz, 2H, H7), 1.58 – 1.49 (m, 4H, H2, H6), 1.36 – 1.26
(m, 6H, H3, H4, H5). 13C NMR (400 MHz, CDCl3) δ 62.8 (C1), 51.5 (C7), 32.8 (C2),
29.0 (C6), 28.8 (C3 or C4 or C5), 26.7 (C3 or C4 or C5), 25.7 (C3 or C4 or C5). MS (ESI
+ve) m/z 158 ([M + H]+, 100%).
8-azidooctan-1-ol 122d249
Following General Procedure B, alkyl bromide 121d
(836 mg, 4.00 mmol) and NaN3 (390 mg, 6.00 mmol)
were stirred in anhydrous DMF (20 mL) to afford the azide 122d (622 mg, 91%) as a pale
yellow oil which was used for the next reaction without further purification. The
spectroscopic data was in agreement with that previously reported. TLC (CH2Cl2/MeOH
– 95:5): Rf = 0.38. 1H NMR (400 MHz, CDCl3) δ 3.60 (t, J = 6.4 Hz, 2H, H1), 3.23 (t, J
= 6.8 Hz, 2H, H8), 1.75 (br s, 1H, OH), 1.61 – 1.50 (m, 4H, H2, H7), 1.36 – 1.30 (m, 8H,
H3, H4, H5, H6). 13C NMR (400 MHz, CDCl3) δ 63.0 (C1), 51.5 (C8), 32.8 (C2), 29.3
(C7), 29.2 (C3 or C4 or C5 or C6), 28.9 (C3 or C4 or C5 or C6), 26.7 (C3 or C4 or C5 or
C6), 25.7 (C3 or C4 or C5 or C6). MS (ESI +ve) m/z 172 ([M + H]+, 100%).
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2-(2-azidoethoxy)ethan-1-ol 122e250
Following General Procedure B, alkyl bromide 121e (676
mg, 4.00 mmol) and NaN3 (390 mg, 6.00 mmol) were stirred
in anhydrous DMF (20 mL) to afford the azide 122e (499 mg, 95%) as a pale yellow oil
which was used for the next reaction without further purification. The spectroscopic data
was in agreement with that previously reported. TLC (CH2Cl2/MeOH – 95:5): Rf = 0.41.
1

H NMR (400 MHz, CDCl3) δ 3.78 – 3.74 (m, 2H, H1), 3.71 – 3.69 (m, 2H, H2) 3.63 –

3.61 (m, 2H, H1'), 3.43 – 3.41 (m, 2H, H2'), 2.38 (t, J = 6.0 Hz, 1H, OH). 13C NMR (400
MHz, CDCl3) δ 72.5 (C2), 70.1 (C1'), 61.8 (C1), 50.8 (C2'). MS (ESI +ve) m/z 132 ([M
+ H]+, 100%).

2-(4-(6-methoxybenzo[d]thiazol-2-yl)-1H-1,2,3-triazol-1-yl)ethan-1-ol 59a
Following General Procedure A1, alkyne 101 (40
mg, 0.21 mmol), CuSO4.5H2O (5 mg, 0.02 mmol),
sodium ascorbate (8 mg, 0.04 mmol), and azide 122a
(37 mg, 0.42 mmol) were stirred in t-BuOH/H2O (1:1, 4.2 mL) to afford the 1,4disubtituted-1,2,3-triazole 59a (49 mg, 84%) as a pale yellow solid after preparative TLC
plate chromatography (CH2Cl2/MeOH – 95:5). TLC (CH2Cl2/MeOH – 95:5): Rf = 0.74.
Mp 178 ºC (decomp). 1H NMR (400 MHz, DMSO) δ 8.78 (s, 1H, H5'), 7.91 (d, J = 8.8
Hz, 1H, H4), 7.73 (d, J = 2.4 Hz, 1H, H7), 7.14 (dd, J = 8.8, 2.4 Hz, 1H, H5), 5.09 (t, J =
5.2 Hz, 1H, OH), 4.52 (t, J = 5.6 Hz, 2H, H2''), 3.86 (s, 3H, ArOCH3), 3.85 (dt, J = 5.6,
5.2 Hz, 2H, H1''). 13C NMR (400 MHz, CDCl3) δ 157.5 (C6), 156.6 (C2), 147.6 (C3a),
141.8 (C4'), 135.3 (C7a), 123.7 (C5'), 123.1 (C4), 115.9 (C5), 105.0 (C7), 59.6 (C1''),
55.7 (ArOCH3), 52.7 (C2''). IR (neat) 𝜈 max 3216 (br), 2922 (w), 2853 (w), 1608 (m), 1560
(w), 1434 (m), 1420 (m), 1258 (s), 1229 (s), 1081 (s), 1069 (m), 959 (m), 834 (s), 715
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(w), 676 (m) cm-1. MS (ESI +ve) m/z 277 ([M + H]+, 100%). HRMS (ESI +ve TOF) calcd
for C12H13N4O2S+ 277.0754, found 277.0754 ([M + H]+).
3-(4-(6-methoxybenzo[d]thiazol-2-yl)-1H-1,2,3-triazol-1-yl)propan-1-ol 59b251
Following General Procedure A1, alkyne 101 (40
mg, 0.21 mmol), CuSO4.5H2O (5 mg, 0.02 mmol),
sodium ascorbate (8 mg, 0.04 mmol), and azide
122b (43 mg, 0.42 mmol) were stirred in t-BuOH/H2O (1:1, 4.2 mL) to afford the 1,4disubtituted-1,2,3-triazole 59b (50 mg, 82%) as a pale yellow solid after preparative TLC
plate chromatography (CH2Cl2/MeOH – 95:5). The spectroscopic data was in agreement
with that previously reported. TLC (CH2Cl2/MeOH – 95:5): Rf = 0.77. Mp 131 ºC. 1H
NMR (400 MHz, DMSO) δ 8.85 (s, 1H, H5'), 7.91 (d, J = 8.8 Hz, 1H, H4), 7.73 (d, J =
2.4 Hz, 1H, H7), 7.15 (dd, J = 8.8, 2.4 Hz, 1H, H5), 4.71 (t, J = 5.2 Hz, 1H, OH), 4.53 (t,
J = 6.8 Hz, 2H, H3''), 3.85 (s, 3H, ArOCH3), 3.44 (dt, J = 6.8, 5.2 Hz, 2H, H1''), 2.05
(quint, J = 6.8 Hz, 2H, H2'').
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C NMR (400 MHz, DMSO) δ 157.5 (C6), 156.6 (C2),

147.6 (C3a), 142.0 (C4'), 135.4 (C7a), 123.4 (C5'), 123.1 (C4), 115.9 (C5), 105.0 (C7),
57.6 (C1''), 55.7 (ArOCH3), 47.3 (C3''), 32.7 (C2''). IR (neat) 𝜈 max 3306 (br), 2926 (w),
2834 (w), 1604 (m), 1556 (w), 1434 (m), 1411 (m), 1266 (s), 1223 (s), 1066 (s), 1040 (s),
950 (s), 838 (s), 711 (w), 679 (m) cm-1. MS (ESI +ve) m/z 291 ([M + H]+, 100%). HRMS
(ESI +ve TOF) calcd for C13H15N4O2S+ 291.0910, found 291.0910 ([M + H]+).

7-(4-(6-methoxybenzo[d]thiazol-2-yl)-1H-1,2,3-triazol-1-yl)heptan-1-ol 59c
Following General Procedure A1,
alkyne 101 (40 mg, 0.21 mmol),
CuSO4.5H2O (5 mg, 0.02 mmol),
sodium ascorbate (8 mg, 0.04 mmol), and azide 122c (66 mg, 0.42 mmol) were stirred in
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t-BuOH/H2O (1:1, 4.2 mL) to afford the 1,4-disubtituted-1,2,3-triazole 59c (55 mg, 76%)
as a pale yellow solid after preparative TLC plate chromatography (CH2Cl2/MeOH –
90:10). TLC (CH2Cl2/MeOH – 90:10): Rf = 0.67. Mp 108 ºC. 1H NMR (400 MHz,
DMSO) δ 8.87 (s, 1H, H5'), 7.90 (d, J = 8.8 Hz, 1H, H4), 7.73 (d, J = 2.4 Hz, 1H, H7),
7.13 (dd, J = 8.8, 2.4 Hz, 1H, H5), 4.46 (t, J = 6.8 Hz, 2H, H7''), 4.32 (t, J = 5.2 Hz, 1H,
OH), 3.85 (s, 3H, ArOCH3), 3.35 (dt, J = 6.8, 5.2 Hz, 2H, H1''), 1.89 (quint, J = 6.8 Hz,
2H, H6''), 1.42 – 1.25 (m, 8H, H2'', H3'', H4'', H5''). 13C NMR (400 MHz, DMSO) δ 157.5
(C6), 156.6 (C2), 147.6 (C3a), 142.0 (C4'), 135.4 (C7a), 123.2 (C5'), 123.1 (C4), 115.9
(C5), 104.9 (C7), 60.6 (C1''), 55.7 (ArOCH3), 49.9 (C7''), 32.5 (C2'' or C3'' or C4'' or C5''),
29.5 (C6''), 28.3 (C2'' or C3'' or C4'' or C5''), 25.8 (C2'' or C3'' or C4'' or C5''), 25.3 (C2''
or C3'' or C4'' or C5''). IR (neat) 𝜈 max 3423 (br), 3128 (w), 2930 (m), 2854 (m), 1609 (m),
1554 (w), 1493 (s), 1436 (s), 1268 (s), 1216 (s), 1070 (s), 1057 (m), 944 (s), 833 (s), 704
(w), 666 (m) cm-1. MS (ESI +ve) m/z 347 ([M + H]+, 100%). HRMS (ESI +ve TOF) calcd
for C17H23N4O2S+ 347.1536, found 347.1542 ([M + H]+).

8-(4-(6-methoxybenzo[d]thiazol-2-yl)-1H-1,2,3-triazol-1-yl)octan-1-ol 59d
Following General Procedure A1,
alkyne 101 (40 mg, 0.21 mmol),
CuSO4.5H2O (5 mg, 0.02 mmol),
sodium ascorbate (8 mg, 0.04 mmol), and azide 122d (72 mg, 0.42 mmol) were stirred in
t-BuOH/H2O (1:1, 4.2 mL) to afford the 1,4-disubtituted-1,2,3-triazole 59d (56 mg, 74%)
as a pale yellow solid after preparative TLC plate chromatography (CH2Cl2/MeOH –
90:10). TLC (CH2Cl2/MeOH – 90:10): Rf = 0.66. Mp 106 ºC. 1H NMR (400 MHz,
DMSO) δ 8.87 (s, 1H, H5'), 7.90 (d, J = 8.8 Hz, 1H, H4), 7.73 (d, J = 2.4 Hz, 1H, H7),
7.14 (dd, J = 8.8, 2.4 Hz, 1H, H5), 4.46 (t, J = 6.8 Hz, 2H, H8''), 4.30 (t, J = 5.2 Hz, 1H,
OH), 3.85 (s, 3H, ArOCH3), 3.36 (dt, J = 6.8, 5.2 Hz, 2H, H1''), 1.93 – 1.86 (m, 2H, H2''
222

or H7''), 1.41 – 1.23 (m, 10H, H2'' or H7'', H3'', H4'', H5'', H6'').
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C NMR (400 MHz,

DMSO) δ 157.5 (C6), 156.6 (C2), 147.6 (C3a), 142.0 (C4'), 135.3 (C7a), 123.2 (C5'),
123.1 (C4), 115.9 (C5), 104.9 (C7), 60.7 (C1''), 55.7 (ArOCH3), 49.9 (C8''), 32.5 (C2'' or
C7''), 29.5 (C2'' or C7''), 28.7 (C3'' or C4'' or C5'' or C6''), 28.4 (C3'' or C4'' or C5'' or C6''),
25.7 (C3'' or C4'' or C5'' or C6''), 25.4 (C3'' or C4'' or C5'' or C6''). IR (neat) 𝜈 max 3425
(br), 3127 (w), 2929 (m), 2852 (m), 1609 (m), 1554 (w), 1493 (s), 1435 (s), 1269 (s),
1215 (s), 1070 (s), 1056 (m), 945 (s), 836 (s), 704 (w), 667 (m) cm-1. MS (ESI +ve) m/z
361 ([M + H]+, 100%). HRMS (ESI +ve TOF) calcd for C18H25N4O2S+ 361.1693, found
361.1693 ([M + H]+).

2-(2-(4-(6-methoxybenzo[d]thiazol-2-yl)-1H-1,2,3-triazol-1-yl)ethoxy)ethan-1-ol 59e
Following General Procedure A1, alkyne
101 (40 mg, 0.21 mmol), CuSO4.5H2O (5 mg,
0.02 mmol), sodium ascorbate (8 mg, 0.04
mmol), and azide 122e (55 mg, 0.42 mmol) were stirred in t-BuOH/H2O (1:1, 4.2 mL) to
afford the 1,4-disubtituted-1,2,3-triazole 59e (49 mg, 73%) as a pale yellow solid after
preparative TLC plate chromatography (CH2Cl2/MeOH – 90:10). TLC (CH2Cl2/MeOH –
90:10): Rf = 0.54. Mp 106 ºC. 1H NMR (400 MHz, CDCl3) δ 8.38 (s, 1H, H5'), 7.89 (d, J
= 8.8 Hz, 1H, H4), 7.39 (d, J = 2.4 Hz, 1H, H7), 7.09 (dd, J = 8.8, 2.4 Hz, 1H, H5), 4.66
(t, J = 5.2 Hz, 2H, H1''b or H2''b), 3.95 (t, J = 5.2 Hz, 2H, H1''b or H2''b), 3.89 (s, 3H,
ArOCH3), 3.76 (t, J = 5.2 Hz, 2H, H1''a), 3.61 (t, J = 5.2 Hz, 2H, H2''a), 2.34 (br s, 1H,
OH). 13C NMR (400 MHz, CDCl3) δ 158.1 (C6), 157.2 (C2), 148.2 (C3a), 143.5 (C4'),
136.2 (C7a), 123.5 (C4), 122.9 (C5'), 116.1 (C5), 104.3 (C7), 72.9 (C2''a), 69.3 (C1''b or
C2''b), 61.8 (C1''a), 56.0 (ArOCH3), 50.8 (C1''b or C2''b). IR (neat) 𝜈 max 3258 (br), 3153
(w), 2958 (m), 2836 (m), 1608 (m), 1560 (s), 1490 (s), 1431 (s), 1260 (s), 1223 (s), 1062
(s), 1040 (m), 940 (s), 827 (s), 700 (w), 656 (m) cm-1. MS (ESI +ve) m/z 321 ([M + H]+,
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100%). HRMS (ESI +ve TOF) calcd for C14H17N4O3S+ 321.1016, found 321.1021 ([M +
H]+).
5-((trimethylsilyl)ethynyl)pyridin-2-amine 123a252
A mixture of amino pyridine 102 (2.00 g, 11.56 mmol),
ethynyltrimethylsilane (1.48 g, 15.03 mmol), CuI (70 mg, 0.37
mmol), PdCl2(PPh3)2 (260 mg, 0.37 mmol), triethylamine (14
mL, 100.04 mmol), and anhydrous THF (14 mL) was stirred at 65 ºC for 8 h. After cooling
to rt, the mixture was filtered through a layer of Celite, and concentrated. The residue was
subjected to flash chromatography over SiO2 gel (EtOAc/hexanes – 60:40) to afford the
protected alkyne 123a (1.66 g, 82%) as a light yellow oil. The spectroscopic data was in
agreement with that previously reported. TLC (EtOAc/hexanes – 60:40): Rf = 0.77. 1H
NMR (400 MHz, CDCl3) δ 8.19 (d, J = 2.0 Hz, 1H, H6), 7.46 (dd, J = 8.4, 2.0 Hz, H4),
6.38 (d, 1H, J = 8.4 Hz, H3), 4.65 (br s, 2H, NH2), 0.23 (s, 9H, (CH3)3). 13C NMR (400
MHz, CDCl3) δ 157.7 (C2), 152.1 (C6), 140.9 (C4), 110.0 (C5), 107.9 (C3), 102.9 (C1'),
94.7 (C2'), 0.15 (Si(CH3)3). MS (ESI +ve) m/z 191 ([M + H]+, 100%).
5-ethynylpyridin-2-amine 124a253
To a solution of the protected alkyne 123a (1.20 g, 6.85 mmol) in
MeOH (10 mL) was added KF (1.20 g, 20.69 mmol), and the mixture
was stirred at rt for 2 h. The solvent was removed, and the residue
was subjected to flash chromatography over SiO2 gel (EtOAc/hexanes – 60:40) to afford
the free alkyne 124a (0.69 g, 85%) as a light yellow solid. The spectroscopic data was in
agreement with that previously reported. TLC (EtOAc/hexanes – 60:40): Rf = 0.70. 1H
NMR (500 MHz, CDCl3) δ 8.21 (d, J = 2.0 Hz, 1H, H6), 7.50 (dd, J = 8.0, 2.0 Hz, H4),
6.42 (d, 1H, J = 8.0 Hz, H3), 4.70 (br s, 2H, NH2), 3.25 (s, 1H, H2'). 13C NMR (500 MHz,
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CDCl3) δ 158.0 (C2), 152.2 (C6), 141.0 (C4), 108.7 (C5), 108.0 (C3), 81.5 (C1'), 77.8
(C2'). MS (ESI +ve) m/z 119 ([M + H]+, 100%).

N-methyl-5-((trimethylsilyl)ethynyl)pyridin-2-amine 123b210
A mixture of mono-N-methyl 104 (200 mg, 1.07 mmol),
ethynyltrimethylsilane (136 mg, 1.38 mmol), CuI (6 mg, 0.03
mmol), PdCl2(PPh3)2 (24 mg, 0.03 mmol), triethylamine (1.3 mL,
9.25 mmol), and anhydrous THF (4.0 mL) was stirred at 65 ºC for 8 h. After cooling to
rt, the mixture was filtered through a layer of Celite, and concentrated. The residue was
subjected to flash chromatography over SiO2 gel (EtOAc/hexanes – 60:40) to afford the
protected alkyne 123b (160 mg, 73%) as a light yellow oil. The spectroscopic data was
in agreement with that previously reported. TLC (EtOAc/hexanes – 60:40): Rf = 0.81. 1H
NMR (400 MHz, CDCl3) δ 8.21 (d, J = 2.0 Hz, 1H, H6), 7.49 (dd, J = 8.4, 2.0 Hz, H4),
6.29 (d, 1H, J = 8.4 Hz, H3), 4.84 (br s, 1H, NH), 2.91 (d, J = 5.0 Hz, 1H, NHCH3), 0.23
(s, 9H, (CH3)3). 13C NMR (400 MHz, CDCl3) δ 158.7 (C2), 152.2 (C6), 140.9 (C4), 108.5
(C5), 105.3 (C3), 103.4 (C1'), 94.3 (C2'), 29.1 (NHCH3), 0.21 (Si(CH3)3). MS (ESI +ve)
m/z 205 ([M + H]+, 100%).
5-ethynyl-N-methylpyridin-2-amine 124b210
To a solution of the protected alkyne 123b (150 mg, 0.73 mmol) in
MeOH (3.0 mL) was added KF (150 g, 2.21 mmol), and the mixture
was stirred at rt for 2 h. The solvent was removed, and the residue was
subjected to flash chromatography over SiO2 gel (EtOAc/hexanes – 60:40) to afford the
free alkyne 124b (90 mg, 93%) as a light yellow solid. The spectroscopic data was in
agreement with that previously reported. TLC (EtOAc/hexanes – 60:40): Rf = 0.75. 1H
NMR (500 MHz, CDCl3) δ 8.24 (d, J = 2.0 Hz, 1H, H6), 7.50 (dd, J = 8.0, 2.0 Hz, H4),
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6.30 (d, 1H, J = 8.0 Hz, H3), 4.87 (br s, 1H, NH), 3.05 (s, 1H, H2'), 2.92 (d, J = 5.0 Hz,
NHCH3). 13C NMR (500 MHz, CDCl3) δ 158.9 (C2), 152.3 (C6), 140.6 (C4), 107.2 (C5),
105.5 (C3), 82.0 (C1'), 77.4 (C2'), 29.1 (NHCH3). MS (ESI +ve) m/z 133 ([M + H]+,
100%).

2-azidobenzo[d]thiazol-6-ol 125
To a stirred solution of hydroxy benzothiazole 108 (1.00 g,
5.99 mmol) in 1,4 dioxane (25 mL) at 0 ºC, 2.0 M H2SO4 (15
mL, 30.00 mmol) was added dropwise. After 5 min, 3.0 M NaNO2 (4.0 mL, 12.00 mmol)
was added dropwise, and after 1 h 3.0 M NaN3 (6.0 mL, 18.00 mmol) was added carefully
over a 30 min period causing the solution to transform into a brown foam. The resulting
solution was stirring at rt for 4 h, and extracted with EtOAc (4 x 50 mL). The combined
organic layers were washed with saturated NaHCO3 solution (2 x 50 mL), H2O (50 ml),
brine (50 mL), dried (Na2SO4), and concentrated. The crude product was purified by flash
chromatography (CH2Cl2/MeOH 90:10) to afford the benzothiazole azide 125 (695 mg,
60%) as a light red gum. TLC (CH2Cl2/MeOH – 90:10): Rf = 0.41. 1H NMR (400 MHz,
DMSO) δ 9.04 (s, OH), 7.86 (d, J = 8.8 Hz, 1H, H4), 7.01 (d, J = 2.4 Hz, 1H, H7), 6.73
(dd, J = 8.8, 2.4 Hz, 1H, H5).
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C NMR (400 MHz, DMSO) δ 156.0 (C2), 152.7 (C6),

147.0 (C3a), 135.3 (C7a), 123.9 (C4), 116.4 (C5), 106.9 (C7). MS (ESI +ve) m/z 191 ([M
– H]–, 100%). HRMS (ESI +ve TOF) calcd for C 7H3N4OS– 191.0033, found 191.0028
([M – H]–).
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2-(4-(6-aminopyridin-3-yl)-1H-1,2,3-triazol-1-yl)benzo[d]thiazol-6-ol 60a
Following General Procedure A2, alkyne 124a
(30 mg, 0.25 mmol), CuSO4.5H2O (6 mg, 0.02
mmol), sodium ascorbate (10 mg, 0.05 mmol), and
azide 125 (96 mg, 0.50 mmol) were stirred in t-BuOH/H2O (1:1, 5.0 mL) to afford the
1,4-disubtituted-1,2,3-triazole 60a (40 mg, 52%) as a pale yellow solid after sequential
trituration with CH2Cl2, MeCN, and hot MeOH. TLC (CH2Cl2/MeOH – 90:10): Rf = 0.05.
1

H NMR (400 MHz, DMSO + 1 drop of D2O) δ 9.19 (s, 1H, H5'), 9.08 (d, J = 2.0 Hz,

1H, H2''), 7.89 (d, J = 8.8 Hz, 1H, H4), 7.86 (d, J = 2.4 Hz, 1H, H7), 7.43 (d, J = 8.5, 2.0
Hz, 1H, H4''), 7.22 (d, J = 8.5 Hz, 1H, H5''), 6.99 (dd, J = 8.8, 2.4 Hz, 1H, H5). 13C NMR
(400 MHz, DMSO) δ 155.7 (C2), 153.1 (C6''), 152.1 (C2''), 151.5 (C6), 146.7 (C3a),
146.5 (C4''), 135.4 (C7a), 135.0 (C4'), 123.4 (C4), 122.2 (C5'), 116.5 (C5), 115.8 (C3''),
110.8 (C5''), 106.7 (C7). IR (neat) 𝜈 max 3401 (br), 2923 (w), 2257 (w), 1648 (m), 1560
(w), 1505 (w), 1484 (w), 1452 (m), 1344 (m), 1250 (m), 1048 (m), 1023 (s), 988 (s), 824
(m), 763 (m) cm-1. MS (ESI +ve) m/z 311 ([M + H]+, 100%); (ESI –ve) m/z 309 ([M –
H]–, 100%). HRMS (ESI +ve TOF) calcd for C14H9N6OS– 309.0564, found 309.0559 ([M
– H]–).

2-(4-(6-(methylamino)pyridin-3-yl)-1H-1,2,3-triazol-1-yl)benzo[d]thiazol-6-ol 60b
Following General Procedure A2, alkyne 124b
(33 mg, 0.25 mmol), CuSO4.5H2O (6 mg, 0.02
mmol), sodium ascorbate (10 mg, 0.05 mmol), and
azide 125 (96 mg, 0.50 mmol) were stirred in t-BuOH/H2O (1:1, 5.0 mL) to afford the
1,4-disubtituted-1,2,3-triazole 60b (40 mg, 50%) as a pale yellow solid after sequential
trituration with CH2Cl2, MeCN, and hot MeOH. TLC (CH2Cl2/MeOH – 90:10): Rf = 0.05.
1

H NMR (400 MHz, DMSO + 1 drop of D2O) δ 9.27 (s, 1H, H5'), 8.63 (d, J = 2.0 Hz,
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1H, H2''), 7.97 (d, J = 8.8 Hz, 1H, H4), 7.84 (d, J = 2.4 Hz, 1H, H7), 7.50 (d, J = 8.5, 2.0
Hz, 1H, H4''), 7.06 (d, J = 8.5 Hz, 1H, H5''), 6.57 (dd, J = 8.8, 2.4 Hz, 1H, H5), 2.81 (s,
3H, NHCH3). 13C NMR (400 MHz, DMSO) δ 159.9 (C2), 156.4 (C6''), 153.5 (C2''), 147.0
(C6), 145.9 (C3a), 143.2 (C4''), 134.7 (C7a), 134.6 (C4'), 124.1 (C4), 123.9 (C5'), 117.0
(C5), 116.9 (C3''), 113.5 (C5''), 107.9 (C7), 28.3 (NHCH3). IR (neat) 𝜈 max 3405 (br), 2929
(w), 2256 (w), 1658 (m), 1561 (w), 1505 (w), 1487 (w), 1459 (m), 1364 (m), 1260 (m),
1049 (m), 1029 (s), 980 (s), 824 (m), 764 (m) cm-1. MS (ESI +ve) m/z 325 ([M + H]+,
100%); (ESI –ve) m/z 323 ([M – H]–, 100%). HRMS (ESI +ve TOF) calcd for
C15H13N6OS+ 325.0866, found 325.0872 ([M + H]+).

6.3.2 Synthesis of Benzo[d]thiazolyl Amide Derivatives
6-methoxybenzo[d]thiazole-2-carboxylic acid 127254
To a solution of benzothiazole nitrile 126 (1.00 g, 5.26 mmol) in
EtOH (30 mL) was added a solution of 1.0 N NaOH (6.0 mL,
6.00 mmol). The reaction was stirred at reflux for 18 h. The EtOH was removed under
reduced pressure at 40 ºC, and the minimum volume of H2O was added to the residue to
dissolve completely any solid material. A solution of 18% HCl (1.6 mL) was added until
pH reached 3, yielding a yellow precipitate. The resulting precipitate was collected by
filtration, washed with H2O (30 mL), and dried in vacuo to afford the benzothiazole
carboxylic acid 127 (1.01 g, 92%) as a pale yellow solid. The spectroscopic data was in
agreement with that previously reported. TLC (CH2Cl2/MeOH – 90:10): Rf = 0.53. 1H
NMR (400 MHz, DMSO) δ 8.06 (d, J = 9.2 Hz, 1H, H4), 7.74 (d, J = 2.0 Hz, 1H, H7),
7.22 (dd, J = 9.2, 2.0 Hz, 1H, H5), 3.86 (s, 3H, ArOCH3). 13C NMR (400 MHz, DMSO)
δ 161.6 (C=O), 159.0 (C2), 158.0 (C6), 147.5 (C3a), 138.3 (C7a), 125.4 (C4), 117.4 (C5),
104.5 (C7), 55.9 (ArOCH3). MS (ESI +ve) m/z 208 ([M – H]–, 100%).
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General Procedure C: Amide Coupling
The acid (1.0 eq), the appropriate aromatic amine (1.0 eq), HOBT (1.0 eq), EDCI (1.3
eq), and DIPEA (4.0 eq) were combined in anhydrous DMF (10 mL/mmol), and stirred
at rt for 24 h under N2 atmosphere. The resulting reaction mixture was poured into H2O
(50 mL), and extracted with EtOAc (3 x 50 mL). The organic layer was washed with H2O
(2 x 50 mL), brine (2 x 50 mL), dried (Na2SO4), filtered, and concentrated. The residue
was purified by preparative TLC plate chromatography to afford the desired amide
product.

6-methoxy-N-(6-methylpyridin-3-yl)benzo[d]thiazole-2-carboxamide 61a
Following General Procedure C, benzothiazole
carboxylic acid 127 (100 mg, 0.48 mmol), amine
128a (52 mg, 0.48 mmol), HOBT (72 mg, 0.48
mmol), EDCI (119 mg, 0.62 mmol), and DIPEA (334 µL, 1.92 mmol) were stirred in
anhydrous DMF (4.8 mL) for 24 h to afford the amide 61a (101 mg, 70%) as a pale yellow
solid after preparative TLC plate chromatography (CH2Cl2/MeOH – 97:3). TLC
(CH2Cl2/MeOH – 97:3): Rf = 0.63. Mp 114 ºC. 1H NMR (400 MHz, DMSO) δ 11.17 (br
s, 1H, NH), 8.93 (br s, 1H, H2'), 8.15 (dd, J = 8.4, 2.4 Hz, 1H, H4'), 8.05 (d, J = 9.2 Hz,
1H, H4), 7.82 (d, J = 2.0 Hz, 1H, H7), 7.29 – 7.23 (m, 2H, H5, H5'), 3.88 (s, 3H, ArOCH3),
2.45 (s, 3H, ArCH3). 13C NMR (400 MHz, DMSO) δ 161.2 (C=O), 158.8 (C6), 158.5
(C2), 153.4 (C3'), 147.0 (C3a), 141.5 (C2'), 138.3 (C7a), 132.3 (C6'), 128.4 (C4'), 124.8
(C4), 122.8 (C5'), 117.4 (C5), 102.8 (C7), 55.9 (ArOCH3), 23.4 (ArCH3). IR (neat) 𝜈 max
3200 (w), 3088 (w), 1652 (m), 1605 (s), 1555 (s), 1492 (s), 1450 (m), 1430 (m), 1330
(m), 1293 (s), 1263 (s), 1226 (m), 1182 (m), 1045 (m), 1026 (m), 876 (m), 835 (m), 741
(m) cm-1. MS (ESI +ve) m/z 300 ([M + H]+, 100%). HRMS (ESI +ve TOF) calcd for
C15H14N3O2S+ 300.0801, found 300.0807 ([M + H]+).
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6-methoxy-N-(pyridin-4-yl)benzo[d]thiazole-2-carboxamide 61b
Following General Procedure C, benzothiazole
carboxylic acid 127 (100 mg, 0.48 mmol), amine 128b
(45 mg, 0.48 mmol), HOBT (72 mg, 0.48 mmol), EDCI
(119 mg, 0.62 mmol), and DIPEA (334 µL, 1.92 mmol) were stirred in anhydrous DMF
(4.8 mL) for 24 h to afford the amide 61b (105 mg, 77%) as a pale yellow solid after
preparative TLC plate chromatography (CH2Cl2/MeOH – 90:10). TLC (CH2Cl2/MeOH –
90:10): Rf = 0.46. Mp 220 ºC (decomp). 1H NMR (500 MHz, DMSO) δ 11.41 (s, 1H,
NH), 8.52 (d, J = 6.5 Hz, 2H, H2', H6'), 8.11 (d, J = 9.0 Hz, 1H, H4), 7.93 (d, J = 6.5 Hz,
2H, H3', H5'), 7.84 (d, J = 2.5 Hz, 1H, H7), 7.27 (dd, J = 9.0, 2.5 Hz, 1H, H5), 3.89 (s,
3H, ArOCH3).

C NMR (500 MHz, DMSO) δ 160.8 (C=O), 159.3 (C2), 158.9 (C6),
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150.4 (C2', C6'), 147.0 (C3a), 145.0 (C4'), 138.5 (C7a), 125.0 (C4), 117.7 (C5), 114.5
(C3', C5'), 104.8 (C7), 55.9 (ArOCH3). IR (neat) 𝜈 max 2944 (w), 2840 (w), 2224 (w), 1741
(m), 1682 (m), 1596 (m), 1551 (m), 1495 (s), 1432 (m), 1326 (m), 1275 (m), 1226 (s),
1209 (s), 1187 (m), 1044 (m), 1024 (m), 907 (m), 830 (m), 810 (s) cm-1. MS (ESI +ve)
m/z 286 ([M + H]+, 100%). HRMS (ESI +ve TOF) calcd for C14H12N3O2S+ 286.0645,
found 286.0645 ([M + H]+).

(3-cyanophenyl)(6-methoxybenzo[d]thiazole-2-carbonyl)amide 61c
Following General Procedure C, benzothiazole
carboxylic acid 127 (100 mg, 0.48 mmol), amine 128c
(57 mg, 0.48 mmol), HOBT (72 mg, 0.48 mmol), EDCI
(119 mg, 0.62 mmol), and DIPEA (334 µL, 1.92 mmol) were stirred in anhydrous DMF
(4.8 mL) for 24 h to afford the amide 61c (111 mg, 75%) as a pale yellow solid after
preparative TLC plate chromatography (CH2Cl2/MeOH – 90:10). TLC (CH2Cl2/MeOH –
90:10): Rf = 0.39. Mp 168 ºC. 1H NMR (500 MHz, CDCl3) δ 9.30 (s, 1H, NH), 8.16 (s,
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1H, H2'), 7.98 (d, J = 9.0 Hz, 1H, H4), 7.95 – 7.93 (m, 1H, H4'), 7.50 – 7.46 (m, 2H, H5',
H6'), 7.40 (d, J = 2.0 Hz, 1H, H7), 7.19 (dd, J = 9.0, 2.5 Hz, 1H, H5), 3.92 (s, 3H,
ArOCH3). 13C NMR (500 MHz, CDCl3) δ 160.2 (C=O), 159.6 (C2), 158.2 (C6), 147.2
(C3a), 139.2 (C1'), 138.1 (C7a), 130.3 (C5' or C6'), 128.3 (C5' or C6'), 125.3 (C4), 123.9
(C4'), 122.9 (C2'), 118.4 (CN), 118.0 (C5), 113.5 (C3'), 104.1 (C7), 56.0 (ArOCH3). IR
(neat) 𝜈 max 3329 (m), 2956 (w), 2224 (m), 1784 (w), 1675 (m), 1589 (m), 1533 (s), 1499
(s), 1426 (s), 1326 (m), 1259 (m), 1237 (m), 1218 (s), 1188 (m), 1044 (m), 1023 (m), 886
(m), 849 (s), 789 (s), 674 (s) cm-1. MS (ESI –ve) m/z 308 ([M – H]–, 100%). HRMS (ESI
–ve TOF) calcd for C16H10N3O2S– 308.0499, found 308.0488 ([M – H]–).

N-(5-fluoropyridin-3-yl)-6-methoxybenzo[d]thiazole-2-carboxamide 61d
Following

General

Procedure

C,

benzothiazole

carboxylic acid 127 (100 mg, 0.48 mmol), amine 128d
(54 mg, 0.48 mmol), HOBT (72 mg, 0.48 mmol), EDCI
(119 mg, 0.62 mmol), and DIPEA (334 µL, 1.92 mmol) were stirred in anhydrous DMF
(4.8 mL) for 24 h to afford the amide 61d (106 mg, 73%) as a pale yellow solid after
preparative TLC plate chromatography (CH2Cl2/MeOH – 95:5). TLC (CH2Cl2/MeOH –
95:5): Rf = 0.60. Mp 204 ºC. 1H NMR (500 MHz, DMSO) δ 11.37 (br s, 1H, NH), 8.72
(s, 1H, H2'), 8.46 – 8.41 (m, 1H, H4'), 8.09 (d, J = 9.2 Hz, 1H, H4), 7.83 (d, J = 2.0 Hz,
1H, H7), 7.27 – 7.22 (m, 2H, H5, H6'), 3.88 (s, 3H, ArOCH3).
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C NMR (125 MHz,

DMSO) δ 160.9 (C=O), 159.2 (d, 1JCF = 232.5 Hz, C5'), 158.8 (C6), 158.7 (C2), 147.0
(C3a), 139.5 (d, 2JCF = 15.6 Hz, C6'), 138.4 (C7a), 134.3 (C2'), 133.2 (C3'), 124.9 (C4),
117.6 (C5), 109.4 (d, 2JCF = 39.1 Hz, C4'), 104.8 (C7), 55.9 (ArOCH3). IR (neat) 𝜈 max
3254 (br), 3066 (w), 1686 (m), 1590 (m), 1540 (s), 1499 (s), 1448 (m), 1426 (m), 1333
(m), 1312 (s), 1296 (s), 1247 (s), 1228 (m), 1124 (m), 1048 (m), 1018 (m), 871 (m), 727
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(s) cm-1. MS (ESI +ve) m/z 304 ([M + H]+, 100%). HRMS (ESI +ve TOF) calcd for
C14H11FN3O2S+ 304.0551, found 304.0556 ([M + H]+).

N-(4-fluoropyridin-2-yl)-6-methoxybenzo[d]thiazole-2-carboxamide 61e
Following

General

Procedure

C,

benzothiazole

carboxylic acid 127 (100 mg, 0.48 mmol), amine 128e
(54 mg, 0.48 mmol), HOBT (72 mg, 0.48 mmol), EDCI
(119 mg, 0.62 mmol), and DIPEA (334 µL, 1.92 mmol) were stirred in anhydrous DMF
(4.8 mL) for 24 h to afford the amide 61e (110 mg, 76%) as a pale yellow solid after
preparative TLC plate chromatography (CH2Cl2/MeOH – 95:5). TLC (CH2Cl2/MeOH –
95:5): Rf = 0.61. Mp 202 ºC. 1H NMR (500 MHz, DMSO) δ 10.61 (br s, 1H, NH), 8.49 –
8.47 (m, 1H, H6'), 8.12 (d, J = 9.2 Hz, 1H, H4), 7.97 – 7.94 (m, 1H, H5'), 7.87 (d, J = 2.0
Hz, 1H, H7), 7.28 (dd, J = 9.2, 2.0 Hz, 1H, H5), 7.22 – 7.18 (m, 1H, H3'), 3.89 (s, 3H,
ArOCH3). 13C NMR (125 MHz, DMSO) δ 169.0 (d, 1JCF = 255.8 Hz, C4'), 159.9 (C=O),
159.0 (C2), 158.6 (C6), 152.7 (C6'), 151.3 (C2'), 146.8 (C3a), 138.7 (C7a), 125.2 (C4),
117.8 (C5), 108.7 (d, 2JCF = 17.4 Hz, C3'), 104.9 (C7), 101.7 (d, 2JCF = 23.4 Hz, C5'), 55.9
(ArOCH3). IR (neat) 𝜈 max 3179 (br), 3071 (w), 1668 (m), 1595 (m), 1555 (s), 1507 (s),
1466 (m), 1427 (m), 1416 (m), 1329 (s), 1297 (s), 1258 (s), 1220 (m), 1130 (m), 1043
(m), 1016 (m), 857 (m), 767 (s) cm-1. MS (ESI +ve) m/z 304 ([M + H]+, 100%). HRMS
(ESI +ve TOF) calcd for C14H11FN3O2S+ 304.0551, found 304.0556 ([M + H]+).
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N-(6-fluoropyridin-3-yl)-6-methoxybenzo[d]thiazole-2-carboxamide 61f
Following General Procedure C, benzothiazole
carboxylic acid 127 (100 mg, 0.48 mmol), amine 128f
(54 mg, 0.48 mmol), HOBT (72 mg, 0.48 mmol),
EDCI (119 mg, 0.62 mmol), and DIPEA (334 µL, 1.92 mmol) were stirred in anhydrous
DMF (4.8 mL) for 24 h to afford the amide 61f (112 mg, 77%) as a brown solid after
preparative TLC plate chromatography (CH2Cl2/MeOH – 95:5). TLC (CH2Cl2/MeOH –
95:5): Rf = 0.66. Mp 202 ºC. 1H NMR (500 MHz, DMSO) δ 11.50 (br s, 1H, NH), 8.98
(s, 1H, H2'), 8.35 – 8.31 (m, 1H, H4'), 8.26 – 8.22 (m, 1H, H5'), 8.09 (d, J = 9.2 Hz, 1H,
H4), 7.82 (d, J = 2.0 Hz, 1H, H7), 7.25 (dd, J = 9.2, 2.0 Hz, H5), 3.88 (s, 3H, ArOCH3).
C NMR (125 MHz, DMSO) δ 160.7 (C=O), 158,5 (d, 1JCF = 252.0 Hz, C6'), 159.0 (C6),
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158.9 (C2), 147.0 (C3a), 138.5 (C7a), 138.4 (C3'), 136.1 (C2'), 132.8 (d, 2JCF = 30.0 Hz,
C5'), 125.0 (C4), 117.6 (C5), 114.4 (d, 3JCF = 22.5 Hz, C4'), 104.8 (C7), 55.9 (ArOCH3).
IR (neat) 𝜈 max 3234 (br), 3052 (w), 1656 (m), 1603 (m), 1532 (s), 1499 (s), 1449 (m),
1429 (m), 1381 (m), 1331 (m), 1298 (s), 1271 (s), 1220 (m), 1121 (m), 1045 (m), 1022
(m), 870 (m), 733 (s) cm-1. MS (ESI +ve) m/z 304 ([M + H]+, 100%). HRMS (ESI +ve
TOF) calcd for C14H11FN3O2S+ 304.0551, found 304.0556 ([M + H]+).

N-(4-(hydroxymethyl)phenyl)-6-methoxybenzo[d]thiazole-2-carboxamide 61g
Following General Procedure C, benzothiazole
carboxylic acid 127 (100 mg, 0.48 mmol), amine
128g (59 mg, 0.48 mmol), HOBT (72 mg, 0.48
mmol), EDCI (119 mg, 0.62 mmol), and DIPEA (334 µL, 1.92 mmol) were stirred in
anhydrous DMF (4.8 mL) for 24 h to afford the amide 61g (112 mg, 71%) as a pale yellow
solid after preparative TLC plate chromatography (CH2Cl2/MeOH – 90:10). TLC
(CH2Cl2/MeOH – 90:10): Rf = 0.35. Mp 158 ºC (decomp). 1H NMR (400 MHz, CDCl3)
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δ 10.93 (s, 1H, NH), 8.08 (d, J = 9.2 Hz, 1H, H4), 7.84 (d, J = 8.4 Hz, 2H, H2', H6'), 7.81
(d, J = 2.4 Hz, 1H, H7), 7.32 (d, J = 8.4 Hz, 2H, H3', H5'), 7.25 (dd, J = 9.2, 2.4 Hz, 1H,
H5), 5.14 (t, J = 5.6 Hz, 1H, OH), 4.48 (d, J = 5.6 Hz, 2H, CH2OH), 3.88 (s, 3H, ArOCH3).
C NMR (400 MHz, CDCl3) δ 161.9 (C=O), 158.6 (C6), 158.1 (C2), 147.1 (C3a), 138.6
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(C1'), 138.3 (C7a), 136.5 (C4'), 126.8 (C3', C5'), 124.8 (C4), 120.4 (C2', C6'), 117.3 (C5),
104.8 (C7), 62.6 (CH2OH), 55.8 (ArOCH3). IR (neat) 𝜈 max 3452 (br), 3258 (br), 1645 (m),
1596 (m), 1529 (s), 1494 (s), 1412 (m), 1332 (m), 1269 (m), 1223 (s), 1186 (m), 1048
(m), 1018 (m), 977 (m), 910 (m), 876 (m), 824 (s), 733 (m) cm-1. MS (ESI +ve) m/z 315
([M + H]+, 100%). HRMS (ESI +ve TOF) calcd for C16H15N2O3S+ 315.0798, found
315.0798 ([M + H]+).

6-methoxy-N-((6-methylpyridin-3-yl)methyl)benzo[d]thiazole-2-carboxamide 61h
Following General Procedure C, benzothiazole
carboxylic acid 127 (100 mg, 0.48 mmol), amine 128h
(59 mg, 0.48 mmol), HOBT (72 mg, 0.48 mmol),
EDCI (119 mg, 0.62 mmol), and DIPEA (334 µL, 1.92
mmol) were stirred in anhydrous DMF (4.8 mL) for 24 h to afford the amide 61h (123
mg, 82%) as a pale yellow solid after preparative TLC plate chromatography
(CH2Cl2/MeOH – 95:5). TLC (CH2Cl2/MeOH – 95:5): Rf = 0.71. Mp 201 ºC. 1H NMR
(400 MHz, CDCl3) δ 8.44 (br s, 1H, H2'), 8.32 (br s, 1H, NH), 7.96 (dd, J = 8.4, 2.4 Hz,
1H, H4'), 7.49 (d, J = 9.2 Hz, 1H, H4), 7.37 (d, J = 2.0 Hz, 1H, H7), 7.26 (d, J = 8.4 Hz,
1H, H5'), 7.14 (dd, J = 9.2, 2.0 Hz, 1H, H5), 4.76 (d, J = 6.0 Hz, 2H, NHCH2) 3.90 (s,
3H, ArOCH3), 2.34 (s, 3H, ArCH3). 13C NMR (400 MHz, CDCl3) δ 161.1 (C=O), 160.3
(C2), 159.0 (C6), 153.4 (C3'), 149.9 (C2'), 147.7 (C3a), 139.0 (C7a), 137.6 (C4), 132.2
(C6'), 125.2 (C4'), 121.7 (C5'), 117.2 (C5), 104.0 (C7), 56.0 (ArOCH3), 44.7 (NHCH2),
18.3 (ArCH3). IR (neat) 𝜈 max 3366 (m), 3300 (w), 1657 (s), 1604 (m), 1516 (s), 1497 (s),
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1448 (m), 1428 (m), 1326 (s), 1263 (s), 1226 (m), 1226 (m), 1183 (m), 1058 (s), 1023
(m), 872 (m), 822 (s), 764 (m) cm-1. MS (ESI +ve) m/z 314 ([M + H]+, 100%). HRMS
(ESI +ve TOF) calcd for C16H16N3O2S+ 314.0958, found 314.0963 ([M + H]+).

N-benzyl-6-methoxybenzo[d]thiazole-2-carboxamide 61i
Following

General

Procedure

C,

benzothiazole

carboxylic acid 127 (100 mg, 0.48 mmol), amine 128i (51
mg, 0.48 mmol), HOBT (72 mg, 0.48 mmol), EDCI (119
mg, 0.62 mmol), and DIPEA (334 µL, 1.92 mmol) were
stirred in anhydrous DMF (4.8 mL) for 24 h to afford the amide 61i (122 mg, 85%) as a
white solid after preparative TLC plate chromatography (CH2Cl2/MeOH – 98:2). TLC
(CH2Cl2/MeOH – 98:2): Rf = 0.76. Mp 155ºC. 1H NMR (400 MHz, CDCl3) δ 7.89 (d, J
= 9.2 Hz, 1H, H4), 7.67 (br s, 1H, NH), 7.40 – 7.30 (m, 5H, H7, H2', H3', H5', H6'), 7.13
(dd, J = 9.2, 2.0 Hz, 1H, H5), 4.68 (d, J = 6.0 Hz, 2H, NHCH2) 3.90 (s, 3H, ArOCH3).
C NMR (400 MHz, CDCl3) δ 161.1 (C=O), 160.1 (C2), 159.1 (C6), 147.5 (C3a), 139.0
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(C7a), 137.6 (C1'), 129.0 (C2', C6' or C3', C5'), 128.2 (C2', C6' or C3', C5'), 127.9 (C4'),
125.0 (C4), 117.4 (C5), 104.0 (C7), 56.0 (ArOCH3), 44.0 (NHCH2). IR (neat) 𝜈 max 3363
(w), 3296 (w), 1656 (s), 1603 (m), 1526 (s), 1495 (s), 1457 (m), 1428 (m), 1328 (m),
1265 (s), 1249 (m), 1228 (m), 1187 (m), 1055 (m), 1023 (m), 894 (m), 831 (s), 764 (s)
cm-1. MS (ESI +ve) m/z 299 ([M + H]+, 100%). HRMS (ESI +ve TOF) calcd for
C16H15N2O2S+ 299.0849, found 299.0854 ([M + H]+).

6-methoxy-N-(3-methylbenzyl)benzo[d]thiazole-2-carboxamide 61j
Following General Procedure C, benzothiazole
carboxylic acid 127 (100 mg, 0.48 mmol), amine
128j (58 mg, 0.48 mmol), HOBT (72 mg, 0.48
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mmol), EDCI (119 mg, 0.62 mmol), and DIPEA (334 µL, 1.92 mmol) were stirred in
anhydrous DMF (4.8 mL) for 24 h to afford the amide 61j (125 mg, 83%) as a pale yellow
solid after preparative TLC plate chromatography (CH2Cl2/MeOH – 98:2). TLC
(CH2Cl2/MeOH – 98:2): Rf = 0.77. Mp 99 ºC. 1H NMR (400 MHz, CDCl3) δ 7.88 (d, J =
9.2 Hz, 1H, H4), 7.64 (br s, 1H, NH), 7.37 – 7.05 (m, 6H, H5, H7, H2', H4', H5', H6'),
4.63 (s, 2H, NHCH2), 3.89 (s, 3H, ArOCH3), 2.35 (s, 3H, ArCH3). 13C NMR (400 MHz,
CDCl3) δ 161.2 (C=O), 160.1 (C2), 159.1 (C6), 147.5 (C3a), 139.0 (C7a), 138.7 (C3'),
137.5 (C1'), 128.9 (C2' or C4' or C5' or C6'), 128.8 (C2' or C4' or C5' or C6'), 128.7 (C2'
or C4' or C5' or C6'), 125.2 (C2' or C4' or C5' or C6'), 125.0 (C4), 117.3 (C5), 104.0 (C7),
56.0 (ArOCH3), 44.0 (NHCH2), 21.5 (ArCH3). IR (neat) 𝜈 max 3363 (w), 3296 (w), 1656
(s), 1603 (m), 1528 (s), 1495 (s), 1457 (m), 1431 (m), 1327 (m), 1263 (s), 1252 (m), 1227
(m), 1187 (m), 1055 (m), 1021 (m), 897 (s), 831 (s), 763 (s) cm-1. MS (ESI +ve) m/z 313
([M + H]+, 100%). HRMS (ESI +ve TOF) calcd for C17H17N2O2S+ 313.1005, found
313.1011 ([M + H]+).

N-(4-fluorobenzyl)-6-methoxybenzo[d]thiazole-2-carboxamide 61k
Following

General

Procedure

C,

benzothiazole

carboxylic acid 127 (100 mg, 0.48 mmol), amine 128k
(60 mg, 0.48 mmol), HOBT (72 mg, 0.48 mmol), EDCI
(119 mg, 0.62 mmol), and DIPEA (334 µL, 1.92 mmol)
were stirred in anhydrous DMF (4.8 mL) for 24 h to afford the amide 61k (115 mg, 76%)
as a yellow solid after preparative TLC plate chromatography (CH2Cl2/MeOH – 95:5).
TLC (CH2Cl2/MeOH – 95:5): Rf = 0.63. Mp 103 ºC. 1H NMR (400 MHz, CDCl3) δ 7.88
(d, J = 8.8 Hz, 1H, H4), 7.70 (br s, 1H), 7.37 – 7.32 (m, 3H, H2', H6', H7), 7.13 (dd, J =
8.8, 2.4 Hz, 1H, H5), 7.05 – 7.01 (m, 2H, H3', H5'), 4.64 (d, J = 6.4 Hz, 2H, NHCH2),
3.89 (s, 3H, ArOCH3). 13C NMR (100 MHz, CDCl3) δ 162.4 (d, 1JCF = 244.6 Hz, C4'),
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160.9 (C=O), 160.0 (C2), 159.0 (C6), 147.4 (C3a), 138.9 (C7a), 133.4 (C1'), 129.7 (d,
3

JCF = 8.1 Hz, C2', C6'), 124.9 (C4), 117.3 (C5), 156.7 (d, 2JCF = 21.2 Hz, C3', C5'), 103.9

(C7), 55.9 (ArOCH3), 43.2 (NHCH2). IR (neat) 𝜈 max 33365 (m), 3010 (w), 1653 (s), 1603
(m), 1556 (s), 1456 (s), 1440 (m), 1425 (m), 1328 (m), 1304 (s), 1282 (s), 1255 (s), 1217
(m), 1118 (m), 1058 (m), 1025 (m), 848 (m), 747 (s) cm-1. MS (ESI +ve) m/z 317 ([M +
H]+, 100%). HRMS (ESI +ve TOF) calcd for C16H14FN2O2S+ 317.0755, found 317.0760
([M + H]+).

N-(3-fluorobenzyl)-6-methoxybenzo[d]thiazole-2-carboxamide 61l
Following General Procedure C, benzothiazole
carboxylic acid 127 (100 mg, 0.48 mmol), amine 128l
(60 mg, 0.48 mmol), HOBT (72 mg, 0.48 mmol),
EDCI (119 mg, 0.62 mmol), and DIPEA (334 µL, 1.92 mmol) were stirred in anhydrous
DMF (4.8 mL) for 24 h to afford the amide 61l (103 mg, 68%) as a pale yellow solid after
preparative TLC plate chromatography (CH2Cl2/MeOH – 95:5). TLC (CH2Cl2/MeOH –
95:5): Rf = 0.69. Mp 122 ºC. 1H NMR (400 MHz, DMSO) δ 9.67 (t, J = 6.4 Hz, 1H, NH),
8.01 (d, J = 9.2 Hz, 1H, H4), 7.78 (d, J = 2.4 Hz, 1H, H7), 7.40 – 7.35 (m, 1H, H5'), 7.25
– 7.15 (m, 3H, H5, H2', H6'), 7.10 – 7.06 (m, 1H, H4'), 4.50 (d, J = 6.4 Hz, 2H, NHCH2),
3.87 (s, 3H, ArOCH3). 13C NMR (100 MHz, DMSO) δ 162.2 (d, 1JCF = 242.0 Hz, C3'),
161.4 (C=O), 159.7 (C2), 158.5 (C6), 147.1 (C3a), 141.9 (d, 3JCF = 7.0 Hz, C1'), 138.0
(C7a), 130.3 (d, 3JCF = 8.4 Hz, C5'), 124.6 (C4), 123.42 (d, 4JCF = 2.4 Hz, C6'), 117.2
(C5), 114.1 (d, 2JCF = 21.7 Hz, C2'), 113.7 (d, 2JCF = 20.7 Hz, C4'), 104.8 (C7), 55.8
(ArOCH3), 42.2 (NHCH2). IR (neat) 𝜈 max 3303 (m), 1655 (s), 1603 (m), 1589 (s), 1530
(s), 1495 (s), 1466 (m), 1448 (m), 1328 (m), 1301 (s), 1270 (s), 1248 (s), 1229 (m), 1149
(m), 1055 (m), 1023 (m), 888 (m), 831 (m), 733 (m) cm-1. MS (ESI +ve) m/z 317 ([M +
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H]+, 100%). HRMS (ESI +ve TOF) calcd for C16H14FN2O2S+ 317.0755, found 317.0760
([M + H]+).

6-methoxy-N-(4-(trifluoromethyl)benzyl)benzo[d]thiazole-2-carboxamide 61m
Following General Procedure C, benzothiazole
carboxylic acid 127 (100 mg, 0.48 mmol), amine 128m
(84 mg, 0.48 mmol), HOBT (72 mg, 0.48 mmol), EDCI
(119 mg, 0.62 mmol), and DIPEA (334 µL, 1.92 mmol)
were stirred in anhydrous DMF (4.8 mL) for 24 h to afford the amide 61m (129 mg, 73%)
as a pale yellow solid after preparative TLC plate chromatography (CH2Cl2/MeOH –
95:5). TLC (CH2Cl2/MeOH – 95:5): Rf = 0.71. Mp 123 ºC. 1H NMR (400 MHz, DMSO)
δ 9.74 (t, J = 6.4 Hz, 1H, NH), 8.01 (d, J = 9.2 Hz, 1H, H4), 7.78 (d, J = 2.8 Hz, 1H, H7),
7.70 (d, J = 8.0 Hz, 2H, H3', H5'), 7.57 (d, J = 8.0 Hz, 2H, H2', H6'), 7.22 (dd, J = 9.2,
2.8 Hz, 1H, H5), 4.57 (d, J = 6.4 Hz, 2H, NHCH2), 3.87 (s, 3H, ArOCH3). 13C NMR (100
MHz, DMSO) δ 161.3 (C=O), 159.8 (C2), 158.5 (C6), 147.1 (C3a), 143.8 (C1'), 138.0
(C7a), 128.1 (C2', C6'), 127.7 (q, 2JCF = 31.8 Hz, C4'), 126.5 (q, 3JCF = 3.5 Hz, C3', C5'),
125.2 (q, 1JCF = 270.4 Hz, ArCF3), 124.6 (C4), 117.2 (C5), 104.8 (C7), 55.8 (ArOCH3),
42.4 (NHCH2). IR (neat) 𝜈 max 3392 (m), 1676 (m), 1620 (m), 1602 (s), 1554 (s), 1494 (s),
1453 (m), 1436 (m), 1332 (m), 1300 (s), 1270 (s), 1247 (s), 1224 (m), 1150 (m), 1056
(m), 1015 (m), 848 (m), 831 (m), 747 (m) cm-1. MS (ESI +ve) m/z 367 ([M + H]+, 100%).
HRMS (ESI +ve TOF) calcd for C17H14F3N2O2S+ 367.0723, found 367.0728 ([M + H]+).

6.3.3 Synthesis of Benzo[d]thiazolyl Ester Derivatives
sodium 6-methoxybenzo[d]thiazole-2-carboxylate 129255
To a solution of benzothiazole carboxylic acid 127 (500 mg,
2.39 mmol) in MeOH (25 mL) was added a solution of 0.1 M
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NaOH (25 mL, 2.50 mmol), and the reaction was stirred at rt for 2 h. The solvents were
removed under reduced pressure at 40 ºC, and the resulting material suspended in H2O
(1.0 mL) and EtOH (5.0 mL), and evaporated to dryness. The solid was dissolved in
CH2Cl2, and evaporated to afford the benzothiazole salt 129 (520 mg, 98%) as a pale
yellow solid. The spectroscopic data was in agreement with that previously reported. TLC
(CH2Cl2/MeOH – 90:10): Rf = 0.73. 1H NMR (400 MHz, DMSO) δ 7.92 (d, J = 8.8 Hz,
1H, H4), 7.57 (d, J = 2.8 Hz, 1H, H7), 7.09 (dd, J = 8.8, 2.8 Hz, 1H, H5), 3.82 (s, 3H,
ArOCH3). 13C NMR (400 MHz, DMSO) δ 170.1 (C=O), 162.0 (C2), 157.6 (C6), 147.7
(C3a), 138.0 (C7a), 124.2 (C4), 115.4 (C5), 104.4 (C7), 55.6 (ArOCH3). MS (ESI) m/z
231 ([M], 100%).

General Procedure D: Ester Formation
The benzothiazole salt (1.0 eq) and the appropriate alkyl bromide (1.0 eq) were combined
in anhydrous DMF (10 mL/mmol), and stirred at rt for 24 h under N2 atmosphere. The
resulting reaction mixture was poured into H2O (50 mL), and extracted with EtOAc (3 x
50 mL). The organic layer was washed with H2O (2 x 50 mL), brine (2 x 50 mL), dried
(Na2SO4), filtered, and concentrated. The residue was purified by preparative TLC plate
chromatography to afford the desired ester product.

4-cyanobenzyl 6-methoxybenzo[d]thiazole-2-carboxylate 62a
Following General Procedure D, benzothiazole salt
129 (90 mg, 0.39 mmol) and alkyl bromide 130a (76
mg, 0.39 mmol) were stirred in anhydrous DMF (3.9
mL) for 24 h to afford the ester 62a (108 mg, 85%) as a
yellow solid after preparative TLC plate chromatography (CH2Cl2/MeOH – 97:3). TLC
(CH2Cl2/MeOH – 97:3): Rf = 0.79. Mp 120 ºC. 1H NMR (500 MHz, CDCl3) δ 8.11 (d, J
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= 8.8 Hz, 1H, H4), 7.70 (d, J = 8.0 Hz, 2H, H3', H5'), 7.61 (d, J = 8.0 Hz, 2H, H2', H6'),
7.36 (d, J = 2.8 Hz, 1H, H7), 7.19 (dd, J = 8.8, 2.8 Hz, 1H, H5), 5.53 (s, 2H, OCH2), 3.91
(s, 3H, ArOCH3). 13C NMR (500 MHz, CDCl3) δ 160.6 (C=O), 160.0 (C6), 154.5 (C2),
148.0 (C3a), 140.4 (C1'), 139.0 (C7a), 132.9 (C3', C5'), 128.9 (C2', C6'), 126.4 (C4),
118.6 (C4'), 118.1 (C5), 112.7 (ArCN), 103.5 (C7), 67.0 (OCH2), 56.0 (ArOCH3). IR
(neat) 𝜈 max 2944 (w), 2840 (w), 2224 (m), 1741 (s), 1682 (w), 1604 (m), 1547 (m), 1494
(s), 1452 (m), 1325 (m), 1274 (m), 1236 (s), 1221 (m), 1179 (m), 1056 (m), 1028 (m),
903 (m), 858 (m), 830 (s), 751 (m) cm-1. MS (ESI +ve) m/z 325 ([M + H]+, 100%). HRMS
(ESI +ve TOF) calcd for C17H13N2O3S+ 325.0641, found 325.0631 ([M + H]+).

3-fluorobenzyl 6-methoxybenzo[d]thiazole-2-carboxylate 62b
Following General Procedure D, benzothiazole salt
129 (90 mg, 0.39 mmol) and alkyl bromide 130b (74
mg, 0.39 mmol) were stirred in anhydrous DMF (3.9
mL) for 24 h to afford the ester 62b (109 mg, 88%) as a pale yellow solid after preparative
TLC plate chromatography (CH2Cl2/MeOH – 95:5). TLC (CH2Cl2/MeOH – 95:5): Rf =
0.71. Mp 89 ºC. 1H NMR (500 MHz, DMSO) δ 8.10 (d, J = 8.8 Hz, 1H, H4), 7.80 – 7.78
(m, 1H, H5'), 7.50 – 7.46 (m, 1H, H6'), 7.38 – 7.34 (m, 2H, H7, H2'), 7.25 – 7.21 (m, 2H,
H5, H4'), 5.45 (s, 2H, OCH2), 3.86 (s, 3H, ArOCH3). 13C NMR (125 MHz, DMSO) δ
162.2 (d, 1JCF = 242.8 Hz, C3'), 159.9 (C=O), 159.4 (C6), 154.8 (C2), 147.3 (C3a), 138.3
(C7a), 138.0 (d, 3JCF = 7.6 Hz, C1'), 130.8 (C6'), 125.8 (C4), 124.5 (C5'), 118.0 (C5),
115.3 (d, 2JCF = 43.0 Hz, C2'), 115.3 (C4'), 104.5 (C7), 66.9 (OCH2), 56.0 (ArOCH3). IR
(neat) 𝜈 max 3667 (w), 2951 (w), 2224 (w), 1740 (s), 1690 (m), 1599 (m), 1552 (m), 1493
(s), 1452 (m), 1433 (m), 1378 (m), 1331 (m), 1306 (m), 1247 (m), 1224 (s), 1180 (s),
1047 (m), 1024 (m), 956 (s), 873 (m), 738 (s) cm -1. MS (ESI +ve) m/z 318 ([M + H]+,
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100%), 340 ([M + Na]+, 20%). HRMS (ESI +ve TOF) calcd for C16H13FNO3S+ 318.0595,
found 318.0595 ([M + H]+).

4-(trifluoromethyl)benzyl 6-methoxybenzo[d]thiazole-2-carboxylate 62c
Following General Procedure D, benzothiazole salt
129 (90 mg, 0.39 mmol) and alkyl bromide 130c (93
mg, 0.39 mmol) were stirred in anhydrous DMF (3.9
mL) for 24 h to afford the ester 62c (112 mg, 78%) as
a pale yellow crystal after preparative TLC plate chromatography (CH2Cl2/MeOH –
95:5). TLC (CH2Cl2/MeOH – 95:5): Rf = 0.81. Mp 106 ºC. 1H NMR (500 MHz, DMSO)
δ 8.11 (d, J = 8.8 Hz, 1H, H4), 7.82 – 7.79 (m, 3H, H7, H3', H5'), 7.73 (d, J = 8.0 Hz, 2H,
H2', H6'), 7.25 (dd, J = 8.8, 2.4 Hz, 1H, H5), 5.55 (s, 2H, OCH2), 3.87 (s, 3H, ArOCH3).
C NMR (125 MHz, DMSO) δ 159.9 (C=O), 159.4 (C6), 154.7 (C2), 147.3 (C3a), 140.1
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(C1'), 138.4 (C7a), 128.9 (C2', C6'), 127.7 (q, 2JCF = 32.0 Hz, C4'), 126.6 (q, 3JCF = 3.2
Hz, C3', C5'), 125.8 (C4), 125.6 (q, 1JCF = 270.4 Hz, ArCF3), 118.0 (C5), 104.5 (C7), 66.8
(OCH2), 56.0 (ArOCH3). IR (neat) 𝜈 max 2965 (w), 2926 (w), 2840 (w), 1700 (m), 1600
(m), 1550 (m), 1498 (s), 1455 (m), 1434 (m), 1419 (m), 1381 (m), 1326 (s), 1305 (m),
1244 (s), 1223 (m), 1116 (s), 1107 (s), 1092 (s), 1066 (s), 1048 (s), 829 (s), 760 (m), 737
(m) cm-1. MS (ESI +ve) m/z 368 ([M + H]+, 100%). HRMS (ESI +ve TOF) calcd for
C17H13F3NO3S+ 368.0563, found 368.0563 ([M + H]+).

4-nitrophenethyl 6-methoxybenzo[d]thiazole-2-carboxylate 62d
Following

General

Procedure

D,

benzothiazole salt 129 (90 mg, 0.39 mmol) and
alkyl bromide 130d (90 mg, 0.39 mmol) were
stirred in anhydrous DMF (3.9 mL) for 24 h to afford the ester 62d (105 mg, 75%) as a
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pale yellow solid after preparative TLC plate chromatography (CH2Cl2/MeOH – 97:3).
TLC (CH2Cl2/MeOH – 97:3): Rf = 0.77. Mp 130 ºC. 1H NMR (400 MHz, CDCl3) δ 8.19
(d, J = 8.4 Hz, 2H, H3', H5'), 8.11 (d, J = 8.8 Hz, 1H, H4), 7.48 (d, J = 8.4 Hz, 2H, H2',
H6'), 7.36 (d, J = 2.4 Hz, 1H, H7), 7.19 (dd, J = 8.8, 2.4 Hz, 1H, H5), 4.71 (t, J = 7.2 Hz,
2H, H1''), 3.91 (s, 3H, ArOCH3), 3.27 (t, J = 7.2 Hz, 2H, H2'').

13

C NMR (400 MHz,

CDCl3) δ 160.5 (C=O), 160.0 (C6), 154.7 (C2), 148.0 (C3a), 147.2 (C4'), 145.1 (C1'),
138.9 (C7a), 130.1 (C2', C6'), 126.4 (C4), 124.0 (C3', C5'), 118.0 (C5), 103.5 (C7), 66.0
(C1''), 56.0 (ArOCH3), 35.1 (C2''). IR (neat) 𝜈 max 3122 (w), 2900 (w), 1609 (m), 1554 (s),
1520 (s), 1490 (m), 1433 (m), 1377 (m), 1356 (m), 1310 (m), 1270 (s), 1214 (m), 1159
(m), 1059 (m), 1025 (m), 898 (m), 811 (m) cm-1. MS (ESI +ve) m/z 359 ([M + H]+, 100%).
HRMS (ESI +ve TOF) calcd for C17H15N2O5S+ 359.0696, found 359.0697 ([M + H]+).

6.4 Biological Studies
6.4.1 Biological Studies of Fluorescent Probes
6.4.1.1 Animals
Male Spanrague-Dawley rats and C57BL/6J mice were purchased from Japan SLC
(Shizuoka, Japan), kept in temparature-controlled enviroment with a 12 h light-dark
cycle, and fed a standard diet (MB-1/Funabashi Farm, Chiba, Japan). All animal
experiments were approved by the Committee for the Care and Use of Laboratory
Animals of the National Institutes for Quantum and Radiologic Science and Technology
and were performed in accordance with the ethical standards of the Institutes. For in vitro
fluorescence staining, six-months-old mice anesthetized with 1.5% (v/v) isoflurane were
injected with 2 μL of LSP in saline (2 mg/ml) into striatum (interaural 3.82 mm, lateral
2.0 mm, Depth 2.5 mm) of right hemisphere via glass capillary. For in vivo real-time twophoton scanning, two-months-old mice anesthetized with 1.5% (v/v) isoflurane were
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unilaterally injected with 2 μL of LSP in saline (2 mg/ml) into three locations in
somatosensory cortex (interaural 1.26 mm, lateral 2.0-3.0 mm, depth 0.375 mm) via glass
capillary, and a cranial window (4.5-5 mm in diameter) was attached over the
somatosensory cortex, centered at 1.8 mm caudal and 2.5 mm lateral from bregma,
according to Seylaz-Tomita method.256

6.4.1.2 In Vitro Binding Assay
Four rats were sacrificed by cervical dislocation under anesthesia (5% isoflurane in air).
The brains were rapidly removed and homogenized in ten volumes of 50 mM Tris-HCl
(pH 7.4) containing 320 mM sucrose (Tris-buffer) using a Silent Crusher S homogenizer
(Heidolph Instruments, Schwabach, Germany). The homogenate was centrifuged in a
polypropylene tube at 800 g for 10 min at 4 °C. The supernatant was collected and then
centrifuged at 9,000g for 10 min at 4 °C using an Optima-TLX (Beckman Coulter, Brea,
CA). After discarding the supernatant, the pellet was suspended in Tris-buffer and
centrifuged at 9,000g for 10 min at 4 °C. Subsequently, the resulting pellet was
resuspended in Tris-buffer and centrifuged at 12,000g for 10 min at 4 °C. Finally, the
crude mitochondrial pellet was resuspended in 50 mM Tris-HCl buffer containing 120
mM NaCl, 2.0 mM KCl, 1.0 mM MgCl2, and 1.0 mM CaCl2 (wash-buffer) at a
concentration of 100 µg original wet tissue/mL and used for binding assays.
Each crude mitochondrial preparation of 0.1 mL was incubated with [11C]PK11195 6
(final concentration: 3.4 ± 2.6 nM) and various concentrations of test compounds (55a-d,
83, 56a-b, and 89) in a final volume of 1.0 mL buffer. These mixtures were incubated for
30 min at rt. The bound and free radioactivities were separated by vacuum filtration
through 0.3% polyethylenimine-pretreated Whatman GF/C glass fiber filters using a cell
harvester (M-24, Brandel, Gaithersburg, MD), followed by three washes with prechilled
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Wash-buffer. The radioactivity of filters containing the bound [11C]PK11195 6 was
counted with a 2480 Wizard2 autogamma scintillation counter (Perkin-Elmer, Waltham,
MA). Nonspecific binding was determined in the presence of PK11195 6 (10 μM). All
assays were performed in duplicate. Specific binding at each compound concentration
was calculated as a percentage in relation to the control specific binding, and which were
converted to probit values to determine the IC50 of each compound. The IC50 value was
further converted to Ki according to the Cheng–Prusoff equation.257 In that equation, the
dissociation constant of [11C]PK11195 6 was referred from a previous paper.258

6.4.1.3 Fluorescence Staining
Mice were deeply anesthetized and sacrificed by cervical dislocation, and brains were
subsequently dissected and frozen in OCT compound (SaKuRa). 20-μm thick fixed
frozen sections were prepared by cryostat and incubated in 50 mM Tris-HCl buffer
containing 0.001% (w/v) of ligand at room temperature for 30 min. The brain samples
were rinsed with 50 mM Tris-HCl twice for 2 min, dipped into distilled water for 10 secs,
and mounted in

non-fluorescent

mounting

media (VECTASHIELD, Vector

Laboratories). Fluorescence images were captured using a DM4000 microscope equipped
with filter cube for FITC (excitation filter: band-pass at 460-500 nm; suppression filter:
band-pass at 512-542 nm) and Rhodamine (excitation filter: band-pass at 515-560 nm;
suppression filter: long-pass at 590 nm), and a BZ-X710 fluorescence microscope
equipped with filter cube for FITC (excitation filter: band-pass at 450-490 nm;
suppression filter: band-pass at 500-550 nm). Sections labelled with ligands were fixed
in 4% PFA in PBS for overnight at 4 ℃ and autoclaved for antigen retrieval and
immunostained with anti-TSPO antibody (1:1000, ab109497, Abcam). Immunolabelling
was then examined using DM4000 and BZ-X710.
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6.4.1.4 Real-Time Two Photon Scanning
Two-photon imaging was performed in awake mice after one weeks of the cranial window
surgery at the earliest. Vessels were fluorescently-leveled with sulforhodamine 101
dissolved in saline (5 mM). Sulforhodamine 101 was intraperitoneally administrated (4
µl/g body weight) just before initiation of the imaging, and ligand dissolved in 0.1%
DMSO solution was intraperitoneally administrated (2 µl/g body weight). The awake
animal was placed on a custom-made apparatus, and real-time imaging was conducted by
two-photon laser scanning microscopy (TCS-SP5 MP, Leica Microsystems) with an
excitation wave-length of 900 nm. An emission signal was separated by a beam splitter
(560/10 nm) and simultaneously detected with a band-pass filter for ligands (500-550 nm)
and sulforhodamine 101 (573-648 nm). A single image plane consisted of 1024 x 1024
pixels, and in-plane pixel size was 0.45 μm. Volume images were acquired up to a
maximum depth of 50-200 μm from the cortical surface with a z-step size of 2.5 μm.

6.4.2 Biological Studies of Tau Ligands
6.4.2.1 Fluorescence Staining
Fluorescence staining was performed on brain sections of AD patient (postmortem) using
method as previously described in section 6.4.1.3 above.

6.4.2.2 Heterologous blocking assay
In a set of heterologous blocking assay for tested derivatives, ligands were tested at 12
different concentrations (final concentration: 0.001 nM, 0.01 nM, 1.0 nM, 2.5 nM, 5.0
nM, 10 nM, 25 nM, 50 nM, 100 nM, 500 nM, and 1000 nM; 0 nM as baseline), and were
separately mixed with [11C]PBB3 30 (final concentration: 5.0 nM) and brain homogenates
(final concentration: 0.01mg/mL) (Table 6.1), and the mixtures were then incubated for
30 min at rt. After incubation, mixtures were filtered by glass filter (Whatman glass fiber,
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M-24 without Deposit System, Whatman GF/B, BRANDEL FP-100) through suction to
achieve bound/free (B/F) separation. The radioactivity of the homogenates harvested by
the glass filters were quantified by a gamma counter (2480 WIZARD2, ParkinElmer). The
readouts from the gamma counter from each set of assays were further analyzed to obtain
the Ki and % of inhibition of the corresponding ligand against [11C]PBB3 30. A set of
homologous blocking assay with non-labeled PBB3 30 was used for calculating the Kd of
PBB3 30.
1.

The Kd of non-labeled PBB3 30 (KdL)
◼

IC50 of non-labeled PBB3 30 was obtained from its binding curve from the
homologous blocking assays (where PBB3 30 compete with [11C]PBB3 30
for binding sites at the brain homogenate).

◼

The dissociative constant (Kd) of RI ligand (PBB3 30) was obtained through
the following equation:
𝑲𝒅𝑳 = 𝑲𝒊 = 𝑰𝑪𝟓𝟎 − Ｌ where L stands for [[11C]PBB3 30]final (5 nM).

2.

The Ki of new ligands
◼

IC50 of each ligand was obtained accordingly from their binding curves
from the heterologous blocking assays (where new compounds compete
with [11C]PBB3 30 respectively for binding sites at the brain homogenate).

◼

The dissociative constant (Kd) of PBB3 30 was obtained through the
following equation:
𝑳

𝑲𝒊 = 𝑰𝑪𝟓𝟎 /(𝟏 + 𝑲 ) where L stands for [[11C]PBB3 30] final (5 nM) and
𝒅𝑳

KdL stands for the Kd of non-labeled PBB3 30.
The % inhibition was determined by calculating the portion of [11C]PBB3 30 being
blocked by 1.0 μM (working concentration) of each ligand comparing to the inhibition of
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1.0 μM non-labeled PBB3 30 (as 100%). If the gamma counter readout from the assay of
1.0 μM compound is abnormally high (means higher than that of 0.5 μM, usually due to
low solubility), the lowest readout in the corresponding series of assays will be used for
calculation instead.237, 259

Table 6.1 Brain sample used for heterologous blocking assay

Brain sample information
Brain region

Middle frontal cortex

Sex

Male

Age at death

58

Clinical diagnosis

Alzheimer's disease probable

Pathological diagnosis

Alzheimer's disease

Braak stage

3
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Appendix A. Supporting Information for Fluorescent Probes
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A.1 Spectroscopic Data
1. 1H NMR and 13C NMR spectra of all synthesised compounds
1

H NMR of 70 (400 MHz, DMSO-d6)

13

C NMR of 70 (400 MHz, DMSO-d6)

275

1

H NMR of 71 (400 MHz, DMSO-d6)

13

C NMR of 71 (400 MHz, DMSO-d6)

276

1

H NMR of 72 (400 MHz, DMSO-d6)

13

C NMR of 72 (400 MHz, DMSO-d6)

277

1

H NMR of 67 (400 MHz, DMSO-d6)

13

C NMR of 67 (400 MHz, DMSO-d6)

278

1

H NMR of 78 (400 MHz, DMSO-d6)

13

C NMR of 78 (400 MHz, DMSO-d6)
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1

H NMR of 80a (400 MHz, CDCl3)

13

C NMR of 80a (400 MHz, CDCl3)
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1

H NMR of 80b (400 MHz, CDCl3)

13

C NMR of 80b (400 MHz, CDCl3)
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1

H NMR of 80c (400 MHz, DMSO-d6)

13

C NMR of 80c (400 MHz, DMSO-d6)
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1

H NMR of 80d (400 MHz, DMSO-d6)

13

C NMR of 80d (400 MHz, DMSO-d6)
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1

H NMR of 81a (400 MHz, DMSO-d6)

13

C NMR of 81a (400 MHz, DMSO-d6)

284

1

H NMR of 81b (400 MHz, DMSO-d6)

13

C NMR of 81b (400 MHz, DMSO-d6)

285

1

H NMR of 81c (400 MHz, DMSO-d6)

13

C NMR of 81c (400 MHz, DMSO-d6)
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1

H NMR of 81d (400 MHz, DMSO-d6)

13

C NMR of 81d (400 MHz, DMSO-d6)
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1

H NMR of 55a (500 MHz, DMSO-d6)

13

C NMR of 55a (500 MHz, DMSO-d6)

288

1

H NMR of 55b (400 MHz, DMSO-d6)

13

C NMR of 55b (400 MHz, DMSO-d6)

289

1

H NMR of 55c (500 MHz, DMSO-d6)

13

C NMR of 55c (500 MHz, DMSO-d6)

290

1

H NMR of 55d (400 MHz, DMSO-d6)

13

C NMR of 55d (400 MHz, DMSO-d6)

291

1

H NMR of 82 (400 MHz, DMSO-d6)

13

C NMR of 82 (400 MHz, DMSO-d6)

292

1

H NMR of 83 (500 MHz, CD3OD)

13

C NMR of 83 (500 MHz, CD3OD)

293

1

H NMR of 84 (400 MHz, DMSO-d6)

13

C NMR of 84 (400 MHz, DMSO-d6)

294

1

H NMR of 85 (400 MHz, DMSO-d6)

13

C NMR of 85 (400 MHz, DMSO-d6)

295

1

H NMR of 87a (400 MHz, DMSO-d6)

13

C NMR of 87a (400 MHz, DMSO-d6)

296

1

H NMR of 87b (400 MHz, DMSO-d6)

13

C NMR of 87b (400 MHz, DMSO-d6)

297

1

H NMR of 88a (400 MHz, DMSO-d6)

13

C NMR of 88a (400 MHz, DMSO-d6)
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1

H NMR of 88b (400 MHz, DMSO-d6)

13

C NMR of 88b (400 MHz, DMSO-d6)
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1

H NMR of 56a (500 MHz, DMSO-d6)

13

C NMR of 56a (500 MHz, DMSO-d6)
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1

H NMR of 56b (500 MHz, DMSO-d6)

13

C NMR of 56b (500 MHz, DMSO-d6)
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1

H NMR of 89 (400 MHz, DMSO-d6)

13

C NMR of 89 (400 MHz, DMSO-d6)
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2. HRMS spectra of fluorescent probes
HRMS spectrum of fluorescent probe 55a

303

HRMS spectrum of fluorescent probe 55b

304

HRMS spectrum of fluorescent probe 55c

305

HRMS spectrum of fluorescent probe 55d

306

HRMS spectrum of fluorescent probe 83

307

HRMS spectrum of fluorescent probe 56a

308

HRMS spectrum of fluorescent probe 56b

309

HRMS spectrum of fluorescent probe 89

310

3. HPLC chromatograms of fluorescent probes
HPLC chromatogram of fluorescent probe 55a

311

HPLC chromatogram of fluorescent probe 55b

312

HPLC chromatogram of fluorescent probe 55c

313

HPLC chromatogram of fluorescent probe 55d

314

HPLC chromatogram of fluorescent probe 83

315

HPLC chromatogram of fluorescent probe 56a

316

HPLC chromatogram of fluorescent probe 56b

317

HPLC chromatogram of fluorescent probe 89
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Appendix B. Supporting Information for Tau Ligands
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B.1 Spectroscopic Data
1. 1H NMR and 13C NMR spectra of tau ligands
1

H NMR of 57a (400 MHz, DMSO-d6)

13

C NMR of 57a (400 MHz, DMSO-d6)
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H NMR of 57b (400 MHz, DMSO-d6)
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C NMR of 57b (400 MHz, DMSO-d6)
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H NMR of 57c (500 MHz, DMSO-d6)

13

C NMR of 57c (500 MHz, DMSO-d6)
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H NMR of 58a (500 MHz, DMSO-d6)

13

C NMR of 58a (125 MHz, DMSO-d6)
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H NMR of 58b (400 MHz, DMSO-d6)

13

C NMR of 58b (100 MHz, DMSO-d6)
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H NMR of 58c (400 MHz, DMSO-d6)
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C NMR of 58c (100 MHz, DMSO-d6)
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H NMR of 58d (400 MHz, DMSO-d6)
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C NMR of 58d (100 MHz, DMSO-d6)
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H NMR of 58e (500 MHz, DMSO-d6)

13

C NMR of 58e (125 MHz, DMSO-d6)
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H NMR of 58f (500 MHz, DMSO-d6)

13

C NMR of 58f (500 MHz, DMSO-d6)
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H NMR of 58g (400 MHz, DMSO-d6)
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C NMR of 58g (400 MHz, DMSO-d6)
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H NMR of 58h (400 MHz, DMSO-d6)
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C NMR of 58h (500 MHz, DMSO-d6)
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H NMR of 58i (400 MHz, DMSO-d6)
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C NMR of 58i (400 MHz, DMSO-d6)
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H NMR of 58j (400 MHz, DMSO-d6)
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C NMR of 58j (400 MHz, DMSO-d6)
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H NMR of 58k (400 MHz, DMSO-d6)

13

C NMR of 58k (100 MHz, DMSO-d6)
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H NMR of 58l (400 MHz, DMSO-d6)

13

C NMR of 58l (100 MHz, DMSO-d6)

334

1

H NMR of 58m (400 MHz, DMSO-d6)

13

C NMR of 58m (100 MHz, DMSO-d6)
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1

H NMR of 58n (400 MHz, DMSO-d6)

13

C NMR of 58n (400 MHz, DMSO-d6)
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H NMR of 58o (500 MHz, DMSO-d6)

13

C NMR of 58o (500 MHz, DMSO-d6)
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H NMR of 59a (400 MHz, DMSO-d6)

13

C NMR of 59a (400 MHz, DMSO-d6)
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1

H NMR of 59b (400 MHz, DMSO-d6)

13

C NMR of 59b (400 MHz, DMSO-d6)
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1

H NMR of 59c (400 MHz, DMSO-d6)

13

C NMR of 59c (400 MHz, DMSO-d6)
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1

H NMR of 59d (400 MHz, DMSO-d6)

13

C NMR of 59d (400 MHz, DMSO-d6)
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1

H NMR of 59e (400 MHz, CDCl3)

13

C NMR of 59e (400 MHz, CDCl3)
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1

H NMR of 61a (400 MHz, DMSO)

13

C NMR of 61a (400 MHz, DMSO)
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1

H NMR of 61b (500 MHz, DMSO)
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C NMR of 61b (500 MHz, DMSO)
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H NMR of 61c (500 MHz, CDCl3)
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C NMR of 61c (500 MHz, CDCl3)
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1

H NMR of 61d (500 MHz, DMSO)

13

C NMR of 61d (125 MHz, DMSO)
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H NMR of 61e (500 MHz, DMSO)

13

C NMR of 61e (125 MHz, DMSO)
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1

H NMR of 61f (500 MHz, DMSO)

13

C NMR of 61f (125 MHz, DMSO)
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1

H NMR of 61g (400 MHz, CDCl3)

13

C NMR of 61g (400 MHz, CDCl3)
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1

H NMR of 61h (400 MHz, CDCl3)

13

C NMR of 61h (400 MHz, CDCl3)

350

1

H NMR of 61i (400 MHz, CDCl3)
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C NMR of 61i (400 MHz, CDCl3)
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H NMR of 61j (400 MHz, CDCl3)

13

C NMR of 61j (400 MHz, CDCl3)

352

1

H NMR of 61k (400 MHz, CDCl3)

13

C NMR of 61k (100 MHz, CDCl3)
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1

H NMR of 61l (400 MHz, DMSO)

13

C NMR of 61l (100 MHz, DMSO)
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1

H NMR of 61m (400 MHz, DMSO)

13

C NMR of 61m (100 MHz, DMSO)
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H NMR of 62a (500 MHz, CDCl3)

13

C NMR of 62a (500 MHz, CDCl3)
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C NMR of 62b (125 MHz, DMSO)

357

1

H NMR of 62c (500 MHz, DMSO)
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C NMR of 62c (125 MHz, DMSO)
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1

H NMR of 62d (400 MHz, CDCl3)

13

C NMR of 62d (400 MHz, CDCl3)
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2. HRMS spectra of selected tau ligands
HRSM spectrum of ligand 58a
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HRSM spectrum of ligand 58d
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HRSM spectrum of ligand 58f
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HRSM spectrum of ligand 58i
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3. HPLC chromatograms of selected tau ligands
HPLC chromatogram of ligand 58a
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HPLC chromatogram of ligand 58d
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HPLC chromatogram of ligand 58f
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HPLC chromatogram of ligand 58i
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HPLC chromatogram of ligand 58n
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Appendix C. Biological Evaluations

369

C.1 Fluorescence Staining of Tau Ligands (FITC Filter)
Filter cube for FITC: [excitation] band-pass at 460-500 nm; [suppression] band-pass at
512-542 nm.
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C.1 Heterologous Blocking of Radioligand Binding in Human Brain Homogenates
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Appendix D. Fluorescent Probe 56b
(upon long-wave (λ = 365 nm) UV irradiation)
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